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Summary  
 
Culicoides biting midges are the biological vector for Bluetongue virus (BTV), the aetiological agent of 
bluetongue disease (BT) in ruminants. Like all other hematophagous arthropods, Culicoides midges 
secrete pharmacologically active saliva during the acquisition of a blood meal. This saliva acts to 
counteract the mammalian host blood coagulation and local immune responses that are initiated as a 
result of vector blood feeding. As shown for numerous other arthropod-pathogen systems, Culicoides 
saliva may play a role in BTV infection, beyond simple virus transmission during blood meal acquisition. 
The work of this thesis highlights for the first time, that Culicoides sonorensis saliva can enhance BTV 
infection and replication within bovine monocytes, most likely via a mechanism that influences the early 
stages of virus infection. Furthermore, the undertaken studies identify that the saliva of C. sonorensis 
naturally contains bacterial lipopolysaccharides (LPS), and suggest that this non-protein salivary 
component is likely responsible for the observed saliva induced enhancement of BTV infection and 
replication. C. sonorensis saliva induced modification of the bovine host cytokine response was also 
assessed in this thesis. The presence of saliva during BTV infection was shown to enhance the 
production of the immunomodulatory cytokine IL-10 and also reduce the BTV induced production of 
IFN- from PBMC cultures from some, but not all, cattle.  
Collectively the results of this thesis highlight the active properties of C. sonorensis saliva in the context 
of enhancing BTV infection and the complex relationships between BTV, Culicoides midges, their 
salivary material and the bovine host, indicating the continuing need to elucidate these multifaceted 
virus-vector-host interactions. Furthermore, the study of these interactions will enable a greater 
understanding of the underlying mechanisms of BTV pathogenesis thus leading to potential applications 
to novel methods of viral control. 
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RT-PCR Reverse-transcription polymerase chain reaction 
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THOV Thogoto virus 
TLR Toll like receptor 
TNF-α Tumour necrosis factor α 
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UV Ultraviolet 
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VP 1-7 Viral protein 1 - 7 
VSP(s) Viral structural protein(s) 
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WBE Whole body extract 
WNV West Nile virus 
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1.1 Bluetongue virus introduction  
Bluetongue (BT) is an economically important, non-contagious disease of ruminants caused by the 
aetiological agent Bluetongue virus (BTV). BTV is an arthropod-borne virus that is transmitted between 
susceptible ruminants via infected Culicoides biting midges (Du Toit, 1944). The virus must therefore 
infect and replicate in both invertebrate and vertebrate hosts in order  for successful transmission to 
occur. The clinical signs of BT range from a severe haemorrhagic disease in sheep, to an often 
asymptomatic infection in cattle, goats and wild ruminants (MacLachlan, 1994). BT is a listed disease by 
The World organisation for Animal Health (OIE) (OIE, 2017e) and must be reported in the event of an 
outbreak. BT is also a notifiable disease in the United Kingdom and any suspected cases must therefore 
be reported to the Animal and Plant Health Agency (APHA) immediately upon suspicion (DEFRA, 2014). 
1.2 BTV history  
BT has historically been described as an African disease and was potentially first described as early as 
the 18th century as ‘tong-sikte’, meaning a ‘prodigious swelling of the tongue’, by the French biologist 
Francois de Vaillant (Vaillant, 1790). The first detailed descriptions of the disease did not, however, 
emerge until the early 1900s where the clinical manifestation of BTV infection was described as 
‘malarial catarrhal fever’ of sheep. The disease was renamed ‘Bluetongue’ in 1905 with reference to 
the cyanotic tongue that can be seen, although infrequently, as a clinical sign in infected sheep 
(Hutcheon, 1902, Spreull, 1905).  
In 1943, the first spread of BTV outside of Africa was confirmed in Cyprus leading to the death of 
approximately (~) 2,500 sheep and mortality rates of up to 70% in some flocks (Gambles, 1949). Due to 
the severity of clinical disease observed during this outbreak and subsequent BT outbreaks within the 
region (e.g. Palestine in 1943, Turkey in 1944, 1946 and 1947 and Israel in 1949), BT att racted 
considerable focus as a newly emerging disease (Gambles, 1949, Komarov and Goldsmith, 1951). BT 
was first reported in the United States of America in Texas in 1918 and subsequently in California in 
1952. These American outbreaks were first reported as ‘sore-muzzle’ disease, however it was later 
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confirmed that BTV was the causal agent, again solidifying the importance of BT as an emerging disease 
(Hardy and Price, 1952, McGowan, 1953). Meanwhile, between 1956 and 1960, a European outbreak 
caused by BTV serotype 10 (BTV-10) spread amongst the sheep populations of Portugal and Spain. 
Although severe, leading to the death of over 179, 000 sheep, the outbreak was bought under control 
by movement restrictions and the slaughter of infected animals. Europe subsequently remained free 
of BT for almost 20 years until the virus returned to Greece in 1979 (Wilson and Mellor, 2009). 
Prior to 1998 Europe had largely remained BT free however, between 1998 and 2005 the spread of at 
least five BTV serotypes including BTV-1, 2, 4, 9 and 16 significantly changed the epidemiology of BT. 
BTV spread throughout at least 12 European countries, alongside North Africa and Israel leading to an 
estimated death of over one million animals, either due to the disease itself or culling for control 
purposes (Purse et al., 2005). In 2006, BTV-8 subsequently emerged in northern Europe for the first 
time, initially in the Netherlands and Belgium and shortly afterwards in Germany, Luxemburg and 
Northern France (Wilson and Mellor, 2009). BTV-8 circulation continued in 2007, with onward 
transmission into Switzerland, Denmark, the Czech republic and the United Kingdom (Wilson and 
Mellor, 2009). Following a successful eradication campaign in Northern European countries, mostly 
attributed to the implementation of livestock vaccination campaigns, the last cases of BTV-8 were 
reported in Italy in 2011. However in 2015, the re-emergence of the same BTV-8 strain was reported in 
France (Breard et al., 2016) with a proposed source of low level virus circulation since the previous 
epizootic in 2007-2008 (Defra, 2016). BTV-8 is currently circulating in France, Switzerland and Italy (OIE, 
2017a) whilst BTV-4 is also currently circulating throughout mainland Europe in countries such as 
Croatia (OIE, 2017b), Austria (OIE, 2017c) and Italy (OIE, 2017d) (Figure 1.1).  
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Figure 1.1 – Current geographic distribution of BT in Europe 
Current geographic distribution of BT in Europe for the period of September 1st to September 26th 2017 
in all species. Figure obtained from (OIE, 2017a). ©World Organisation for Animal Health (OIE). 
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1.3 Virus taxonomy, genome and structure 
1.3.1 Orbiviruses  
BTV is the ‘type’ species of the Orbivirus genus which encompasses 22 recognised viral species including 
African horse sickness virus (AHSV), Epizootic haemorrhagic disease virus (EHDV) and Peruvian horse 
sickness virus (PHSV) (ICTV, 2016).The Orbivirus genus was first proposed in 1971 (Borden et al., 1971) 
to include certain arthropod-borne viruses with similar morphological and physiological characteristics 
such as the distinctive ring shaped structure and a ten-segmented double stranded RNA (dsRNA) 
genome (Mertens et al., 2004). However, the Orbivirus genus is ever expanding and newly emerging 
viruses of this genus are regularly being discovered. For example, the tentatively named Parry’s Lagon 
Virus (PLV) has recently been isolated from mosquitoes in Australia (Harrison et al., 2016).  
1.3.2 BTV genome and structure 
The dsRNA genome of BTV is ~ 19, 200 base pairs and consists of ten segments. The assignment of 
these genomic segments to expressed viral proteins was first determined in 1984 and for a long time it 
was proposed that each genomic segment encoded a single viral protein (Mertens et al., 1984). Seven 
distinct viral structural proteins (VSP) (VP1 – VP7) and three non-structural proteins (NSP) (NS1 – NS3) 
were initially identified. Subsequent to these initial findings, it has been identified that genomic 
segments nine and ten in fact each encode for two viral proteins; VP6 and NS4 are encoded by segment 
nine (Belhouchet et al., 2011, Ratinier et al., 2011), whilst NS3/3A and NS5 are encoded by segment ten 
(Stewart et al., 2015). Table 1.1 indicates the viral proteins encoded by the segmented genome of BTV.  
 
  
~ 21 ~ 
 
Table 1.1 – Viral proteins encoded by BTV genomic segments 
 
Genomic 
segment 
Protein(s) 
encoded 
Protein size 
(kilo Dalton) 
Location Function Reference(s) 
1 VP1 150 Inner sub 
core 
RNA dependant RNA 
polymerase 
(Urakawa et al., 
1989) 
2 VP2 111 Outer 
capsid 
Determinant of viral 
serotype 
Viral entry 
(Forzan et al., 2007, 
Forzan et al., 2004, 
Hassan and Roy, 
1999) 
3 VP3 103 Sub core Core particle 
formation 
(Grimes et al., 1998) 
4 VP4 76 Inner sub 
core 
Capping enzyme (Martinez-Costas et 
al., 1998, Ramadevi 
et al., 1998, 
Ramadevi and Roy, 
1998) 
5 NS1 64 Non-
structural 
Replication and 
morphogenesis, 
regulator of viral 
protein synthesis 
(Boyce et al., 2012, 
Owens and Roy, 
2004) 
6 VP5 59 Outer 
capsid 
Viral entry, 
membrane fusion 
(Forzan et al., 2007, 
Forzan et al., 2004, 
Hassan et al., 2001) 
7 VP7 38 Outer core Sero-group reactive 
antigen 
(Gumm and 
Newman, 1982, 
Huismans and 
Erasmus, 1981) 
8 NS2 42 Non-
structural 
Viral replication and 
major component of 
viral inclusion bodies 
(VIBs) that are the 
sites of virus 
replication 
(Matsuo and Roy, 
2013, Thomas et al., 
1990) 
9 VP6 and 
NS4 
36 (VP6) 
17 (NS4) 
Non-
structural 
and non-
structural 
Helicase (VP6) 
Virulence factor 
(NS4) 
(Ratinier et al., 2016, 
Stauber et al., 1997) 
10 NS3/3A 
and NS5 
26 (NS3) 
25 (NS3A) 
Non-
structural 
Virus release from 
infected cells, IFN 
antagonist (NS3/3A) 
Undetermined/ 
possible role in the 
control of gene 
expression (NS5) 
(Brookes et al., 
1993, Chauveau et 
al., 2012, Feenstra 
et al., 2015, Han and 
Harty, 2004, Hyatt et 
al., 1993, Ruscanu et 
al., 2012, Stewart et 
al., 2015, Vitour et 
al., 2014) 
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The BTV virion is a non-enveloped, icosahedral structure of ~ 80 nm in diameter and consists of three 
protein shells; the outer-capsid, core and sub-core (Hewat et al., 1992) (Figure 1.2). Early studies 
identified that the BTV particle is made up of seven structural proteins (Mertens et al., 1984, Verwoerd 
et al., 1972) and subsequent X-ray crystallography and cryo-electron microscopy determined the 
structure of the BTV core and elucidated the self-assembly of the proteins that make up the virion 
(Gouet et al., 1999, Grimes et al., 1998, Grimes et al., 1997, Loudon and Roy, 1991, Mertens and 
Diprose, 2004) 
The outer capsid shell comprises of two proteins, VP2 and VP5 (Hewat et al., 1992), encoded by genome 
segments two and six respectively. Both proteins are considered to play a major (VP2) and supporting 
(VP5) role in viral entry (Forzan et al., 2007, Forzan et al., 2004, Hassan et al., 2001, Hassan and Roy, 
1999).  VP2 also acts as the virus hemagglutinin enabling binding to red blood cells, and the host 
neutralising antibody target, of which the latter is thought to play a role in the protective immune 
response (DeMaula et al., 2000, Huismans and Erasmus, 1981, Huismans and Van Dijk, 1990, Maan et 
al., 2008, Maan et al., 2007, Mertens et al., 2007, Roy et al., 1990a).  
VP2 is the most antigenically diverse of all the viral proteins and due to this, it is the major determinant 
in the classification of BTV serotypes. BTV serotype can be determined via traditional methods such as 
virus or serum neutralisation tests (VNT or SNT) however BTV type identification has more recently 
been achieved by the genome sequencing of segment two, thus leading to the discussion that viruses 
should be classified based upon their genotype (Davies et al., 1992, Maan et al., 2012, Maan et al., 
2008, Maan et al., 2007, Mertens et al., 2007). SNT and/or VNT reactions have been shown to have a 
close relationship with the nucleotide sequence of VP2 and have been used to identify the 29 currently 
known serotypes of BTV (Maan et al., 2016, Maan et al., 2015). Real-time or conventional reverse-
transcription polymerase chain reaction (RT-PCR) assays have not only become increasingly important 
for the detection and identification of BTV strains and respective serotypes but, in combination with 
genome sequencing, have also allowed the classification of viruses into regional groups, termed 
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‘topotypes’. It is known that BTV topotypes, within a single serotype, can vary in segment two 
nucleotide sequence by up to 31% and hence it is of great importance to identify the reference strains 
for the major topotypes belonging to each serotype (Maan et al., 2013, Maan et al., 2016, Maan et al., 
2011, Mertens et al., 2007, Rao et al., 2012). The observed variations of VP2 are likely to reflect the 
viruses’ need to attach and penetrate both mammalian and insect host cells whilst also evading the 
immunological defences in both hosts (Maan et al., 2007).  
 
Figure 1.2 – The structure of BTV particles 
Schematic obtained from (Mertens and Diprose, 2004). Permission for use granted by Elsevier 
publisher. 
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The second outer capsid protein, VP5, appears to work synergistically with VP2 and has been reported 
to be involved in the late stages of virus entry (Forzan et al., 2004, Hassan et al., 2001), and possibly 
virus assembly (Bhattacharya and Roy, 2008), due to its membrane fusion activity. Furthermore, VP5 
may play a partial role in serotype determination (Mertens et al., 1989) and be a target for neutralising 
antibodies for some virus strains (DeMaula et al., 2000, Huismans and Erasmus, 1981, Roy et al., 1990a). 
VP2 and VP5 are thought to minimally interact, however they have been shown to individually interact 
strongly with the underlying core protein, VP7 (Nason et al., 2004). 
VP7 trimers form the outer layer of the viral core particle and are organised on an icosahedral lattice 
(Grimes et al., 1995) (Grimes et al., 1998). VP7 is highly immune-dominant and acts as the major BTV 
sero-group reactive antigen (Gumm and Newman, 1982, Huismans and Erasmus, 1981). The core 
protein trimers surround a monolayer of VP3 that forms sub-core viral particles that function to encase 
the viral genome (Grimes et al., 1998). Due to the ability of VP3 to self-assemble into viral particles and 
bind RNA, this protein is considered to be critical for the successful formation of the BTV core (Grimes 
et al., 1998, Loudon and Roy, 1991). 
Three minor proteins are enclosed within the viral sub-core which becomes transcriptionally active 
once the virus core reaches the cytoplasm of the infected host cell; the RNA dependant RNA 
polymerase, VP1 (Urakawa et al., 1989), the capping enzyme, VP4 (Ramadevi et al., 1998) and the 
helicase, VP6 (Stauber et al., 1997). 
Six non-structural proteins (NS1, 2, 3, 3A, 4 and 5) are encoded by the BTV genome and play an integral 
role in virus replication. As one of the most abundantly expressed viral proteins, NS1 is expressed early 
in replication and has been found to be involved in virus replication and morphogenesis (Owens et al., 
2004). Furthermore, NS1 has been identified as a positive regulator of viral protein synthesis via 
upregulating the synthesis of all viral proteins, including itself (Boyce et al., 2012). NS2 is an essential 
component of viral replication and has been shown to be a major component of cytoplasmic viral 
inclusion bodies (VIBs) that are the predominant sites for viral replication (Matsuo and Roy, 2013, 
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Thomas et al., 1990). NS2 also interacts directly with single stranded RNA (ssRNA), VP3 and indirectly 
with VP7 and is therefore thought to be involved in viral core and genome assembly (Kar et al., 2007).  
NS3 exists as two isoforms NS3 and NS3A, of which the latter lacks the N-terminal ten amino acid 
residues. Both NS3 proteins are glycoproteins that localise within the golgi apparatus and membrane 
of infected cells (Bansal et al., 1998, Hyatt et al., 1991, Wu et al., 1992) and are involved in the release 
of viral particles from infected cells via increasing plasma membrane permeability through viroporin 
activity (Han and Harty, 2004) or by viral budding (Hyatt et al., 1993). Although there is some evidence 
that NS3/A are not essential for BTV replication in mammalian cells (van Gennip et al., 2014), it is 
thought that these NSPs are essential for infection in the Culicoides midge vector as indicated by the 
inability NS3/A knockout viruses to replicate and disseminate within Culicoides sonorensis (Feenstra et 
al., 2015). BTV is a strong inducer of type I interferon (IFN) (Section 1.6.4) and NS3 has been implicated 
to interfere with the BTV induced host IFN synthesis pathways (Chauveau et al., 2012, Ruscanu et al., 
2012, Vitour et al., 2014). Furthermore, NS4 has also been implicated in the control of the host IFN 
response to BTV infection. A NS4 knockout BTV-8 (BTV-8ΔNS4) virus has been shown to induce a 
significantly greater level of IFN- production from primary ovine endothelial cells (ECs) compared to 
wild type BTV-8 (BTV-8WT) infected cultures (Ratinier et al., 2016). NS4 has also been implicated as a 
virulence factor; sheep infected in vivo with a BTV-8ΔNS4 strain did not develop pyrexia and displayed 
a delayed onset of viremia compared to BTV-8WT infected sheep (Ratinier et al., 2016).  
A second open reading frame (ORF) in segment ten was identified by Stewart et al., (2015), who 
proposed this ORF to encode for a fifth BTV NSP, NS5. Initial observations of this protein were unable 
to definitely determine the function, however results did indicate a potential role for this protein in the 
inhibition of gene expression via reporter gene assays. BTV-8 strains with a deletion of the ORF encoding 
NS5 (BTV8ΔS10-ORF2) were shown to display similar in vitro replication kinetics in both mammalian 
and insect cells and during in vivo BTV infection of mice, when compared to wild type BTV-8 infection 
(Stewart et al., 2015). 
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1.4 Virus replication within mammalian and insect cells  
1.4.1 Mammalian cells  
The molecular mechanisms of the BTV infection cycle within the mammalian host have mostly been 
characterised in tissue culture cell lines such as African green monkey kidney epithelial (Vero) cells, 
human cervix epithelial (HeLa) cells and baby hamster kidney (BHK-21) cells,  hence the exact influences 
of different ruminant host target cells still remains to be elucidated. The first stage of the BTV 
replication cycle is viral entry which is initiated via the contact of viral particles with unknown cellular 
receptors on the surface of susceptible cells. VP2, as the larger and more protruding of the two capsid 
proteins, is responsible for receptor binding (Forzan et al., 2007, Nason et al., 2004), leading to 
internalisation of the viral particle. VP5 is reported as a pH dependant fusion protein that, once 
activated, leads to membrane fusion allowing the release of the viral core into the cytoplasm of the cell 
(Hassan et al., 2001). 
Viral entry into Vero cells and HeLa cells has been reported via clathrin-dependant endocytosis into an 
early endosome (Forzan et al., 2007) (Figure 1.3) whilst others have reported a BTV entry mechanism 
into BHK-21 cells similar to clathrin independent macropinocytosis leading to delivery of the virus into 
a late endosomal compartment (Gold et al., 2010). Furthermore, subsequent studies into the entry 
mechanisms of BTV into bovine foetal aorta endothelial (BFA) cells also highlighted clathrin 
independent macropinocytosis as the most likely entry mechanism into these natural ruminant target 
cells (Stevens, 2016). Within endosomes, BTV particles are exposed to a low pH environment leading 
to the loss of the viral outer capsid proteins (VP2 and VP5) and the release of the viral core into the 
host cytoplasm via an unknown mechanism. Once in the host cell cytoplasm the viral core remains 
intact thus enabling the protection of the dsRNA viral genome and preventing its detection by host 
antiviral mechanisms (Forzan et al., 2007, Forzan et al., 2004, Hassan et al., 2001, Mertens and Diprose, 
2004).  
Within the BTV core, messenger RNA (mRNA) copies of each of the ten BTV genomic segments are 
transcribed by VP1 and subsequently 5 prime capped by VP4 (Boyce et al., 2004, Sutton et al., 2007). 
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Within two hours post-infection (h.p.i), this newly transcribed viral mRNA next leaves the core particle, 
via pores, and acts as a template for the translation of viral proteins (Diprose et al., 2001, Mertens and 
Diprose, 2004). Progeny virus assembly takes place within cytoplasmic, NS2 dense, VIBs (Brookes et al., 
1993, Kar et al., 2007, Lourenco and Roy, 2011). The correct ten ssRNA segments, along with VP1, VP4 
and VP6, are recruited and packaged into the VP3 subcore that acts as a scaffold for the addition of VP7 
trimers (Noad and Roy, 2009, Schwartz-Cornil et al., 2008). The recruited ssRNA act as a template for 
the synthesis of viral genomic dsRNA within the core thus again attempting to avoid the host anti-viral 
responses (Lourenco and Roy, 2011). VP2 and VP5, the outer capsid proteins, are believed to be added 
to the progeny viruses as they leave the VIBs and enter the host cytoplasm. Newly assembled virions 
are thought to be transported via microtubules, or as recently proposed, attached to intra-cellular 
vesicles, to the cell surface and released predominantly via budding (mostly seen in the early stages of 
infection) or cellular membrane destabilisation leading to cell lysis (late stages of infection) 
(Bhattacharya et al., 2007, Bhattacharya and Roy, 2010, Brookes et al., 1993).  
 
 
Figure 1.3 - The replication cycle of BTV in mammalian cells  
Schematic obtained and adapted from (Patel and Roy, 2014). Permission for use granted by Elsevier 
publisher.  
~ 28 ~ 
 
1.4.2 Insect cells 
BTV entry into Culicoides cells has been proposed via a clathrin mediated-like endocytosis pathway 
(Stevens, 2016). The infectivity of specific BTV particle types for the Culicoides embryo derived (KC) cell 
line and adult Culicoides also differs considerably to that of mammalian cells. Infectious subviral 
particles (ISVPs), that result from the enzymatic cleavage of VP2 by trypsin or chymotrypsin, have been 
reported to have an ~ 100 times higher infectivity for KC cells and adult Culicoides midges compared to 
mammalian tissue culture cell lines (Mertens et al., 1996). Furthermore, the core particles of BTV 
remain highly infectious for insect cells lines whilst in comparison they have a significantly reduced 
infectivity for mammalian cells thus suggesting that the core protein, VP7, may play a role in virus entry 
into insect cells (Fu, 1995, Mertens et al., 1996).  
Key differences in the duration of infection of mammalian (BHK-21) and insect (KC) cells lines have also 
been proposed. As determined by electron microscopy studies, VIB development is reported to be 
comparable in these two cells lines at early stages of BTV infection, such as 6 h.p.i, whilst infection in 
KC cells has been reported to result in persistently infected cultures for several weeks (Fu, 1995). At      
> 14 h.p.i, KC cells have also been shown to contain a single large VIB, that has not been reported in 
mammalian cells, thus indicating a potential role for VIB fusion in insect cells (Fu, 1995). Despite this 
observation of large VIBs within KC cells, very low levels of viral particles have been shown to be 
associated with these structures at late stages of virus infection (Fu, 1995) thus indicating that insect 
cells are somewhat able to control BTV infection and replication.  
NS3/3A are reported to be involved in the exit of BTV from infected insect cells via budding through the 
cell membrane (Hyatt et al., 1993), thus the virus does not induce cytopathic effect in insect cells 
coinciding with the apparent lack of clinical or pathological signs observed in this host (Mellor, 1990). 
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1.5 BTV transmission and Culicoides biting midges  
BTV transmission to its ruminant host principally occurs during the blood feeding of BTV infected female 
Culicoides midges that act as the biological vector for the virus. Over 1,400 Culicoides spp are recognised 
worldwide, however only a small number of these have been described as vectors for BTV (Mellor and 
White, 2009). Those species that are able to transmit BTV are said to be ‘competent’ vectors and the 
vector competence (VC) of arthropod species for specific pathogens is determined by genetic factors 
of both the vector and the pathogen. The VC rate of certain Culicoides species for specific strains of 
Orbiviruses is mostly expressed as the proportion of individuals that can become infected and support 
virus replication, dissemination and ultimately transmission following the uptake of a virus containing 
blood meal. BTV must effectively disseminate to the salivary glands of respective Culicoides thus 
allowing for the subsequent transmission from one susceptible vector host to another susceptible 
mammalian host (Mullens et al., 2004, Paweska et al., 2002, Venter et al., 2009, Venter et al., 2005) 
(Figure 1.4).  
Following the acquisition of a BTV infected blood meal from a viraemic mammalian host, the virus must 
infect the epithelial cells of the midgut which are considered to be the first major barrier (known as the 
mesenteron infection barrier (MIB)) in the infection of female Culicoides midges. Once BTV has infected 
and been amplified within the midgut epithelial cells it must then escape the mesenteron escape barrier 
(MEB) and be released into the haemocoel from where susceptible secondary organs, such as the 
salivary glands, can become infected (Fu, 1995). In contrast to several mosquito vectors, it has been 
shown that a salivary gland infection barrier does not appear to be present in Culicoides biting midges 
(Veronesi et al., 2013). Following replication in the salivary gland, BTV is then released into the salivary 
ducts leading to subsequent viral transmission to a mammalian host upon the acquisition of a blood 
meal by the infected vector.  
VC rates of Culicoides midges for specific strains of BTV has largely been characterised via the usage of 
the laboratory reared species of midge C. sonorensis (Batten et al., 2014, Carpenter et al., 2011, 
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Veronesi et al., 2013, Wittmann et al., 2002) originating from North America (Tabachnick et al., 1996). 
However, it should be considered that it is currently unknown if the estimates of laboratory reared C. 
sonorensis VC, for specific BTV strains, are also applicable to other un-colonised species of midge from 
different geographic locations or if the VC determinants to date may be as a result of selection pressures 
imposed by colonisation of C. sonorensis midges for a prolonged duration of time (Carpenter et al., 
2015).  
Alternative routes of BTV transmission include trans-placental transmission in ruminants infected 
during pregnancy (Darpel et al., 2009, van der Sluijs et al., 2013a, van der Sluijs et al., 2013b). Prior to 
the 2006 - 2009 European outbreak of BTV-8 where a trans-placental transmission rate of 33% was 
reported in cattle (Darpel et al., 2009), this route of viral transmission had not been described for other 
BTV strains circulating in southern Europe (BTV-1, 2, 4, 9 and 16) (van der Sluijs et al., 2013b). 
Cumulative evidence now suggests that different BTV strains and serotypes have a varying ability to 
cross the placenta and infect a foetus in utero (Darpel et al., 2009, van der Sluijs et al., 2013a, van der 
Sluijs et al., 2013b).  
Contact transmission of BTV has also been reported for specific virus strains, such as BTV-26, whereby 
the infection of goats in direct close contact with experimentally infected goats was confirmed (Batten 
et al., 2014). Interestingly, BTV-26 has also been shown to be unable to replicate in KC cells in vitro 
(Batten et al., 2012). Furthermore, although the blood feeding of C. sonorensis on a BTV-26 blood 
mixture led to the positive detection of viral RNA within the vector directly after feeding, viral loads 
appeared to have decreased following the incubation of Culicoides midges, thus indicating that BTV-26 
is unlikely to replicate in C. sonorensis. This vector is therefore considered unlikely to be implicated in 
the transmission of BTV-26 (Batten et al., 2014).  
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Figure 1.4 – The transmission cycle of BTV between Culicoides vectors and ruminant hosts 
Schematic indicating the transmission of BTV from an infected Culicoides midge to an uninfected 
mammalian host during the acquisition of a blood meal by the infected insect vector. The virus next 
infects and disseminates throughout the infected mammalian host (intrinsic incubation period). BTV is 
then transmitted from an infected, viraemic mammalian host to an uninfected Culicoides midge when 
the insect takes a blood meal. The virus next replicates in the Culicoides midge and eventually reaches 
the salivary gland for subsequent transmission to a mammalian host (extrinsic incubation period; the 
time period within the midge vector from acquiring the virus to dissemination to the salivary gland). 
Adapted from (Wilson et al., 2008a).  
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1.6 BT disease 
BTV infects both domestic and wild ruminants with clinical disease principally seen in sheep, whilst 
infections of cattle and wild ruminants are typically asymptomatic (Maclachlan et al., 2009). Despite 
this generalisation, disease severity further depends on the immune status of the herd and also the 
particular breed of host that becomes infected, for example European fine wool breeds of sheep are 
particularly susceptible to disease (Erasmus, 1975, Parsonson, 1992, Shimshony et al., 1988).  
1.6.1 BT of sheep and cattle  
Following BTV infection of sheep, the first clinical symptom to be detected is often a rise in body 
temperature (Darpel et al., 2007, Erasmus, 1975, Pini, 1976). At the same time or shortly after the onset 
of pyrexia, sheep typically develop additional clinical signs such as hyperaemia and congestion of the 
oral and nasal mucosa, lacrimation, oedema of the face and lips, watery (sometimes blood stained) 
nasal discharge and excessive salivation (Figure 1.5)(Erasmus, 1975, Pini, 1976). Occasionally sheep will 
also display signs of respiratory distress and a swelling of the tongue (Darpel et al., 2012, Erasmus, 1975, 
Williamson et al., 2008). At the later stages of infection (8 – 14 days post infection (d.p.i)) sheep will 
typically develop coronitis which may present as a reddening of the coronary band, lameness and a 
resistance to stand or move. Pathological signs of disease include lesions, congestion and 
haemorrhages within the mucosa of the oral cavity and oesophagus, oedema and haemorrhages of the 
lymph nodes, haemorrhages in the pulmonary artery, haemorrhages within and oedema on the 
subcutaneous layer of skin (particularly the face and neck), pulmonary enlargement and interstitial 
oedema (Darpel et al., 2007, MacLachlan et al., 2008). Clinical severity in sheep greatly varies according 
to the specific BTV strain, sheep breed, individual susceptibility and can range from mild disease to 
death (Darpel et al., 2007). Although the majority of sheep that develop severe clinical disease following 
BTV infection die within 14 days, some may also develop chronic manifestations such as severe muscle 
wastage with many animals becoming anorexic (Darpel et al., 2007, Williamson et al., 2008).   
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Figure 1.5 - Clinical signs of BT in sheep 
Clinical signs of BT disease in sheep may include: lacrimation (A), oedema of the face (B/C), hyperaemia 
of mucosal membranes of the nose and muzzle (C) and hyperaemia, reddening and ulceration of the 
mucosal membranes of the mouth (D). At the later stages of infection, sheep may also developed 
coronitis leading to a reddening of the coronary band (E) and bleeding in between the toes (F). Photos 
kindly provided by Dr. Karin Darpel. 
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Prior to the 2006, BT disease in cattle was typically reported as asymptomatic (MacLachlan, 1994, 
MacLachlan et al., 1992a, MacLachlan et al., 1990), however following the introduction of BTV-8 into 
Europe in 2006, some infected cattle showed clinical signs similar to those observed in sheep including 
ulceration of the oral mucosa and muzzle, lacrimation and muco-haemorrhagic discharge (Elbers et al., 
2008, Thiry et al., 2006, Zanella et al., 2013). Natural infection of cattle with BTV-8 has been highlighted 
to result in cattle displaying clinical signs for up to seven weeks post-infection including loss of appetite, 
weight loss, reduction in milk yield and ulcerations of the nasal mucosa (Zanella et al., 2013). Other 
recent incursions of specific BTV strains (BTV-4) into Europe have resulted in asymptomatic infections 
in cattle (Katsoulos et al., 2016), similar to that reported in early studies of BT disease cattle, thus 
highlighting a specificity in the ability of certain BTV strains to induce clinical signs in certain species. 
1.6.2 BT of other ruminants  
BTV infection of wild ruminants has classically been reported to result in asymptomatic disease 
(MacLachlan, 1994). However, certain species of wild ruminants have been shown to succumb to 
symptomatic disease under natural conditions, such as wild sheep (Fernandez-Pacheco et al., 2008), 
red and roe deer (Ruiz-Fons et al., 2008) and antelopes (Bosnic et al., 2015) leading to the development 
of a range of clinical signs similar to those observed in sheep. Furthermore, experimental infection 
studies in white-tailed deer (Howerth et al., 1988) and American bisons (Tessaro and Clavijo, 2001) have 
indicated that these hosts may develop symptomatic BT disease. Due to these varying disease 
outcomes, which may be driven by the host species and viral serotype/strain, wild ruminants will 
inevitable play a role in the transmission of BTV and must therefore be considered when studying the 
epidemiology of BT (García-Bocanegra et al., 2011, Linden et al., 2010). 
1.6.3 Pathogenesis, cellular tropism and viral dissemination in the mammalian host  
Following the inoculation of BTV into the ruminant skin during the blood feeding of infected Culicoides 
midges, BTV infects leukocytes such as dendritic cells (DCs) that migrate to the regional lymph node 
where initial replication occurs (Barratt-Boyes and MacLachlan, 1994, Ellis et al., 1991, Hemati et al., 
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2009, Melzi et al., 2016, Pini, 1976). Additionally, the skin has also been identified as a site for virus 
replication as indicated by the detection of viral proteins in ECs of capillaries and lymphatic vessels and 
leukocytes (determined by cluster of differentiation (CD) 45 labelling) within the dermis of infected 
sheep (Darpel et al., 2012, Melzi et al., 2016). The continuous migration of cells from the blood, through 
the lymphatic system towards the skin under steady state conditions, provides a reservoir of cells that 
can therefore become infected and potentially readily support BTV replication within the skin of the 
mammalian host (Andrade et al., 1998, Cahill et al., 1996, Mackay et al., 1988, Young et al., 2000). 
Furthermore, conventional DCs (cDCs) have been shown to actively recruit in large numbers to the skin 
following virus infection of sheep, thus facilitating the initial stages of virus infection and replication 
within the skin (Hemati et al., 2009). 
Migration of infected cells from the skin following BTV infection has been demonstrated to be 
important in the progression of BT disease as interruption of the lymphatic flow from the skin to the 
regional lymph node has been shown to delay the onset of viremia (Barratt-Boyes and MacLachlan, 
1994). Following viral replication at the site of BTV inoculation within the skin and the adjacent draining 
lymph node, the virus is thought to disseminate via the lymph and vascular systems, either within 
infected leukocytes or adsorbed to erythrocytes, to a range of tissues throughout the body where 
secondary replication occurs. In some studies BTV has been detected within the blood as early as 1 
d.p.i, with BTV being detected within organs such as the spleen, liver and kidneys throughout the course 
of viremia, possibly as a reflection of virus within the blood of these organs (MacLachlan et al., 1990, 
Parsonson, 1992). At the later stages of infection BTV has been isolated from a range of organs including 
the lungs, liver, muscle and heart where replication is supposed to mainly occur within ECs (MacLachlan 
et al., 1990, Parsonson, 1992, Pini, 1976).  
BTV dissemination throughout the ruminant host is thought to be largely characterised by the 
associations of virus particles with erythrocytes (Brewer and MacLachlan, 1992, Singer et al., 2001). 
Transmission electron microscopy has confirmed the association of BTV particles with the cellular 
membrane of erythrocytes, however no evidence was found for virus particle entry into the cytosol 
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(Brewer and MacLachlan, 1992, Brewer and MacLachlan, 1994). BTV infection of cattle is associated 
with a prolonged viremia of up to 60 d.p.i (Singer et al., 2001). In comparison, viremia in sheep has been 
detected for a shorter period of time of up to 28 d.p.i (Chatzinasiou et al., 2010). BTV-erythrocyte 
interactions are likely responsible for the prolonged viremia associated with BTV infection of cattle. 
These interactions are therefore considered advantageous for the transmission of BTV as the virus can 
remain within the blood for a prolonged duration of time, thus enabling transmission to blood feeding 
Culicoides midges, with limited detection of the virus by the host immune response (Brewer and 
MacLachlan, 1994).  
Despite the generalised differences in the clinical signs associated with BT disease in cattle and sheep 
(Section 1.6.1), the pathogenesis of BTV is thought to be comparable in both species and attributable 
to a tropism of BTV for vascular ECs leading to clinical signs associated with vascular injury. The 
differences in clinical signs may however be attributable to specific host factors and it has been 
proposed that the increased susceptibility of ovine ECs to BTV infection and respective vasoactive 
molecule production, as a result of virus infection, are perhaps implicated (DeMaula et al., 2001, 
DeMaula et al., 2002a, DeMaula et al., 2002b). 
In vitro experiments in bovine and ovine lung microvascular ECs (lmECs) and pulmonary artery ECs 
(paECs) have indicated that BTV infection leads to differing modes of virus induced cell death in these 
different EC types from both cattle and sheep. Ovine paECs were predominantly seen to undergo 
apoptosis whilst bovine paECs and lmECs from both species were seen to predominantly undergo 
necrosis following infection with a purified BTV strain (DeMaula et al., 2001). However, utilising a BTV-
infected EC lysate to infect paECs, led to ECs from both species predominantly undergoing apoptosis 
and as a consequence producing less progeny virus. These results therefore point towards the 
production of active molecules by ECs that could influence EC viability and susceptibility to BTV infection 
(DeMaula et al., 2001). Further studies indicated that BTV infection of ovine and bovine lmECs enhanced 
the expression of vasoactive and inflammatory mediators such as Interleukin 1 (IL-1) and IL-8, whilst 
infection of ovine lmECs led to a lesser induction of IL-6, cyclooxygenase-2 (COX-2) and inducible nitric 
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oxide synthetase (iNOS), compared to bovine lmECs (DeMaula et al., 2002a, DeMaula et al., 2002b). 
Additionally, in vivo infection studies carried out in cattle and sheep by the same group indicated that 
plasma concentrations of prostacyclin differed in both species with an increase over the 21 day 
infection period in cattle, compared to a sharp decrease in the plasma concentrations of prostacyclin 
at 7 d.p.i in sheep. Although thromboxane levels increased in both cattle and sheep throughout the 
course of infection, the thromboxane response in sheep occurred earlier throughout the course of 
disease, coinciding with the onset of clinical signs, and were more pronounced than in cattle (DeMaula 
et al., 2002a). The ratio of thromboxane to prostacyclin was found to be significantly greater in BTV 
infected sheep, compared to cattle, indicating enhanced coagulation mechanisms within the ovine host 
and an altered release of vasoactive molecules that may lead to a differing effect on vascular 
permeability with these species.  
Within the ruminant host, BTV is believed to be able to infect and replicate within a wide range of 
susceptible target cells. The tropism for microvascular ECs leads to vascular injury and the clinical 
haemorrhagic disease manifestations associated with BT. Indeed, the presence of BTV within vascular 
ECs has been determined by a range of techniques such as in situ hybridization, PCR and 
immunofluorescence microscopy (Brodie et al., 1998) whilst replicating virus has also been confirmed 
within ECs of ovine skin capillaries via the detection of NSP by confocal microscopy (Darpel et al., 2012, 
Melzi et al., 2016). Initial in vivo studies have also reported an association of BTV with leucocytes and 
BTV has been shown to be isolated from peripheral blood mononuclear cells (PBMCs) earlier than from 
whole blood thus indicating the likely role of these cells in the early stage of virus dissemination (Barratt-
Boyes and MacLachlan, 1994).  
Bovine monocytes (Barratt-Boyes et al., 1992, Whetter et al., 1989) and lymphocytes, particularly the 
CD4+ T cell population, have been shown to be susceptible to BTV infection in vitro (Barratt-Boyes et 
al., 1992). Furthermore, the presence of activating stimulus such as IL-2 or Concanavalin A (ConA) is 
further demonstrated to enhance the proportion of lymphocytes becoming infected in vitro (Barratt-
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Boyes et al., 1992) or the progeny virus production from activated lymphocyte cultures (Stott et al., 
1990) thus indicating that cellular activation may be advantageous for BTV infection. Furthermore, 
gamma delta () T cell lines derived from the bovine and ovine host have also been shown to be in 
vitro infected with BTV leading to persistent infections of up to 6 and 10 weeks, respectively (Takamatsu 
et al., 2003). Additionally, purified and cultured  T cells from in vivo infected sheep (up to 6 weeks in 
the presence of IL-2) have also been shown to produce infectious virus thus further contemplating a 
potential role for  T cells in persistent BTV infections of sheep (Takamatsu et al., 2003). Hemati et al., 
(2009) highlighted in vitro BTV infection of skin draining DCs whilst Darpel et al., (2012) described the 
infection of leucocytes that phenotypically resembled monocytes, DCs and lymphocytes. 
1.6.4  Innate immune responses to BTV infection 
The innate immune response forms the first line of defence against pathogens and is largely composed 
of mechanisms that are able to block pathogen entrance into a host (e.g epithelial barriers) while others 
are able to directly eliminate the pathogen (e.g phagocytic cells and the complement system). BTV entry 
into a mammalian host is advantaged by direct inoculation into the ruminant skin during the blood 
feeding of Culicoides midges, thus bypassing the initial epithelial skin barrier. Pattern recognition 
receptors (PRRs), on the surface or within the cytoplasm of host cells, will however likely detect viral 
pattern associated molecules patterns (PAMPs) such as dsRNA (Meylan and Tschopp, 2006), thus 
leading to immune activation to limit BTV infection and encourage the development of an effective 
acquired immune response.  
Although the local immune responses initiated in the ruminant skin following BTV inoculation have not 
been assessed in vivo, in vitro studies have indicated that BTV infection of skin draining ovine DCs led 
to the production of a range of pro-inflammatory cytokines such as IL-12, IL-1 and IL-6. BTV infection 
also stimulated the expression of cell surface membrane proteins, MHC class II and CD80 on the surface 
of ovine DCs, leading to the activation and proliferation of autologous skin draining CD4+ and CD8+ T 
cells and the production of IFN- and IL-10 from mixed DC and T cell cultures (Hemati et al., 2009). 
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Blood derived ovine plasmacytoid DCs (pDCs) have also been shown to upregulate the expression of IL-
6, tumour necrosis factor α (TNF-α) and IL-12 genes in response to culture in the presence of ultraviolet 
(UV) light inactivated BTV (Ruscanu et al., 2012). Furthermore, CD80 and CD86 cell surface membrane 
protein expression was also upregulated in response to UV inactivated BTV thus indicating that viral 
presence, and not replication, are required for pDC activation. Additionally, BTV infection of monocyte 
derived DCs also resulted in the increased expression of mRNA from genes encoding for IL-1, IL-8 , 
TNF-α and iNOS (Drew et al., 2010). Investigations into the cytokine response of PBMCs from naïve and 
vaccinated sheep infected with BTV in vitro have highlighted that the mRNA expression of IFN, IL-12 
and IL-2 cytokines was upregulated by this heterogeneous mixture of cells within 12 h.p.i and 
expression was increased to a greater extent in PBMCs from vaccinated sheep, albeit the cellular 
population(s) within PBMCs responsible for this upregulation in gene expression was not elucidated 
(Umeshappa et al., 2011).  
BTV is known to be a strong inducer of type I IFN as has been demonstrated in vivo in cattle (MacLachlan 
and Thompson, 1985) and sheep (Foster et al., 1991). Furthermore, studies to elucidate the role of IFN 
in BTV infection of the murine model have been carried out. Adult mice have been shown on numerous 
occasions to be resistant to productive BTV infection, whilst in comparison IFN-α/ receptor knockout 
(IFNAR [-/-])mice succumbed to a highly lethal BTV infection (Calvo-Pinilla et al., 2010, Calvo-Pinilla et 
al., 2009, Franceschi et al., 2011, Jameson et al., 1978, Rodriguez-Calvo et al., 2014). Moreover, studies 
have highlighted that this response of IFNAR [-/-] mice to BTV infection can also be observed ex vivo. 
Bone marrow derived DCs (BM-DCs) were generated from WT and IFNAR [-/-] mice and it was reported 
that cells generated from WT mice did not support BTV replication, whilst BTV was able to replicate in 
BM-DC cultures from IFNAR [-/-] mice, thus indicating a role for IFN in controlling BTV infections in 
murine immune cells (Rodriguez-Calvo et al., 2014). Recent studies have also highlighted potential 
divergence in IFN signalling in different host cells. BTV infection of ovine pDCs has been shown to induce 
an IFN response via a MyD88 dependant Toll like receptor (TLR) 7/8-independent sensing and signalling 
pathway (Ruscanu et al., 2012), whilst infection of a human embryonic kidney endothelial cell line (293T 
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cells) with BTV triggers an IFN response via cytoplasmic helicase (RIG-I and MDA-5) sensing of the virus 
(Chauveau et al., 2012).  
BTV has also been shown to encode two proteins specifically in order to interfere with the host 
induction of IFN; both NS3 (Chauveau et al., 2013) and NS4 (Ratinier et al., 2016) reportedly block the 
RIG-I like receptor pathway in 293T cells and downregulate IFN- and IFN stimulated gene expression 
in human lung epithelial cells (A549) (Ratinier et al., 2016).  
1.6.5 Adaptive immune responses to BTV infection 
The adaptive immune response consists of humoral and cell mediated response mechanisms, both of 
which are thought to potentially play a role in conferring host immunity to BTV. BTV infection of 
ruminants leads to the generation of BTV specific antibodies to both VSP and NSP (Huismans and 
Erasmus, 1981, MacLachlan et al., 1987). In particular, antibodies are directed towards the highly 
immune-dominant protein, VP7. These antibodies are broadly reactive across BTV serotypes due to the 
conserved nature of VP7 and therefore the detection of these antibodies, in samples from BTV infected 
animals, forms the basis of the group specific enzyme linked immunosorbent assays (ELISA) (Afshar et 
al., 1992). BTV serotype specific neutralising antibodies are also generated following BTV infection and 
can provide long lasting resistance to repeat infection with strains from homologous BTV serotypes 
(Huismans et al., 1987, Jeggo et al., 1984b). Neutralising antibodies are generated against specific 
epitopes on the highly variable outer coat protein, VP2, and it has been shown that the inoculation of 
in vitro expressed VP2 or VP2 derived from virus particles leads to the generation of a neutralising 
antibody response in sheep and the resistance to subsequent infection with a strain from a homologous 
BTV serotype (Roy et al., 1994, Roy et al., 1992, Roy et al., 1990b, Stewart et al., 2012). In addition to 
VP2, neutralising antibody responses to selected BTV strains have also been shown to involve VP5. 
DeMaula et al., (2000) reported the generation of neutralising antibody resistant viral mutants that had 
differing amino acid substitutions in key regions of VP2. Additionally, a virus mutant with no change in 
VP2 but an amino acid substitution in VP5 was also observed to be resistant to neutralisation, thus 
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indicating a role for the interaction between VP2 and VP5 in the neutralising antibody response to this 
BTV strain (DeMaula et al., 2000).  
Although neutralising antibody responses to BTV are largely thought to be serotype specific, there is 
some evidence for neutralising epitopes that may be conserved across serotypes as indicated by the 
cross reactivity of neutralising antibodies from infected animals to BTV strains from a different serotype 
(MacLachlan et al., 1992b). Furthermore, serial infection of sheep with two or more BTV serotypes has 
been shown to generate a neutralising antibody response to BTV of heterologous serotypes (Jeggo et 
al., 1983). These findings highlight the likely role for neutralising antibodies in BTV immunity, at least to 
homologous infection, although neutralising antibody titres do not correlate to protection and in some 
cases detectable levels of homologous or heterologous neutralising antibodies may not even be 
generated in response to BTV infection (Dal Pozzo et al., 2013, Jeggo et al., 1983). 
Overall there have been only a limited number of studies attempting to determine the role of cell 
mediated immunity (CMI) in either clearance of BTV infection or subsequent immune protection. Early 
studies utilised the adoptive transfer of thoracic duct lymphocytes from a previously BTV infected 
monozygotic sheep to its naïve twin. The recipient twin was subsequently partially protected to 
challenge with a heterologous strain highlighting a potential role of T lymphocytes in the protection of 
sheep against heterologous BTV infection (Jeggo et al., 1984a). The cellular population eliciting the 
protection of sheep to BTV challenge was undetermined at the time, however, it was subsequently 
proposed that cross reactive anti-BTV CD8+ cytotoxic T lymphocytes (CTLs) were most likely to confer 
protection to subsequent challenge (Jeggo et al., 1985). Furthermore, BTV-specific CTLs, generated in 
the murine model following BTV infection with different BTV strains were found to be cross reactive 
against heterologous strains determined by the recognition of in vitro infected fibroblasts by murine 
splenocytes derived from BTV infected mice (Jeggo and Wardley, 1982). Subsequent studies in sheep, 
using vaccine vectors expressing single BTV proteins, identified subsequent CTL recognition especially 
to VP2, VP7 and NS1 whilst VP5 and NS3 elicited minor responses, although the CTL response in 
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individual sheep was seen to vary considerably (Andrew et al., 1995, Bouet-Cararo et al., 2014, 
Janardhana et al., 1999). NS1 has also been identified to contain epitopes that are recognised by ovine 
CTLs (Janardhana et al., 1999) and CD4+ T cells (Rojas et al., 2014) from BTV infected sheep, both of 
which may react across BTV serotype. Due to these observations of cross reactive T cell responses to 
BTV infection, it is largely thought that the development of a vaccine that is able to induce cross-reactive 
T cells may hold some promise in developing a cross-serotype vaccine. Nevertheless, the role of BTV 
specific T cells and neutralising antibodies in the immunity to BTV needs further elucidation. 
1.6.6 Vaccination  
The control of the spread of BTV has previously utilised conventional methods such as the 
implementation of movement restrictions and the culling of infected ruminants. These methods are 
logistically challenging, economically devastating and alone pose significant challenges due to the 
asymptomatic infections observed in some ruminants and the prolonged viremia in cattle 
(Papadopoulos, 2009). Furthermore, the presence of BTV within the insect vector is incredibly hard to 
control and any measures directed at Culicoides population control, or biting prevention, will only 
mitigate but not prevent viral spread, hence vaccination is therefore the current preferred method of 
BT control (Carpenter et al., 2008, Harrup et al., 2016, Maclachlan and Mayo, 2013, Papadopoulos, 
2009). There are currently two types of commercially available vaccines; modified live vaccines and 
inactivated vaccines, both of which have their limitations. 
Commercially available modified live vaccines are generated by the serial passage of field isolates of 
BTV through embryonated chicken eggs and subsequently in tissue culture leading to virus attenuation 
(Dungu et al., 2004a, Mayo et al., 2017). These vaccines are cheap to produce and have been shown to 
limit clinical signs and reduce the circulation of BTV in endemic settings (Dungu et al., 2004b). 
Limitations to live attenuated vaccines include trans-placental transmission in sheep, cattle and goats 
resulting in abortion and congenital malformations (Savini et al., 2014). Furthermore, the chance of 
onward transmission of the modified live vaccines is significant as these vaccines can induce a viraemia 
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of >103 TCID50/ml which could result in transmission to the midge vector (Veronesi et al., 2005). 
Furthermore, these modified viruses pose a risk for re-assortment with field isolates and the reversion 
to virulence (Batten et al., 2008, Ferrari et al., 2005, Savini et al., 2014, Veronesi et al., 2005).  
Inactivated vaccines provide a safe and effective alternative to modified live vaccine and hence they 
are the preferred vaccine type for use in Europe. Indeed, the use of inactivated vaccines towards BTV-
8 was heavily implicated in the control and eradication of this BTV serotype from certain European 
countries since 2006 (Eschbaumer et al., 2009, Moulin et al., 2012, Oura et al., 2009). These vaccine 
strains are however more expensive compared to live attenuated vaccines and only fully protect against 
BTV challenge with viruses of the same serotype due to the low levels of cross-protective immunity that 
are induced (Alpar, 2009). 
Driven by the emergence of BT and the need for vaccines with an ability for differentiating between 
infected and vaccinated animals (DIVA), which both of the above vaccine types do not encompass, there 
has been great interest in BT vaccine development in recent years resulting in a variety of approaches 
such as the development of novel subunit vaccines or Disabled Infectious Single Animal (DISA) vaccines. 
Experimental vaccine trials in cattle have highlighted that subunit vaccines based upon VP2 from BTV-
8 and NS1 and NS2 from BTV-2 can induce neutralising antibody responses against these viral proteins 
and T cell responses to NS1 (Anderson et al., 2013) and provide protection to subsequent BTV-8 
challenge (Anderson et al., 2014). DISA vaccines are generated as NS3/NS3A knockout strains and, 
although still infectious in the ruminant host, the absence of NS3 seemingly reduces viral replication in 
the ruminant host and completely abolishes replication in Culicoides whilst also enabling DIVA capability 
based upon the lack of NS3 detection (Feenstra et al., 2015, Feenstra et al., 2014).  
1.7 Arthropod saliva and its effect on host haemostasis, the immune response and arbovirus infection 
More than 14,000 species and 400 genera of hematophagous arthropods have evolved to require the 
act of blood feeding on a vertebrate host as a source of nutrition and to facilitate egg production 
(Andrade et al., 2005, Ribeiro, 1995). In order to take a successful blood meal, the arthropod must 
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overcome the physical skin barrier and the vertebrate haemostatic, inflammatory and immune 
responses. The saliva of hematophagous arthropods has therefore evolved to comprise a complex mix 
of pharmacologically active components with a diverse range of functions in order to counteract these 
physiological responses. 
1.7.1 The role of arthropod saliva in the acquisition of a blood meal  
Arthropods may adopt one of two feeding strategies in order to acquire a blood meal; laceration of 
dermal capillaries resulting in the formation of a ‘pool’ of blood on which the arthropod can feed, or by 
direct insertion of the mouthpiece into capillaries within the skin of the mammalian host (Lavoipierre, 
1965). Culicoides midges, certain species of ticks and sand flies are all pool feeders, whilst mosquitoes 
and Triatomine bugs are classed as direct vessel feeders. In addition to these differing routes of blood 
meal acquisition, arthropods may feed for varying lengths of time, for example minutes for mosquitoes, 
hours for soft ticks and up to two weeks for hard ticks. In all cases, the arthropod must evade host 
haemostasis; a complex physiological cascade resulting in the cessation of blood flow at the site of an 
injury.  
Firstly, following the breach of the skin barrier and the resulting exposure of the sub-endothelial tissue, 
circulating platelets adhere to collagen and undergo activation. Once activated, the platelets aggregate 
leading to the formation of a platelet plug and the release of vasoconstriction mediators in order to 
reduce blood loss at the site of injury. Initiation of the blood-clotting cascade next follows which 
involves many essential enzymes and proteolytic proteins, all of which exist as zymogens that circulate 
in an inactive form. The activation of these proteins results in a reaction cascade, ending with the 
production of active thrombin, which subsequently cleaves the soluble fibrinogen into the insoluble 
fibrin. Fibrin then stabilises the platelet plug, leading to a blood clot and complete termination of blood 
loss (Furie and Furie, 1992, Troy, 1988, Wu and Thiagarajan, 1996).  
Arthropods must overcome these complex haemostatic functions to successfully acquire a blood meal 
and thus their saliva, as a rule, contains at least one antiplatelet, one vasodilatory and one anti-clotting 
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agent (Ribeiro and Francischetti, 2003). The generation of a complementary deoxyribonucleic acid 
(cDNA) library from Culicoides nubeculosus salivary gland extract (SGE) has revealed transcripts for a 
range of proteins that are involved in the blockage of the host homeostatic responses such as 
coagulation cascade (factor Xa) inhibitors and tissue factor pathway inhibitors (Russell et al., 2009). 
Additionally, Campbell et al., (2005) highlighted expressed sequence tags (short cDNA fragments) for 
numerous platelet aggregation and coagulation inhibitors when carrying out C. sonorensis SGE 
ribonucleic acid (RNA) extraction and reverse transcription (Campbell et al., 2005). Analysis of the 
enzymatic activity of SGE from C. sonorensis has also highlighted apyrase activity that is responsible for 
the inhibition of ADP-induced platelet aggregation (Perez de Leon and Tabachnick, 1996) and factor Xa 
inhibitors (Perez de Leon et al., 1998). Furthermore, recent proteomic analysis of the secreted saliva 
from C. sonorensis has also confirmed the presence of tissue factor pathway inhibitors and apyrase 
proteins (Lehiy and Drolet, 2014). Additionally, kunitz-like protease inhibitors have also been 
highlighted as a major group of proteins within the secreted saliva of C. sonorensis and these proteins 
can function to inhibit the proteases involved in the blood coagulation cascade (Lehiy and Drolet, 2014). 
Collectively, these salivary proteins act to evade the host haemostatic response thus enabling the 
formation of a blood pool in the skin surface from which Culicoides can take a blood meal.  
1.7.2 Arthropod saliva induced modulation of the host immune response 
Alongside evading the host haemostatic responses, arthropod saliva has also evolved to evade and 
modulate the host immune response. Arthropod saliva has been identified to have an effect on innate 
immune responses such as the complement system (Ferreira et al., 2016) and the expression of cell 
membrane co-stimulatory protein expression (Brake and Pérez de León, 2012). Furthermore, arthropod 
saliva has also been implicated to modulate certain immune responses such as cellular proliferation 
(Wanasen et al., 2004). However by far the majority of studies have evaluated the effect of arthropod 
saliva on the host cytokine response, thus this will take the predominant focus in the following Sections 
(summarised in Table 1.2).  
~ 46 ~ 
 
 
Table 1.2 – The effects of arthropod saliva, SGE or direct arthropod feeding on pathogen infections in the mammalian host 
 
Pathogen In vitro/ 
in vivo 
Host/ 
cell type 
Salivary origin Effect on virus infection/disease 
compared to pathogen infection alone 
Saliva modification of the pathogen 
induced immune response 
Reference(s) 
Sand fly- borne pathogens  
Leshmania 
Spp. 
In vivo Mice  SGE Exacerbation in cutaneous leishmaniasis ND (Titus and Ribeiro, 
1988) 
In vivo Mice  SGE Exacerbation in cutaneous leishmaniasis ↑ IL-4 protein expression  (Lima and Titus, 
1996) 
In vivo Mice  SGE Exacerbation in cutaneous leishmaniasis ↓IFN-, ↑ IL-4 protein expression (Belkaid et al., 
1998) 
In vivo Mice  SGE Exacerbation in cutaneous leishmaniasis ↑IL-10 gene expression (Norsworthy et 
al., 2004) 
In vivo Mice  SGE Enhanced parasitemia ND (Thiakaki et al., 
2005) 
In vivo Mice  SGE Enhanced parasitemia ND (Morris et al., 
2001) 
Triatomine - borne pathogens 
Trypanosom
a Cruzi 
In vivo Mice  SGE Enhanced parasitemia ↓NO (Mesquita et al., 
2008) 
Tick - borne pathogens  
Powassan 
virus 
In vivo Mice SGE Enhanced clinical scores and disease ↑IFN-, IL-1, IL-2, IL-4, IL-10, IL-12, 
TNF-α gene expression  
(Hermance and 
Thangamani, 
2015) 
African 
swine fever 
virus 
In vivo Pig SGE Elevated pyrexia No difference in IFN-α, IL-12 or IL-6 
protein expression 
(Bernard et al., 
2016) 
Mosquito -borne pathogens  
Cache Valley 
fever virus 
 
In vivo Mice Infected 
mosquito bite 
Viremia and seroconversion following 
mosquito inoculation, infection was 
absent in needle inoculated mice  
ND (Edwards et al., 
1998) 
Vesicular 
stomatitis 
virus 
In vivo Mice  Infected 
mosquito bite 
Enhancement Enhanced seroconversion  (Limesand et al., 
2000) 
In vitro Fibroblast 
(L929) cells 
SGE Enhanced viral replication ↓IFN-α gene expression (Limesand et al., 
2003) 
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West Nile 
virus 
In vivo Chickens Infected 
mosquito bite 
Elevated viremia ND (Styer et al., 2011) 
In vitro Mouse 
fibroblast 
(L929) cells 
SGE Enhancement ↓IFN-α gene expression (Limesand et al., 
2003) 
In vivo Mice  SGE Enhanced disease and mortality  ND (Schneider et al., 
2006) 
In vivo Mice  Infected 
mosquito bite 
Enhanced viral RNA in skin and draining 
lymph node  
↑IL-10 gene expression (Schneider et al., 
2010) 
Saint Louis 
encephalitis 
virus 
In vivo Chicken, 
finch 
Infected 
mosquito bite 
No difference in viremia or 
seroconversion 
ND (Reisen et al., 
2000) 
Dengue virus In vivo Mice  SGE Elevated viremia ND (Schmid et al., 
2016) 
In vitro Monocyte 
derived DCs 
Secreted 
mosquito saliva 
Reduction in infection levels ↑IL-12, TNF-α protein expression  (Ader et al., 2004) 
In vivo Mice  Infected 
mosquito bite 
Elevated viremia, erythema, reduced 
temperatures  
↓ IFN-, TNF-α protein expression  (Cox et al., 2012) 
In vitro Keratinocyte
s 
SGE Enhanced viral replication  ↓ IFN-α, IFN-, IFN- gene 
expression  
(Surasombatpatta
na et al., 2012) 
In vivo Mice  Uninfected 
mosquito bite 
alongside 
needle 
inoculation of 
virus 
Elevated viremia ↓ IFN- and IL-10 gene expression (McCracken et al., 
2014) 
In vitro Mouse 
embryonic 
fibroblasts 
SGE Enhanced viral replication ND (Conway et al., 
2014) 
Semliki 
forest virus 
In vivo Mice  Uninfected 
mosquito bite 
alongside 
needle 
inoculation of 
virus  
Enhanced viral RNA in skin and draining 
lymph node, reduced survival rate  
↑IL-10 protein expression in skin and 
serum, ↑ IFN- gene expression in 
skin  
(Pingen et al., 
2016) 
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Bunyamwer
a virus 
In vivo Mice  Uninfected 
mosquito bite 
alongside 
needle 
inoculation of 
virus  
Enhanced viral RNA in skin and spleen  ND (Pingen et al., 
2016) 
Chikungunya 
virus 
In vivo Mice  Uninfected 
mosquito bite 
alongside 
needle 
inoculation of 
virus 
Reduced survival rate, higher viral 
genome load in liver, spleen and muscle,  
↑IL-10 and IL-4 gene expression, 
↓IL-2, IFN-, IFN-  and TNF-α gene 
expression in skin  
(Agarwal et al., 
2016) 
Rift Valley 
fever virus 
In vivo  Mice Uninfected 
mosquito bite 
alongside 
needle 
inoculation of 
virus 
Reduced survival rates, enhanced 
viremia and viral load in brain and liver  
ND (Le Coupanec et 
al., 2013) 
Sindbis virus In vivo Mice SGE ND ↑IL-10 and IL-4 gene expression, ↓ 
IFN- and IL-12 gene expression 
(Schneider et al., 
2004) 
Culicoides -borne pathogens 
Bluetongue 
virus 
In vivo Sheep C. sonorensis 
secreted salivary 
proteins 
Enhanced and prolonged clinical signs  ND (Drolet et al., 
2015) 
In vivo Sheep  Infected C. 
nubeculosus 
midge bite 
Enhanced viremia, clinical scores ↑ CXCL-10 and MX1 gene expression  (Pages et al., 
2014) 
In vivo Sheep  Uninfected C. 
nubeculosus bite 
alongside 
needle 
inoculation of 
virus 
Reduced clinical scores NO effect on CXCL-10 and MX1 gene 
expression 
(Pages et al., 
2014) 
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The concept of saliva induced immune modulation has largely been studied for tick arthropods due to 
prolonged feeding time that requires an undisturbed attachment to the mammalian host (Stibraniova 
et al., 2013). A study of particular importance, due to the usage of bovine immune cells, assessed the 
effect of Rhipicephalus microplus (a tick of livestock species, in particular cattle) SGE on the expression 
levels of specific cytokines and cell surface membrane proteins. PBMCs were isolated, cultured and 
adherent cells were deemed to be macrophages based on their morphological characteristics. The 
expression of cell surface membrane proteins definitively indicative of bovine macrophages was not 
determined, however cells did express mRNA of typical antigen presenting cell surface membrane 
proteins, such as CD40, CD80 and CD86 upon bacterial lipopolysaccharide (LPS) stimulation. LPS 
induced CD80 and CD86 mRNA expression was seen to be reduced following cellular treatment with R. 
microplus SGE. LPS induced cytokine production was also assessed in the absence or presence of R. 
microplus SGE; TNF-α, IFN- and IL-12 mRNA expression was significantly reduced following SGE 
treatment whilst in comparison IL-4 mRNA expression was only slightly reduced. Collectively, this study 
highlights the ability of activated bovine immune cells to respond to arthropod SGE.  
The concept of saliva induced immunomodulation is also largely believed for other arthropods such as 
mosquitoes and has been validated by studies utilising the saliva from multiple different mosquito 
vectors. Early in vitro work by Bisonette et al., (1993) highlighted the ability of Aedes aegypti SGE to 
modulate the production of the pro-inflammatory cytokine TNF-α from activated mast cells 
(Bissonnette et al., 1993) whilst subsequent studies by Cross et al., (1994) also highlighted an 
immunosuppressive effect of Ae. aegypti SGE on IL-2 and IFN- production from murine splenocytes 
(Cross et al., 1994). Furthermore, later studies also identified a role for Ae. aegypti SGE in 
downregulating IFN- cytokine production from in vitro stimulated murine splenocytes (Wanasen et al., 
2004) or a role for direct mosquito feeding on the ex vivo production of IFN- from activated splenocytes 
(Zeidner et al., 1999) .This later study also identified an upregulation of IL-10 and IL-4 production by 
stimulated murine splenocytes obtained from mice that had been exposed to mosquito feeding 
(Zeidner et al., 1999).  
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The immune response to Culicoides saliva has been minimally considered, aside for in the context of a 
delayed type hypersensitivity reaction know as insect bite hypersensitivity (IBH) (outlined further in 
Section 1.8.3). One study by Bishop et al., (2006), highlighted that C. sonorensis SGE inhibited the LPS 
and Con A induced proliferation of murine B and T lymphocytes, respectively, and also reduced the LPS 
stimulated production of nitric oxide (NO) from murine macrophages (Bishop et al., 2006) thus 
indicating that Culicoides saliva contains components with immunomodulatory properties. 
Furthermore, Culicoides midge feeding has been shown to induce an influx and accumulation of cells 
within ovine skin at the biting site. In particular  T cells have been shown to influx to the skin in 
response to midge feeding (Darpel, 2007, Takamatsu et al., 2003), thus indicating potential chemotactic 
properties of Culicoides saliva. In context of BTV infection, this also indicates the Culicoides saliva may 
actively recruit cells to the skin surface that can become infected with BTV.  
Collectively these studies, among others (Table 1.2), have led to the generalised perception that salivary 
material, whether utilised in vitro as SGE, or administered via blood feeding of an arthropod, leads to 
immune modulation that is characteristic of the suppression of cytokines that would otherwise drive 
the immune response towards a pro-inflammatory, T helper 1 (Th1) response and an increase in the 
cytokines to send the immune response towards a T helper 2 (Th2) response (Schneider and Higgs, 
2008). Although poorly characterised in the bovine host, a Th1 response would characteristically be 
driven by and lead to the production of inflammatory cytokines such as IFN-, TNF-α and IL-12 thereby 
creating a pro-inflammatory environment responsible for the killing of intracellular pathogens, such as 
viruses, and triggering the induction of cell-mediated immunity. In comparison a Th2 response, which 
would induce strong allergic immunity and act to counteract the actions of Th1 responses, is induced 
by and leads to the production of cytokines such as IL-4, IL-5 and IL-13 (Romagnani, 2000). An additional 
cytokine that has been heavily studied in the context of arboviral modulation of the host immune 
response is IL-10, which has strong anti-inflammatory and regulatory properties (Saraiva and O'Garra, 
2010) and has been shown to be upregulated in response to arthropod saliva on numerous occasions 
(Table 1.2). Although this need to evade the host responses are evidently necessary for arthropods that 
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feed over a longer duration of time, such as hard ticks, it is less clear however why arthropods with a 
short feeding time may need to initiate an immunomodulatory response. As rapidly feeding arthropods 
such as sand flies and Culicoides usually feed in vast numbers it may be proposed that the exposure of 
the mammalian host, to arthropod saliva, may have a long term beneficial effect for the arthropod 
population by supressing host immune responses to subsequent arthropod feeding (Schneider and 
Higgs, 2008). 
1.7.3 Arthropod saliva associated modification of arbovirus infection  
The effect of arthropod saliva on the modulation of the host immune response is of particular 
importance if the arthropod serves as a biological vector for a pathogen. Thus, the effect of saliva on 
pathogen transmission and the establishment of infection within the mammalian host has become of 
great interest and studies have elucidated a role for arthropod saliva in the modulation of numerous 
pathogen infections (selected studies outlined in Table 1.2).  
The first reports of saliva enhanced pathogen infection came from Titus and Ribeiro (1988), where SGE 
from Lutzomyia longipalpis sand flies augmented Leishmania major infection of mice leading to an 
exacerbation in cutaneous leishmaniasis (Titus and Ribeiro, 1988). These initial observations were 
subsequently confirmed by others highlighting an enhancing effect of sand fly SGE on in vivo Leishmania 
spp. infection of mice, as indicated by an early onset of disease and larger lesion size with a higher 
protozal load, when compared to infection of mice in the absence of salivary material (Belkaid et al., 
1998, Lima and Titus, 1996, Norsworthy et al., 2004). Furthermore, Morris et al., (2001) was able to 
decipher a single protein within the SGE that was able to enhance leishmaniasis. A synthetic protein 
equivalent to that of maxadilan, a L. longipalpis salivary protein with vasodilatory and immune 
inhibitory/modulatory function, was shown to exacerbate L. major infection to the same extent as total 
salivary proteins (Morris et al., 2001). Further studies on protozoal parasites have highlighted that 
Triatominae bug SGE can also increase the in vivo infectivity of Trypanosoma Cruzi in mice, inducing up 
~ 52 ~ 
 
to six fold higher blood parasitemia levels when compared to infection in the absence of SGE (Mesquita 
et al., 2008).  
Arthropod saliva is also largely accepted to have a role in the transmission and infection of many tick-
borne pathogens. Initially, a role of Rhipicephalus appendiculatus tick saliva in enhancing the infection 
of Thogoto virus (THOV) was proposed. Experiments that mimicked the natural transmission route of 
THOV from an infected tick vector to an uninfected guinea pig, highlighted that the co-feeding of 
infected and uninfected ticks can result in the transmission of THOV between arthropods despite the 
ticks feeding on an apparently non-viraemic guinea pig host (Jones et al., 1987). This mode of 
transmission was subsequently named non-viraemic transmission (NVT) and has been shown for other 
arbovirus infections such as tick-borne encephalitis virus (TBEV) infection of guinea pigs and mice 
(Khasnatinov et al., 2016, Labuda et al., 1993a, Labuda et al., 1993b), Crimean-Congo haemorrhagic 
fever virus (CCHFV) infection of guinea pigs (Gordon et al., 1993) and West Nile virus (WNV) infection 
of mice (Lawrie et al., 2004). NVT was also originally classified as a type of ‘saliva assisted/activated 
transmission’ (SAT) which can be defined as “the promotion of arthropod-borne pathogen transmission 
via the actions of arthropod saliva molecules on the vertebrate host”. However, as NVT does not directly 
account for the role of salivary components specifically, this type of transmission was subsequently 
classified as indirect evidence of SAT (Nutall and Labuda, 2008). Direct evidence of SAT has been 
demonstrated via the needle inoculation of THOV into the skin of naïve guinea pigs either alone or 
alongside the SGE of partially fed R. appendiculatus ticks or Amblyomma variegatum female nymphs. 
Subsequent feeding of R. appendiculatus nymphs led to an increased acquisition of THOV from guinea 
pigs inoculated with the THOV and SGE mixture compared to THOV inoculation alone (Jones and Nuttall, 
1989). Collectively, it was proposed that this enhanced transmission was as a result of arthropod saliva 
induced immunomodulation of the host instead of a direct interaction between SGE and THO, although 
the latter cannot be discarded.  
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The saliva of ticks have also been shown to enhance the severity of arbovirus infections such as 
Powassan virus (POWV) infection of mice under certain conditions. Mice infected with a low dose of 
POWV in the presence of Ixodes scapulari tick SGE developed higher clinical scores and signs of disease 
compared to mice infected with the same dose in the absence of salivary proteins (Hermance and 
Thangamani, 2015). Furthermore, recent reports have highlighted a role for the SGE of Ornithodorous 
porcinus ticks in the potential enhancement of African swine fever virus (ASFV) infection of pigs, as co-
inoculation of SGE and ASFV led to a significant increase in the body temperature of pigs, compared to 
pigs ASFV infected in the absence of saliva (Bernard et al., 2016) (Table 1.2).  
Mosquito saliva has also been heavily implicated in the enhancement of arbovirus infections. Many 
studies have shown that when arboviruses such as vesicular stomatitis virus (VSV) (Limesand et al., 
2000), Cache Valley fever virus (CVFV) (Edwards et al., 1998) and West Nile Virus (WNV) (Moser et al., 
2015, Styer et al., 2006) (Table 1.2) are transmitted to a host via mosquito bites or in association with 
mosquito saliva, infection is enhnaced when compared to needle inoculation of the same virus (Table 
1.2). Furthermore, the impact of Ae. aegypti SGE on dengue virus (DENV) pathogenesis and infection 
within murine skin has recently been investigated. Schmid et al., (2016), found that intradermal (ID) 
inoculation of IFN-α/β knockout mice with DENV in the presence of Ae. aegypti SGE significantly 
enhanced DENV titres in the skin at 14 h.p.i. Additionally, this study highlighted that under antibody-
dependant enhancement (ADE) conditions, SGE significantly enhanced morbidity and lethal disease in 
mice when compared to DENV in the absence of SGE. Furthermore, DENV infection of dermal cDCs and 
macrophages was assessed by NSP expression and found to be enhanced in the presence of ADE and 
SGE (Schmid et al., 2016). These findings somewhat conflict earlier reports by Ader et al., (2004), that 
demonstrate the ability of Ae. aegypti saliva to reduce DENV infection of in vitro generated DCs when 
both virus and saliva was simultaneously applied to cultures (Ader et al., 2004)(Table 1.2), albeit these 
studies did have experimental and target cell differences. Pre-treatment of the DCs with saliva was 
additionally seen to augment the observed reduction in DENV infection further highlighting the ability 
of Ae. aegypti saliva to suppress in vitro DENV infection of DCs (Ader et al., 2004). 
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Although the effect of Culicoides saliva on BTV infection in the ruminant host has been uncharacterised, 
two studies have identified a role for Culicoides saliva in the enhancement of BTV infection in the ovine 
host. Drolet et al., (2015), utilised ID inoculation of sheep with BTV alongside the secreted saliva from 
C. sonorensis. All infected sheep were reported to display clinical signs of BTV, however the severity of 
disease in sheep infected with BTV alongside C. sonorensis salivary proteins was enhanced and 
prolonged (Drolet et al., 2015). Another study by Pages et al., (2014), further highlighted a possible role 
for Culicoides saliva in enhancing BTV infection as indicated by an enhancement in viremia and clinical 
scores of sheep inoculated via infected C. nubeculosus compared to ID inoculation of the virus alone 
(Table 1.2). Interestingly, the feeding of uninfected midges alongside BTV ID inoculation of sheep did 
not, however, lead to an enhancement in BT disease but rather led to no significant difference in viremia 
and a significant reduction in body temperature and clinical score compared to ID inoculated or 
Culicoides inoculated sheep. Culicoides midge feeding was seen to induce a local inflammatory response 
which was found to inversely correlate to viremia as the sheep that developed the greatest 
inflammatory skin reaction, appeared to have a reduced viremia and vice versa. Furthermore, sheep 
infected with BTV intradermally alongside uninfected midge feeding developed the highest local 
immune reaction, compared to sheep bitten by infected Culicoides. A minimal local immune response 
was observed to ID inoculation alone, thus indicating that saliva from uninfected or infected Culicoides 
may differentially induce a local immune response at the bite site that can influence subsequent BT 
disease progression. Pages et al., (2014) also highlighted that the infection of sheep via Culicoides 
midges led to a reduction in the expression of IFN induced CXCL10 and MX1 genes (inducible by IFN 
type II and type I/III, respectively), within ovine blood cells, when compared to ID infected sheep either 
alone or alongside uninfected midge bites. Collectively, this therefore indicates the possibility that 
infected Culicoides midges can modulate the host inflammatory and immune response leading to an 
enhancement of viremia and clinical scores in BTV infected sheep. When interpreting these results 
variation in the BTV dosage administered to sheep by varying methods, such as needle inoculation and 
infected Culicoides should be considered. At present the virus amounts inoculated into the skin of a 
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ruminant host during the blood feeding of Culicoides is unknown and will inevitably be dependent on 
factors such as the volume of saliva deposited by and the viral load within the biting midge. 
Nevertheless, these results indicate a role for Culicoides saliva in the infection of the ruminant host, 
thus leading to the consideration of natural infection routes for experimental studies, and a possible 
differential role for the saliva originating from infected and uninfected midges. 
1.7.4 The arthropod microbiome and the effect on vector-borne pathogen transmission  
The microbiome of the arthropod has been shown to be a diverse community of microorganisms 
ranging from bacteria (Boissiere et al., 2012, Buck et al., 2016, Campbell et al., 2004, Coon et al., 2016, 
Duguma et al., 2015, Muturi et al., 2016, Osei-Poku et al., 2012, Segata et al., 2016, Tchioffo et al., 2015) 
to fungi (Akhoundi et al., 2012, Martin et al., 2016, Muturi et al., 2016, Ricci et al., 2011). By far, the 
majority of studies to date have however focused on endosymbiotic and commensal bacterial 
colonisation and have highlighted a fundamental role for the arthropod microbiome in vector nutrition, 
reproduction, immunity, behaviour and survival. Furthermore, these studies have also shown that the 
microbiome itself may be influenced by arthropod host factors such as origin (wild caught or laboratory 
reared), life stage and sex (Boissiere et al., 2012, Buck et al., 2016, Campbell et al., 2004, Casadevall et 
al., 2011, Coon et al., 2016, Duguma et al., 2015, Muturi et al., 2016, Osei-Poku et al., 2012, Segata et 
al., 2016, Tchioffo et al., 2015).  
The majority of studies that have considered the arthropod microbiome, in the context of arbovirus 
infections, have focused on the mosquito vector and the endosymbiotic bacteria Wolbachia; a gram 
negative bacteria that infects ~60% of insects (Hilgenboecker et al., 2008). Wolbachia has gained great 
interest due to evidence that has highlighted its ability to reduce the VC of Ae. aegypti for certain 
arbovirus infections such DENV (Joubert et al., 2016), CHIKV (Aliota et al., 2016b), Yellow fever virus 
(YFV) (van den Hurk et al., 2012) and Zika virus (ZIKV) (Aliota et al., 2016a). The basis for Wolbachia 
mediated reductions in arthropod VC are based upon an ability of the bacteria to manipulate the 
reproduction of its host via a mechanism known as cytoplasmic incompatibility (CI) whereby the mating 
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of Wolbachia infected males and uninfected females results in highly reduced hatch rates or even 
embryo lethality (reviewed in (Werren et al., 2008)). CI can therefore be utilised as population 
suppression technique. In addition, Wolbachia has been shown to have direct antiviral properties that, 
although not fully elucidated, are thought to be based upon the upregulation of the mosquito immune 
response or the competition for host derived sources such as cholesterol (Caragata et al., 2013).  
Although there have been few studies on the microbiome of Culicoides arthropods, it has been 
highlighted that certain species of midge are able to support the infection of bacterial species. For 
example, bacteria from soil and ruminant sources such as Pseudomonas and Klebsiella, respectively, 
have been identified within the C. sonorensis midgut by 16s rDNA sequencing and terminal restriction 
fragment length polymorphism (Campbell et al., 2004). Additional studies have also focused on the 
microbiome of the whole insect (Lewis et al., 2014, Mee et al., 2015, Nakamura et al., 2009) thus 
selected microbiomes of specific organs of Culicoides midges have not been considered.  
1.8 Culicoides sonorensis saliva 
1.8.1 C. sonorensis salivary proteins 
The saliva of Culicoides midges, like the saliva of all other arthropods, has been shown to be a 
pharmacologically active mixture of molecules. Salivary proteins have predominantly been identified 
either via direct mass spectroscopy (Langner et al., 2007, Lehiy and Drolet, 2014), transcriptomic 
analysis (Campbell et al., 2005, Russell et al., 2009) or functional analysis (Darpel et al., 2011, Perez de 
Leon and Tabachnick, 1996, Perez de Leon et al., 1998). Lehiy and Drolet (2014), have recently classified 
the salivary proteins of C. sonorensis into five major groups with the following salivary functions; sugar 
metabolism, D7 like proteins, vasodilation and immunomodulation, kunitz-like protease inhibitors and 
a group of proteins with an unknown function of which over half of all salivary proteins identified are 
assigned to the latter.  
One of the most abundant proteins within the secreted saliva from C. sonorensis is the salivary maltase 
which facilitates sugar meal digestion. Maltase proteins are found within the salivary glands of several 
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hematophagous insects, for example the maltase from C. sonorensis has a 68% similarity to α-
glucosidases that are associated with the midgut of Ae. aegypti (Lehiy and Drolet, 2014). Interestingly, 
α-glucosidases within the midgut of Rhodnius prolixus have also been implicated in the sequestration 
of heme following a blood meal, thus implying that the maltase within the saliva of arthropods may 
have a dual function; sugar digestion or the protection of midgut epithelial cells from heme toxicity 
following a blood meal by female arthropods (Mury et al., 2009). 
D7 proteins are members of the superfamily of pheromone-general odorant binding proteins that are 
found within the saliva of a range of arthropods and have been shown to be expressed as long and 
short forms in a range of arthropods saliva (Calvo et al., 2006). Nine proteins of this type were found to 
be present within the secreted saliva of C. sonorensis and, although the exact function of these salivary 
proteins are unknown, the function of D7 proteins from other arthropods may indicate a potential 
function of these C. sonorensis saliva proteins. The expression of D7 proteins of Anopholes gambiae 
and Ae. aegypti saliva has demonstrated that these salivary proteins scavenge host biogenic amines, 
such as serotonin, that would be released during platelet aggregation, and histamine that is released 
from tissue mast cells and platelets during inflammation and tissue damage. Thus the potential 
scavenging of these molecules by arthropod salivary D7 proteins would serve to limit host platelet 
aggregation, vasoconstriction and inflammation that may otherwise have deleterious effects on 
arthropod blood feeding (Calvo et al., 2005). Further studies on the D7 proteins within other arthropods 
saliva have also indicated a potential role in blood-feeding; D7 proteins were found to be highly 
expressed in the salivary glands of female Anopheles stephensi whilst they were non-detectable within 
the saliva of male mosquitoes of the same species (Suwan et al., 2002).  
Kunitz-like protease inhibitors are a large superfamily of functionally diverse proteins that are 
characterised by the presence of at least one disulfide rich alpha-beta KU domain of less than 60 amino 
acids. Although not definitively characterised from Culicoides salivary origin, proteins with a kunitz-like 
domain have been highly studied as components of tick saliva. The expression of proteins with kunitz –
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like domains from Ixodes scapularis tick saliva were shown to inhibit tissue factor X activation 
(Francischetti et al., 2004, Francischetti et al., 2002) whilst the purification of a specific protein with a 
kunitz-like domain from Ornithodoros savignyi tick saliva highlighted a role in the inhibition of platelet 
aggregation (Mans et al., 2002). The presence of these proteins within the saliva of C. sonorensis 
therefore further confirms the likely role of salivary proteins in the modulation of host haemostatic 
responses as a result of Culicoides feeding. 
1.8.2 The interactions of C. sonorensis salivary proteins and the BTV virion 
The beneficial effects of arthropod saliva on co-transmitted pathogens is, broadly speaking, thought to 
be an indirect consequence of a modulation of the host immune response leading to favourable local 
conditions (Section 1.7.2). Interestingly however, it has been shown that C. sonorensis saliva can directly 
modify BTV particles leading to an altered infectivity for specific cells. The secreted saliva of C. 
sonorensis has been shown to contain an ~ 29 kDa protein identified as a ‘late trypsin’ (Darpel et al., 
2011, Lehiy and Drolet, 2014). Following the co-incubation with purified viral particles, the secreted 
saliva from C. sonorensis and commercially available trypsin were shown to be able to cleave BTV VP2, 
resulting in the generation of ISVPs. The resulting ISVPs are up to ten times more infectious for KC cells, 
whilst also up to six times less infectious for BHK-21 cells. Similarly, BTV incubation with trypsin results 
in ISVPs that are 12 times more infectious for KC cells and up to two times less infectious for BHK-21 
cells. Although trypsin is thought to be the predominant protease present within the C. sonorensis 
saliva, others proteases are also likely present, potentially with chymotrypsin-like activity (Darpel et al., 
2011). This increased infectivity of ISVPs for insect derived cells is consistent with early studies whereby 
viral particles were treated with proteases, such as chymotrypsin, leading to the generation of ISVPs 
that had an ~100 increased infectivity for Culicoides derived cells compared to mammalian BHK-21 cells 
(Mertens et al., 1987, Mertens et al., 1996). Furthermore, ISVPs were found to be ~ 110 fold and 20 
fold more infectious for individual C. sonorensis and C. nubeculosus respectively, compared to either 
aggregated virus or viral cores (Mertens et al., 1996). Interestingly, this reduced level of ISVP infectivity 
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for C. nubeculosus and the minimal levels of trypsin (and therefore protease activity towards VP2) 
reported within the saliva of C. nubeculosus (Darpel et al., 2011), could potentially play a partial role in 
the lower VC of this midge species for BTV (Boorman, 1974, Jones, 1957).  
1.8.3 Immune and allergic responses to C. sonorensis blood feeding and salivary proteins in the 
mammalian host 
The saliva of Culicoides midges has so far been studied to the greatest extent in the context of Insect 
Bite Hypersenstivity (IBH); a severe allergic dermatitis in response to Culicoides midge feeding. IBH, 
colloquially known as ‘sweet itch’, is specifically relevant in equids where the condition leads to severe 
pruitis and subsequent alopecia as a result of excessive itching (Langner et al., 2009). IBH has however 
also been reported in cattle and sheep (Yeruham et al., 1993, Yeruham et al., 2000).  
The identification of at least ten allergens within the SGE of C. nubeculosus was first identified by 
recombinant protein expression, and the subsequent use in ELISAs, to determine the specific binding 
of recombinant salivary proteins to Immunoglobulin E (IgE) produced by IBH affected horses. 
Additionally, eight of the recombinant proteins were applied to ID skin testing in IBH affected horses, 
all of which elicited a type I hypersensitivity reaction thus confirming the in vivo relevance of these 
allergens (Hellberg et al., 2006, Schaffartzik et al., 2011). Furthermore, the salivary maltase of C. 
sonorensis has specifically been identified as an allergen. The recombinant expression of this salivary 
protein, so called Cul s 1 (rCul s 1), was expressed in a baculovirus cell system and the positive binding 
of serum IgE from IBH affected horses was confirmed. Furthermore, rCul s 1 displayed allergenicity both 
in vitro and in vivo by histamine release testing and ID skin reactivity testing, respectively (Langner et 
al., 2009). Although the underlying immunopathology of IBH has only partially been characterised, 
legional skin biopsies from IBH affected horses have been shown to contain a significantly higher 
proportion of CD4+ cells compared to skin biopsies from non IBH affected horses. IL-13 expression was 
also seen to be significantly enhanced in skin biopsies from IBH affected horses whilst IL -4 and IL-5 
expression was not altered when compared to cytokine expression in skin biopsies from unaffected 
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horses. Furthermore, FoxP3, the T regulatory cell transcription factor, is expressed to significantly 
higher levels in skin biopsies from IBH affected horses compared to unaffected horses (Heimann et al., 
2011). An additional study by Hamza et al., (2008), also highlighted the role of the immunomodulatory 
cytokines, IL-10 and transforming growth factor  (TGF), in downregulating the production of IL-4 from 
in vitro cultured PBMCs derived from IBH affected horses, treated with C. nubeculosus whole body 
extract (WBE) (Hamza et al., 2008). Thus the underlying pathogenesis of IBH is predominantly thought 
to be based upon an imbalance between Th2 biased cells and T regulatory expressing cells (Hamza et 
al., 2007, Heimann et al., 2011). Furthermore, there is also an additional potential involvement for 
salivary antigen activated cellular mediator release such as platelet activating factor that may induce 
cellular migration to the bite site (Foster et al., 1995). Specific to equids, Culicoides midges also transmit 
AHSV and PHSV, thus the modified allergic and immune response of IBH affected horses may be of 
importance when considering the relationship between these viruses and Culicoides vector saliva. As 
IBH has also been reported in cattle and sheep (Yeruham et al., 1993, Yeruham et al., 2000), the 
described allergens may also be of relevance in the immune response to Culicoides feeding in the 
ruminant host. Indeed a significant inflammatory response of exposed skin, including severe dermal 
oedema, has been observed in both cattle and sheep following experimental exposure to C. sonorensis 
blood feeding (Figure 1.6; unpublished data) that may impact on BTV infection in these hosts. 
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Figure 1.6 – Inflammatory response of bovine and ovine skin towards experimental blood feeding of 
Culicoides midges 
A pill box containing ~ 300 mixed sex C. sonorensis midges was applied to the rump of cattle (A-D) or 
the inner thigh of sheep (E/F). Severe inflammatory reactions were often observed following this 
intensive exposure to C. sonorensis midge feeding. Immediate inflammatory reactions in ruminant skin 
(A/B/D) and ovine skin (E/F) were observed following midge feeding and the inflammatory response 
was also visible at 3 – 4 days post-midge feeding (B; circled, C and D; circled). Photos kindly provided 
by Dr. Karin Darpel.  
C 
A B 
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1.9 Hypothesis and objectives  
The saliva of numerous arthropods can indirectly alter virus infection via mechanisms such as 
modulation of the host immune response. It has previously been demonstrated that the saliva of C. 
sonorensis is proteolytically active towards VP2, the outer coat protein of BTV, resulting in a 
modification of viral protein structure and infectivity. This direct interaction between an arthropod and 
its arbovirus, resulting in modified arbovirus infection, is however unique to C. sonorensis saliva and 
BTV. Given the strong local inflammatory response of ruminants and equines to Culicoides blood 
feeding, it remains likely that Culicoides saliva will also modulate the local skin immune response, which 
might influence BTV infectivity for natural target cells indirectly. Additionally, up until now, potential 
effects of Culicoides saliva and modified BTV infectivity have not been investigated in vitro within the 
context of natural ruminant target cell infection.  
The overarching aim of this thesis is therefore to elucidate if C. sonorensis saliva can modulate BTV 
infection of bovine immune cells via possible indirect mechanisms with the major hypothesis that:  
“Culicoides saliva elicits an innate response in bovine immune cells that influences BTV replication”. 
This hypothesis has been investigated by completing the following objectives: 
 To collect large quantities of secreted saliva from C. sonorensis via a modified artificial midge 
feeding system and validate batch composition for in vitro infection studies 
 To determine if the infection of bovine PBMCs with BTV is altered in the presence of C. 
sonorensis saliva  
 To elucidate the salivary component likely responsible for the observed C. sonorensis saliva 
induced modification of BTV infection in bovine cells 
 To carry out initial investigations into the role of C. sonorensis saliva and/or BTV infection in 
modulating the host cytokine response and influencing cellular viability.  
 
 
 
 
 
 
 
 
 
 
Chapter 2  
 Materials and methods 
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2.1 Animals  
A total of five Holstein Friesian male cattle (Table 2.1) from The Pirbright Institute (TPI) herd were used 
as blood donors for the work carried out in the thesis. The cattle were sampled under the appropriate 
Animals Scientific Procedures Act (ASPA) license and local ethical review. A summary table of the cattle 
used for specific experiments throughout this thesis can be found in the appendix (Table A1). 
Table 2.1 – Blood donor cattle details 
 
 
 
 
2.2 Cells 
2.2.1 Culture of continuous cell lines  
BHK-21 (clone 13) cells were kindly provided by Dr. Barbara Holzer (TPI) and originated from the 
American type culture collection (ATCC). BHK-21 cells were maintained at 37°C, with 5 % carbon 
dioxide, in BHK-21 growth medium consisting of: Glasgow modified Eagle’s medium (GMEM) (Gibco™ 
by Life Technologies) containing 10% heat-inactivated (56°C for 30 minutes), BTV antibody free, filter 
sterilised FCS (GemCell™), 100 units/ml penicillin and 100 µg/ml streptomycin (Gibco™ by Life 
Technologies). Every 3 to 4 days, once reaching confluency, BHK-21 cells were washed with 5 ml 0.25% 
trypsin-EDTA (Sigma-Aldrich) three times and on the final wash the cells were incubated with 3 ml 
trypsin for 5 minutes at 37°C. BHK-21 cells were visualised by light microscopy to confirm detachment 
from the cell culture plastic and resuspended in BHK-21 media. Cells were pelleted at 300 x g for 5 
minutes at room temperature (RT), the supernatant was discarded and the cells were split 1 in 8 into a 
new tissue culture flask containing growth media. Alternatively, cells were diluted 1 in 100 with 0.4% 
Trypan blue and viable cells were visualised and counted in a haemocytometer for subsequent seeding 
into 96 well plates for virus titration (Section 2.4.2). 
Cattle number Date of birth MHC haplotype 
1 February 2011 A31 
2 June 2012 A14 
3 June 2012 A14 
4 June 2014 A31 
5 June 2014 A18 
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2.2.2 Isolation of PBMCs from bovine blood and subsequent culture 
Heparinised bovine blood was mixed with equal volumes of calcium and magnesium free Dulbecco’s 
phosphate buffered saline (PBS) and centrifuged at 1, 300 x g for 45 minutes at RT over a histopaque 
1083 (Sigma-Aldrich) gradient. The mononuclear cells were removed from the interface into PBS and 
pelleted at 680 x g for 10 minutes at RT. Cells were resuspended in a 1 X red blood cell lysis solution 
(Miltenyi Biotec), pulse vortexed and incubated for 10 minutes at RT and subsequently washed a further 
two times by re-suspension in 50 ml PBS followed by centrifugation at 310 x g for 10 minutes. Cell yield 
was determined by diluting cells 1 in 10 with PBS to a final volume of 1 ml and incubating with 3 µl of 1 
mg/ml Propidium Iodide (PI) (Life technologies) for 3 minutes. One-hundred µl was loaded into a 
Moxiflow cassette (Orflo®) and read on the Moxiflow hand held flow cytometer (Orflo®). The number 
of live cells was determined based on the Moxiflow reading and adjusted for the 1 in 10 dilution. Cells 
were next processed for infection (Section 2.4.3) or cultured in low adherence 6 well tissue culture 
plates (Corning) at a density of 7 x 10 6 monocytes/well in 3 ml of PBMC medium consisting of Roswell 
Park Memorial Institute medium (RPMI) 1640 (Gibco™ by Life Technologies), 10% FCS, 1 X non-essential 
amino acids (Thermo Fisher Scientific), 1 mM sodium pyruvate (Thermo Fisher Scientific), 50 μg/ml 
gentamicin (Gibco™ by Life Technologies) and 10 mM β-mercaptoethanol (Sigma-Aldrich®). 
2.2.3 Positive selection of monocytes from bovine PBMCs and subsequent culture 
PBMCs were isolated according to Section 2.2.2. At the wash step prior to determining the number of 
cells isolated, PBMCs were resuspended in ice cold 1% bovine serum albumin (BSA) (Sigma-Aldrich) in 
PBS (1 % BSA/PBS). Cells were counted as described above and pelleted at 300 x g for 10 minutes at 
4°C. The fluid of the cell pellet was aspirated using a pipette and the cells were resuspended in 40 µl 
ice cold 1% BSA/PBS and 10 µl of human CD14 MicroBeads (Miltenyi Biotec) per 1 x 107 PBMCs. The 
cell/buffer/bead combination was gently mixed by pipetting and incubated at 4°C for 15 minutes. PBS 
was added to the cell/buffer/bead mixture to a final volume of 50 ml and the bead labelled cells were 
pelleted at 300 x g for 10 minutes at 4°C. Cells were washed once further by resuspension and 
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centrifugation prior to resuspension in 500µl ice cold 1% BSA/PBS per 1 x 108 bead labelled cells. A pre-
chilled 30 µm pre-separation filter and LS column (Miltenyi Biotec) was placed into the magnetic field 
of a magnetic-activated cell sorting (MACS) separator (Miltenyi Biotec) and was primed by the addition 
of 3 ml ice cold 1% BSA/PBS. Once the buffer had passed through the column, bead labelled cells were 
added onto the edge of the column allowing the specific bead labelled population to be captured by 
the magnetic field whilst non-bead labelled cells flowed through the column. Once the column reservoir 
had emptied, it was washed three times by the addition of 3 ml ice cold 1% BSA/PBS. The column was 
next removed from the separator and placed into a fresh tube. Five ml of PBMC medium was added to 
the column and the magnetically captured cells were now eluted from the column by firmly pushing 
the plunger into the column. Cells were counted as above and cultured overnight in low adherence 
tissue culture plates (Corning) at a density of 3 x10 6 monocytes/well in 3 ml prior to infection (Section 
2.4.3). 
To check the purity of the purified monocytes, 1 x 10 5 PBMCs, CD14 MicroBead labelled PBMCs and 
CD14 MicroBead purified monocytes were placed into a U bottom plate and pelleted at 300 x g for 5 
minutes at RT. Cells were subsequently washed once with 0.5% BSA/PBS by resuspension and 
centrifugation. Cells were labelled with a goat anti-mouse IgG, Alexa-Fluor 488 conjugated secondary 
antibody (Life Technologies) at a dilution of 1 in 250 for 10 minutes at RT in a final volume of 25 µl. Cells  
were washed twice further by resuspension in 0.5% BSA/PBS and centrifugation. Cells were fixed with 
4 % paraformaldehyde (PFA) (Santa-Cruz) for 10 minutes. Data was collected on the MACS Quant® flow 
cytometer (Miltenyi Biotec) using MACS Quantify™ software and analysed using FlowJo®. Monocyte 
purity was determined to be consistently > 98% based upon the labelling with the Alexa Fluor 488 
secondary antibody as indicated by the example in Figure 2.1.  
~ 67 ~ 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 – Example purity confirmation of purified monocytes from bovine PBMCs 
Monocytes from bovine PBMCs were purified by positive magnetic cell separation utilising human CD14 
MicroBeads. Monocyte purity was subsequently confirmed by the detection of bead labelled, purified 
monocytes with a goat anti-mouse IgG, Alexa-Fluor 488 conjugated secondary antibody. Background 
Alexa Fluor 488 antibody labelling of PBMCs that had not been exposed to CD14 microbeads was used 
to set the respective gates (A). Positive bead labelling of monocytes within PBMCs (B) and a >98% purity 
of isolated monocytes was confirmed (C). 
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2.3 Culicoides sonorensis saliva collection, concentration and processing  
2.3.1 C. sonorensis midges 
TPI maintains colonies of two Culicoides species; C. sonorensis, a competent biological vector for BTV 
transmission that originated in the United States of America and C. nubeculosus, a British species of low 
VC (Boorman, 1974, Jones, 1957). Only newly emerged C. sonorensis midges which had never been 
blood fed were used for the salivary collections carried out in this project. 
2.3.2 C. sonorensis saliva collection 
The method used for the collection of C. sonorensis salivary proteins was based upon a modified system 
derived from the artificial Hemotek™ feeding unit utilised for the maintenance of the midge colony and 
the previously described method for the collection of C. sonorensis saliva by Langner et al., (2007). The 
inner chamber of the heated feeder system was first sealed with Parafilm™ and filled with endotoxin 
free water (Gibco™ by Life Technologies) (Figure 2.2; A/B). An additional layer of Parafilm™ was next 
overlaid, followed by a Durapore PVDF 0.2 μ membrane (Millipore) dipped into endotoxin free water 
to provide a liquid for the midges to take up (Figure 2.2; C). A final layer of thinly stretched Parafilm™ 
was placed over the filter to prevent contamination with non-salivary proteins whilst allowing the midge 
proboscis to reach through to the filter membrane beneath (Figure 2.2; D). Excess Parafilm™ was 
trimmed from the edges of the insert (Figure 2.2; E) and the complete insert was screwed into the outer 
heating element and allowed to warm to 37°C prior to applying a pot of midges (Figure 2.2; F). Three 
pill boxes, each containing ~ 300 mixed sex C. sonorensis midges, were placed onto the filter setup for 
approximately 12 minutes per box (Figure 2.2; G). After three midge sets had fed, the setup was 
disassembled by carefully removing the top Parafilm™ layer with a needle, ensuring that the filter and 
the lower layers of Parafilm™ below were not pierced. The filter was placed into PBS using sterile 
forceps and was stored at 4°C for a maximum time of one week. The process was repeated for the 
duration of one week utilising midges that had newly emerged at two to three day intervals (Figure 2.2: 
H).  
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In order to ensure that the saliva did not contain any environmental contaminants, negative collections 
were performed with the exact set-up as described above. Prior to the negative collection, midge 
containing pill boxes that were used for the saliva collection were placed into the freezer for 48 hours 
in order to kill the midges. The pots were then applied to the setup during the negative feeding as would 
have been carried out during the saliva collection. By doing this, any environmental contamination 
within the method due to the gauze of the pill box or the pill box itself coming in contact with the top 
Parafilm™ layer could be accounted for.
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Figure 2.2- C. sonorensis saliva collection 
Artificial heated feeders were set up, as above, to permit the collection of C. sonorensis saliva. Once the midges, from three pots, had fed for ~ 12 minutes 
each the setup was disassembled and repeated until ~ 70 filters were collected. 
The setup was disassembled, the filter 
was placed into PBS and the process was 
repeated. Over the collection time of 
one week, multiple pots of C. sonorensis 
midges were used to obtain large 
quantities of saliva  
A B C D 
The insert was filled with 
endotoxin free water 
A Parafilm™ layer was 
secured around the insert 
An additional layer of Parafilm™ was 
added over the insert and a 0.2 µ 
filter membrane, dipped in endotoxin 
free water, was placed on top 
An additional layer of Parafilm™ 
was stretched over the insert 
and secured with an elastic band  
Excess Parafilm™ was 
trimmed from the insert 
The insert was screwed into 
the heated feeder and 
allowed to warm to 37 °C 
Three pots of midges were 
fed per filter, for ~ 12 
minutes each  
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2.3.3 C. sonorensis saliva concentration 
At the end of the saliva collection the filter membranes, onto which C. sonorensis saliva had been 
collected, were cut into four irregular shaped pieces and returned to the PBS in which they were stored 
during the collection. The tubes of filters were placed onto a roller at 4°C overnight, in order to elute 
the salivary proteins. Post-elution the salivary proteins were suspended within a large volume of PBS 
(100ml) and therefore needed to be concentrated to a smaller volume that would allow protein 
quantification and in vitro use of the salivary proteins. The elute was sterilised through a 0.2 μ filter 
(Merck Millipore) and applied to a 3 kilo Dalton (kDa) cut off Vivaspin column (Sartorius Steadium 
Biotech) and concentrated by centrifugation at 1,950 x g and + 10°C to a final volume of ~ 1000 μl. 
Throughout this work, the final concentrated product is termed ‘saliva’ and refers to saliva components 
greater than 3 kDa in size. The filter membranes collected during the negative collection were 
processed in the same manner.  
2.3.4 C. sonorensis saliva quantification 
Protein concentrations within collected C. sonorensis saliva were quantified using the 2-D Quant kit (GE 
Healthcare Life Sciences) according to the manufacturer’s instructions. Protein content was 
determined, based upon a standard curve that was generated from samples containing known 
quantities of proteins, using a four parameter logistic regression in Graph Pad Prism software version 7 
for Windows. 
2.3.5 LPS quantification in C. sonorensis saliva 
LPS content within collected C. sonorensis saliva was quantified using the Pierce™ LAL Chromogenic 
endotoxin quantification kit (Thermo Fisher Scientific) according to the manufacturer’s instructions. 
Endotoxin units (EU) per ml of samples were determined using a four parameter logistic regression in 
Graph Pad Prism software version 7 for Windows. The final EU/ml was converted into ng per ml based 
upon the assumption that 1 EU/ml = ~ 0.1 ng endotoxin per ml according to the manufacturers’ 
instructions.  
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2.3.6 LPS removal from C. sonorensis saliva 
The LPS component of C. sonorensis saliva was removed using the Pierce™ high capacity endotoxin 
removal spin column with a 0.5 ml reservoir (Thermo Fisher Scientific). LPS removal was confirmed by 
testing the eluted LPS removed saliva using the Pierce™ LAL Chromogenic endotoxin quantification kit 
(Section 2.3.5).  
2.3.7 C. sonorensis saliva protein and BTV particle interaction 
To determine the proteolytic activity of C. sonorensis saliva towards BTV VP2, 2.5 µg of C. sonorensis 
saliva and an estimated 2.5 µg of BTV-1 Gibraltar 2007/1 KC3 virus particles were combined into a final 
volume of 25 µl using 0.2M TRIS – hydrochloride (Tris-HCl) pH8. Reactions were incubated at 37 °C for 
30 minutes in a water bath. Virus alone was also incubated at 37°C in the same final volume. After 30 
minutes samples were processed for SDS-PAGE analysis (Section 2.3.10).  
2.3.8 C. sonorensis salivary protein and commercial trypsin proteolytic activity comparison 
Variable amounts of C. sonorensis saliva or commercial trypsin (Sigma-Aldrich; L1426) were incubated 
with 2.5 µg of BTV-1 Gibraltar 2007/1 KC3 virus particles in a final volume of 25 µl with 0.2M Tris-HCl 
pH8. Reactions were incubated at 37 °C for 30 minutes in a water bath. Virus alone was prepared in a 
comparable manner and also incubated at 37°C. After 30 minutes samples were processed for SDS-
PAGE analysis (Section 2.3.10). 
2.3.9 Comparison of the proteolytic activity of arthropod salivary proteins towards BTV VP2 
The saliva from Ae. aegypti mosquitoes was collected and kindly provided by Laura Jones (MSc project, 
University of Surrey). Either 1.5 µg or 4.5 µg of Ae. aegypti or C. sonorensis saliva proteins were 
incubated with 1 µg of purified BTV-1 Gibraltar 2007/1 KC3 particles in a final volume of 25 µl with 0.2M 
Tris-HCl pH8. One group of reactions was incubated at 37 °C for 30 minutes and the other for 2 hours. 
Virus alone was also incubated at 37°C for the respective times. After the incubation time samples were 
processed for SDS-PAGE analysis (Section 2.3.10).  
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2.3.10 Sample analysis by SDS - polyacrylamide gel electrophoresis (SDS-PAGE) and silver staining 
Samples for SDS-PAGE were prepared by adding one part sample to two parts sample loading buffer; 
the latter was previously prepared by adding one part 1.25 M, 30 x dithiothreitol (DTT) to nine parts 3 
x SDS sample buffer (New England BioLabs®). Samples in loading buffer were heated to 95°C for 5 
minutes. 
SDS-PAGE was used to separate C. sonorensis salivary proteins or viral proteins for subsequent 
visualisation by silver staining (Section 2.3.10). Ten percent resolving gels of 0.75 mm thickness were 
poured and set utilising the Bio-Rad Mini-Protean® apparatus (Bio-Rad laboratories). Resolving gels 
were made by combining 5ml of 40% acrylamide (Sigma-Aldrich), 5 ml 1.5 M Tris-HCl (pH 8.8) (Bio-Rad 
laboratories), 9.6 ml MilliQ water, 200 µl Ultrapure 10% SDS (Invitrogen by Life Technologies), 200 µl 
10% ammonium persulfate (APS) (Sigma-Aldrich), and 20 µl tetramethylethylenediamine (TEMED) 
(Sigma-Aldrich). The gel mixture was poured into gel casts, overlaid with 70% ethanol and allowed to 
polymerise. Once the gels had set, the 70% ethanol was washed off from the resolving gel with MilliQ 
water and overlaid with the stacking gel. Stacking gels consisted of 500 µl 40% acrylamide, 1.3ml 0.5 M 
Tris-HCl (pH6.8) (Bio-Rad laboratories), 3.2 ml MilliQ water, 50 µl Ultrapure 10% SDS, 50 µl 10% APS 
and 5 µl TEMED. Once poured, a comb was inserted into the gel cast to mould the wells into which the 
samples for separation would be loaded and the stacking gels were allowed to polymerise. Running 
buffer was prepared by dissolving 14.4 g glycine (Thermo Fisher Scientific), 3 g Trizma base (Sigma-
Aldrich) and adding 10 ml UltraPure 10% SDS and Milli – Q water to a final volume of one litre. Running 
buffer was cooled in the fridge prior to use. Set gels were transferred into the BioRad Mini-Protean 
apparatus and running buffer was added to the gels tank to fully submerge the gels. Combs were 
removed and the wells were flushed with running buffer prior to the loading of samples. The 
Amersham™ ECL™ Rainbow™ marker was loaded alongside the samples for protein size references. 
Electrophoresis was carried out at 100 volts until the dye front reached or just exceeded the end of the 
resolving gel. Silver staining was subsequently performed using the Pierce™ Silver stain kit (Thermo 
Fisher scientific) according to the manufacturer’s instructions.  
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2.4 Viruses and cell infection 
2.4.1 Virus propagation in BHK-21 cells  
BTV serotype 1, originating from an infected sheep in the Gibraltar 2007 outbreak of BTV was isolated 
by the Non-Vesicular Reference Laboratory (NVRL) at TPI and was subsequently passaged through KC 
cells twice and through BHK-21 cells twice by Dr. Katy Moffat generating a BTV-1 Gibraltar 2007/1 KC2 
BHK2 strain. This strain was provided by Dr. Katy Moffat and used to infect a T175 cm2 flask of BHK-21 
cells at ~90% confluency. BHK-21 media was removed and the cells were subsequently incubated with 
400 µl BTV-1 Gibraltar 2007/1 KC2 BHK2 and 3.6 ml maintenance media; GMEM containing 100 units/ml 
penicillin and 100 µg/ml streptomycin. Virus adsorption was allowed to occur for 20 minutes at 37°C 
after which time 40 ml of maintenance media was added to the flasks. Infected cells were cultured for 
3 – 4 days until full cytopathic effect (CPE) was observed. Cells and BTV-1 Gibraltar 2007/1 KC2 BHK3 
virus containing cell culture supernatant were harvested and cell debris was pelleted at 1000 x g for 10 
minutes. Non-infected flasks were set up in the same manner, minus the viral inoculum, to generated 
mock infected cell culture supernatants. BHK-21 cells were lysed by freeze thawing at -80 °C and cell 
debris was subsequently pelleted at 1000 x g for 10 minutes. Virus and mock infected cell culture 
supernatants were stored at 4°C and virus titre was determined by virus titration (Section 2.4.2).  
2.4.2 Virus titration 
Virus titres of virus stocks (Section 2.4.1) or sample supernatants (Section 2.4.3) were quantified by 
microplate titrations to determine the 50 % tissue culture infective dose (TCID50). Three x 105 BHK-21 
cells were seeded into 96 well flat bottom (Thermo Fisher Scientific) plates in 100 µl BHK-21 media ~ 
24 hours prior to virus titration to ensure that the cells were ~90% confluent at the point of use. Media 
was removed and replaced with 100 µl maintenance media per well. Tenfold dilutions of the samples 
for titration were prepared in maintenance media and 100 µl of each sample dilution was applied to 
BHK-21 cells in at least quadruplicates. Cells were incubated for 3 days at 37 °C after which time cells 
were fixed in 4% PFA for 30 minutes. Cells were washed three times with PBS and stored in PBS for a 
maximum of one week prior to internal immunofluorescence labelling. 
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BHK-21 cells were permeabilised with 0.2% Triton x-100 (Sigma-Aldrich) diluted in PBS for 20 minutes 
at RT. Cells were subsequently washed once with PBS prior to incubation with the BTV structural protein 
specific antibody, O279, at a dilution of 1 in 2000 in 0.5% BSA/PBS (Sigma-Aldrich) for 1 hour. Cells were 
washed three times with PBS and subsequently incubated with a goat anti-guinea pig IgG, Alexa-Fluor 
488 conjugated secondary antibody at a dilution of 1 in 250 in 0.5 % BSA/PBS for 1 hour (Table 2.4). 
Cells were washed a further three times with PBS prior to examination with the fluorescent Enzyme-
Linked ImmunoSpot (ELISPOT) reader (AID Elispot) or on a Nikon Eclipse TE300 fluorescent inverted 
microscope. Infected cells were determined by the positive labelling for VSP and virus titres were 
calculated as log10 TCID50/ml as described by Kaerber (Kaerber, 1931). 
2.4.3 Cell infection with BTV in the presence of C. sonorensis saliva 
2.4.3.1 BTV infection of bovine PBMCs 
PBMCs were infected in suspension (1.4 x 107 cells at 3.5 x 106/ml) in PBMC medium with BTV-1 
Gibraltar 2007/1 KC2 BHK3 at a multiplicity of infection (MOI) of 0.1 for 1 hour on a shaker at RT. C. 
sonorensis saliva or other stimuli were added to the cells at specified concentrations. Cells were 
subsequently pelleted at 300 x g for 5 minutes at RT and washed three times by resuspension and 
centrifugation at 300 x g for 10 minutes with 35 ml PBMC wash medium consisting of RPMI containing 
50 μg/ml gentamycin. Cells were resuspended in PBMC wash medium and pelleted a final time at 300 
x g for 5 minutes and a sample of cell culture supernatant was collected to be titrated as 1 h.p.i time 
point to determine the efficiency of viral inoculum removal by the wash steps. Cells were subsequently 
resuspended and C. sonorensis saliva or other stimuli were re-applied to the relevant conditions at 
specified concentrations. Cells were cultured in low-adherence six well tissue culture plates (Corning) 
at a density of 7 x 10 6 cells/ml in two ml media. Cells were given an extra one ml of PBMC medium at 
48 h.p.i.  
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2.4.3.2 BTV infection of purified monocyte cultures 
As purified monocytes were cultured overnight prior to infection in order to allow the detachment of 
CD14 MicroBeads (Miltenyi Biotec), one well of purified monocytes were used for the determination of 
cell survival per well to allow appropriate MOI calculations. Cells were subsequently infected in culture 
with BTV-1 Gibraltar 2007/1 KC2 BHK3 at an MOI of 0.1 for one hour in two ml PBMC media at RT in the 
presence of C. sonorensis saliva. Cell culture media was subsequently removed, and any non-adherent 
cells were pelleted at 300 x g for 5 minutes. Two ml PBMC wash media was added to the cell culture 
well to wash adherent cells prior to the addition of this media to the pelleted cells. An additional 10 ml 
of wash media was added to the two ml wash media prior to pelleting non-adherent cells at 300 x g for 
5 minutes at RT. This wash step was repeated a further two times prior to the resuspension of any non-
adherent cells in PBMC media and the addition back to the originating cell culture well. C. sonorensis 
saliva was reapplied to the relevant conditions and cells were cultured until the point of harvest. 
2.4.4 Sample harvest post-infection 
At the specified time point post-infection, supernatants were collected from cell cultures and cells were 
harvested for flow cytometry and confocal microscopy analysis as outlined in Figure 2.3. Cell culture 
supernatants were harvested and stored at 4°C for virus titration (Section 2.4.2) or -80°C for the 
determination of cytokine content by ELISA (Section 2.8). Non-adherent cells within the supernatants 
were collected by pelleting at 300 x g for 5 minutes prior to supernatant storage. Pelleted cells were 
resuspended in ice cold cell dissociation buffer (Life Technologies) containing 1% BSA. Adherent cells 
were removed from the cell culture plastic by treatment with ice cold cell dissociation buffer for 20 
minutes prior to the addition to previously collected non-adherent cells. Cells were centrifuged at 300 
x g for 5 minutes at 4°C and the pellet was resuspended in 500 µl fresh ice cold cell dissociation buffer. 
Cells were diluted 1 in 10 with 0.4% Trypan blue and viable cells were visualised and counted in a 
haemocytometer or cells were counted on the MACS Quant® flow cytometer (Miltenyi Biotec) using 
MACS Quantify™ software and analysed using FlowJo®. Cells were subsequently adjusted to the desired 
concentration and further processed for flow cytometry (Section 2.6) or confocal analysis (Section 2.7). 
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Figure 2.3 - Schematic diagram outlining the experimental setup of bovine PBMC infections with BTV in 
the absence or presence of C. sonorensis saliva (or control stimuli) and subsequent harvest of cells and 
respective cell culture supernatants for various downstream analysis 
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2.5  Antibodies and dyes for flow cytometry and confocal microscopy 
2.5.1 Antibodies and dyes  
Antibodies utilised throughout this thesis for the labelling of external cell surface membrane proteins 
for flow cytometry analysis (Section 2.6) or confocal microscopy analysis (Section 2.7) are summarised 
in Tables 2.2 and 2.3. Antibodies utilised for one step labelling were directly conjugated and the amount 
of antibody used was based upon prior titration of the antibody conjugate (Section 2.5.4). As the 
optimal antibody amount for use varied between batches of antibody conjugate, respective amounts 
of directly conjugated antibodies used are not included in Table 2.2 but were based upon individual 
batch titration results. The amount of isotype control (IC) antibody utilised per well was matched in 
amounts to that of the test antibody. The antibodies utilised for two step labelling were used at the 
given dilutions (Table 2.2). Primary antibodies were titrated for optimal use (Section 2.5.4) and the IC 
antibodies were used at matched dilutions. Respective details are summarised in Table 2.4.  
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Table 2.2 – Monoclonal antibodies used for the labelling of cell surface membrane proteins for flow cytometry 
Antibody Epitope Isotype Format Dilution Fluorochrome Origin  Reference  
One step labelling: directly conjugated murine antibodies for flow cytometry 
CCG33 Bovine CD14 G1 Directly conjugated  - RPE  TPI  
CC30 Bovine CD4 G1 Directly conjugated - RPE TPI (Bensaid and Hadam, 1991) 
CC58 Bovine CD8 G1 Directly conjugated - RPE TPI (MacHugh et al., 1991) 
CC21 Bovine CD21 G1 Directly conjugated - RPE TPI (Howard et al., 1991) 
TRT1  TRTV (IC) G1 Directly conjugated - RPE TPI (Cook et al., 1993) 
Two step labelling: murine primary and goat secondary antibodies for flow cytometry  
Primary antibodies 
GB21a Bovine  TCR G2b Primary antibody 1 in 250 - Kingfisher 
Biotech  
(Brodersen et al., 1998) 
AV29 Chicken CD4 G2b Primary antibody 1 in 250 - TPI (Kwong et al., 2002) 
Secondary antibodies 
RPE 
conjugate, 
goat 
Mouse IgG - Secondary antibody  1 in 250 RPE Life 
Technologies 
- 
 
Optimal antibody amounts/dilutions for use were determined by antibody titration (Section 2.5.4). Antibodies from TPI were kindly provided by Dr. 
Karin Darpel and Dr. Katy Moffat. The TRT1 antibody utilised specifically detects Turkey rhinotracheitis virus (TRTV), which would not be present within 
bovine cells and was hence used as an isotype control antibody. Similarly, the AV29 antibody specifically detects chicken CD4, which is not expressed 
by bovine cells and was hence used an isotype control antibody. Abbreviations: RPE: R – phycoerythrin. 
 
Table 2.3 – Monoclonal antibodies used for the labelling of cellular membrane proteins for confocal microscopy  
Antibody Epitope Isotype Dilution Origin Reference 
Primary antibodies 
CCG33 Bovine CD14 G1 1 in 1000  TPI (Sopp et al., 1996) 
TRT 1 TRTV (IC) G1 1 in 1000 TPI (Cook et al., 1993) 
Secondary antibodies 
Alexa Fluor  405, goat Mouse IgG - 1 in 250 Life Technologies  - 
 
Antibodies from TPI were kindly provided by Dr. Karin Darpel and Dr. Katy Moffat. 
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Table 2.4 - Polyclonal antibodies for the detection of viral protein expression by flow cytometry and 
confocal microscopy 
Antibody Epitope Species Dilution 
used 
Origin Flow cytometry 
or confocal 
microscopy use 
Primary antibodies 
ORAB 279  VSP (raised against 
purified BTV-1) 
Guinea pig  1 in 1000 TPI Both 
ORAB 1  NSP (raised against 
expressed and 
purified NS2) 
Rabbit  1 in 1000 TPI Both 
-cop -cop Rabbit 1 in 200 TPI Both 
Secondary antibodies 
Alexa Fluor 
488, goat 
Guinea pig IgG  1 in 250 Life 
Technologies 
Both 
Alexa Fluor 
647, goat 
Rabbit IgG  1 in 250 Life 
Technologies 
Flow cytometry 
Alexa Fluor 
568, goat 
Rabbit IgG  1 in 250 Life 
Technologies 
Confocal 
microscopy 
Alexa Fluor 
488, goat 
Rabbit IgG  1 in 250 Life 
Technologies 
Both  
 
Optimal primary antibody dilutions for use in flow cytometry were determined by antibody titration 
(Section 2.5.4). Antibodies from TPI were kindly provided by Dr. Karin Darpel. 
  
 
2.5.2 Antibody quantification 
Antibody quantification was performed using the BCA™ Protein assay (Thermo Fisher Scientific) 
according to the manufacturer’s instructions. Protein content was determined based upon the line of 
best fit of the standard curve using GraphPad Prism software version 7 for Windows.  
2.5.3 Direct antibody conjugation 
Antibodies were directly conjugated using the Lightning link ® antibody labelling kit (Innova Biosciences) 
according to the manufacturer’s instructions. Antibody conjugates were titrated for their optimal usage 
(Section 2.5.4) and stored at 4°C.  
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2.5.4 Antibody and dye titration for flow cytometry 
The optimal amount/dilution of antibodies for the detection of specific cellular and viral antigens was 
determined by antibody titration on target cell populations. The optimal antibody amounts of dilution 
for use were determined by analysis of the signal to noise ratio of positively and negatively labelled cells 
(Hulspas, 2010) and the stain index of labelled cells that was calculated based upon the median 
fluorescent intensity (MFI) of the positively labelled population minus the MFI of the negatively labelled 
population divided by two times the standard deviation of the negative population (MFIpos - 
MFIneg)/2xSDneg) (Maecker et al., 2004).  
Cell surface membrane protein antibody titration: 
Titration of directly conjugated antibodies was carried out via one step labelling of cells (Section 2.6.1) 
with seven antibody amounts ranging from 50 ng to 1600 ng in a final volume of 25 µl 0.5% BSA/PBS. 
Figure 2.4 shows an example titration of a CD14 directly conjugated antibody (CCG33-PE) on PBMCs. 
Cells that were subjected to two step labelling with semi-purified antibodies (100 µg/ml) were labelled 
with eight antibody dilutions ranging from 1 in 200 to 1 in 3000 whilst the secondary antibodies were 
used at a fixed dilution of 1 in 250 (Table 2.3). 
Viral protein antibody titration: 
Two step labelling of infected cells was used for the determination of viral protein expression as 
described in Section 2.6.2 and the optimal dilution for antibody use was determined by labelling cells 
with five antibody dilutions ranging from 1 in 250 to 1 in 4000.  
Live dead cell exclusion dye titration: 
The 633 nm excitable live dead (LD) exclusion dye (Zombie NIR™ Fixable Viability kit, Biolegend) was 
reconstituted according to the manufacturer’s instructions and cells were incubated with five dye 
volumes ranging from 0.25 µl to 2 µl. A final volume of 1µl LD stain per 5 x 105 PBMCs or 1 x 105 purified 
monocytes in a final volume of 25 µl 0.5% BSA/PBS was found to be optimal (Section 2.6). 
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Figure 2.4 - Determining the optimum amount of directly conjugated CD14 – PE antibody to label target 
monocytes within PBMCs 
A typical titration of a directly conjugated CD14 antibody targeting the cell surface membrane protein 
on monocytes within PBMCs. Positively labelled cells were denoted as those cells to which the antibody 
had bound indicating the expression of CD14, whilst negatively labelled cells were denoted as those to 
which the CD14 antibody had not bound or had bound to background levels. Cells were labelled with a 
range of antibody amounts (50 to 1000 ng) per 5 x 105 cells. The MFI of CD14 expression on positively 
and negatively labelled cells within PBMCs (A) was used to determine the stain index of CD14 expression 
(B). An antibody amount of 625 ng would be used per well of 5 x 105 cells based upon this antibody 
titration.  
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2.6 Flow cytometry 
2.6.1 Cell surface membrane protein labelling  
At specified time points post-infection cells were harvested (Section 2.4.4) and 5 x 105 cells were 
dispensed into U bottom plates (Thermo Fisher Scientific). Cells were next pelleted at 300 x g for 5 
minutes at 4°C and externally labelled with antibodies specifically targeting cell surface membrane 
proteins (Table 2.2) by one or two step labelling methods. All single and two step labelling reactions 
were set up in duplicate as a minimum. Control labelled fluorescent minus one (FMO) plus IC (FMO+IC) 
and single colour reactions were set up where applicable to enable subsequent flow cytometry analysis. 
One step labelling:  
Direct antibody conjugates recognising either CD14, CD4, CD8 or CD21 cell surface membrane proteins 
were incubated alongside a LD dye in a final volume of 25 µl 0.5% BSA/PBS with cells for 30 minutes in 
the dark at 4°C. Cells were subsequently washed twice by resuspension and centrifugation at 300 x g 
for 5 minutes at 4°C to a final volume of 150 µl with 0.5% BSA/PBS. Cells were fixed with 4% PFA for 30 
minutes at 4°C.  
Two step labelling:  
The antibody recognising the  TCR was incubated with cells for 10 minutes at RT in a final volume of 
25 µl 0.5% BSA/PBS and the cells were subsequently washed twice by resuspension and centrifugation 
at 300 x g for 5 minutes at RT to a final volume of 150 µl with 0.5% BSA/PBS. Cells were incubated with 
a species specific secondary antibody in the presence of a LD dye in a final volume of 25 µl for 10 
minutes at RT in the dark. Cells were washed once by resuspension and centrifugation at 300 x g for 5 
minutes at RT to a final volume of 150 µl with 0.5% BSA/PBS. Cells were fixed with 4% PFA for 30 minutes 
at 4°C.  
Post-one or two step cell surface membrane protein labelling and subsequent fixation, cells were 
pelleted at 300 x g for 5 minutes, resuspended in PBS and stored for up to one week prior to internal 
labelling (Section 2.6.2). 
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2.6.2 Internal labelling  
Following fixation, cells were treated with 50 µl 0.2% saponin (Sigma-Aldrich)/ 2 % normal goat serum 
in 0.5% BSA/PBS (sap/NGS/BSA/PBS) for 20 minutes to permeabilise the cells and block non-specific 
antibody binding, respectively. Primary antibodies specific to VSP and NSP (Table 2.4) were 
subsequently added to the relevant labelling reactions at a 2x concentration in 50 µl sap/NGS/BSA/PBS. 
An antibody specific to the host coatomer-protein (-COP) was used as a positive control for internal 
labelling.  
Cells were washed twice with 0.2% saponin in 0.5% BSA/PBS (sap/BSA/PBS) to a final volume of 200 µl 
and 150 µl respectively by centrifugation at 300 x g for 5 minutes and resuspension. Cells were 
incubated with species specific secondary antibodies in 50 µl sap/BSA/PBS. Cells were washed once 
further to a volume of 175 µl and cells were pelleted at 300 x g for 5 minutes prior to fixation with 4% 
PFA for 30 minutes. Finally, cells were pelleted by centrifugation at 300 x g for 5 minutes once more, 
resuspended in PBS and data was acquired by flow cytometry within two days of internal labelling 
(Section 2.6.3). 
2.6.3 Data acquisition and analysis  
Cells were analysed on the LSR Fortessa II (Becton Dickinson) flow cytometer using FACSDiva™ version 
8 software. For the analysis of monocyte populations within PBMCs, a minimum of 1,000 events were 
collected within a live, CD14 cell surface membrane protein labelled, single gate whilst for the analysis 
of lymphocyte populations within PBMCs a minimum of 5,000 events were collected within a live, 
respectively cell surface membrane protein labelled, single gate. For the analysis of purified monocytes 
a minimum of 5,000 live, single events were acquired. A fixed number of events were collected within 
each experiment across conditions. Fluorescence expression was subsequently analysed using Flow Jo 
version 10 (DeNovo Software). Figure 3.5 indicates a typical gating strategy for VSP and NSP expression 
within live, CD14 expressing, single cells in PBMCs. 
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Figure 2.5 - Example gating strategy for viral protein expression in the monocyte population of PBMCs 
Flow cytometry gating analysis for viral protein expression included only live, cell surface membrane protein 
positive, single cells (A). VSP and the NSP, NS2 expression was determined by setting background labelling gates 
on antibody labelled mock infected cells that were subsequently applied for the determination of VSP and NSP 
expression by BTV infected cells. The mock infected background labelling gates were applied to antibody labelled 
saliva treated cells and the gates were adjusted to any minimal differences in background antibody labelling of 
these cells and subsequently applied to saliva treated/BTV infected cells. Cells expressing VSP are shown within 
the red gate and cells expressing NSP are shown within the blue gate. Cells expressing both VSP and NSP fall within 
the overlapping red and blue gate.   
Debris exclusion Dead cell exclusion 
Isotype control 
antibody labelling  
CD14 cell surface membrane 
protein antibody labelling  
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2.7 Confocal microscopy  
2.7.1 Cell surface membrane protein labelling 
At 72 h.p.i, cells were harvested (Section 2.4.4) and subsequently externally two step labelled in 
suspension. Five x 105 cells were incubated with an anti-CD14 antibody in a final volume of 25 µl with 
0.5% BSA/PBS for 10 minutes at RT (Table 2.3). Cells were subsequently washed twice with 0.5% 
BSA/PBS by centrifugation and resuspension and incubated with a species specific secondary antibody 
diluted 1/250 (Table 2.3) and washed once further with 0.5% BSA/PBS. Cells were resuspended in 
plating media; RPMI, 10% FCS, 1 X non-essential amino acids and50 μg/ml gentamycin. Cells were 
allowed to settle onto polylysine (Sigma-Aldrich®) coated coverslips for 1 hour at room temperature 
followed by fixation with 4 % PFA for 30 minutes.  
2.7.2 Internal labelling  
Post-fixation, cells were concurrently permeabilised and blocked with 200 µl sap/BSA/PBS per coverslip 
for 20 minutes at RT. Cells were subsequently labelled with antibodies for the detection of viral proteins 
(Table 2.4) for 1 hour in sap/BSA/PBS. Cells were washed three times with sap/PBS for 5 minutes each. 
Cells were incubated with species specific secondary antibodies (Table 2.4) in 200 µl sap/BSA/PBS for 1 
hour at RT and washed three times with sap/PBS for 5 minutes each. The nuclear stain TO-PRO™-3 
(Sigma-Aldrich®) was diluted in 1 in 8000 in PBS and 200 µl was applied to the coverslips for 5 minutes. 
The coverslips were mounted onto glass slides using vectashield mounting medium (Vector 
Laboratories) and were sealed with nail varnish. Labelling was observed on a Leica TCS SP8 laser 
scanning confocal microscope using Leica Application Suite X (LASX) software.  
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2.8 ELISA 
2.8.1 Antibodies and standards  
Antibodies and cytokine standards used throughout this thesis for the determination of cytokine 
content within cell culture supernatants by ELISA are summarised in Table 2.5 and 2.6, respectively.  
Table 2.5 –  Antibodies for the detection of bovine cytokines by ELISA 
Antibody name 
 
Capture or 
detector 
Final working 
concentration (µg/ml) 
Origin Reference 
Bovine IL-10 ELISA 
CC318 Capture  4 Serotec (Kwong et al., 
2002) CC320 – biotinylated (B) Detector  1 TPI 
Bovine IL-4 ELISA 
CC314 Capture  6 TPI (Hope et al., 
2005) CC313 – B Detector  6 TPI 
Bovine IFN- ELISA 
CC330 Capture  2 TPI (Wattegedera 
et al., 2010) CC302-B Detector  2 TPI 
Bovine IL-12 ELISA 
CC301 Capture  4 Serotec (Hope et al., 
2002) CC326-B Detector  8 TPI 
Bovine TNF-α ELISA 
CC327 Capture  4 TPI (Kwong et al., 
2010) CC328-B Detector  1 TPI 
 
Antibodies acquired from TPI were kindly provided by Dr. Efrain Guzman, Dr. Katy Moffat and Dr. 
Geraldine Taylor. 
 
Table 2.6 - Protein standards for detection by ELISA 
Standard Protein source Origin Range of standard curve (ng/ml) 
IL-10  Recombinant purified protein  Serotec 0.08 - 60 
IL-4 In vitro expressed protein  TPI 0.0005 - 2 
IFN- Recombinant purified protein Serotec 0.04 - 30 
IL-12(p40) Purified protein Kingfisher 0.08 - 5 
TNF-α Recombinant purified protein Serotec 0.1 - 30 
 
ELISA standards acquired from TPI were kindly provided by Dr. Efrain Guzman, Dr. Katy Moffat and 
Dr. Geraldine Taylor. 
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2.8.2 ELISA procedure  
ELISA utilising chemiluminescent substrate: 
The detection of IL-10 and IL-12 by ELISA was carried out using white Maxisorp™ plates (Thermo Fisher 
Scientific). Plates were coated with the relevant capture antibody at 100 µl per well in coating buffer 
generated by dissolving one carbonate/bicarbonate buffer capsule (Sigma-Aldrich) in 100 ml of 
deionised water (Gibco™ by Life Technologies). Plates were incubated at RT overnight. The next day 
plates were washed five times with 300 µl per well 0.05% Tween 20 (Sigma-Aldrich) in PBS (PBS-T) and 
subsequently blocked with 300 µl per well of freshly prepared 0.1% sodium casein (Sigma-Aldrich)/ PBS-
T (casein/PBS-T) for one hour. Plates were subsequently washed five times with PBS-T. Standards 
containing known quantities of cytokines and samples for testing were diluted in casein/PBS-T and 100 
µl was applied to the ELISA plates at least in duplicate. Casein/PBS-T and media only controls were also 
applied in a minimum of duplicate. After 1 hour incubation time, plates were washed five times with 
PBS-T. The relevant detector antibody was diluted in casein/PBS-T and 100 µl was applied to each well 
of the ELISA plates. Plates were incubated for 1 hour after which time they were washed five times with 
PBS-T. A streptavidin HRP conjugate (GE Healthcare) was diluted 1 in 500 in casein/PBS-T and 100 µl 
was applied to each well of the ELISA plates. Plates were incubated for 45 minutes and subsequently 
washed three times with PBS-T for a 5 minute incubation time. The Supersignal® ELISA Femto maximum 
sensitivity substrate solution (Thermo Fisher Scientific) was prepared according to manufacturer’s 
instruction and was applied at 100 µl per well. Plates were placed on a shaker for 1 minute and relative 
light unit emissions from each well of the ELISA plates was measured on the Synergy II plate reader 
(Biotech) using Gen 5 software version 1.11.5 within 5 minutes of the addition of the substrate. Blank 
absorbance values were next subtracted from the results and a standard curve was generated based 
upon the samples containing known quantities of cytokines using a four parameter logistic regression 
in Graph Pad Prism software version 7 for Windows.  
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ELISA utilising a TMB substrate: 
The detection of IFN-, IL-4 and TNF-α by ELISA was carried out using clear Maxisorp™ plates (Thermo 
Fisher Scientific). The ELISA was carried out as above but with the exception that the blocking buffer 
utilised consisted of 0.1% sodium casein/ PBS (casein/PBS) Following the incubation with the 
streptavidin HRP conjugate, plates were incubated for 45 minutes and were subsequently washed five 
times with PBS-T. The TMB substrate solution (Thermo Fisher Scientific) was next applied at 100 µl per 
well and allowed to develop for 30 minutes or until colour began to show in the control wells. The 
reaction was stopped by adding 50 µl 1M Sulfuric acid (Sigma-Aldrich) to each well of the ELISA plate. 
The absorbance was measured on the Synergy II plate reader (Biotech) using Gen 5 software version 
1.11.5 at 450 and 690 nm. To increase the specificity of the assay, the non-specific absorbance at 690 
nm was subtracted from the absorbance at 450nm. Blank absorbance values were next subtracted from 
the corrected 450 nm absorbance results and a standard curve was generated based upon the samples 
containing known quantities of cytokines using a four parameter logistic regression in Graph Pad Prism 
software version 7 for Windows. 
2.9 Statistical analysis 
Statistical analysis was carried out in Minitab® 17.1.0. Where the data fitted the analysis of variance 
(ANOVA) general linear model, statistical differences were determined using the Tukey multiple 
comparison test. PBMC donor source, time point of harvest and condition were treated as fixed 
variables whilst biological replicate and technical replicate were treated as random variables. Technical 
replicates were nested within biological replicates and biological replicates were nested within the 
corresponding PBMC donor cattle number. Where data did not fit the ANOVA general linear model, 
statistical differences were determined by the Mann Whitney non-parametric test. Spearman’s rank 
correlation coefficient was used to determine if two output variables within treatment groups were 
positively or negatively correlated to statistically significant levels. In order to account for the total 
number of comparisons and reduce the chance of false significant correlations, the value at which a 
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correlation was deemed significant was adjusted using the Bonferroni correction. The corrected p value 
was determined based upon the critical p value (p = 0.05) divided by the number of comparisons that 
were carried out. 
 
 
 
 
 
 
 
 
 
Chapter 3 
Culicoides sonorensis salivary protein 
collection and their ability to cleave       
BTV VP2 
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3.1 Introduction 
The saliva from numerous blood feeding arthropods has been shown to be a pharmacologically active 
mixture of proteins that function to facilitate the acquisition of a blood meal, which is required as a 
source of nutrition and for egg production (Andrade et al., 2005, Ribeiro, 1995). The importance of 
salivary proteins from those arthropods which are biological arbovirus vectors has been discovered in 
the last two decades and remains an area of significant scientific interest. A number of highly important 
arboviruses, for example WNV (Schneider et al., 2006), VSV (Limesand et al., 2000) and DENV (Schmid 
et al., 2016, Surasombatpattana et al., 2012) are all more virulent in animal studies when inoculated 
together with saliva from their arthropod vector.  
The collection of arthropod saliva has long been established, albeit only for the larger hematophagous 
insects such as mosquitoes whereby salivation into a capillary tube is drug enforced (Anderson et al., 
1991). This saliva collection method has also been reported to obtain saliva from Culicoides midges, 
predominantly for the identification of virus within secreted saliva (Boorman, 1987, Veronesi et al., 
2013). However, the yield of salivary proteins obtained via this method is very low and utilises a carrier 
protein such as FCS, or oil, thereby making the downstream identification and analysis of salivary 
proteins challenging. In the absence of pure salivary proteins from Culicoides midges, many studies 
have utilised SGE (Bishop et al., 2006, Campbell et al., 2005, Hellberg et al., 2006, Russell et al., 2009, 
Wilson et al., 2008b) in order to characterise the proteins present within Culicoides saliva and their 
functions. WBE has also been utilised, predominantly to characterise the role of Culicoides proteins in 
IBH, an allergic dermatitis in horses that is induced by allergens within the saliva of Culicoides midges 
(Langner et al., 2008, Radrova et al., 2016, Wilson et al., 2008b). These substitute sources of salivary 
proteins will, however, result in the presence of non-secreted, salivary gland or insect body proteins 
within the final preparations. Furthermore, the dissection of salivary glands to generate SGE from 
Culicoides midges is time-consuming, requires an in depth knowledge of Culicoides anatomy and is 
challenging due to the small size of these insects, whilst still only yielding low salivary protein amounts.  
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The collection of secreted Culicoides salivary proteins was published by Langner et al., (2007) and 
describes the use of an artificial heated feeder system to collect large quantities of protein. This method 
led to the initial sequencing of C. nubeculosus saliva proteins (Langner et al., 2007) and was 
subsequently applied by Lehiy and Drolet., (2014), who concluded the presence of ~ 45 secreted 
proteins within the saliva of C. sonorensis; a major North-American vector species for Culicoides-borne 
Orbiviruses such as BTV and EHDV. In comparison, transcriptome analysis of C. sonorensis SGE by 
Campbell et al., (2005), reported over 700 expressed sequence tags (short cDNA fragments) when 
carrying out SGE RNA extraction and reverse transcription. Genes expressed within the salivary glands 
of Culicoides midges are therefore likely differentially and selectively translated into protein. 
These studies of the secreted salivary proteins or SGE of Culicoides have highlighted that like many 
other hematophagous insects Culicoides saliva is a pharmacologically active mix of proteins, many of 
which are thought to counteract the blood coagulation response employed by the vertebrate host 
thereby facilitating successful blood uptake. Indeed, Culicoides saliva has been shown to contain 
coagulation inhibitors (Langner et al., 2007, Perez de Leon and Tabachnick, 1996, Perez de Leon et al., 
1998) and vasodilators (Lehiy and Drolet, 2014, Perez de Leon et al., 1997). Although the effect of 
Culicoides saliva on the ruminant immune response which may indirectly impact on BTV infection is 
unknown, the collection of secreted salivary proteins has nevertheless allowed the identification of a 
direct interaction between C. sonorensis saliva and purified BTV particles. The saliva of C. sonorensis 
contains proteases that are able to cleave the outer coat protein of BTV, VP2, resulting in an altered 
viral structure and a subsequent differential infectivity of the virus for insect KC cells and mammalian 
BHK-21 cells, in vitro. Furthermore, C. sonorensis saliva has also been shown to cleave VP2 of Culicoides-
borne EHDV (Darpel et al., 2011). This direct interaction between Culicoides saliva and Culicoides-borne 
pathogens is however unique and has not been reported for other vector and arbovirus interactions 
thus indicating that other indirect mechanisms such as saliva induced modulation of the host immune 
response or of BTV-induced immune responses may play a greater role in the potential for C. sonorensis 
to modulate BTV infection.  
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The aim of this chapter was to collect high quantities of C. sonorensis saliva, using a modified artificial 
midge feeding system that was adapted from the setup reported by Langner et al., (2007), and to 
subsequently confirm the salivary protein composition across all collections to those previously 
published (Darpel et al., 2011, Lehiy and Drolet, 2014). Such confirmation will then allow for the 
subsequent application of the collected C. sonorensis saliva to in vitro biological assays to investigate 
the impact of the secreted saliva on BTV infection and replication and the host immune response 
(Chapter 4, 5 and 6). Furthermore, the ability of C. sonorensis saliva to cleave the outer coat protein of 
BTV-1 was validated by comparing the proteolytic activity of the collected saliva, towards VP2, with that 
of commercial trypsin. Verification of BTV-1 VP2 cleavage by C. sonorensis saliva would also offer the 
required evidence that salivary proteins utilised have retained their respective activity throughout the 
collection and concentration process. The final aim of this chapter was to analyse if other insect saliva 
can also cleave VP2. The collection of Ae. aegypti saliva and the comparison of proteolytic cleavage of 
BTV VP2 by C. sonorensis and Ae. aegypti saliva was carried out in collaboration with Laura Jones as part 
of her MSc project at the University of Surrey entitled: ‘Collecting and Analysing Saliva Proteins from 
Mosquitoes’. 
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3.2 C. sonorensis salivary protein quantification and visualisation 
C. sonorensis saliva was successfully obtained on multiple occasions via the collection method described 
in material and methods Section 2.3.2, which represents an adapted method developed within this 
project based upon the previously published setup by Langer et al., (2007). A few major changes were 
implemented including; the replacement of a glass-chamber water circulation system with a Hemotek™ 
artificial midge feeding system that was readily available in the laboratory and the application of 
multiple extra layers of Parafilm™ underneath the Durapore™ membrane in order to avoid the 
mouthparts of Culicoides midges from reaching the fluid reservoir of the Hemotek™. Additionally, the 
filter membranes onto which Culicoides midges fed and deposited their saliva were soaked solely in 
endotoxin free water, instead of the previously used 5% sugar (Langner et al., 2007). Lastly, the salivary 
protein elution method (Section 2.3.3) was also slightly adapted in order to avoid the use of 
cholamidopropyl dimethylammonio propanesulfonate (CHAPS) as the detergent for protein removal 
from the filters. Instead, proteins were eluted in endotoxin free PBS alone. Collectively, these 
modifications did not reduce the efficiency of midge feeding or the yield of salivary proteins whilst they 
did reduce the potential for external contamination into the final secreted saliva sample.  
Six C. sonorensis saliva collections were carried out to enable the studies within this thesis. The saliva 
collections were carried out at approximately six months intervals and used ~ 19, 000 individual 
Culicoides midges per collection, with the exception of collection number 4 which used only ~ 9, 000 
individual Culicoides. Post-collection, the final saliva samples were concentrated to ~ 1000 µl and the 
protein content was confirmed using the 2-D Quant Kit (GE Healthcare Life Sciences, UK) according to 
the manufacturers’ guidelines. Approximately 500 µg of protein was obtained from each saliva 
collection carried out, with the exception of collection batch four which only yielded ~ 250 µg salivary 
protein (Table 3.1). Saliva collection batches 2 – 6 were used for the in vitro studies presented in this 
thesis (Chapters 4, 5 and 6), as summarised in the appendix (Table A1). Mock collections carried out in 
parallel with killed C. sonorensis, in order to confirm the absence of environmental contaminants 
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(Section 2.3.2), did not result in a protein yield thus confirming that the proteins within the collected C. 
sonorensis saliva samples are deposited by feeding individuals.  
 
 
Table 3.1 - Quantification of C. sonorensis secreted salivary proteins 
Collection type  Batch 
number 
Total protein quantification  
(µg, ~1 ml final volume of saliva) 
C. sonorensis saliva 1 552 
2 560 
3 535 
4 252 
5 432 
6 501 
Negative  1 0 
2 0 
 
 
In order to confirm the protein profile of the collected C. sonorensis saliva to that previously published 
(Darpel et al., 2011, Lehiy and Drolet, 2014), salivary proteins (1 µg) were analysed by 10% SDS-PAGE 
in order to separate the salivary proteins for subsequent visualisation by silver staining (Section 2.3.10). 
A minimum of 11 visible salivary protein bands were detectable amongst three clusters of proteins with 
molecular weights (Mr) between 40 – 70 kDa, 25 – 30 kDa or 12 – 20 kDa (Figure 3.1). The protein profile 
seen in Figure 3.1 is representative of the six saliva collections that were independently carried out, 
resulting in the salivary proteins used for the work presented throughout this thesis. Two prominent 
bands can be seen which are indicative of ~68 kDa and ~29 kDa proteins which have previously been 
identified as a maltase (black arrow) and a trypsin (blue arrow) respectively (Darpel et al., 2011, Langner 
et al., 2007). 
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Figure 3.1- The protein profile of secreted saliva proteins from C. sonorensis 
Collected and concentrated salivary proteins from C. sonorensis (1 µg) were analysed by 10% SDS-PAGE 
and subsequently visualised using silver staining. Three predominant clusters of proteins can be 
observed at 40 – 70 kDa, 25 – 30 kDa and 12 – 20 kDa. Two prominent proteins are visualised to be 
migrating at ~68 kDa (black arrow) and the other at ~29 kDa (blue arrow).  
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3.3 Cleavage of BTV-1 VP2 by arthropod salivary proteins and trypsin  
Early studies have indicated that in the presence of serine proteases VP2, the outer coat protein of BTV 
particles, can be cleaved by proteases resulting in the formation of ISVPs (Mertens et al., 1987). Purified 
ISVPs, generated by the cleavage of VP2 using chymotrypsin followed by sucrose gradient purification, 
were subsequently found to have an ~100 times increased infectivity for Culicoides-derived KC cells as 
well as C. sonorensis midges (Mertens et al., 1996). The presence of a ~29 kDa late trypsin was later 
confirmed to be a component of C. sonorensis saliva that could cleave VP2 resulting in two predominant 
cleavage products of ~110 and 67 kDa. Additionally, there was also some evidence of chymotrypsin like 
activity of C. sonorensis saliva as indicated by enzyme activity and inhibition assays (Darpel et al., 2011).  
To ensure that the saliva obtained via the modified collection method maintained proteolytic activity 
and was able to cleave BTV VP2, purified BTV-1 Gibraltar 2007/01 KC3 particles (2.5 µg) were incubated 
in the absence or presence of C. sonorensis salivary proteins (1 µg), at 37°C for 30 minutes and the 
protein profile was analysed by 10% SDS-PAGE and subsequently visualised by silver staining. Following 
incubation in the absence of salivary proteins VP2 appeared to remain intact (Figure 3.1; black arrow, 
lane 1) indicating that any observed effect was not solely due to the heat treatment of virus particles. 
In comparison, following the incubation of BTV-1 particles with C. sonorensis saliva, VP2 was found to 
be completely cleaved (Figure 3.2; red arrow, lane 3) generating a single visible cleavage product of ~ 
67 kDa (Figure 3.2; blue arrow, lane 3). A faint detectable band can be seen below VP3 which is observed 
in the presence of an intact VP2 and therefore does not represent a cleavage product (Figure 3.2; lane 
1 and 3). Salivary proteins alone were also heat treated for the respective time and loaded at the same 
amount as used for BTV particle incubation. Salivary proteins were only minimally visible (Figure 3.2; 
lane 2) due to the development time being based on the optimal visualisation of viral proteins. 
However, this does confirm that the additional band observed in lane 3 (Figure 3.2; blue arrow) is not 
of salivary protein origin and is thus a product of VP2 cleavage.  
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Figure 3.2 – Collected C. sonorensis salivary proteins cleave VP2 of purified BTV-1 particles 
Purified BTV-1 particles (2.5 µg) were incubated with C. sonorensis salivary proteins (1 µg) for 30 
minutes at 37°C. BTV-1 viral proteins were analysed by 10% SDS-PAGE and visualised using silver 
staining. When incubated in the absence of C. sonorensis saliva, BTV-1 VP2 remained intact and 
migrated at ~ 110 kDa (black arrow, lane 1) whilst when BTV-1 particles were incubated in the presence 
of C. sonorensis saliva, BTV-1 VP2 was completely cleaved (red arrow, lane 3) resulting in the migration 
of one visible breakdown product of ~ 67 kDa (blue arrow, lane 3). C. sonorensis saliva was also heat 
treated at 37 °C (lane 2) however the proteins are for the majority not visible on this gel due to the 
development time being based on the visualisation of BTV proteins.  
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C. sonorensis saliva is a complex mixture of ~45 proteins, with the trypsin being only one of these 
proteins (Campbell et al., 2005, Langner et al., 2007, Lehiy and Drolet, 2014). The amount of protein 
used throughout this thesis therefore does not offer any indication of its serine protease activity against 
BTV VP2. In order to further compare the trypsin activity of C. sonorensis saliva, purified BTV-1 particles 
were incubated in the presence of varying amounts of C. sonorensis saliva or commercially available 
trypsin (Sigma; T 1426) at 37 °C for 30 minutes. The salivary proteins were analysed by 10% SDS-PAGE 
and visualised by silver staining. Complete cleavage of VP2 was observed following the incubation of 
BTV-1 particles with 1 and 0.5 µg of salivary proteins (Figure 3.3; gel A, lane 3 and 4 respectively) as 
indicated by the loss of VP2 and the visualisation of a cleavage band at ~67 kDa (Figure 3.3; gel A, red 
arrow). In comparison, VP2 remained intact following the incubation of purified particles with the lower 
amounts of salivary proteins; 0.1 to 0.001 µg (Figure 3.3; gel A, lane 5 to 8). The incubation of BTV-1 
particles with 0.1 µg of trypsin resulted in the complete cleavage of VP2 and the generation of a ~67 
kDa cleavage product (Figure 3.3; gel B, lane 3, red arrow). In contrast, the presence of 0.01 and 0.005 
µg trypsin resulted in the incomplete cleavage of VP2 (Figure 3.3; gel B, lane 4 and 5). VP2 was still 
visualised to be partially present, albeit slightly fainter than in the control incubations and a cleavage 
product could be visualised to be migrating below VP3 (Figure 3.3; gel B, blue arrow). Although VP2 
appears to be present following the incubation of BTV-1 particles with 0.01 and 0.005 µg trypsin, due 
to the non-quantitative nature of SDS-PAGE and silver staining the degree of VP2 cleavage, following 
the incubation of BTV-1 particles in the presence of these two amounts of trypsin, could not be 
conclusively determined. In summary, similar levels of VP2 cleavage were found following the 
incubation of purified BTV-1 particles with 0.5 µg of saliva and 0.1 µg of trypsin. 
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Figure 3.3 - Comparison of the proteolytic activity of C. sonorensis salivary proteins and trypsin 
Purified BTV-1 particles (2.5 µg) were incubated with varying amounts of C. sonorensis salivary proteins 
(A) or trypsin (B) for 30 minutes at 37°C. BTV viral proteins were analysed by 10% SDS-PAGE and 
visualised using silver staining. Lane 1 on both gels indicates the incubation of BTV-1 particles in the 
absence of either saliva or trypsin, and lane 2 on gel A and B indicates the incubation of 1 µg saliva or 
0.1 µg trypsin in the absence of BTV-1 particles, respectively. Gel A indicates the incubation of BTV-1 
particles with varying amounts of salivary proteins: lane 3 = 1 µg, lane 4 = 0.5 µg, lane 5 = 0.1 µg, lane 
6 = 0.01 µg, lane 7 = 0.005 µg and lane 8 = 0.001 µg. Gel B indicates the incubation of BTV-1 particles 
with varying amounts of trypsin: lane 3 = 0.1 µg, lane 4 = 0.01 µg, lane 5 = 0.005 µg, lane 6 = 0.001 µg 
and lane 7 = 0.0001 µg. Complete cleavage of VP2 was shown to occur following incubation of BTV-1 
particles with 0.5 µg of saliva and 0.1 µg of trypsin, as indicated by the absence of VP2 and the presence 
of a visible cleavage product at ~67 kDa (red arrow; gel A and B). .   
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The final aim of this chapter was to test the specificity of the proteolytic activity of arthropod saliva 
towards BTV VP2. The proteolytic ability of C. sonorensis saliva to cleave VP2 was compared to that of 
Ae. aegypti, a mosquito arthropod that has not been implicated in the transmission of BTV. Ae. aegypti 
saliva was collected by Laura Jones (MSc Project, University of Surrey), via a technique that was adapted 
from the method used in this thesis for the collection of C. sonorensis saliva. Purified BTV-1 particles (1 
µg) were incubated with C. sonorensis or Ae. aegypti salivary proteins (either 1.5µg or 4.5 µg) at 37 °C 
for 30 minutes or 2 hours and the incubated samples were subsequently analysed by 10% SDS-PAGE 
and visualised by silver staining. Incubation of BTV-1 particles with 1.5 µg or 4.5 µg of C. sonorensis 
salivary proteins were shown to result in the almost complete cleavage of BTV-1 VP2 after 30 minutes 
incubation (Figure 3.4; lane 3 and 4, respectively) resulting in a ~ 67 kDa cleavage product (Figure 3.4; 
lane 3 and 4, red arrow). In contrast, BTV-1 particle incubation with 1.5 µg or 4.5 µg Ae. aegypti salivary 
proteins did not result in VP2 cleavage; an intact VP2 protein was observed following BTV-1 incubation 
with either amount salivary protein (Figure 3.4; lane 5 and 6, blue arrow). In order to test if a longer 
incubation time was needed for VP2 cleavage by Ae. aegypti saliva, purified BTV-1 particles (1 µg) were 
incubated with 1.5 µg or 4.5 µg C. sonorensis or Ae. aegypti salivary proteins at 37 °C for 2 hours. 
Complete cleavage of VP2 was observed for both amounts of C. sonorensis saliva incubated with BTV-
1 particles (Figure 3.5; lane 3 and 4) resulting in the migration of a ~67 kDa cleavage product (Figure 
3.5; lane 3 and 4, red arrow). The longer incubation time did not appear to have an effect on the ability 
of Ae. aegypti saliva to cleave VP2 which remained intact after the 2 hour incubation time (Figure 3.5; 
lanes 5 and 6, blue arrow). Incubation of BTV-1 particles alone for either duration, alongside the 
corresponding conditions, appeared to have no effect on VP2 (Figure 3.4, lane 2; Figure 3.5, lane 2).  
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Figure 3.4 - BTV-1 VP2 remains intact following a 30 minute incubation at 37 °C with Ae. aegypti salivary 
proteins 
Purified BTV-1 particles (1 µg) were incubated with salivary proteins from C. sonorensis or Ae. aegypti 
for 30 minutes at 37 °C. BTV-1 viral proteins were analysed on a 10% SDS-PAGE and visualised using 
silver staining. VP2 of non-heat treated, mock incubated BTV-1 particles (lane 1) and heat treated BTV-
1 particles (lane 2) in the absence of arthropod saliva remained intact. Incubation of BTV-1 particles in 
the presence of either 1.5 µg (lane 3) or 4.5 µg (lane 4) of C. sonorensis saliva, resulted in almost 
complete cleavage of BTV-1 VP2 and in the formation of a ~ 67 kDa cleavage product (red arrow). In 
comparison, the incubation of 1.5 µg (lane 5) or 4.5 µg (lane 6) of Ae. aegypti saliva with BTV-1 particles, 
resulted in VP2 remaining un-cleaved (blue arrow) and hence cleavage products were not visualised. 
Picture generated by L. Jones.  
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Figure 3.5 - BTV-1 VP2 remains intact following a 2 hour incubation at 37 °C with Ae. aegypti salivary 
proteins 
Purified BTV-1 particles (1 µg) were incubated with salivary proteins from C. sonorensis or Ae. aegypti 
for 2 hours at 37 °C. BTV-1 viral proteins were analysed on a 10% SDS-PAGE and visualised using silver 
staining. VP2 of non-heat treated, mock incubated BTV-1 particles (lane 1) and heat treated BTV-1 
particles (lane 2) in the absence of arthropod saliva remained intact. Incubation of BTV-1 particles in 
the presence of either 1.5 µg (lane 3) or 4.5 µg (lane 4) of C. sonorensis saliva, resulted in almost 
complete cleavage of BTV-1 VP2 and in the formation of a ~ 67 kDa cleavage product (red arrow). In 
comparison, the incubation of 1.5 µg (lane 5) or 4.5 µg (lane 6) of Ae. aegypti saliva with BTV-1 particles, 
resulted in VP2 remaining un-cleaved (blue arrow) and hence cleavage products were not visualised. 
Picture generated by L. Jones.  
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3.4 Discussion  
In 2007, a method utilising an artificial membrane feeding system for the collection of Culicoides 
secreted saliva was published (Langner et al., 2007). Due to the large quantities of saliva that could be 
collected via this method, it was advantageous to the earlier approaches for the collection of insect 
saliva via forced midge salivation with pilocarpine and malathion drug treatments (Boorman, 1987). 
The use of the midge feeding system also avoided the presence of contaminating, non-salivary proteins 
that may be present in dissected salivary glands homogenates. The 2007 method of saliva collection 
did, however, use a glass collection and water circulation setup that required an external pump 
combined with the close proximity and handling of large quantities of non-sterile water. Furthermore, 
the feeder reservoir was filled with heparinised horse blood as a stimulus for midge feeding thus, both 
of these components increased the chance of salivary protein contamination with non-salivary proteins 
in the event of a breach in the collection set-up. An adaptation of the Langner et al., (2007) method, 
addressing the above highlighted points as described in materials and methods Section 2.3.2, was 
therefore developed. The glass collection and water circulation setup was substituted for a Hemotek™ 
heated feeder system that was readily available and commonly used for the maintenance of Culicoides 
colonies whilst the use of blood to fill the fluid reservoir was substituted for endotoxin free water in 
order to minimise any potential introduction of non-salivary proteins to the saliva collections.  
Using the Hemotek™ artificial midge feeding system, the collection of C. sonorensis saliva was 
successfully achieved throughout this work resulting in a yield of ~ 250 – 500 µg salivary proteins on 
multiple occasions. Quantities of saliva proteins obtained seemed to be dependant only on the number 
of C. sonorensis supplied at the point of salivary protein collection as the collection that yielded 250 µg 
of proteins utilised less C. sonorensis individuals compared to other collections. The salivary proteins 
collected via the stated method were analysed by SDS-PAGE and subsequently visualised by silver 
staining for each separate batch, thus allowing the confirmation that the collected salivary proteins 
have a profile similar to those previously published (Darpel et al., 2011, Lehiy and Drolet, 2014). Two 
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predominant proteins were identified via silver staining and estimated by their size to most likely 
represent a maltase and a trypsin that have previously been identified using mass spectrometry (Darpel 
et al., 2011, Lehiy and Drolet, 2014). Furthermore, the functions of these two salivary proteins have 
been elucidated; the maltase as an allergen in the context of IBH (Langner et al., 2009) and the trypsin 
in the context of C. sonorensis saliva – BTV interactions (Darpel et al., 2011). The salivary trypsin has 
been characterised for its role in the cleavage of BTV VP2, the outer coat protein of BTV, resulting in 
the generation of ISVPs that have an altered viral structure and infectivity for both mammalian and 
Culicoides cell lines (Darpel et al., 2011). Interestingly, the abundance of this salivary protein appears 
to be vastly reduced in the saliva of C. nubeculosus (Darpel et al., 2011), a vector with low competence 
for BTV (Boorman, 1974, Jones, 1957) thus implying that the presence of proteases within the saliva of 
different Culicoides species may specifically influence VC.  
Prior to the assessment of the biological activity of C. sonorensis salivary proteins in the context of BTV 
infection and immune response modulation, an additional major aim of this chapter was to confirm the 
proteolytic activity of the collected C. sonorensis saliva. Following the incubation of purified BTV-1 
particles with C. sonorensis salivary proteins, VP2 was shown to be cleaved resulting in the generation 
of a single cleavage product of ~ 67 kDa thus confirming the proteolytic activity of the saliva collected 
via the modified method. Although two visible VP2 derived cleavage products have previously been 
reported (Darpel et al., 2011, Mertens et al., 1996), it is possible that the apparently absent ~110 kDa 
cleavage product was present at such low quantities that it was not visible or had migrated very close 
to VP3 on several SDS-PAGE gels analysed and hence it could not be differentiated. The SDS-PAGE and 
silver staining analysis presented in this chapter, and previously highlighted by others (Darpel, 2007), 
has indicated that the analysis of BTV structural proteins by 10% SDS-PAGE results in estimated protein 
sizes slightly lower than those of the previously reported actual protein size, as determined by the 
sequence of the encoding genomic segment (Mertens et al., 1984). This is potentially a function of 
protein charge or the percentage SDS-PAGE gels utilised. It is therefore possible that the cleavage 
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products of VP2 may also migrate at slightly different speeds thus providing another explanation for 
the lack of detectable ~ 110 kDa cleavage product in all cleavage assays.  
Throughout the results presented in this thesis, the amount of C. sonorensis saliva protein used 
represents the sum of a mixture of proteins and the amounts of each salivary protein is not definitively 
characterised. The proteolytic activity of the saliva preparations towards VP2 was therefore determined 
by comparing the cleavage of VP2 by salivary proteins to commercial trypsin. It was found that 0.5 µg 
of saliva and 0.1 µg of trypsin have the same proteolytic activity towards VP2. This matched proteolytic 
activity of C. sonorensis saliva and trypsin towards VP2 is similar to that reported by Darpel., (2007) 
whereby 2 µg of saliva and 0.5 µg of trypsin were shown to comparably cleave VP2. However, the higher 
quantity of saliva (2 µg) that was needed to cleave VP2 of a comparable amount of viral particles (2.5 
µg) presented by Darpel., (2007), may be a reflection of differences in the salivary protein quantification 
between studies. Furthermore, in the present study, purified virus particles used for the saliva cleavage 
assays were not directly quantified but the virus was rather used based upon a previous assumption 
that 2.5 µg of proteins were present within 10 µl of purified virus sample, thus differences in the 
number of virus particles added to the cleavage reaction may also explain these differences. Although 
the salivary trypsin is thought to be the predominant proteolytic enzyme within C. sonorensis saliva, 
enzyme activity and inhibition assays have also highlighted the possible presence of a chymotrypsin like 
protease (Darpel et al., 2011). The estimation of the proteolytic activity of C. sonorensis saliva towards 
VP2, in comparison to commercial trypsin, does not take into account the presence of other proteolytic 
enzymes but nevertheless, confirms the proteolytic ability of the collected C. sonorensis saliva to cleave 
BTV-1 VP2. 
The specificity of VP2 cleavage was assessed by analysing the ability of the saliva from another 
arthropod, Ae. aegypti, to cleave BTV-1 VP2. Transcriptomics has revealed that the saliva of female Ae. 
aegypti contains nine known serine proteases, including a trypsin-like and a chymotrypsin-like protease 
(Ribeiro et al., 2007) thus it is possible that the saliva of Ae. aegypti may be able to cleave VP2 of BTV 
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(Ribeiro et al., 2007). Conversely, it was found that Ae. aegypti saliva was unable to cleave VP2 of BTV-
1, indicating a specificity in the ability of the proteases within the saliva from different arthropods to 
modify the structure of BTV. This specificity may be accountable to the low to moderate sequence 
homology (47 %) between the trypsin of C. sonorensis saliva and the serine proteases within Ae. aegypti 
saliva (Darpel et al., 2011). These findings also partially imply a potential specificity in the ability of 
different vectors to transmit BTV. Ae. aegypti mosquitoes have not been implicated in the transmission 
of BTV and a study by Jennings and Boorman., (1979), highlighted that a cell line derived from Ae. 
aegypti was not able to support BTV replication (Jennings and Boorman, 1979). Furthermore, the saliva 
of C. nubeculosus, a vector that is considered to be non-competent for BTV transmission, has a reduced 
efficiency of VP2 cleavage possibly as a result of very low trypsin levels within secreted saliva thus 
further indicating a specificity of BTV VP2 cleavage even between Culicoides species (Darpel et al., 
2011).  
The strain of virus, and thus potential differences in the viral proteins targeted by salivary proteases, 
may also be implicated in the ability of C. sonorensis saliva to cleave viral proteins. Indeed the saliva of 
C. sonorensis has been shown to selectively cleave VP2 of certain strains of EHDV, whilst VP2 from one 
other strain of EHDV appears to be unaffected by incubation in the presence of C. sonorensis saliva 
(Darpel et al., 2011). Although BTV VP2 cleavage has been confirmed for BTV-1 (Darpel et al., 2011, 
Mertens et al., 1996) and BTV-16 (Darpel et al., 2011), it is currently unknown if C. sonorensis saliva can 
cleave VP2 from all BTV serotypes to the same efficiency. AHSV VP2 has also been shown to be 
susceptible to cleavage by chymotrypsin, thus the ability of Culicoides saliva to directly modify the 
structure of this arbovirus also needs further clarification (Burroughs et al., 1994). Collectively, it is 
therefore highlighted that direct interactions and the modification of arbovirus particles are reliant on 
a number of vector and viral factors that need further elucidation. 
The work presented in the forthcoming chapters of this thesis have investigated the effect of C. 
sonorensis salivary proteins, as a whole, on BTV infection in the ruminant host and the potential 
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immunomodulatory properties of C. sonorensis saliva. Although it has previously been shown, and 
confirmed in this chapter, that C. sonorensis saliva is able to directly modify BTV particles, resulting in a 
modified infectivity for mammalian and insect derived cells (Darpel et al., 2011), this virus-vector saliva 
interaction is unique and has only been shown for BTV and EHDV Culicoides-borne pathogens. Thus, 
although the effect of BTV cleavage on BTV infection in the ruminant host cannot be ignored, it is 
equally likely that C. sonorensis saliva may modulate the host immune response and indirectly alter BTV 
infection.  
3.5 Summary  
The findings presented in this chapter confirm the collection of large quantities of C. sonorensis saliva 
containing a mixture of proteins, comparable with previously reported protein profiles. The saliva 
remains proteolytically active and is capable of cleaving VP2, the outer coating protein of BTV. The 
cleavage of BTV VP2 by C. sonorensis saliva, but not Ae aegypti saliva implies a specificity in the 
proteases present within the saliva from different arthropod vectors. The collection of C. sonorensis 
secreted salivary proteins enables the investigation of their role in BTV infection of host cells and the 
effect of the salivary proteins on the host immune response. Collectively the results of this chapter are 
presented in Figure 3.6.  
 
 
 
 
 
 
Figure 3.6 – Summary schematic highlighting the major findings of Chapter 3. 
C. sonorensis saliva was collected via a modified method resulting in high protein yields. 
The collected C. sonorensis saliva was confirmed to be proteolytically active and able to 
cleave BTV VP2. 
0.5 µg of C. sonorensis saliva and 0.1 µg of trypsin comparably cleaved BTV VP2. 
Ae. aegypti saliva was unable to cleave BTV VP2, potentially highlighting a specificity in the 
ability of C. sonorensis saliva to cleave BTV VP2. 
 
 
 
 
 
 
 
 
Chapter 4 
The effect of 1 µg/ml Culicoides 
sonorensis saliva on BTV infection and 
replication in bovine PBMC 
subpopulations 
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4.1 Introduction 
The saliva of hematophagous arthropods is enriched with a range of pharmacologically active molecules 
that counteract the host haemostatic, immune and inflammatory responses to mediate the successful 
acquisition of a blood meal (Ribeiro, 1995). However, vector saliva may have a greater role than merely 
overcoming the host haemostatic responses as the saliva of arthropods has been implicated to alter 
the infection dynamics of vector-borne pathogens such as protozoa or arboviruses (Table 1.2). Although 
the majority of these studies that have elucidated a role for arthropod saliva in enhancing pathogen 
infections have been carried out in vivo, the collection of secreted arthropod saliva, or alternatively the 
dissection and homogenisation of salivary glands of respective vectors, has enabled detailed in vitro 
investigations to characterise the effects of arthropod saliva on arbovirus infectivity in culture. In vitro 
studies have revealed that the treatment of mouse fibroblast cultures with Aedes triseriatus SGE can 
enhance VSV replication, when compared to untreated infected cultures (Limesand et al., 2003). 
Furthermore, Ae. aegypti SGE can also enhance DENV replication in human keratinocytes 
(Surasombatpattana et al., 2012) and mouse embryonic fibroblasts (Conway et al., 2014) as determined 
by the detection of elevated levels of viral RNA, compared to infection in the absence of SGE. To the 
contrary, Ae. aegypti secreted saliva may also inhibit DENV infection of cultured human monocyte 
derived DCs. Pre-culture of respective monocyte derived DCs with Ae. aegypti secreted saliva also 
further enhanced the saliva induced inhibition of DENV infection as determined by the detection of viral 
proteins by flow cytometry (Ader et al., 2004).  
For all arthropods and arboviruses, the definitive relationship between how much/what concentration 
of salivary proteins and how many virus particles would be deposited into the host skin is unknown. In 
the absence of this knowledge, some publications have reported the usage of exact secreted salivary 
protein or SGE concentrations of 1 µg/ml or above, in order to determine the biological functions of 
the respective salivary proteins in the context of arbovirus infections (Ader et al., 2004, 
Surasombatpattana et al., 2014) or modulation of the host immune response (Bishop et al., 2006, Brake 
and Pérez de León, 2012, Menezes et al., 2008). C. sonorensis saliva was therefore initially trialled at a 
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concentration of 1 µg/ml in the present study to observe if the presence of saliva during BTV infection 
can alter viral replication.  
Although numerous studies have observed a role for arthropod saliva in modifying arbovirus infections 
in the murine model (Table 1.2), this host is often not a natural target for the arboviruses that are being 
studied. The work presented here, it was therefore aimed to determine the effect of C. sonorensis saliva 
on BTV replication in natural ruminant target cells. Although infected sheep succumb to clinical BT 
disease to a greater extent compared to other ruminants, infected cattle are often considered the main 
reservoir hosts for BTV in the field due to their predominant lack of clinical signs and a prolonged cell 
associated viremia of up to 60 d.p.i (Singer et al., 2001). Of great importance, cattle also attract greater 
numbers of host-seeking Culicoides, compared to other smaller ruminant species such as sheep (Elbers 
and Meiswinkel, 2014), due to their large size and the preferred habitat of Culicoides larvae often being 
associated with cattle dung (Kettle and Lawson, 2009). In addition, as a consequence of the farming 
structure in the industrial sector of many Northern European and North American countries, the 
number of cattle at risk of BT is often greater than sheep, leading to a high number of cattle being 
infected during epidemic outbreaks (Conraths et al., 2009). Bovine cells are therefore an ideal target to 
initially determine the effect of Culicoides saliva on BTV replication.  
PBMCs were utilised throughout this work as a readily available source of ruminant target cells that 
have previously been shown to be infected in cattle (MacLachlan et al., 1990) and sheep (Rojas et al., 
2011, Umeshappa et al., 2010b) following in vivo BTV infection. Furthermore, studies have utilised 
bovine PBMCs to carry out in vitro infection studies and have highlighted BTV infection within the 
monocyte population (Barratt-Boyes et al., 1992, Whetter et al., 1989) and within the lymphocyte 
populations following ex vivo activation (Barratt-Boyes et al., 1992, Stott et al., 1990).  
The foremost aim of this chapter was to investigate BTV infection and replication in bovine T and B 
lymphocyte and monocyte populations, within PBMCs, in the absence or presence of 1 µg/ml C. 
sonorensis saliva. To allow quantitative detection of BTV infected cells, flow cytometry assays were 
established and utilised across multiple experiments. BTV infection was determined based upon the 
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proportion of cells expressing BTV VSP, whilst replication was assessed based on the proportion of cells 
co-expressing VSP and the NSP, NS2. Viral protein expression in specific target cells, infected in the 
absence or presence of 1 µg/ml C. sonorensis saliva, was additionally visualised by immunofluorescence 
and subsequent laser scanning confocal microscopy, thereby allowing for comparison and confirmation 
of those results obtained by flow cytometry analysis. These studies were complemented by determining 
the yield of progeny virus production, released by PBMCs infected in the absence or presence of 1 
µg/ml C. sonorensis saliva, to thereby quantify the impact of treatment conditions on the production of 
infectious virus. 
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4.2 Viral protein detection in the subpopulations of PBMCs infected in the absence or presence of C. 
sonorensis saliva  
To determine the cell population(s) within bovine PBMCs that support BTV infection and replication, in 
the absence or presence of C. sonorensis saliva, an initial screen was carried out to identify the 
proportions of different PBMC populations that were expressing VSP and the NSP, NS2. Based upon 
previous studies in mammalian tissue culture cell lines (Hyatt et al., 1989) and sheep ex vivo cell lines 
(Darpel, 2007), a time point of 72 h.p.i was selected as a representative time point of a late stage of 
virus infection. PBMCs were isolated from bovine blood (Section 2.2.2) and infected in suspension with 
a low passage tissue culture BTV-1 strain (Gibraltar 2007/1 KC2 BHK3) at an MOI of 0.1 for one hour in 
the absence (BTV) or presence (saliva 1/BTV) of 1 µg/ml C. sonorensis saliva. Control cells were treated 
with a BHK-21 cell lysate of matched inoculum volume in the absence (mock) or presence of 1 µg/ml C. 
sonorensis saliva (saliva 1) in order to mimic virus infection. Post-infection, the cells were washed three 
times and media plus respective additions were replaced for each of the conditions. At the point of 
harvest, cells were externally labelled with antibodies to specific cellular membrane proteins (Section 
2.6.1), washed and fixed with 4% PFA. BTV infection within PBMC populations was determined by VSP 
expression, whilst BTV replication was determined based on the co-expression of VSP and NSP, above 
background labelling of control conditions. The proportion of identified cell subpopulations expressing 
viral proteins was analysed by flow cytometry assays utilising a standardised gating procedure (Figure 
2. 5). The proportion of live, cell surface membrane protein positively labelled, single cells supporting 
BTV infection and replication was determined at 72 h.p.i for cattle 2, 3 and 4. No or minimal differences 
in background viral antibody labelling were observed between mock and saliva treated conditions 
which were accounted for by the application of background labelling gates that were subsequently 
applied to BTV and saliva 1/BTV conditions, respectively (Figure 4.1 and all Figures thereafter). 
At 72 h.p.i, the proportion of CD4+ T cells expressing VSP appeared to be greatest following BTV 
infection of PBMCs from cattle 2 (Figure 4.1; A). In the absence of saliva, ~ 3.3% of CD4+ T cells within 
PBMCs from cattle 2 expressed VSP (Figure 4.1; A), whilst the proportion of CD4+ T cells, within PBMCs 
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from animals 3 and 4, was minimally detected above the control conditions, irrespective of the 
presence of saliva (Figure 4.1; B and C respectively). In comparison, the presence of saliva during BTV 
infection of PBMCs from animal 2 appeared to slightly reduce the proportion of VSP+ CD4+ T cells (Figure 
4.1; A). When the results from all three animals are combined there is no significant difference in the 
proportion of VSP+ CD4+ T cells from BTV infected or saliva 1/BTV infected cultures (Figure 4.1; D).  
The proportion of CD8+ T cells expressing VSP was also seen to be very low and did not exceed 3% of 
PBMCs from all cattle (Figure 4.1; E – G). The combined results from all cattle indicate the presence of 
saliva during PBMC infection fractionally increased (~1%) the proportion of CD8+ T cells expressing VSP, 
although this difference was not statistically different (Figure 4.1; H).  
Infection within the  TCR+ cells was not affected by the presence of saliva following the infection of 
PBMCs from cattle 2 and 4 (Figure 4.1; I and K respectively). Infection of PBMCs from cattle 3 in the 
presence of saliva did, however, lead to ~ 2% of  T cells expressing VSP whilst in the absence of saliva, 
the proportion of this cell population expressing VSP was minimally detectable above control labelling 
(Figure 4.1; J). Despite this difference, when the results from all three cattle are combined, the presence 
of saliva during infection did not significantly alter the proportion of VSP+  T cells (Figure 4.1; L).  
Following the infection of PBMCs from cattle 2, ~ 8.5% of CD21+ B cells expressed BTV VSP irrespective 
of the presence of saliva during infection (Figure 4.1; M). In comparison, infection of PBMCs from cattle 
3 and 4 (Figure 4.1; N and O, respectively), in the absence or presence of saliva, resulted in a lower 
proportion of CD21+ B cells expressing VSP that did not exceed ~ 2.5%. Collectively, saliva did not 
significantly alter the percentage of VSP+ CD21+ B cells from all three cattle (Figure 4.1; P).  
CD14+ monocytes were shown to be the population of PBMCs from all cattle that were predominantly 
expressing VSP. However, the proportion of monocytes expressing VSP differed greatly in the absence 
of saliva between the PBMCs obtained from different cattle and ranged from ~ 4 (cattle 3 and 4) to 40% 
(cattle 2)(Figure 4.1; R/S and Q, respectively). The presence of saliva during BTV infection of PBMCs was 
also seen to result in a differential effect on monocyte infection between the three animals. The 
presence of saliva during infection was not seen to alter the proportion of VSP expressing monocytes 
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from cattle 2. In comparison, the presence of C. sonorensis saliva during infection of PBMCs from cattle 
3 and 4, resulted in a ~ four times and two times increase in the percentage of monocytes expressing 
VSP (Figure 4.1; R and S, respectively). When the data from the three animals used in this initial screen 
were combined, despite the presence of C. sonorensis saliva enhancing BTV infection in the monocyte 
population of two out of the three cattle tested, the combined difference in the proportion of cells 
expressing VSP, following BTV infection in the absence or presence of saliva was not statistically 
different (Figure 4.1; T).  
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Figure 4.1 – Within PBMCs, a higher proportion of monocytes express BTV structural proteins compared to 
respective lymphocyte populations 
Bovine PBMCs were infected with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour in the absence or 
presence of 1 µg/ml C. sonorensis saliva (cattle 2 – saliva batch number 5, cattle 3 and 4 – saliva batch number 
4). Cells were washed three times and saliva was replaced onto the relevant conditions. PBMC populations from 
three cattle were identified based on their expression of specific cellular membrane proteins. Virus infection 
within PBMC populations was determined at 72 h.p.i based on the expression of VSPs. Data from all replicates 
were combined and plotted as the mean ± standard deviation and statistical differences between the treatment 
groups of BTV infected and saliva 1/BTV infected cells were determined using the Mann Whitney test.  
 
   Cattle 2                     Cattle 3                          Cattle 4                            Combined  
NOTE: different axis. 
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VSP expression has been used as a marker of BTV infection, but it does not definitely indicate successful 
replication of the virus. The NSP, NS2, is only expressed during BTV replication and is a major 
component of cytoplasmic VIBs that are the sites of viral replication and morphogenesis (Kar et al., 
2007, Matsuo and Roy, 2013, Thomas et al., 1990). The expression of NS2, was therefore used to 
investigate the effect of C. sonorensis saliva on BTV replication. 
A very low proportion (≤ 1.5%) of the CD4+, CD8+ and  TCR+ T cell populations within PBMCs from 
cattle 2, 3 and 4 were seen to express NSP at 72 h.p.i, irrespective of the presence of C. sonorensis saliva 
during BTV infection (Figure 4.2; A – L). Furthermore, when the results from each cellular subset from 
all three cattle were combined, the presence of saliva during PBMC infection did not result in a 
significant alteration in the proportion of these cells expressing NSP (Figure 4.2; D, H and L).  
BTV infection, in the absence or presence of C. sonorensis saliva, led to NSP expression in ~6% of B cells 
within PBMCs from cattle 2 (Figure 4.2; M) and ~1% of B cells within PBMCs from cattle 3 and 4 (Figure 
4.2; N and O, respectively). When present during infection, C. sonorensis saliva therefore did not appear 
to impact on the proportion of B cell expressing NSP during infection as reflected in the combined 
results from all cattle (Figure 4.2; P). 
BTV infection of PBMCs in the presence of saliva resulted in a notable enhancement in the proportion 
of monocytes expressing NSP in all cattle (Figure 4.2; Q - S) and collectively the presence of saliva 
significantly enhanced the proportion of monocytes expressing NSP (p = 0.0051; Figure 4.2; T). A ~ four 
times increase in the frequency of NSP expressing monocytes was seen following BTV infection of 
PBMCs from cattle 2 and 4 in the presence of saliva (Figure 4.2; Q and S, respectively). Furthermore, 
infection of PBMCs from cattle 3, resulted in a ~ seven times increase in the proportion of monocytes 
expressing NSP in the presence of saliva compared to BTV infection alone (Figure 4.2; Q). Interestingly, 
despite the very high proportion of VSP expressing monocytes within PBMCs from cattle 2, NSP 
expression was seen in a much smaller proportion of cells (~1.5 – 5%), comparable to that seen in the 
other cattle.  
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Collectively, the results from this initial screen highlight that a greater proportion of the CD14+ 
monocyte population within PBMCs become infected with BTV when compared to the lymphocyte 
populations. Furthermore, BTV infection and replication is enhanced within the monocyte population 
in the presence of C. sonorensis saliva. As infection within the assayed lymphocyte populations of 
PBMCs was detectable, albeit minimal, the role of lymphocytes in BTV infection and replication cannot 
be discounted.  
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Figure 4.2 – A greater proportion of the monocyte population within PBMCs express NSP following BTV 
infection and culture in the presence C. sonorensis saliva 
Bovine PBMCs were infected with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour in the absence or presence of 1 
µg/ml C. sonorensis saliva (cattle 2 – saliva batch number 5, cattle 3 and 4 – saliva batch number 4). Cells were washed 
three times and saliva was replaced onto the relevant conditions. PBMC populations from three cattle were identified based 
on their expression of specific cellular membrane proteins. Virus replication was determined at 72 h.p.i, based upon the 
proportion of assessed PBMC populations expressing the NSP, NS2 (within the population of VSP positive cells). Data from 
all replicates were combined and, plotted as the mean ± standard deviation and statistical  differences between the 
treatment groups of BTV infected and saliva 1/BTV infected cells were determined using the Mann Whitney test.  
NOTE: different axis. 
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4.3 Viral protein detection in the monocyte population of PBMCs following infection, for a varying time 
after inoculation, in the absence or presence of C. sonorensis saliva   
The presence of C. sonorensis saliva during BTV infection of PBMCs was seen to enhance the proportion 
of CD14+ monocytes expressing VSP in two of the three cattle tested in the initial screen (Section 4.2). 
In addition, a significant increase in the proportion of monocytes, within PBMCs, expressing NSP was 
seen in all cattle tested. To further characterise BTV infection dynamics in the monocyte population of 
PBMCs in the presence of C. sonorensis saliva, PBMCs from a single cattle (cattle 1) were isolated on 
four separated occasions and infected with a BTV-1 Gibraltar 2007/1 KC2BHK3 strain at an MOI of 0.1 in 
the absence or presence of 1 µg/ml C. sonorensis saliva. After this time the viral inoculum was washed 
off and C. sonorensis saliva was reapplied to the relevant conditions. Furthermore, to allow a better 
assessment of BTV infection dynamics in the monocyte population of PBMCs in the absence or presence 
of saliva, an extended range of time points were tested and VSP and NSP expression was determined 
within the CD14+ monocytes at 2, 24, 48 and 72 h.p.i. These time points were selected to establish 
whether BTV proteins could be detected by flow cytometry at 2 h.p.i, simply as a consequence of viral 
uptake despite the low MOI used, and to determine the proportion of monocytes expressing VSP and 
NSP following multiple rounds of virus replication at 24, 48 and 72 h.p.i in the absence or presence of 
saliva (Hyatt et al., 1989).  
At 2 h.p.i, BTV VSP was detected in only a small proportion (0.5 - 2%) of monocytes infected in the 
absence or presence of saliva (Figure 4.3; A) therefore confirming that VSP and NSP detection at 
subsequent time points was due to viral protein expression. The proportion of monocytes expressing 
VSP increased by 24 h.p.i and remained roughly constant up to 72 h.p.i, following BTV infection in the 
absence of saliva. In comparison, when BTV infected cells were cultured in the presence of salivary 
proteins, the proportion of monocytes expressing VSP increased across the time points post-infection 
when compared to the preceding time point. Furthermore, a greater proportion of monocytes cultured 
in the presence of salivary proteins expressed VSP at 24 h.p.i, 48 and 72 h.p.i compared to cells cultured 
in the absence of salivary proteins (Figure 4.3; A, p = 0.0457, 0.0021 and 0.0081, respectively).  
~ 122 ~ 
 
In the absence of saliva, a very low proportion of monocytes expressed NSP (≤ ~ 0.5%) at all time points 
post-infection whilst in comparison, infection in the presence of saliva, lead to ~ 7% of monocytes 
expressing NSP at 72 h.p.i (Figure 4.3; B). Furthermore, the proportion of monocytes expressing NSP 
following infection and culture in the presence of salivary proteins, was significantly greater than of 
cells infected and cultured in the absence of salivary proteins at 24 , 48 and 72 h.p.i (Figure 4.3; B, p = 
0.0009, 0.0013 and 0.0006, respectively). These results indicate that VSP and NSP expression is 
significantly enhanced in CD14+ monocytes within PBMCs of cattle 1 in the presence of C. sonorensis 
saliva. 
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Figure 4.3- BTV infection of PBMCs from cattle 1 in the presence of C. sonorensis saliva significantly 
enhances the proportion of monocytes expressing VSP and NSP 
Bovine PBMCs were incubated with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour in the absence 
or presence of 1 µg/ml C. sonorensis saliva (batch number 2), washed three times and saliva was 
replaced onto the relevant conditions. The proportion of CD14+ monocytes expressing VSP (A) and the 
NSP, NS2 (B) was determined by flow cytometry at 2, 24, 48 and 72 h.p.i. Data shown is the mean ± 
standard deviation of three independent experiments at 2 h.p.i and four independent experiments at 
the subsequent time points using PBMCs isolated from the same animal. Statistically significant 
differences, between the treatment groups of BTV infected and saliva 1/BTV infected cells at each time 
point, were determined using the Mann Whitney test. 
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To ensure that the observed results are reproducible across different animals, and not due to a unique 
response of cattle 1 PBMC derived monocytes, similar experiments were carried out using PBMCs from 
three additional cattle, one of which was used for the initial screen. PBMCs were isolated on numerous 
occasions, and infected with the BTV-1 Gibraltar 2007 KC2BHK3 strain at an MOI of 0.1. After a 1 hour 
infection time, cells were washed three times and saliva was replaced onto the relevant conditions.  
Following BTV infection of PBMCs from cattle 3, in the absence or presence of 1 µg/ml C. sonorensis 
saliva, minimal levels of VSP were detected at 2 h.p.i (Figure 4.4; A). The percentage of monocytes 
expressing VSP, irrespective of the presence of saliva, was seen to have increased by 24 h.p.i and 72 
h.p.i. Furthermore, the presence of saliva during infection enhanced the proportion of monocytes 
expressing VSP at 24 h.p.i and 72 h.p.i, with this increase being significantly different at 24 h.p.i, 
compared to cells infected in the absence of saliva (Figure 4.4; A, p = 0.0304). NSP expression was also 
detected in a statistically greater proportion of monocytes at 24 and 72 h.p.i following the infection of 
PBMCs from cattle 3 in the presence of saliva, compared to respective cells infected in the absence of 
saliva (Figure 4.4; B, p = 0.0304, both time points).  
When comparing conditions within each time point post-infection of PBMCs from cattle 5, a significant 
increase in the proportion of monocytes expressing VSP was seen following infection in the presence 
of saliva at 24 and 72 h.p.i (Figure 4.5; A, p = 0.0051 and p= 0.0131, respectively). Furthermore, the 
presence of saliva also significantly increased the proportion of monocytes expressing NSP at 24 and 72 
h.p.i (Figure 4.5; B, p = 0.0051, both time points), compared to respective cells infected in the absence 
of saliva. 
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Figure 4.4 - BTV infection of PBMCs from cattle 3 in the presence of C. sonorensis saliva significantly 
enhances the proportion of monocytes expressing VSP and NSP 
Bovine PBMCs were incubated with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour in the absence 
or presence of 1 µg/ml C. sonorensis saliva (batch number 3), washed three times and saliva was 
replaced onto the relevant conditions. The proportion of CD14+ monocytes expressing VSP (A) and the 
NSP, NS2 (B) was determined by flow cytometry at 2, 24 and 72 h.p.i. Data shown is the mean ± standard 
deviation of two independent experiments at all time points using PBMCs isolated from the same 
animal. Statistically significant differences, between the treatment groups of BTV infected and saliva 
1/BTV infected cells at each time point, were determined using the Mann Whitney test.  
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Figure 4.5 - BTV infection of PBMCs from cattle 5 in the presence of C. sonorensis saliva significantly 
enhances the proportion of monocytes expressing VSP and NSP 
Bovine PBMCs were incubated with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour in the absence 
or presence of 1 µg/ml C. sonorensis saliva (batch number 5 and 6), washed three times and saliva was 
replaced onto the relevant conditions. The proportion of CD14+ monocytes expressing VSP (A) and the 
NSP, NS2 (B) was determined by flow cytometry at 24 and 72 h.p.i. Data shown is the mean ± standard 
deviation of three independent experiments at both time points using PBMCs isolated from the same 
animal. Statistically significant differences, between the treatment groups of BTV infected and saliva 
1/BTV infected cells at each time point, were determined using the Mann Whitney test.  
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The infection of PBMCs from cattle 2 in the initial screen was shown to result in ~ 40% of the monocyte 
population expressing VSP, regardless of the presence of saliva during infection. These results obtained 
when carrying out infection studies using PBMCs from this cattle therefore do not follow the same 
trend of Culicoides saliva enhanced BTV infection, as was observed when carrying out infection studies 
using PBMCs from the remaining cattle tested. To investigate if the observed high level of VSP 
expression by the monocyte population of cattle 2 PBMCs was an irregular response on the day of 
PBMC isolation and infection, or as a result of a cattle PBMC donor that does not typically respond to 
the presence of saliva during infection, cells were isolated from this animal on a further occasion. The 
analysis of statistical differences could not be carried out on this single repeat, however this replicate 
highlighted that BTV infection in the presence of saliva resulted in a greater proportion of monocytes 
within PBMCs from cattle 2 expressing VSP (Figure 4.6; A) and NSP (Figure 4.6; B) at 24 and 72 h.p.i. 
The results from cattle 1, 2, 3 and 5 (excluding the initial screen data) were next combined. BTV 
infection of PBMCs in the presence of 1 µg/ml C. sonorensis saliva resulted in a significantly greater 
proportion of monocytes expressing VSP at 24, 48 and 72 h.p.i (Figure 4.7; A, p = 0.0041, 0.0021 and 
0.0001, respectively). Furthermore, the combined results from all four cattle indicate that the 
percentage of monocytes expressing NSP was significantly increased, following infection in the 
presence of saliva, at 24, 48 and 72 h.p.i (Figure 4.7; B, p = <0.0001, 0.0015 and <0.0001, respectively), 
thus further highlighting the enhancing effect of C. sonorensis saliva on BTV replication. 
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Figure 4.6 - BTV infection of PBMCs from cattle 2 in the presence of C. sonorensis saliva results in a 
significantly greater proportion of monocytes expressing VSP and NSP 
Bovine PBMCs from cattle 2 were incubated with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour 
in the absence or presence of 1 µg/ml C. sonorensis saliva (batch number 3), washed three times and 
saliva was replaced onto the relevant conditions. The proportion of CD14+monocytes expressing VSP 
(A) and NSP (B) was analysed at 2, 24 and 72 h.p.i. As the data represented here is a single replicate, 
statistical analysis could not be carried out.  
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Figure 4.7 - BTV infection of PBMCs from four cattle, in the presence of C. sonorensis saliva, significantly 
enhances the proportion of monocytes expressing viral proteins  
Bovine PBMCs were incubated with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour in the absence 
or presence of 1 µg/ml C. sonorensis saliva, washed three times and saliva was replaced onto the 
relevant conditions. The proportion of CD14+ monocytes expressing VSP (A) and the NSP, NS2 (B) was 
analysed at 2, 24, 48 and 72 h.p.i in PBMCs from cattle 1, 2, 3 and 5. The following number of replicates 
are displayed; cattle 1 – 2 h.p.i (n = 3), 24 h.p.i (n = 4), 48 h.p.i (n = 4), 72 h.p.i (n = 4); cattle 2 - 2 h.p.i 
(n = 1), 24 h.p.i (n = 1), 72 h.p.i (n = 1); cattle 3 - 2 h.p.i (n = 2), 24 h.p.i (n = 2), 72 h.p.i (n = 2) and cattle 
5 - 24 h.p.i (n = 3), 72 h.p.i (n = 3). Data from all replicates were combined, plotted as the mean ± 
standard deviation and statistical differences between the treatment groups of BTV infected and saliva 
1/BTV infected cells, at each time point, were determined using the Mann Whitney test.   
NOTE: different axis. 
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BTV entry into ruminant immune cells has previously been shown to be slow (Moffat et al., personal 
communication), therefore it is possible that a low number of virus particles were able to enter 
monocytes prior to the wash step at 1 h.p.i and the removal of the majority of the viral inoculum. To 
further investigate this possibility and to determine the effect of a prolonged cellular viral inoculum 
exposure time on infection dynamics, PBMCs from cattle 1 were isolated on three separate occasions 
and infected in culture at MOI 0.1 with a BTV-1 Gibraltar 2007/1 BTV-1 KC2BHK3 strain in the absence 
or presence of 1 µg/ml C. sonorensis saliva. The viral inoculum was not removed for this set of 
experiments, thereby allowing for maximal viral uptake. VSP and NSP expression was determined within 
the CD14+ monocyte population of PBMCs at 2, 24, 48 and 72 h.p.i. 
At 2 h.p.i of PBMCs with BTV, VSP was only detected in a very low proportion (~2%) of CD14+ monocytes 
and the presence of saliva during infection appeared to have little or no effect on the proportion of 
monocytes expressing VSP (Figure 4.8; A). By 24, 48 and 72 h.p.i, VSP was detected in a higher 
proportion of monocytes, compared to the proceeding time point, whether cells were infected in the 
absence or presence of saliva. Furthermore, the presence of saliva during PBMC infection, from all three 
replicates, did not alter the proportion of monocytes expressing VSP to a statistically significant level at 
24, 48 and 72 h.p.i (Figure 4.8; A). In comparison, a significantly higher proportion of monocytes were 
found to express NSP at 24, 48 and 72 h.p.i in the presence of saliva, when compared to BTV infection 
in the absence of saliva (Figure 4.8; B, p = 0.0453, 0.0051 and 0.0022, respectively). When comparing 
NSP expression across time points but within condition, it was found that in the absence of saliva, the 
percentage of monocytes expressing NSP only fractionally increased over time reaching a maximum of 
~1% of monocytes at 72 h.p.i. To the contrary, infection in the presence of saliva resulted in a marked 
increase in the percentage of monocytes expressing NSP by 24, 48 and 72 h.p.i (Figure 4.8; B). 
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Figure 4.8 – The presence of C. sonorensis saliva during prolonged BTV infection of bovine PBMCs 
enhances the proportion of monocytes expressing BTV NSP, but not VSP 
Bovine PBMCs were infected with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 in the absence or presence 
of 1 µg/ml C. sonorensis saliva (batch number 2). Viral inoculum was not removed. The proportion of 
CD14+ monocytes expressing VSP (A) and the NSP, NS2 (B) was determined by flow cytometry at 2, 24, 
48 and 72 h.p.i. Data shown is the mean ± standard deviation of two independent experiments at 2 
h.p.i and three independent experiments harvested at subsequent time points using PBMCs from cattle 
1. Data from all replicates were combined and statistical differences between the treatment groups of 
BTV infected and saliva 1/BTV infected cells, at each time point, were determined using the Mann 
Whitney test.  
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4.4 Confocal microscopy of the monocyte population of PBMCs infected in the absence or presence of 
C. sonorensis saliva 
The above BTV infection studies suggest that VSP and NSP expression is significantly enhanced in the 
monocyte population of PBMCs, following infection with BTV in the presence of C. sonorensis saliva, 
compared to BTV infection in the absence of saliva. To enable the visualisation of viral protein 
expression in bovine PBMCs and to assess the respective phenotype of infected and non-infected cells 
across conditions, similar infection experiments were carried out utilising immunofluorescence 
labelling and laser scanning confocal microscopy. PBMCs were isolated from cattle 3, infected as above 
in the absence or presence of 1 µg/ml C. sonorensis saliva and at 72 h.p.i, PBMCs were externally 
labelled with an antibody for the detection of the cellular membrane protein CD14 and allowed to settle 
onto poly-lysine coated coverslips. BTV infection and replication was detected by immunofluorescence 
using specific antibodies to BTV VSP and the NSP, NS2, and subsequently analysed by laser scanning 
confocal microscopy (Section 2.7). Secondary antibody only labelled cells showed no background 
fluorescence (Figure 4.9; A). Additionally, VSP and NSP labelling was not detected in cells from mock 
infected (Figure 4.9; B) or saliva treated (Figure 4.9; G) cultures whilst viral protein expression was 
detected in cells from BTV (Figure 4.9; C – F) and saliva 1/BTV (Figure 4.8; H – K) infected cultures.  
In the absence of saliva, VSP labelling of monocytes appeared to be either speckled (Figure 4.9; C and 
D) or entirely distributed throughout the cytoplasm (Figure 4.9; E and F). Cells expressing VSP 
throughout the cytoplasm also typically labelled positively for NSP, indicating the localisation of VIBs 
(Figure 4.9; E and F). In the presence of saliva, VSP labelling of infected monocytes appeared to be 
predominantly dispersed throughout the cytoplasm and less speckled. Almost all of the VSP expressing 
monocytes observed also co-expressed NSP indicating VIBs of various, and often larger, sizes (Figure 
4.9; H - K). 
Although the confocal microscopy analysis shown in Figure 4.9 is not quantitative and only 
representative of one replicate using PBMCs from one cattle, flow cytometry (Figure 4.10; A/B) and 
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confocal microscopy (Figure 4.9) analysis of the same infection replicate was possible (cells were 
divided at the point of harvest) and highlighted consistent results between analysis techniques. Both 
confocal microscopy and flow cytometry analysis indicated that a higher proportion of monocytes 
expressed VSP and NSP following PBMC infection in the presence of saliva, compared to respective cells 
infected in the absence of saliva (Figure 4.9 and Figure 4.10; A/B). Furthermore, following infection in 
the presence of saliva, NSP labelling was also seen to result in a greater number and size of VIBs per 
cell as determined by confocal microscopy (Figure 4.9; H – K).   
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Continued… 
Figure 4.9 – Viral protein expression within the monocyte population of infected PBMCs
Non-specific secondary antibody binding control  
A 
Mock infected cells  Saliva 1 treated cells  
BTV infected cells  
Saliva 1 treated/BTV 
infected cells  
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G 
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TO-PRO-3 2° Ab 2° Ab 2° Ab 
TO-PRO-3 CD14 VSP NSP TO-PRO-3 CD14 VSP NSP 
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Figure 4.9 – Viral protein expression within the monocyte population of infected PBMCs 
Bovine PBMCs were incubated with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour in the absence or 
presence of 1 µg/ml C. sonorensis saliva (batch number 4), washed three times and saliva was replaced onto the 
relevant conditions. At 72 h.p.i cells were externally labelled with an antibody for the detection of the cell surface 
membrane protein, CD14 (Blue), fixed and labelled with antibodies for the detection of BTV VSP (Green) and the 
NSP, NS2 (Red) (Table 2.4). Cell nuclei were TO-PRO-3 stained (Purple). Scale bar represents 10 μm. Panel A 
indicates that secondary antibodies do not bind non-specifically to respective cells and panel B and G indicate the 
absence of background labelling of VSP and NSP antibodies on mock infected or saliva treated cells, respectively. 
Panels C – F outlines representative BTV infected cells in the absence of saliva whilst panels H – K shows 
representative BTV infected cells in the presence of saliva.
BTV infected cells  
Saliva 1 treated/BTV 
infected cells  
D I 
TP-PRO-3 CD14 VSP NSP TO-PRO-3 CD14 VSP NSP 
E 
TO-PRO-3 CD14 VSP NSP 
J 
TO-PRO-3 CD14 VSP NSP 
K 
TO-PRO-3 CD14 VSP NSP 
F 
TO-PRO-3 CD14 VSP NSP 
BTV infected cells  
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Figure 4.10 – The proportion of monocytes within PBMCs from cattle 3 expressing VSP and NSP is 
enhanced following BTV infection in the presence of C. sonorensis saliva as determined by flow 
cytometry 
Bovine PBMCs were incubated with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour in the absence 
or presence of 1 µg/ml C. sonorensis saliva (batch number 4), washed three times and saliva was 
replaced onto the relevant conditions. At 72 h.p.i cell cultures were split to allow simultaneous analysis 
of BTV protein expression by flow cytometry and confocal microscopy. Confocal microscopy analysis 
can be seen in Figure 4.8. The proportion of CD14+ monocytes expressing VSP (A) and the NSP, NS2 (B) 
was assessed and is plotted as the mean ± standard deviation.  
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Confocal microscopy analysis also identified BTV infection in large, non-CD14 membrane protein 
expressing cells within infected PBMC cultures. Although infected cells with this large non-CD14 
expressing phenotype were seen in cultures infected in the absence (Figure 4.11; A, B and C) and 
presence of C. sonorensis saliva (Figure 4.11; E, F and G), they were more frequently seen following 
infection in the presence of saliva. Further characterisation of these cells was not carried out and thus 
their phenotype is unknown. 
Infection in lymphocyte-like cells was rarely observed by confocal microscopy in BTV infected or saliva 
1/BTV infected cultures (Figure 4.11; D and F/H, white arrows). This is consistent with flow cytometry 
data that observed low levels of infection in lymphocyte populations, particularly T cells, of PBMCs. The 
assessments of BTV infection and replication in lymphocyte populations by flow cytometry (Section 4.1) 
and the confocal analysis displayed here are based upon the same replicate using cells from cattle 3. 
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Figure 4.11 – Viral protein expression by non-CD14 expressing cells within BTV infected PBMCs 
Bovine PBMCs were incubated with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour in the absence or 
presence of 1 µg/ml C. sonorensis saliva (batch number 4), washed three times and saliva was replaced onto the 
relevant conditions. At 72 h.p.i, cells were externally labelled with an antibody for the detection of the cell surface 
membrane protein, CD14 (Blue), fixed and labelled with antibodies for the detection of BTV VSP (Green) and the 
NSP, NS2 (Red). Cell nuclei were TO-PRO-3 stained (Purple). Scale bar represents 10 μm. Panel A - D indicates 
representative BTV infected cells in the absence of saliva and panels E – H shows representative BTV infected cells 
in the presence of saliva. White arrows indicate lymphocyte-like cells expressing viral proteins.  
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4.5 Viral protein expression in purified monocyte cultures infected in the absence or presence of C. 
sonorensis saliva 
The presence of C. sonorensis saliva during PBMC infection, as shown in Sections 4.2 – 4.4, can enhance 
BTV infection and replication in the monocyte population of this heterogeneous cell mix. In comparison, 
the effect of saliva on BTV infection and replication within the T and B cells, was seen to be minimal 
(Figure 4.1 and 4.2). Despite this, the presence of saliva during PBMC infection may alter the activity of 
lymphocyte sub-populations leading to, for example, an increase in cytokine production that may in 
turn have a bystander effect on BTV infection of the monocyte population.  
To investigate if the observed increase in BTV infection and replication within monocytes is dependent 
on interactions with other PBMC populations, magnetically sorted monocytes were infected in the 
absence or presence of 1µg/ml C. sonorensis saliva. PBMCs were isolated from four animals on separate 
occasions and monocytes were purified via positive MACS (Section 2.2.3) based on their expression of 
the cell surface membrane protein CD14. All purified monocyte cultures were confirmed to be >98% 
pure (Figure 2.1). Monocyte cultures were rested overnight, to allow the detachment of the antibody 
labelled magnetic beads and subsequently infected in culture at MOI 0.1 with the BTV-1 Gibraltar 
2007/1 BTV-1 KC2BHK3 strain in the absence or presence of 1µg/ml C. sonorensis saliva. Cells were 
washed three times and saliva was replaced onto the relevant conditions. Similarly to the analysis in 
PBMCs, specific antibodies to BTV VSP were used to determine the proportion of monocytes that were 
infected, whilst co-expression of VSP and the NSP, NS2 was used to determine the proportion of 
monocytes supporting virus replication. Viral protein expression was assessed by flow cytometry and 
the application of a standardised gating procedure (Figure 2.5) following the infection of monocytes 
from cattle 2 (n = 1) at 2 h.p.i and from cattle 2 (n = 1), cattle 3 (n = 2), cattle 4 (n = 1) and cattle 5 (n = 
1) at 24 h.p.i. Monocyte viability decreased after two days of culture thus, monocyte infection and 
replication was not assessed at time points later than 24 h.p.i.  
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To investigate the possibility that virus particles taken up by the monocytes at 1 h.p.i may be detected, 
despite the low MOI, the expression of BTV VSP and NSP was determined following the washing-off of 
the viral inoculum. Levels of VSP and NSP detection were not seen above control labelling of mock and 
saliva treated cells therefore confirming that infection at subsequent time points was due to viral 
protein production.  
When the results from all cattle and replicates were combined, the presence of C. sonorensis saliva 
during infection significantly enhanced the proportion of monocytes expressing VSP (Figure 4.12; A, p 
= 0.0173) and NSP (Figure 4.12; B, p = 0.0002) at 24 h.p.i of purified monocytes obtained from four 
cattle on five separate occasions. This enhancement of BTV infection and replication in purified 
monocytes indicates that saliva can directly alter the dynamics of BTV infection in this cell type, 
independently of other cell populations present within PBMCs. 
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Figure 4.12 - The infection of purified monocytes in the presence of C. sonorensis saliva enhances the 
proportion of cells expressing BTV viral proteins 
 
Bovine monocytes were isolated on five separate occasions, from four different cattle PBMCs, and 
infected with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour in the presence of 1 µg/ml C. 
sonorensis saliva (batch number 4), washed three times, and the proportion of monocytes expressing 
VSP (A) and NSP, NS2 (B), was analysed at 2 and 24 h.p.i. Cattle 2 monocytes were harvested at 2 h.p.i 
and cattle 2 (n = 1), cattle 3 (n = 2), cattle 4 (n = 1) and cattle 5 (n = 1) monocytes were harvested at 24 
h.p.i. Data obtained at 24 h.p.i from all cattle and replicates was combined, plotted as the mean ± 
standard deviation and statistical differences between the treatment groups of BTV infected and saliva 
1/BTV infected cells, at each time point, were determined using the Mann Whitney test.   
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4.6 Confocal microscopy of purified monocyte cultures infected in the absence or presence of C. 
sonorensis saliva 
Immunofluorescence labelling and laser scanning confocal microscopy analysis was used to confirm and 
visualise VSP and NSP expression within purified monocyte cultures at 24 h.p.i. Monocytes were 
isolated from cattle 2 PBMCs and infected as above in the absence or presence of 1 µg/ml C. sonorensis 
saliva. Cells from the monocyte cultures were allowed to settle onto poly-lysine coated coverslips, prior 
to fixation and subsequent internal labelling with specific antibodies to BTV VSP and the NSP, NS2 
(Section 2.7). VSP and NSP labelling was not seen in cells from mock infected or saliva 1 treated cultures 
(Figure 4.13; A and G, respectively).  
VSP expression in BTV infected cells in the absence of saliva was predominantly speckled (Figure 4.13; 
B - F) with occasional combined regions of VSP expression (Figure 4.13; B). Although less frequently 
seen, some monocytes also displayed an altered distribution of VSP with labelling throughout the 
cytoplasm and these cells typically expressed NSP (Figure 4.13; E). Monocytes from cultures infected in 
the presence of saliva were also seen to express VSP alone (Figure 4.13; J) however, VSP and NSP co-
expressing cells were more frequently observed (Figure 4.13; H, I, K and L). Furthermore, NSP labelling 
detected VIBs of varying proportions; some cells were seen to contain small VIBs (Figure 4.13; I) whilst 
others contained a range of different sized VIBs (Figure 4.13; H, K and L). Although the confocal analysis 
shown in Figure 4.13 is not quantitative and is only representative of one replicate using purified 
monocytes from one cattle PBMCs, the results observed are consistent with the flow cytometry analysis 
obtained from the same infection replicate (Figure 4.14 A/B) whereby a greater proportion of purified 
monocyte co-express VSP and NSP following infection in the presence of saliva. Flow cytometry (Figure 
4.14; A/B) and confocal microscopy (Figure 4.13) analysis of the same infection replicate was possible 
as the cells were divided at the point of harvest.  
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Continued… 
Figure 4.13 - Viral protein expression within BTV infected, purified monocyte cultures  
Saliva 1 treated cells  
BTV infected cells  
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Figure 4.13 - Viral protein expression within BTV infected, purified monocyte cultures 
Bovine purified monocytes were infected with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour in 
the presence of 1 µg/ml C. sonorensis saliva (batch number 4), washed three times and cultured for 24 
hours. Cells were fixed and labelled with antibodies for the detection of BTV VSP (Green) and the NSP, 
NS2 (Red). Cell nuclei were DAPI stained (Blue). Scale bar represents 10 μm. Panel A and G indicates 
antibody labelled cells from mock and saliva 1 treated cell cultures, respectively. Panels B – F shows 
representative cells from BTV infected cultures in the absence of saliva and panels H – L indicate 
representative cells from BTV infected cultures in the presence of saliva. 
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BTV infected cells  
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infected cells  
D 
E 
F 
J 
K 
L 
DAPI VSP NSP 
DAPI VSP NSP DAPI VSP NSP 
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Figure 4.14 – The proportion of purified monocytes from cattle 3 expressing viral proteins following BTV 
infection and culture in the presence and absence of C. sonorensis saliva as determined by flow 
cytometry 
 
Isolated bovine monocytes from cattle 3 were infected with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 
for 1 hour in the presence of 1 µg/ml C. sonorensis saliva (batch number 4) and washed three times. At 
24 h.p.i cell cultures were split to allow simultaneous analysis of BTV infection by flow cytometry and 
confocal microscopy. Confocal microscopy analysis can be seen in Figure 4.12. Flow cytometry analysis 
allowed the quantification of the proportion of monocytes expressing VSP (A) and the NSP, NS2 (B) at 
24 h.p.i. The percentage of monocytes expressing BTV VSP and NSP was assessed and is plotted as the 
mean ± standard deviation.  
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4.7 Progeny virus production from PBMC and purified monocyte cultures following BTV infection and 
culture in the absence or presence of C. sonorensis saliva 
Alongside the determination of the effect of C. sonorensis saliva on the expression of viral proteins 
within BTV infected PBMC and purified monocyte cultures, supernatants of the cell cultures were also 
obtained at set time points post-infection for the determination of progeny virus production by virus 
titration (Section 2.4.2). The following determination of viral progeny virus production from cattle 1 
PBMCs and purified monocyte cultures, utilised the supernatants of the cell cultures presented in this 
chapter for the determination of viral protein expression (Figure 4.3 and 4.12, respectively). The 
progeny virus production from cattle 2, 3 and 5 PBMCs utilised the supernatants from PBMC cultures 
used for the determination of the minimum dose of saliva to enhance viral protein expression in chapter 
5 (Figure 5.6).  
An efficient removal of the virus inoculum allows a greater ability to detect progeny virus production 
within cell culture supernatants by virus titration. Despite the three wash steps, the efficiency of 
washing off the virus inoculum from cattle 1 PBMCs was generally low and virus titres within cell culture 
supernatants, post-wash, averaged at ~103.8 TCID50/well. No differences in infectivity titres were 
detected in the supernatants collected from different groups at 1 h.p.i and thus the efficiency of 
washing between BTV infected and saliva 1/BTV infected cells is expected to be comparable (Figure 
4.15).  
Overtime, there was no significant increase in progeny virus detection from PBMC cultures that were 
BTV infected in the absence of saliva. The lack of increasing virus titres across the assayed time points 
may be due to an inability to detect progeny virus above the high viral inoculum remaining on the cells. 
In comparison, in the presence of saliva, progeny virus production had significantly increased by 24 h.p.i 
(Figure 4.15, p = 0.001) but then remained constant for the subsequent time points. The presence of 
saliva during infection led to a significant enhancement in progeny virus production from the PBMC 
cultures at 24, 48 and 72 h.p.i (Figure 4.15, p = 0.018, 0.004 and 0.004, respectively). These results 
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further confirm the findings from the above flow cytometry and confocal microscopy assays that 
indicate the presence of saliva during PBMC infection enhances BTV replication.  
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Figure 4.15 - Progeny virus production by PBMCs is enhanced following BTV infection in the presence of 
C. sonorensis saliva. 
Bovine PBMCs from cattle 1 were infected with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour in 
the absence or presence of 1 µg/ml C. sonorensis saliva (batch number 2), washed three times and 
saliva was replaced onto the relevant conditions. Cell culture supernatants were collected at 1, 24, 48 
and 72 h.p.i and progeny virus production was assessed by virus titration. Each set of coloured dots 
represents the supernatant from one biological replicate using PBMCs from cattle 1. Multiple dots 
within each coloured set of dots represents the technical titration replicates of the same cell culture 
supernatant from the specific experiment. A minimum of three technical titration replicates were 
carried out for each supernatant to account for variation within the virus titration assay. Infectivity titres 
were combined are displayed as mean ± standard deviation and statistical differences were determined 
using the Tukey multiple comparison test. Analysis between progeny virus production by BTV and saliva 
1/BTV infected cell cultures within time points is displayed in black and analysis of progeny virus 
production from respective BTV and saliva 1/BTV infected cell cultures across the assayed time points 
is displayed in red and blue, respectively. 
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Similarly to that described above for cattle 1, the cell culture supernatants were also harvested from 
cultures of cattle 2, 3 and 5 PBMCs (n = 1 per cattle) infected in the absence or presence of C. sonorensis 
saliva. Titrations of individual supernatants were repeated at least twice and titres from all replicates 
and animals were combined for each time-point and treatment group to allow statistical analysis. 
Supernatants collected at 1 h.p.i were titrated to determine residual virus inoculum that was remaining 
in the cell culture. Due to the high viral inoculum that was remaining in the cell cultures of PBMCs from 
cattle 1, despite three wash steps, the volume of wash media was increased when washing PBMCs from 
cattle 2, 3 and 5. This increase in wash media volume led to an enhanced washing efficiency resulting 
in an average of ~102.4 TCID50/well viral inoculum remaining in the cell cultures. The presence of saliva 
during BTV infection had no effect on the residual virus remaining in the cell cultures supernatants at 1 
h.p.i (Figure 4.16).  
Progeny virus production was seen to significantly increase from 1 to 72 h.p.i following PBMC infection 
in the absence or presence of saliva (Figure 4.16, p = <0.001, for both). At 72 h.p.i, a slightly higher 
progeny virus production was detected within PBMC cultures following infection in the presence of 
saliva, albeit this higher titre was non-significantly different compared to the progeny virus production 
from PBMCs infected in the absence of saliva.  
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Figure 4.16 - Progeny virus production by PBMCs, from a further three animals, infected with BTV in the 
presence of C. sonorensis saliva 
Bovine PBMCs from three cattle were infected with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 
hour in the absence or presence of 1 µg/ml C. sonorensis saliva (batch number 6), washed three times 
and saliva was replaced onto the relevant conditions. Cell culture supernatants were collected at 1 and 
72 h.p.i and progeny virus production was assessed by virus titration. Each set of coloured dots 
represents a supernatant from one biological replicate using PBMCs from either cattle 2 (black), cattle 
3 (red) or cattle 5 (blue). Multiple dots within each coloured set of dots represents the technical 
titration replicates of the same cell culture supernatant from that cattle. A minimum of two technical 
titration replicates were carried out for each supernatant to account for variation within the virus 
titration assay. Results were combined and are displayed as mean ± standard deviation. Statistical 
differences were determined using the Tukey multiple comparison test. ns = non-significant. Analysis 
between progeny virus production by BTV and saliva 1/BTV infected cell cultures within time points is 
displayed in black and analysis of progeny virus production from respective BTV or saliva 1/BTV infected 
cell cultures across the assayed time points is displayed in red and blue, respectively.  
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In addition to the determination of viral protein expression within purified monocyte populations, that 
were BTV infected in the absence or presence of C. sonorensis saliva, cell culture supernatants were 
collected in order to determine the effect of saliva on progeny virus production from infected purified 
monocyte cultures at 1 and 24 h.p.i. Monocytes were purified from three cattle on separate occasions, 
infected as above in the absence or presence of C. sonorensis saliva, and progeny virus production was 
determined by virus titration. Cell culture supernatants were each titrated once, on a single occasion. 
Low levels of residual virus remained within the cell culture supernatants post-wash, irrespective of the 
presence of saliva during infection (Figure 4.17). When compared to virus titres at 1 h.p.i, by 24 h.p.i a 
non-significant increase in virus titre was detected in supernatants from BTV cultures infected in the 
absence of saliva. In comparison to virus titres in cell culture supernatants from monocyte cultures 
infected the presence of saliva at 1 h.p.i, virus titres in respective cell cultures supernatants were 
significantly increased by 24 h.p.i (Figure 4.17, p = 0.005). Although the average virus titre in monocyte 
culture supernatants (from all three cattle) was higher in the presence of saliva at 24 h.p.i, compared 
to virus titres in the supernatants of cells infected in the absence of saliva, the difference in viral titres 
between conditions is not significantly different. Nonetheless, it can be seen that within each cattle 
replicate, the presence of saliva during monocyte infection resulted in an increase in progeny virus 
production. 
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Figure 4.17 - Progeny virus production by purified monocytes is enhanced following BTV infection in the 
presence of C. sonorensis saliva 
Bovine monocytes were isolated from bovine PBMCs and infected with a BTV-1 Gibraltar 2007/1 strain 
at MOI 0.1 for 1 hour in the absence or presence of 1 µg/ml C. sonorensis saliva (batch number 4), 
washed three times and saliva was replaced onto the relevant conditions. Monocytes were isolated 
from bovine PBMCs from cattle 2 (red), cattle 3 (blue) and cattle 4 (green) on separate occasions. Cell 
culture supernatants were collected at 1 and 24 h.p.i and progeny virus production was assessed by 
virus titration. Each collected supernatant was titrated once and infectivity titres were combined and 
are displayed as mean ± standard deviation. Statistical differences between the combined means were 
determined using the Tukey multiple comparison test. ns = non significant. Analysis between progeny 
virus production by BTV and saliva 1/BTV infected cell cultures within time points is displayed in black 
and analysis of progeny virus production from respective BTV or saliva 1/BTV infected cell cultures 
across the assayed time points is displayed in red and blue, respectively.  
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4.8 Discussion 
The studies presented in this chapter show for the first time that C. sonorensis saliva is able to modify 
BTV infection and replication within bovine monocytes. Analysing viral protein expression within cellular 
subsets of PBMCs, following BTV infection, identified monocytes as the population that expressed the 
greatest proportion of VSP and the NSP, NS2. Furthermore, the presence of C. sonorensis saliva during 
BTV infection consistently enhanced the expression of these viral proteins in monocytes, within PBMCs, 
and in purified monocytes obtained from multiple blood donor cattle. In comparison, we identify that 
a minimal proportion of the lymphocyte populations of PBMCs express viral proteins irrespective of the 
presence of C. sonorensis saliva during BTV infection. Furthermore, we identified that C. sonorensis 
saliva can enhance the production of progeny virus by PBMCs when added to cells concurrently with 
the virus inoculum. 
The utilisation of bovine PBMCs throughout this chapter has allowed for the consideration of the effect 
of C. sonorensis saliva on BTV infection within cells that would naturally become infected in cattle 
(MacLachlan et al., 1990). Furthermore, under steady state conditions, bovine blood cells migrate from 
the blood through the lymphatic system to tissues such as the skin surface (Andrade et al., 1998, Cahill 
et al., 1996, Mackay et al., 1988, Young et al., 2000), thereby providing a source of cells that may 
become infected upon virus inoculation into the ruminant skin by a blood feeding, infected midge. 
Culicoides midge feeding has also been shown to lead to an influx and accumulation of cells within the 
skin at the bite site in sheep (Darpel, 2007, Takamatsu et al., 2003). Although not definitively known, it 
is possible that the cells migrating to the skin, in response to Culicoides midge feeding and/or salivary 
components, originate from the blood. In particular,  T cells have been highlighted as the 
predominant population that accumulates within the skin following Culicoides midge feeding. Indeed, 
this cellular population has also been shown to be infected with BTV in vitro (Darpel, 2007, Takamatsu 
et al., 2003) and encompasses a large proportion (15-60%) of lymphocytes within bovine blood (Davis 
et al., 1996, Hein and Dudler, 1997) and skin draining afferent lymph (Van Rhijn et al., 2007). The pool-
feeding nature of Culicoides midges also results in the generation of a skin injury into which blood flows 
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and pools, allowing the midge to take a blood meal (Lavoipierre, 1965) and as a result, providing a route 
of contact between BTV containing infected Culicoides salivary inoculum and the cellular populations 
within the blood.  
The co - expression of VSP and the NSP, NS2, was used as a marker for replication throughout this 
chapter. NS2 expression is thought to be indicative of VIBs that are the active site of virus replication 
and will only be detectable once the virus has initiated the transcription of its genome, leading to 
subsequent mRNA translation into viral proteins (Matsuo and Roy, 2013, Modrof et al., 2005). 
Compared to PBMC or purified monocyte BTV infection in the absence of C. sonorensis saliva, the 
presence of saliva during BTV infection led to a significantly higher proportion of monocytes, from all 
cell donor cattle, expressing VSP and NSP at high enough levels to be clearly detectable by flow 
cytometry analysis. This therefore indicates that C. sonorensis saliva can alter BTV infection and/or 
replication within this cell type. In comparison, BTV infection alone led to less monocytes expressing 
VSP and NSP thus indicating that this cell population of PBMCs may support BTV infection and 
replication to a lesser extent in the absence of C. sonorensis saliva. Furthermore, the minimal proportion 
of monocytes observed to express NSP, within PBMCs or purified monocyte cultures infected in the 
absence of saliva, only gradually increased over the consecutive time points assayed in some cattle. 
Nevertheless, an increase in the proportion of respective monocytes expressing VSP over the assayed 
time points, compared to at 2 h.p.i, indicates viral protein production thereby suggesting an active 
infection even within monocytes infected in the absence of C. sonorensis saliva. An explanation for the 
apparent low proportion of monocytes expressing NSP, despite also expressing detectable levels of VSP, 
may therefore be that NSP was expressed to such small amounts that it eluded detection above 
background antibody labelling under specific experimental conditions by flow cytometry. NS2 
expression, within in vitro BTV infected monocytes, has previously been described and following the 
infection of PBMCs with a tissue culture BTV-10 strain at a low MOI, 10% of monocytes were reported 
to express NS2 at 18 h.p.i (Whetter et al., 1989). In comparison, in the present study, ~0.5% of CD14+ 
monocytes expressed NS2 following infection in the absence of C. sonorensis saliva whilst ~7% of CD14+ 
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monocytes expressed NS2 following infection in the presence of saliva at 24 h.p.i (Figure 4.7). In the 
study by Whetter et al., (1989) monocytes were classified based on side scatter characteristics, thus the 
phenotype of the cells that were included in the analysis was not definitively confirmed by cell surface 
membrane protein expression. Therefore, monocyte classification, infection with differing BTV 
serotypes and the different antibodies used for virus detection may explain these variable results.  
Interestingly, it was further observed that BTV infection of PBMCs, without removal of the viral 
inoculum, changed the observed dynamics of viral protein expression in monocytes within PBMCs 
infected in the absence or presence of C. sonorensis saliva. In these experiments, a comparable 
proportion of monocytes expressed VSP, irrespective of the presence of C. sonorensis saliva during a 
prolonged infection time. Furthermore, in comparison to PBMCs infected for a restricted 1 hour only, a 
greater proportion of cells also expressed VSP following the extended infection time. Subsequent to the 
prolonged infection time, a greater proportion (~10 fold at 72 h.p.i) of monocytes also expressed 
detectable levels of NSP following infection in the absence of C. sonorensis saliva (Cattle 1; Figure 4.3 
and 4.8 for comparison), although the proportion of monocytes expressing NSP was still minimal (≤ 
~1%). In comparison, a similar proportion of monocytes expressed NSP following infection in the 
presence of C. sonorensis saliva, irrespective of the variable infection time. These results potentially 
suggest that, when present during infection, C. sonorensis saliva can possibly influence the dynamics of 
early infection events as indicated by the augmented proportion of monocytes expressing VSP when 
the viral infection time is not restricted. The low levels of NSP expression, following cell infection in the 
absence of saliva, may therefore potentially be attributed to a low level of virus uptake during the one 
hour PBMC infection time. Although BTV entry mechanisms have not been determined for PBMCs or 
purified monocytes, BTV entry is generally considered to be slow as indicated by infection studies into 
BFA cells (Stevens, 2016), BHK-21 cells (Gold et al., 2010) and primary bovine DCs (Moffat et al., personal 
communication). 
During the initial screen (Section 4.2; Figure 4.1 and 4.2), a non-typical, very high level of VSP expression 
(~40%) was seen within the monocyte population of PBMCs from cattle 2 that appeared to be 
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unaffected by the presence of C. sonorensis saliva during BTV infection. Upon repeat BTV infection of 
PBMCs from cattle 2, the proportion of monocytes expressing VSP was comparable to that observed 
from other animals and the presence of saliva during infection resulted in an enhancement in the 
proportion of monocytes expressing VSP. These results therefore indicate the possibility that  outside 
factors, such as illness/infection of the cattle or pre-activation of the isolated PBMCs, may have affected 
the proportion of cells from cattle 2 becoming infected during the first experimental replicate. 
Furthermore it is possible that cattle 2 PBMCs infected in the initial replicate, where an elevated 
proportion of monocytes expressed VSP, were subjected to a reduced washing efficiency following the 
one hour infection time that may have resulted in a higher infection rate. As highlighted, BTV infection 
of PBMCs without viral inoculum removal, can result in comparable levels of VSP expression that is 
similarly unaffected by the presence of saliva, thereby potentially indicating a reduced efficiency of viral 
inoculum removal that masked the effects of saliva on BTV infection of monocytes within PBMCs.  
 
Immunofluorescence and laser scanning confocal microscopy analysis of infected monocytes, from 
PBMC or purified monocyte cultures, was utilised throughout this chapter to visualise the expression 
of viral proteins and to provide confirmation of the results obtained by flow cytometry. Indeed, it was 
confirmed by this technique that a greater proportion of monocytes appeared to express VSP and NSP 
following the infection of PBMCs or purified monocytes in the presence of C. sonorensis saliva. 
Furthermore, it was observed that a proportion of monocytes within PBMC cultures, infected in the 
absence of saliva, co-express VSP and NSP, thus confirming that this cell population of PBMCs can 
support BTV infection even in the absence of saliva. This indication is based upon one biological replicate 
of PBMCs where, following infection in the absence of saliva, NSP expression was also detectable in 
respective cells by flow cytometry (Figure 4.10). Furthermore, flow cytometry analysis indicated that 
the proportion of monocytes expressing NSP in this replicate was also greater compared to other 
replicates utilising cells from different cattle, such as those experiments using cattle 1 PBMCs, where 
NSP was minimally detectable following infection in the absence of saliva. As NSP labelling of cattle 1 
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monocytes, within PBMCs, was minimally detectable above background antibody labelling of mock 
infected cells by flow cytometry, it would have been beneficial to have observed viral protein expression 
by confocal microscopy in those replicates, in order to confirm if the apparent minimal proportion of 
cells expressing NSP was a true representation or if NSP was expressed at such low amounts that it 
eluded detection by flow cytometry. 
As observed by confocal microscopy, BTV infection of both PBMCs and purified monocytes appeared 
to result in two phenotypes of viral protein expression. One phenotype in which VSP expression within 
monocytes appeared speckled with apparently absent NSP expression and the other phenotype in 
which extensive VSP expression was observed throughout the monocyte cytoplasm alongside punctate 
NSP expression, indicative of VIBs. In the absence of a time course, these differences in viral protein 
expression by individual cells cannot be definitively used to indicate the stage of viral replication or the 
effect of saliva on the dynamics of virus infection or replication. It has, however, previously been shown 
that VIB size increases throughout the course of infection in mammalian cell lines (Brookes et al., 1993), 
ovine skin fibroblasts (Darpel, 2007) and insect derived KC cells (Fu, 1995), albeit this has not been 
characterised in bovine primary cells. Nevertheless, based on this assumption that VIB size increases 
throughout the course of individual cell infection, it can be proposed that monocytes undergoing the 
early stages of virus infection and replication display speckled VSP expression in the absence of NSP, 
whilst cells infected with a virus at the later stages of replication express VSP throughout the cytoplasm, 
alongside VIB structures. Monocytes, at the proposed earlier stages of virus replication, were 
predominantly seen in PBMC or isolate monocyte cultures infected in the absence of saliva, whilst 
monocytes at the proposed later stages of virus replication were principally seen following PBMC 
infection in the presence of saliva. This observation therefore further indicates that C. sonorensis saliva, 
when present during infection, can enhance BTV infection and replication in bovine monocytes or alter 
the dynamics of virus infection in these cells.  
Alongside monocytes, large, non-CD14 expressing infected cells were also seen in BTV infected PBMC 
cultures, assessed by confocal microscopy, predominantly following infection in the presence of C. 
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sonorensis saliva. The phenotype and cell surface membrane protein expression of these cells was not 
characterised and thus any proposition on the cell type would purely be based upon the large and 
complex morphology of these cells. Bovine blood monocytes have predominantly been described as 
CD14+ however a population of CD14- bovine monocytes (~5 - 10%) have also been reported (Corripio-
Miyar et al., 2015, Hussen et al., 2013). This population therefore cannot be ruled out, and may be an 
explanation for the large, non-CD14 expressing cells within PBMCs observed by confocal microscopy. 
Furthermore, the results of chapter 6 of this thesis have indicated that CD14 cell surface membrane 
protein expression on monocytes, within PBMCs, is reduced following culture in the presence of C. 
sonorensis saliva (Figure 6.14) thus further suggesting that these large un-characterised cells may be 
monocytes with low or no expression of the CD14 cell surface membrane protein. 
Purified monocytes were magnetically sorted from other PBMC populations based on their expression 
of the cell surface membrane protein, CD14. At the point of harvest the purified monocyte cultures 
were therefore not labelled with CD14, however changes in the size and granularity of the monocytes, 
cultured in the presence of C. sonorensis saliva, were observed based on their forward scatter (FSC) and 
side scatter (SSC) parameters, respectively (personal observation). These morphological changes of 
differentially treated, purified monocyte cultures, may therefore indicate saliva induced activation 
and/or cellular differentiation of these cells. Contrary to this possibility, it should be noted that SGE, 
from other hematophagous arthropods such as Rhipicephalus microplus, have been shown to reduce 
cellular activation as indicated by a downregulation in the LPS induced expression of the cellular 
activation and co-stimulatory markers, CD69 and CD80 respectively, on bovine macrophages exposed 
to SGE (Brake and Pérez de León, 2012). However, the mammalian response to saliva from different 
arthropod vectors is potentially variable and thus the possibility of cellular differentiation, in response 
to C. sonorensis saliva, cannot be ruled out and may provide an additional hypothesis to explain the 
large non-CD14 cells observed by confocal microscopy. 
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Progeny virus production by infected cultures is the ultimate indication of the success of BTV replication. 
An increase in viral titres was minimally detectable across the assayed time points from cattle 1 PBMCs 
following infection in the absence of C. sonorensis saliva, although this lack of detectable increase may 
be accountable to the high viral inoculum remaining on the cells at 1 h.p.i. In comparison, following the 
implementation of a modified washing procedure, the residual viral inoculum remaining on the cells 
from cattle 2, 3 and 5 was reduced, thus potentially allowing for the detection of the observed increase 
in viral titres from BTV infected PBMCs between 1 and 72 h.p.i in the absence or presence of C. 
sonorensis saliva. PBMC infection in the presence of saliva resulted in a significant increase in the 
progeny virus production from cattle 1 PBMCs, and a non-significant increase in the combined progeny 
virus production from cattle 2, 3 and 5 PBMCs compared to BTV infection in the absence of saliva, thus 
further confirming the role that saliva has in enhancing BTV infection and/or replication within bovine 
PBMCs. Assessing significant differences of viral titres in respective supernatants was limited by the 
levels of variation observed upon repeated titration of the same cell culture supernatant. The titration 
method utilised has previously been modified within the group to replace the subjective assessment of 
CPE with the detection of viral antigen by immunofluorescence labelling (Stevens, 2016). Nonetheless, 
further assay improvements, or multiple technical titration repeats of the same supernatant, may have 
to be carried out to allow for the detection of small, yet potentially significant differences in progeny 
virus production from cell cultures subjected to differing treatments. This observed, inherent variation 
within the titration assay may therefore provide an explanation for the lack of statistical difference in 
the viral titres produced from PBMCs from multiple cattle (Figure 4.16) infected in the absence or 
presence of C. sonorensis saliva.  
Although the monocyte population of PBMCs has been shown to be infected with BTV to the greatest 
proportion, compared to other PBMC populations, it cannot be definitely stated that the monocytes 
are responsible for the detected progeny virus within the PBMC supernatants. Nevertheless, based 
upon the detection of virus within purified monocyte culture supernatants, progeny virus is produced 
from infected monocytes over time following infection in the absence of C. sonorensis saliva. 
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Furthermore, progeny virus production by purified monocytes is enhanced in the presence of saliva 
although, due to the single titration replicate and the variation between cattle, this increase did not 
reach statistical significance. Nonetheless, these results indicate that the monocyte population of PBMC 
may be responsible for the detectable increase in progeny virus production by PBMCs infected in the 
presence of saliva.  
As monocytes are typically ≤ 10% of total PBMCs, an additional explanation for the increase in progeny 
virus production from PBMCs, over time and in the presence of C. sonorensis saliva, is progeny virus 
production from the lymphocyte populations of this heterogeneous cell mixture. The initial screen of 
BTV infection and replication within PBMC populations, that aimed to determine the effect of C. 
sonorensis saliva on BTV infection within the T cell, B cell and monocyte population of PBMCs from three 
separate cattle, highlighted that a minimal proportion of T and B lymphocytes expressed viral proteins 
following BTV infection, irrespective of the presence of saliva. Nevertheless, lymphocyte populations 
compose the majority of PBMCs thus low level infection and virus production by these cells may still 
contribute to the progeny virus production observed from total PBMCs. Indeed, the identification in this 
chapter of a proportion of B cells expressing viral proteins, including NS2, indicates active replication in 
this lymphocyte population and that these cells may contribute to progeny virus production. Most 
notably, irrespective of the presence of C. sonorensis saliva during infection, ~9% of CD21+ B cells from 
cattle 2 expressed VSP and ~6% also expressed NSP. Interestingly, this replicate utilising cattle 2 PBMCs 
also resulted in very high levels of VSP expression within the monocyte population of PBMCs as 
described above. In comparison, CD21+ B cell infection was seen to a lesser extent following the 
infection of PBMCs from the remaining two cattle used in the initial screen. Combined with the recent 
identification of infected CD21+ B cells within ovine lymph nodes that drain the skin site of ID inoculation 
(Melzi et al., 2016), and a significant increase in B cell proliferation within the lymph node of BTV 
infected calves, compared to control calves (Barratt-Boyes et al., 1995), the findings of this chapter may 
implicate B cells in BTV infection under certain conditions.  
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Although the experimental setup utilised throughout this thesis has attempted to use biologically 
relevant materials where possible, as highlighted in the introduction of this chapter, it is currently 
unknown how many viral particles and how much/what concentration of salivary proteins are deposited 
into the skin of the ruminant host when infected Culicoides midges take a blood meal. An MOI of 0.1 
was used throughout the present studies as a representative low MOI that may potentially be 
biologically relevant to the dose of virus inoculated into the skin of the ruminant host, by infected biting 
midges. As the infection of target, bovine immune cells with purified BTV particles has been shown to 
be very slow, possibly as a result of slow virus uptake (Stevens, 2016)(Moffat et al., personal 
communication), the usage of a low passage, mammalian tissue culture virus in the present studies 
enabled cellular infection at this low MOI whilst also resulting in the expression of detectable viral 
proteins within the limited time frame that PBMCs can be maintained in culture.  
The usage of a salivary protein concentration of 1 µg/ml, throughout this chapter, has enabled the initial 
investigations into the impact of C. sonorensis saliva on BTV infection and replication in bovine target 
cells. The usage of this initial salivary protein concentration was based upon those concentrations used 
by others for the determination of arthropod salivary effects on arbovirus infections (Ader et al., 2004, 
Surasombatpattana et al., 2014) and modulation of the host immune response (Bishop et al., 2006, 
Brake and Pérez de León, 2012, Menezes et al., 2008). Thus the biological relevance of this utilised 
concentration, in relation to the salivary protein concentration/amount deposited into the ruminant 
skin by the blood feeding vector, is unknown. It has been estimated for Ae. aegypti mosquitoes that the 
approximate amount of salivary protein inoculated into the skin of the host during the acquisition of a 
blood meal equates to the contents of ~0.3 - 0.4 salivary gland pairs (Wasserman et al., 2004). 
Additionally, it has also been estimated that a pair of Ae. aegypti salivary glands contain ~2.5 µg of 
protein (Ribeiro et al., 2001) whilst in comparison a pair of female Culicoides salivary glands has been 
estimated to contain a considerably lower ~ 0.21 µg of protein (Perez de Leon and Tabachnick, 1996). 
Although interesting, these findings are difficult to relate to the saliva amounts deposited by Culicoides 
midges during a blood meal due differences in insect size, routes of blood meal acquisition and the 
 
 
~ 162 ~ 
 
unknown, and potentially variable, volume of saliva deposited by respective blood feeding insects. It is 
therefore necessary to determine the biological range of C. sonorensis salivary protein concentrations 
and to determine the minimum dose that is able to modify BTV infection and replication.  
The protein component of Culicoides saliva has predominantly been studied resulting in the 
identification of ~ 45 proteins, albeit many within an unknown function (Darpel et al., 2011, Langner et 
al., 2007, Lehiy and Drolet, 2014). The novel saliva induced modification of BTV infection and replication, 
highlighted in this chapter, may therefore be caused by one or more of these salivary proteins or other 
salivary components that may not have been studied to date. Identifying the potential role of active C. 
sonorensis saliva components and the fundamental mechanisms by which insect saliva benefits BTV 
infection in bovine monocytes would therefore be of great value.  
4.9 Summary  
As outlined in Figure 4.18, the results of this chapter highlight, for the first time, that C. sonorensis saliva 
can alter BTV infection and replication within target bovine immune cells. Indeed viral protein 
expression within the bovine monocyte population of a heterogeneous PBMC mixture, or in purified 
monocyte cultures, was seen to be enhanced when cells were concurrently exposed to BTV and C. 
sonorensis saliva. Furthermore, the data of this chapter has shown that PBMC infection, in the presence 
of C. sonorensis saliva, can significantly enhance the progeny virus production from PBMC cultures. 
Collectively, these results therefore lead to the requirement of further studies to elucidate the salivary 
component(s) and the mechanism underlying the saliva induced increase in BTV infection of bovine 
immune cells. At present it is unknown if the observed C. sonorensis saliva induced enhancement of 
BTV infection, replication and progeny virus production is due to a direct effect of the saliva on BTV, or 
an indirect effect of saliva induced modulation of the host immune response, that in turn leads an 
environment permissive to successful and exacerbated BTV infection.  
 
 
 
 
~ 163 ~ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18 - Summary schematic highlighting the major findings of Chapter 4. 
 
 
 
 
 
 
BTV infection of bovine PBMCs, in the absence of C. sonorensis saliva, resulted in an on average 
minimal proportion of the T and B cell populations expressing VSP and NSP. In comparison, an on 
average greater proportion of the monocyte population expressed VSP and NSP. 
The presence of C. sonorensis saliva during bovine PBMC infection did not alter the average 
proportion of T and B cell populations expressing VSP and NSP. In comparison, the presence of C. 
sonorensis saliva during bovine PBMC infection enhanced the proportion of the monocyte 
population expressing VSP and NSP, compared to cells infected in the absence of saliva. 
The presence of C. sonorensis saliva during purified bovine monocyte infection led to an 
enhanced proportion of monocytes expressing VSP and NSP, compared to cells infected in the 
absence of saliva. 
The presence of C. sonorensis saliva during bovine PBMC or purified monocyte infection leads to 
an increase in progeny virus production, compared to the progeny virus production from 
respective cells infected in the absence of saliva. 
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Determining the effect of Culicoides sonorensis 
salivary components on the establishment of 
BTV infection and replication in bovine 
monocytes 
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5.1 Introduction 
The saliva from numerous arthropods has largely been characterised as a complex pharmacologically 
active mixture of proteinaceous molecules (Abdeladhim et al., 2016, Campbell et al., 2005, Langner et 
al., 2007, Lehiy and Drolet, 2014, Ribeiro et al., 2007, Russell et al., 2009, Wongkamchai et al., 2010). In 
comparison, the presence of non-proteinaceous components within the saliva of arthropods has largely 
been uncharacterised although non-protein molecules, such as eicosanoids, have been reported as a 
component of tick saliva (Carvalho-Costa et al., 2015, Oliveira et al., 2011, Poole et al., 2013). Although 
it often remains unknown which salivary component is eliciting an observed effect on the host immune 
response or arbovirus infection, recent studies have highlighted that it is possible to determine the 
nature of salivary components that are likely responsible for an elicited function. For example, Conway 
et al., (2014), elucidated that the serine protease activity of Ae. aegypti saliva was likely responsible for 
the observed enhancement of in vivo DENV infection of the mouse model by showing that SGE mediated 
DENV virus infectivity was blocked in the presence of a protease inhibitor (Conway et al., 2014). To the 
contrary, other Ae. aegypti salivary components, such as D7 proteins, have been implicated to inhibit 
DENV infection in vitro and in vivo (Conway et al., 2016). Conflicting this role for D7 proteins in arbovirus 
infection, similar studies have also highlighted that treatment of the murine model with recombinant 
D7 proteins may otherwise lead to an enhancement of WNV infection in the mouse model (Reagan et 
al., 2012). These varying results highlight the complexity of saliva from different arthropods, and 
indicates that determining the function of a single protein is unlikely to be representative of the 
biological effects of the entire salivary mixture from which a protein originates. Furthermore, multiple 
salivary proteins or components with opposing functions may be present within the saliva from a single 
arthropod. 
The saliva of Culicoides midges contains ~45 proteins, of which more than half have an unknown 
function (Langner et al., 2007, Lehiy and Drolet, 2014). The remaining proteins that have been identified 
have known or predicted functions, based on sequence homology, ranging from sugar metabolism, to 
aiding in the acquisition of a blood meal. The biological function of individual salivary proteins and the 
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role they play in arbovirus infection, either indirectly through modulation of the host immune response 
or directly through interactions with the virus particle, have largely been unexplored. Furthermore, it is 
unknown if non-proteinaceous molecules are present within Culicoides saliva. To date, the direct 
interaction between only one Culicoides salivary protein and BTV has been characterised. The saliva of 
C. sonorensis contains a protease, specifically a trypsin, that has the ability to cleave the outer coat 
protein of BTV, VP2, resulting in the generation of ISVPs. The resulting ISVPs are up to ten times more 
infectious for KC cells, whilst also up to six times less infectious for BHK-21 cells. Similarly, BTV 
incubation with trypsin results in ISVPs that are 12 times more infectious for KC cells and up to two 
times less infectious for BHK-21 cells. Although trypsin is thought to be the predominant protease within 
C. sonorensis saliva, others proteases are also present, potentially with a chymotrypsin-like activity 
(Darpel et al., 2011, Stoner, 2015).  
As highlighted in chapter 4, the infection of bovine PBMCs in the presence of C. sonorensis saliva leads 
to an enhancement of BTV infection and replication, within the monocyte population. However, these 
studies used relatively large quantities of Culicoides saliva and thus the efficiency of lower quantities of 
saliva to induce BTV replication would allow for an estimation of the biological relevance of these 
observations. Hence, studies were carried out to determine the ability of reduced amounts of saliva to 
enhance BTV infection and replication within bovine monocytes. Moreover, this chapter aims to further 
characterise potential saliva components that resulted in the observed increase in BTV infection and 
replication. Specifically, investigations will be carried out to determine if proteases such as trypsin, can 
enhance BTV infection in primary bovine cells. Furthermore, the salivary component eliciting the 
observed enhancement of BTV infection was further examined to determine if it was proteinaceous in 
nature or if non-protein components might be present within the saliva of C. sonorensis that can 
influence BTV infection. Finally, this chapter aims to carry out initial investigations into the mechanisms 
underlying the observed salivary protein/component enhanced BTV infection and replication.  
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5.2 The role of C. sonorensis salivary protease activity on BTV infection and replication in bovine 
monocytes 
The incubation of BTV-1 particles with C. sonorensis saliva or commercially available serine proteases 
results in a direct modification of the virus particle structure and an alteration in virus infectivity (Darpel 
et al., 2011). As confirmed in chapter 3, the saliva collected via the modified saliva collection method 
(Section 2.3.2) is proteolytically active and has been confirmed to be able to cleave VP2 (Section 2.3.7). 
Contrary to the work by Darpel et al., (2011), where virus particles were pre-incubated with Culicoides 
saliva or respective proteases prior to virus titration, here the virus inoculum is not pre-incubated with 
saliva prior their concurrent addition to cells maintained in culture media containing FCS. Indeed, FCS 
has previously been reported to inactivate the activity of the trypsin (Bundy and Mehl, 1958) hence 
rendering salivary protease modification of the BTV particle structure less likely. The first a im of this 
chapter is therefore to assess if serine proteases, such as trypsin, have a role in enhancing BTV infection 
and replication within bovine monocytes. As outlined in chapter 3 the proteolytic ability of C. sonorensis 
saliva, to cleave VP2 into respective cleavage products, can be compared to that of commercial trypsin 
(Section 2.3.8) thereby allowing the respective cleavage activity of these different protease sources to 
be matched.  
PBMCs were isolated from bovine blood and infected in suspension with a low passage tissue culture 
BTV-1 Gibraltar 2007/1 KC2 BHK3 strain at a MOI of 0.1 for 1 hour. Cells were infected with BTV alone 
(BTV) or in the presence of 1 µg/ml C. sonorensis saliva (saliva 1/BTV) or 0.2 µg/ml commercial trypsin 
(Trypsin/BTV) (Sigma-Aldrich; L1426). Control infected cells were treated with a BHK-21 cell lysate in 
the absence (mock) or in the presence of 1 µg/ml C. sonorensis saliva (Saliva 1) or 0.2 µg/ml commercial 
trypsin (Trypsin). Post-infection the cells were washed three times and saliva or trypsin was replaced 
onto the respective conditions. At the point of harvest, live cells were externally labelled with an 
antibody for the detection of the CD14 cell surface membrane protein (Section 2.6.1), washed and fixed 
with 4% PFA. BTV infection was determined within the CD14+ monocyte population by the expression 
of VSP whilst BTV replication was determined based on the co-expression of VSP and the NSP, NS2. The 
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proportion of live, single, CD14+ cells supporting BTV infection and replication was determined via a 
standardised gating strategy (Figure 2.5) at 24 and 72 hours h.p.i for PBMCs obtained from cattle 3 and 
5. 
When combined, the results obtained following the infection of cattle 3 and 5 PBMCs, in the presence 
of C. sonorensis saliva, resulted in a significantly greater proportion of monocytes expressing VSP at 24 
and 72 h.p.i (Figure 5.1; E, p = 0.0304 for both time points) when compared to cells infected with BTV 
in the absence of saliva. Additionally, following infection in the presence of saliva, a significantly greater 
proportion of monocytes expressed NSP at 24 h.p.i (Figure 5.1; F, p = 0.0304) compared to cells infected 
with BTV in the absence of saliva. BTV NSP expression was also seen in an elevated portion of monocytes 
at 72 h.p.i (Figure 5.1; F), albeit the results were found to be non-significantly different, due to the 
variation in NSP expression in response to saliva between cattle (Figure 5.1; B and D). The saliva induced 
enhancement in the percentage of monocytes expressing VSP and NSP was augmented to a greater 
extent in monocytes within PBMCs from cattle 3, compared to cattle 5 (Figure 5.1; A/B and C/D, 
respectively), highlighting the variation in saliva-induced BTV infection between animals. In comparison, 
when PBMCs were infected in the presence of trypsin at matched amounts to that in saliva,  the 
proportion of monocytes expressing viral proteins appeared to be unaffected and remained 
comparable to the proportion of monocytes expressing viral proteins following BTV infection alone 
(Figure 5.1; A – F). The presence of trypsin, with matched proteolytic activity towards VP2, during BTV 
infection therefore did not appear to enhance BTV infection of monocytes, within PBMCs, tentatively 
suggesting that the protease activity of C. sonorensis saliva may not be required to enhance BTV 
infection and replication within monocytes.  
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Figure 5.1 - The presence of trypsin during BTV infection does not lead to changes in viral protein 
expression within the monocyte population of PBMCs 
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Figure 5.1 - The presence of trypsin during BTV infection does not lead to changes in viral protein 
expression within the monocyte population of PBMCs 
 
Bovine PBMCs were infected with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour in the absence 
(BTV) or presence of 1 µg/ml saliva (saliva 1/BTV; cattle 3 – batch number 4, cattle 5 – batch number 5) 
or matched amounts of trypsin (0.2 µg/ml, trypsin/BTV). Post-infection, PBMCs were washed three 
times, and the saliva or trypsin treatment was reapplied to the relevant conditions. The proportion of 
CD14+ monocytes expressing VSP and the NSP, NS2, was analysed at 24 and 72 h.p.i in PBMCs from 
cattle 3 (A and B) and cattle 5 (C and D). Data from the two cattle were combined (E and F) and plotted 
as the mean ± standard deviation. Statistical differences between the treatment groups of BTV infected 
and differentially treated/BTV infected cells, at each time point, were determined using the Mann 
Whitney test.  
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5.3 Determining if non-protein salivary components are involved in the enhancement of BTV infection 
and replication in the presence of C. sonorensis saliva  
Many publications have utilised heat treatment of arthropod saliva to determine if the salivary 
component eliciting an observed response is of proteinaceous nature (Bissonnette et al., 1993, Katz et 
al., 2000, Mendes-Sousa et al., 2016, Waitumbi and Warburg, 1998, Wasserman et al., 2004). If the 
salivary component of interest is a protein, then heat treatment (dependant on temperature) will 
denature the structure and destroy the function of the protein, thus abolishing or reducing the saliva 
induced observed effect. For example, in vitro exacerbation of DENV infection of mouse embryonic 
fibroblasts in the presence of Ae. aegypti SGE was completely abolished following the boiling of SGE 
(Conway et al., 2014). 
To determine if the C. sonorensis salivary component responsible for the observed increase in BTV 
infection and replication in bovine monocytes is a protein, the saliva was heat treated for 10 minutes 
at 56°C to abolish the salivary protease function, as previously determined by zymography analysis 
(Stoner, 2015). Saliva was also heat treated for 10 minutes at 95°C to denature the salivary proteins 
structures. Bovine PBMCs were isolated and infected with BTV-1 Gibraltar 2007/1 BTV-1 KC2BHK3, at an 
MOI of 0.1 for one hour. Cells were infected with BTV alone (BTV) or in the presence of 1 µg/ml saliva 
(saliva 1/BTV), 1 µg/ml saliva heat treated for 10 minutes at 56°C (saliva 1 (56)/BTV) or 1 µg/ml saliva 
heat treated for 10 minutes at 95°C (saliva 1 (95)/BTV). Control infected cells were treated with a BHK-
21 cell lysate alone (mock) or in the presence of 1 µg/ml saliva (saliva 1), 1 µg/ml saliva heat treated for 
10 minutes to 56°C (saliva 1 (56)) or 1 µg/ml saliva heat treated for 10 minutes to 95°C (saliva 1 (95)). 
Live cells from cattle 2 were harvested at 2, 24 and 72 h.p.i whilst cells from cattle 4 were harvested at 
24 and 72 h.p.i. At the point of harvest cells were processed as described above and in Section 2.6.  
At 2 h.p.i, a low proportion of monocytes within PBMCs from cattle 2 were seen to express VSP (<2 %) 
irrespective of the presence of saliva, confirming that viral protein detection at later time points post-
infection was not a function of virus uptake (Figure 5.2; A). The combined VSP expression within the 
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monocyte population of PBMCs from both cattle progressed over time and the presence of saliva 
significantly enhanced the proportion of monocytes expressing VSP at both 24 and 72 h.p.i (Figure 5.2; 
A, C and E, p = 0.0304). Furthermore, the combined results from both cattle indicate that monocyte 
infection, in the presence of heat treated saliva, further augmented this enhancement. A significantly 
higher proportion of saliva 1 (56)/BTV infected monocytes expressed VSP (Figure 5.2; E, p = 0.0304) and 
an even higher proportion of saliva 1 (95)/BTV infected monocytes expressed VSP (Figure 5.2; E, p = 
0.0304) compared to BTV infected monocytes alone, most notably at 72 h.p.i. Although the proportion 
of monocytes within PBMCs from cattle 2 and 4 expressing NSP varied at 24 h.p.i (Figure 5.2; B and D, 
respectively), with much lower levels detected in cattle 2, by 72 h.p.i the NSP expression was detectable 
in the monocyte population of PBMCs from both cattle. The combined results at 72 h.p.i indicate NSP 
expression in a significantly higher proportion of monocytes following saliva 1/BTV, saliva 1 (56)/BTV or 
saliva 1 (95)/BTV infection compared to BTV infection alone (Figure 5.2; F, p = 0.0304). These results 
therefore indicate that the effect of saliva in enhancing BTV infection and replicat ion is not abolished 
following saliva heat treatment, but rather enhanced indicating that an intact salivary protein is less 
likely to be responsible for the augmentation of BTV infection and replication within the bovine 
monocyte population of PBMCs. 
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Figure 5.2 – Heat treatment does not reduce or abolish the effect of C. sonorensis saliva on viral protein 
expression in monocytes within PBMCs 
NOTE: different axis. 
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Figure 5.2 – Heat treatment does not reduce or abolish the effect of C. sonorensis saliva on viral protein 
expression in monocytes within PBMCs 
Bovine PBMCs were infected with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour in the absence 
(BTV) or presence of 1 µg/ml saliva (saliva 1/BTV; cattle 2 – batch number 3, cattle 4 – batch number 4 
)) or 1 µg/ml heat treated saliva (56°C or 95°C treatment for 10 minutes (saliva 1(56)/BTV) and (saliva 
1 (95)/BTV), respectively). Post-infection, PBMCs were washed three times, and the saliva treatment 
was reapplied to the relevant conditions. The proportion of CD14+ monocytes expressing VSP and NSP, 
NS2, was analysed at 0, 24 and 72 h.p.i. in PBMCs from cattle 2 (A and B) and at 24 and 72 h.p.i in PBMCs 
from cattle 4 (C and D). Data from the two cattle were combined (E and F) and plotted as the mean ± 
standard deviation. Statistical differences between the treatment groups of BTV infected and 
differentially treated/BTV infected cells, at each time point, were determined using the Mann Whitney 
test.  
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5.4 Identification of non-protein components within C. sonorensis saliva and their effect on BTV infection 
and replication in bovine monocytes 
Bacterial LPS, also known as endotoxin, is the major component of the outer surface membrane of 
gram-negative bacteria, which have been shown to be part of the microbiota of insect vectors, including 
Culicoides biting midges (Campbell et al., 2004, Lewis et al., 2014, Mee et al., 2015, Nakamura et al., 
2009). LPS has potent immune stimulatory properties and due its ubiquitous nature, has long proven 
to be a challenging contaminant for the pharmaceutical industry (FDA, 2012, Petsch and Anspach, 
2000). Although the C. sonorensis saliva preparations are filtered sterile during the concentration 
process (Section 2.3.3), hence removing the presence of any infectious bacteria or fungal spores, such 
filtering would not remove LPS from already broken down bacterial cell walls. Furthermore, the 
mouthparts of blood-feeding insects are not sterile, yet will also make contact with the filter membrane 
onto which Culicoides midges will secrete their saliva during the collection process. Therefore, as a 
ubiquitous, potent innate immune stimulator and non-protein molecule, the possible presence of LPS 
in C. sonorensis saliva was therefore next investigated. The activity of LPS per saliva collection was 
tested using the Pierce™ LAL chromogenic endotoxin test kit that is based on Food and Drug 
administration (FDA) approved methodology according to the manufacturers’ instructions (FDA, 2012, 
USP, 2011)(Section 2.3.5). The activity of LPS, detected within the saliva samples, can then be converted 
to an approximate mass of endotoxin per sample based on the assumption that 1 EU/ml = ~0.1 ng/ml. 
LPS, within saliva samples that were diluted 10 fold from 1 in 100 to 1 in 100,000, was found to be 
present within all saliva collections carried out, however LPS activity appeared to vastly range from 45 
to nearly 100,000 EU/ml per saliva collection (Figure 5.3, A). The saliva collection that resulted in the 
lowest endotoxin activity of 45 EU/ml (collection 4) also resulted in the collection of reduced amounts 
of salivary protein (Figure 5.3, B and Table 3.1; Section 3.3), potentially due to less individual Culicoides 
midges utilised throughout the saliva collection. 
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In order to confirm that the LPS content within the saliva was inherently introduced due to midge 
feeding, LPS content within the reagents used throughout the saliva collections were also tested using 
the Pierce™ LAL chromogenic endotoxin test kit and confirmed to be below the detection limit of the 
test. Water and PBS used throughout the assays, were also tested negative for LPS even after 
concentrating the buffers (~100 ml) to a small volume by centrifugation in a Vivaspin column to mimic 
the concentration process applied to saliva. Furthermore, negative saliva collections were performed, 
to rule out environmental introduction of LPS to the collected saliva (Section 2.3.2). The LPS content 
within the negative collections was found to be very low (0.38 – 0.72 EU/ml) and likely a reflection of 
the non-sterile nature of the saliva collection and the ubiquitous presence of LPS. Nevertheless, the low 
levels of LPS within the negative collection confirms that the LPS content within the collected saliva is 
introduced due to C. sonorensis feeding.  
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B 
Collection EU/ml 
(1EU/ml = ~0.1 ng/ml) 
Total protein 
quantity (µg/ml) 
~ ng LPS/ 
1 µg protein 
C. sonorensis saliva  1 15629 552 2.8 
2 99757 560 18.8 
3 87643 535 16.4 
4 45 252 0.02 
5 378 (+/-19) 432 0.09 
6 5700 (+/-269) 501 1.1 
Negative  1 0.72 0 - 
2 0.38 0 - 
 
Figure 5.3 - Quantification of endotoxin activity within C. sonorensis salivary protein collections and 
negative collections 
Endotoxin activity within different batches of collected C. sonorensis saliva was determined by the 
Pierce™ LAL endotoxin chromogenic endpoint test kit (A/B). Endotoxin was found to be present in all 
saliva collections but to highly variable amounts (45 – 99757 EU/ml) between different collections. 
Additionally, the ~ ng of LPS content per 1 µg of salivary protein also varied considerably between 
conditions.   
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The quantification of bacterial endotoxin activity via the LAL chromogenic endpoint test kit is reliant on 
the initiation of an enzymatic cascade of serine proteases by LPS, which is potentially from different 
bacterial species and of different potencies. Due to the presence of trypsin in C. sonorensis saliva it is 
theoretically possible that this protease may alter the enzymatic cascade of the LAL kit and therefore 
skew the quantification of LPS content within the saliva (Ding and Ho, 2010). It was therefore 
determined if commercial trypsin, at matched amounts to that present in C. sonorensis saliva (collection 
5), had an effect on the quantification of LPS activity by comparing the results from samples containing 
active trypsin, to those containing denatured trypsin following heat treatment to 95 °C for 10 minutes.  
Saliva and trypsin with the same proteolytic capacity, as determined by matched protease activity 
towards BTV VP2 (Section 3.3), were diluted 1:10, 1:100 and 1:1000 (containing ~0.01 µg, ~0.001 µg 
and ~0.0001 µg trypsin/ml, respectively) with endotoxin free water and quantified using the Pierce™ 
LAL endotoxin test kit according to the manufacturers’ instructions. Saliva samples resulted in EU/ml 
values exceeding the diagnostic range of the standard curve at the 1:10 and 1:100 dilutions and are 
therefore not shown (Figure 5.4). At a 1:10 and 1:100 dilution of the respective trypsin, the non-heated 
samples were shown to apparently contain nearly 5 times more endotoxin than heat treated samples 
thus indicating that active trypsin may lead to an artificial enhancement of endotoxin activity 
quantification at low dilutions (Figure 5.4). The FDA advises that any sample that may contain 
interfering substances should be diluted in order to mitigate the interference (potentially the protease 
activity in this case)(FDA, 2012). A 1:1000 dilution allowed the quantification of endotoxin content 
within the saliva samples whilst no endotoxin activity was detected in trypsin preparations at this 
dilution, highlighting that non-specific protease effects can be diluted out and do not account for the 
LPS activity detected within C. sonorensis saliva at this dilution. Heat treatment can also be used as 
technique in order to mitigate interfering substances and thus saliva and trypsin preparations were also 
heat treated to 95 °C for 10 minutes. Although there was no difference in the lack of detectable LPS 
activity in the trypsin samples at the 1:1000 dilution, irrespective of heat treatment, there was however 
a ~ two fold decrease in the detectable levels of LPS within heat treated saliva (Figure 5.4). Therefore a 
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slight overassessment of endotoxin activity quantification when saliva is non-heat treated cannot be 
entirely ruled out. 
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Figure 5.4 - Determining the effect of C. sonorensis salivary trypsin content and sample heat treatment 
on LPS quantification 
The effect of trypsin and sample heat treatment on the quantification of LPS activity within C. sonorensis 
saliva was determined by testing naïve and heat treated trypsin containing samples at 1:10, 1:100 and 
1:1000 dilutions. Measured LPS activities of samples were adjusted by the respective dilution factor.  
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Despite the vast interest in the immunomodulatory proteins of arthropod saliva and the potent action 
of LPS on the host immune and inflammatory responses, very few publications have considered the 
presence of LPS within the utilised salivary material (Carregaro et al., 2011, Carregaro et al., 2008, 
Schmid et al., 2016) as deliberated further in the discussion of this chapter. Therefore, to determine 
the effect of LPS on BTV infection and replication, bovine PBMCs were infected in the presence of C. 
sonorensis saliva or the corresponding amounts of LPS within the utilised saliva batch as determined by 
the Pierce™ LAL endotoxin test kit (Figure 5.3). PBMCs were isolated from cattle 3 and 5 on separate 
occasions and cells were infected with BTV-1 Gibraltar 2007/1 BTV-1 KC2BHK3 at MOI 0.1 for 1 hour in 
the presence of 1 µg/ml saliva (saliva 1/BTV) or equivalent matched amounts of LPS (LPS 1/BTV). Mock 
infected cells were also treated with 1 µg/ml saliva (saliva 1) or equivalent matched amounts of LPS 
(LPS 1). The saliva utilised alongside BTV infection of cattle 3 contained LPS resulting in a final 
concentration of 0.02 ng/ml, whilst the saliva utilised alongside BTV infection of cattle 5 contained LPS 
resulting in a final concentration of 0.09 ng/ml. Commercially available LPS of S. enterica origin (Sigma 
#L6143) was therefore used at these final concentrations when infecting PBMCs from cattle 3 and 5, 
respectively. At 24 and 72 h.p.i, cells were harvested and processed as described above and in Section 
2.6.  
The presence of either saliva or LPS during BTV infection resulted in an increased proportion of 
monocytes within PBMCs from cattle 3 expressing VSP and NSP compared to BTV infection alone (Figure 
5.5; A and B, respectively). Furthermore, this increase in the proportion of monocytes expressing VSP 
appeared to be more pronounced following LPS 1/BTV infection (~25%) compared to saliva 1/BTV 
infection (~17%) at 72 h.p.i (Figure 5.5; A). The proportion of monocytes, within PBMCs from cattle 5, 
expressing VSP and NSP was also seen to be enhanced in the presence of saliva or LPS, compared to 
infection in the absence of either stimulus (Figure 5.5; C and D). Similarly to the response observed by 
cattle 3 PBMCs, cattle 5 PBMC infection in the presence of LPS also led to much larger proport ion of 
monocytes expressing VSP and NSP (Figure 5.5; C and D, respectively) at 24 and 72 h.p.i when compared 
to VSP and NSP expression by monocytes infected in the presence of saliva. This difference may be 
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attributable to the slightly higher concentration of LPS applied to PBMCs from cattle 5 (0.09 ng/ml) 
compared to that applied to PBMCs from cattle 3 (0.02 ng/ml).  
The combined results confirm that the presence of saliva, or matched amounts of LPS, during BTV 
infection leads to a significantly higher fraction of monocytes expressing VSP and NSP (Figure 5.5; E and 
F, respectively, p = 0.0304, for both) at 24 and 72 h.p.i compared to BTV infection in the absence of 
either stimulus. Interestingly, a significantly greater proportion of monocytes expressed VSP, but not 
NSP, in the presence of LPS compared to cells infected in the presence of saliva (Figure 5.5; E, p = 
0.0304) at 24 and 72 h.p.i. This lack of statistical significance in the proportion of monocytes expressing 
NSP following infection in the presence of saliva, compared to LPS, may be a function of animal to 
animal variation. These results therefore indicate that LPS, when present during infection, can lead to 
an enhancement in BTV infection and replication and therefore, the LPS component of C. sonorensis 
saliva is likely to contribute to the observed saliva induced exacerbation of BTV infection and replication 
within the monocyte population of PBMCs.  
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Figure 5.5 – The presence of LPS during PBMC infection enhances viral protein expression within the 
monocyte population 
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Figure 5.5 – The presence of LPS during PBMC infection enhances viral protein expression within the 
monocyte population 
Bovine PBMCs were infected with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour in the absence 
(BTV) or presence of 1µg/ml C. sonorensis saliva (saliva 1/BTV; cattle 3 – batch number 4, cattle 5 – 
batch number 5) or matched amounts of LPS (LPS  1/BTV). Final LPS concentrations of salivary or 
commercial origin were 0.02ng/ml and 0.09ng/ml for cattle 3 and 5, respectively. Post-infection, PBMCs 
were washed three times, and the saliva or LPS treatment was reapplied to the relevant conditions. The 
proportion of CD14+ monocytes expressing VSP and the NSP, NS2 was analysed at 24 and 72 h.p.i. in 
PBMCs from cattle 3 (A and B) and cattle 5 (C and D). Data from the two cattle were combined (E and 
F) and plotted as the mean ± standard deviation. Statistical differences between the treatment groups 
of BTV infected and differentially treated/BTV infected cells, at each time point, were determined using 
the Mann Whitney test.  
 
 
 
~ 184 ~ 
 
5.5 Determining the minimum dose of C. sonorensis saliva or LPS that induces BTV infection and 
replication 
Throughout chapter 4 and the preceding work of this chapter, C. sonorensis saliva has been used at an 
initial concentration of 1 µg/ml in order to initially determine the effect of saliva on BTV infection and 
replication within the bovine host. However, the biological relevance of this dose or the efficiency of 
saliva induced modification of BTV infection and replication is unknown, thus the minimum dose of 
saliva capable of altering the course of BTV infection was next determined.  
PBMCs were isolated from three cattle on separate occasions and cells were infected with BTV-1 
Gibraltar 2007/1 KC2BHK3 at MOI of 0.1 for 1 hour. Cattle 2 and 3 PBMCs were infected with varying 
final concentrations of saliva over a 10 fold dilution series starting with 1 µg/ml saliva (saliva 1/BTV 
infected) and so forth. Cattle 5 PBMCs were infected in the presence of varying final concentrations of 
saliva over a 10 fold dilution series starting with 0.1 µg/ml saliva (saliva 0.1/BTV infected) and so forth. 
The same saliva preparation was used for the titration in all cattle tested whereby a saliva concentration 
of 1 µg/ml resulted in an equivalent LPS concentration ~1.1 ng/ml whilst a saliva concentration of 0.1 
µg/ml resulted in an equivalent LPS concentration ~0.1 ng/ml and so forth. Mock infected cells were 
also treated with respective amounts of saliva. After a 1 hour infection time, the cells were washed 
three times and the appropriate saliva dilutions were reapplied to the relevant conditions. Cells were 
harvested at 24 and 72 h.p.i and processed as described above and in Section 2.6. 
At 24 and 72 h.p.i of PBMCs from cattle 2 and 3, the highest proportions of monocytes expressing VSP 
and NSP were observed following infection in the presence of 0.01 µg/ml saliva compared to BTV 
infection in the absence of saliva (Figure 5.6; A – D). Progressively lower proportions of monocytes 
expressed VSP and NSP in the presence of higher or lower saliva concentrations. The maximal 
proportion of monocytes, within PBMCs from cattle 5, expressed VSP and NSP following infection in the 
presence of 0.001 µg/ml saliva compared to BTV infection in the absence of saliva (Figure 5.6; E and F). 
Interestingly, a much higher proportion of monocytes (~ 55%) from cattle 5 PBMCs expressed maximal 
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VSP levels compared to the maximal fraction of monocytes from cattle 2 (~20%) and 3 (~16%) PBMCs. 
In comparison, there was less variation in the maximal proportion of monocytes expressing NSP 
between PBMCs from the different cattle PBMC donors; ~17% of monocytes within PBMCs from cattle 
5 and ~9% of monocytes from cattle 2 and 3 expressed NSP at the respective optimal saliva 
concentrations. When combined, the results from all three cattle indicate that the proportion of 
monocytes expressing VSP is significantly enhanced following BTV infection in the presence of 0.01 
µg/ml saliva at 24 h.p.i (Figure 5.6; G, p = 0.0051) and in the presence of 0.1 and 0.01 µg/ml saliva at 
72 h.p.i (Figure 5.6; G, p = 0.0051) compared to BTV infected cells in the absence of saliva at the 
corresponding time point. Furthermore, NSP expression is seen in a significantly higher proportion of 
monocytes infected in the presence of 1 µg/ml and 0.01 µg/ml saliva at 24 h.p.i (Figure 5.6; H, p = 
0.0428 and 0.0051, respectively) and a significantly higher proportion of monocytes following infection 
in the presence of 0.1 and 0.01 µg/ml saliva at 72 h.p.i (Figure 5.6; H, p = 0.0051 for both) compared to 
cells infected in the absence of saliva. Collectively, the results from the saliva titrations therefore 
highlight that salivary protein concentrations of 0.1 and 0.01 µg/ml are applicable to significantly induce 
the proportion of monocytes expressing VSP and NSP at 72 h.p.i, when utilising PBMCs from all cattle 
donors. 
Although saliva induced VSP and NSP expression was seen in a maximal proportion of monocytes in the 
presence of 0.001 µg/ml saliva in PBMCs from cattle 5, monocytes within PBMCs from the remaining 
two cattle did not present an altered viral protein expression in the presence of this saliva 
concentration. The combined results from all three cattle were therefore found to be non-significantly 
different following BTV infection in the presence of 0.001 µg/ml saliva, compared to BTV infection in 
absence of saliva. As observed in previous experiments, infection dynamics can vary based upon animal 
to animal variation as also highlighted here in the differing minimum dose of saliva that enhances BTV 
infection and replication in monocytes within PBMCs from different cattle. As the same saliva 
preparation was used for the saliva titrations on all three cattle PBMCs, this variation cannot be 
accounted for by differences in the salivary LPS content. Despite these variations, the combined results 
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highlight the amount of saliva needed to induce BTV infection and replication within monocytes is much 
lower than the originally used salivary protein concentration of 1 µg/ml. 
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Figure 5.6 - Determining the minimum dose of C. sonorensis saliva that induces the proportion of monocytes expressing viral proteins  
Continued… 
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Figure 5.6 - Determining the minimum dose of C. sonorensis saliva that induces the proportion of monocytes expressing viral proteins 
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Continued… 
Figure 5.6 - Determining the minimum dose of C. sonorensis saliva that induces the proportion of monocytes expressing viral proteins 
 
Bovine PBMCs were infected with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour in the absence (BTV) or presence of varying amounts of C. sonorensis 
saliva (batch number 6). Cattle 2 and 3 PBMCs were infected in the presence of final saliva concentrations starting at 1 µg/ml saliva (saliva 1/BTV) followed by 
consecutive 10 fold dilutions of saliva. Cattle 5 PBMCs were infected in the presence of final saliva concentrations starting at 0.1 µg/ml saliva (saliva 0.1/BTV) 
followed by consecutive 10 fold dilutions of saliva. Mock infected cells were also treated with the same saliva dilution series. The same saliva preparation was 
used for the saliva titrations using PBMCs from all three cattle and a saliva concentration of 1 µg/ml resulted in an equivalent LPS concentration ~1.1 ng/ml. 
Post-infection, PBMCs were washed three times, and the varying saliva concentrations were reapplied to the relevant conditions. The proportion of CD14+ 
monocytes expressing VSP and the NSP, NS2 was analysed at 24 and 72 h.p.i. in PBMCs from cattle 2 (A and B), cattle 3 (C and D) and cattle 5 (E and F). Data 
from the three cattle were combined (G and H) and plotted as the mean ± standard deviation. Statistical differences between the treatment groups of BTV 
infected cells alone and BTV infected cells in presence of varying amounts of saliva, at each time point, were determined using the Mann Whitney test.  
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Following the demonstration that much lower concentrations of Culicoides saliva can lead to an 
increase in BTV protein expression, compared to the 1 µg/ml saliva concentration initially used, similar 
experiments were carried out in order to determine if the LPS content within these reduced amounts 
of saliva were likewise involved in the observed increase in viral infection and replication in monocytes 
within PBMCs. PBMCs were isolated from cattle 3, 4 and 5 on a further three separate occasions and 
cells were infected with BTV-1 Gibraltar 2007/1 KC2 BHK3 at MOI of 0.1 for 1 hour in the presence of 0.1 
and 0.01 µg/ml saliva or matched amounts of LPS, comparable to that in the saliva. Mock infected cells 
were also treated with 0.1 and 0.01 µg/ml saliva or matched amounts of LPS. The same saliva 
preparation was used for all three biological replicates whereby a 0.1 and 0.01 µg/ml saliva 
concentration resulted in a final LPS concentration of ~0.1 and 0.01 ng/ml LPS, respectively. LPS treated 
cells were therefore exposed to a final LPS concentration of 0.1 or 0.01 ng/ml using purified S. enterica 
LPS (Sigma #L6143). After a 1 hour infection time, the cells were washed three times and the 
appropriate saliva or LPS concentrations were reapplied to the relevant conditions. At 72 h.p.i, cells 
were processed as described above and in Section 2.6. 
The infection of PBMCs from all three cattle in the presence of 0.1 and 0.01 µg/ml saliva or matched 
amounts of LPS lead to an enhancement in the proportion of monocytes expressing VSP and NSP 
compared to infection in the absence of either stimulus (Figure 5.7; A – H). Following the infection of 
PBMCs from cattle 3, a greater proportion of monocytes expressed VSP as a result of LPS treatment at 
either dilution, compared to the respective saliva condition (Figure 5.7; A). A higher proportion of 
monocytes expressing NSP was also seen following infection in the presence of 0.1 ng/ml LPS compared 
to infection in the presence of 0.1 µg/ml saliva, whilst infection in the presence of 0.01 ng/ml LPS did 
not lead to an increased proportion of monocytes expressing NSP compared to 0.01 µg/ml saliva, but 
rather a slight decrease (Figure 5.7; B). The response of cattle 4 and 5 PBMCs was less defined and 
resulted in variable proportion of monocytes expressing viral proteins as a result of BTV infection in the 
presence of saliva or matched amounts of LPS. The infection of cattle 4 PBMCs resulted in a comparable, 
yet slightly decreased proportion of monocytes expressing VSP following BTV infection in the presence 
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of 0.1 ng/ml LPS compared to infection in the presence of 0.1 µg/ml saliva (Figure 5.7; C). In comparison, 
the infection of cattle 5 PBMCs resulted in a slight increase in the proportion of monocytes expressing 
VSP in the presence of 0.1 ng/ml LPS compared to 0.1 µg/ml saliva (Figure 5.7; E). VSP expression was 
seen in a consistently lower proportion of monocytes within PBMCs from both cattle 4 and 5 following 
infection in the presence of 0.01 ng/ml LPS compared to 0.01 µg/ml LPS saliva (Figure 5.7; C and E). 
Following PBMC infection in the presence of either matched saliva or LPS concentrations, the 
proportion of monocytes expressing NSP was seen to be reduced in the presence of LPS (0.1 ng/ml or 
0.01 ng/ml) compared to the respective saliva condition (0.1 µg/ml or 0.01 µg/ml, respectively) in 
monocytes within PBMCs from cattle 4 and 5 (Figure 5.7; D and F, respectively).  
When combined, the results from all three cattle further confirm that the infection of PBMCs in the 
presence of 0.1 µg/ml saliva or matched amounts of LPS (0.1 ng/ml) leads to a significantly higher 
proportion of monocytes expressing VSP when compared to infection in the absence of either stimulus 
(Figure 5.7; G, p = 0.0306 for both). Furthermore, NSP expression was seen in a significantly higher 
proportion of monocytes following 0.1 µg/ml saliva treatment (Figure 5.7; H, p = 0.0082) and a non-
significantly higher proportion of monocytes following 0.1 ng/ml LPS treatment compared to BTV 
infected cells alone. VSP and NSP expression was seen in a significantly higher proportion of monocytes 
following BTV infection in the presence of 0.01 µg/ml saliva (Figure 5.7; G and H, p = 0.0051 and 0.0082, 
respectively) and a non-significantly higher proportion of monocytes in the presence of matched 
amounts of LPS (0.01 ng/ml) when compared to BTV infection alone. Combined, there was no-
significant difference in the proportion of monocytes expressing VSP and NSP following matched saliva 
or LPS treatment. VSP and NSP expression was seen in a comparable proportion of monocytes following 
infection in the presence of 0.1 µg/ml saliva or matched amounts of LPS (0.1 ng/ml) whilst BTV infection 
in presence of 0.01 µg/ml saliva lead to a slightly higher proportion of monocytes expressing VSP and 
NSP compared to those infected in the presence of 0.01 ng/ml LPS. Collectively, these results indicate 
that at the lower saliva dilutions used (0.1 µg/ml and 0.01 µg/ml), the LPS component within the saliva 
is likely still active in enhancing BTV infection and replication within monocytes although the degree of 
 
 
~ 192 ~ 
 
BTV protein expression may differ slightly between matched saliva and LPS dilutions, particularly when 
using a salivary protein concentration 0.01 µg/ml saliva.  
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Figure 5.7 – LPS content within C. sonorensis saliva is active, across reduced concentrations, in 
enhancing BTV infection and replication 
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Figure 5.7 – LPS content within C. sonorensis saliva is active, across reduced concentrations, in 
enhancing BTV infection and replication 
Bovine PBMCs were infected with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour in the presence 
of 0.1µg/ml or 0.01ug/ml C. sonorensis saliva (Saliva 0.1 and Saliva 0.01, respectively; batch number 6) 
or matched amounts of LPS (LPS  0.1 and LPS  0.01, respectively). The same saliva preparation was 
used when infecting PBMCs from all three cattle and a saliva concentration of 0.1 µg/ml resulted in an 
equivalent LPS concentration of ~0.1 ng/ml. Cells were washed three times, and the relevant saliva or 
LPS treatments were reapplied to the cells. The proportion of CD14+ monocytes expressing VSP and the 
NSP, NS2 was analysed at 72 h.p.i in PBMCs from cattle 3 (A - B), cattle 4 (C - D) and cattle 5 (E – F). 
Data from the three cattle were combined (G - H) and plotted as the mean ± standard deviation. 
Statistical differences between the treatment groups of BTV infected and BTV infected in the presence 
of differing stimulus, at each time point, were determined using the Mann Whitney test. 
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Following the demonstration that much lower amounts of C. sonorensis saliva, and equivalently lower 
amounts of LPS, are able to enhance BTV infection and replication, a single experiment was carried out 
in order to determine the minimum dosage of LPS that is able to enhance BTV protein expression in 
monocytes within PBMCs. PBMCs from cattle 3 were infected with BTV-1 Gibraltar 2007/1 KC2 BHK3, at 
MOI of 0.1 for one hour in the presence of varying concentrations of S. enterica LPS (Sigma #L6143) 
diluted 10 fold with a starting concentration of 1 x 10-5 µg/ml LPS (LPS 1 x 10-5; 0.01 ng/ml) and so 
forth. Based upon the saliva preparation used for the determination of the minimum dose of the saliva 
that is effective to enhance BTV infection and replication (Figure 5.6) and the effect of the LPS content 
within reduced saliva concentrations on BTV infection and replication (Figure 5.7), this starting 
concentration of LPS would be equivalent to that present in a final saliva concentration of 0.01 µg/ml 
of the saliva.  
The presence of LPS concentrations of 1 x 10-5µg/m LPS (0.01 ng/ml) during BTV infection were seen to 
clearly enhanced the percentage of monocytes expressing VSP and NSP (Figure 5.8; A and B, 
respectively) at 24 and 72 h.p.i. Furthermore, LPS concentrations of 1 x 10-6µg/m LPS (0.001 ng/ml) 
were also shown to enhance the proportion of monocytes expressing VSP and NSP at 72 h.p.i (Figure 
5.8; A and B, respectively). 
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Figure 5.8 - The minimum dose of LPS that enhances the proportion of monocytes expressing viral 
proteins 
Bovine PBMCs were infected with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour in the absence 
(BTV) or presence of varying amounts of LPS. Mock infected cells were also treated with the same LPS 
dilution series; LPS  1 x 10-5 cells were treated with 1 x 10-5 µg/ml LPS (0.01 ng/ml) and so forth over a 
10 fold dilution series. Post-infection, PBMCs were washed three times, and the LPS dilutions were 
reapplied to the relevant conditions. The proportion of CD14+ monocytes expressing VSP (A) and the 
NSP, NS2 (B) was analysed at 24 and 72 h.p.i in PBMCs from cattle 3. As this data is only representative 
of one biological replicate composing two technical flow cytometry replicates, statistical analysis could 
not be carried out.  
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The vast amount of LPS present in collected C. sonorensis saliva is inherently introduced due to midge 
feeding (Section 5.4). Although very low levels of LPS were found within the negative collection, that 
are likely environmentally introduced, we have shown that very low concentrations of LPS can enhance 
BTV infection and replication in the monocyte population of PBMCs (Figure 5.8). Therefore, it was next 
established if the very low levels of LPS present in the negative collection would influence BTV infection 
and replication. PBMCs from cattle 2, 3 and 5 were infected with BTV-1 Gibraltar 2007/1 KC2 BHK3, at 
MOI of 0.1 for 1 hour in the presence of varying amounts of negative collection alongside C. sonorensis 
saliva (saliva titrations shown in Figure 5.6). As the negative collection (Figure 5.3; collection 2) does 
not contain protein, cells were treated with a volume of negative collection that was matched to the 
corresponding saliva condition. For example, negative (1) treated cells were exposed to a volume of 
negative collection matched to that of cells treated with 1 µg/ml saliva and so forth over a 10 fold 
dilution series. Cattle 2 and 5 PBMCs were infected in the presence of negative 1 to negative 0.0001 
conditions whilst cattle 3 PBMCs were infected in the presence of negative 1 and negative 0.1 
conditions. 
The results confirmed that the presence of negative collection during BTV infection does not alter the 
proportion of monocytes expressing VSP (Figure 5.9; A) and NSP (Figure 5.9; B) at 24 and 72 h.p.i within 
PBMCs from all cattle. This therefore suggests that LPS is environmentally introduced to the saliva 
collection process at amounts too low to elicit any enhancement of BTV infection and replication on its 
own. At the highest concentrations used throughout the saliva titrations (1 µg/ml), the corresponding 
volume of negative collection would lead to a final concentration of ~0.076 pg/ml LPS. The minimum 
dose of LPS that enhanced BTV infection and replication in monocytes within PBMCs from cattle 3 was 
determined to be 1 pg/ml further highlighting that the low level of LPS that is environmentally 
introduced during the collection is unlikely to be accountable for these observed effects. 
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Figure 5.9 – Negative saliva collection preparation does not lead to an enhancement of viral protein 
expression in monocytes within PBMCs 
 
Bovine PBMCs were infected with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour in the absence 
(BTV) or presence of varying amounts of negative collection (batch number 2). Negative (1) treated 
cells were treated with a volume of negative collection matched to that of cells treated with 1 µg/ml 
saliva and so forth over a 10 fold dilution series. At the highest concentrations used throughout the 
saliva titrations (1 µg/ml), the corresponding volume of matched negative collection would lead to a 
final concentration of ~ 0.076 pg/ml LPS. Mock infected cells were treated with the same negative 
collection dilution. Post-infection, PBMCs were washed three times and the negative collection 
dilutions were reapplied to the relevant conditions. The proportion of CD14+ monocytes expressing VSP 
(A) and the NSP, NS2 (B) was analysed at 24 and 72 h.p.i. in PBMCs from cattle 2 and 5 for all conditions. 
Additionally, cells from cattle 3 were mock and BTV infected in the presence of negative 1 and 0.1 
conditions. Data from all cattle were combined and plotted as the mean ± standard deviation. Statistical 
differences between BTV infected cells and negative collection/BTV infected cells were determined 
using the Mann Whitney test.  
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5.6 Determining the effect of altering the time of C. sonorensis saliva addition, post-BTV infection, on viral 
protein expression 
So far it has been demonstrated that when added to PBMC cultures concurrently with the viral 
inoculum, C. sonorensis saliva and commercially purified LPS leads to an increased proportion of the 
monocyte population expressing viral proteins. However, the mechanism of this observed effect of C. 
sonorensis saliva and/or LPS on BTV replication is unknown. In order to determine at which stage of BTV 
infection saliva and/or LPS can modulate virus infection, and to elucidate the underlying mechanism, 
the time point at which saliva and/or LPS was added to PBMCs, relative to the viral inoculum, was 
altered. 
PBMCs were isolated from cattle 4 and cattle 5 on separate occasions and cells were infected with BTV-
1 Gibraltar 2007/1 KC2 BHK3 at MOI of 0.1 for 1 hour. Alongside the viral inoculum, some cells were also 
exposed to 0.1 µg/ml saliva or matched amounts of S. enterica LPS (Sigma #L6143). Mock infected cells 
were also treated with 0.1 µg/ml saliva or matched amounts of LPS (0.1 ng/ml). After a one hour 
infection time, the cells were washed three times and the appropriate saliva or LPS concentrations were 
reapplied to the relevant conditions. At 4 or 24 h.p.i, some of the cells that were previously BTV infected 
in the absence of stimulus, were treated with 0.1 µg/ml saliva or matched amounts of LPS for the 
remainder of the 72 hour culture time. The addition of saliva at these time points post-infection was 
chosen in order to observe the effect of saliva and LPS on the proposed early stages of virus infect ion 
or at the proposed late stages or virus infection following initial virus replication (Fu, 1995). The same 
saliva preparation was used for infection experiments in PBMCs from cattle 4 and 5 and a saliva 
concentration of 0.1 µg/ml resulted in an equivalent LPS concentration of ~0.1 ng/ml. 
The infection of PBMCs in the presence of 0.1 µg/ml saliva or matched amounts of LPS lead to a nearly 
five fold or nine fold increase in the proportion of the monocyte population from cattle 4 expressing 
VSP or NSP, respectively (Figure 5.10; A and B, respectively). The infection of cattle 5 PBMCs in the 
presence of saliva or matched amounts of LPS also lead to a two fold or nine fold increase in the 
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proportion of monocytes expressing VSP or NSP, respectively (Figure 5.10; C and D, respectively), 
however the overall level of infection was considerably lower in cattle 5 PBMCs compared to cattle 4 
PBMCs. 
Applying saliva or LPS at 4 h.p.i, also lead to an increase in the proportion of cattle 4 monocytes 
expressing VSP and NSP compared to respective cells without the addition of stimulus. This increase in 
the proportion of monocytes expressing viral proteins was, however to a lesser extent compared to the 
elevated proportion of monocytes expressing viral proteins following concurrent saliva or LPS 
treatment and BTV infection. VSP expression was detected in a two fold higher proportion of monocytes 
whilst NSP expression was seen in a four fold higher proportion of monocytes following saliva or LPS 
treatment at 4 h.p.i compared to cells without the addition of stimulus (Figure 5.10; E and F, 
respectively). In comparison, the application of saliva or LPS to cattle 5 PBMCs, at 4 h.p.i, lead to an 
enhancement in the proportion of monocytes expressing VSP and NSP (Figure 5.10; G and H) 
comparable to the enhancement observed following the application of saliva or LPS to PBMCs 
concurrently with the BTV inoculum. Saliva or LPS treatment at 24 h.p.i did not lead to an enhancement 
in the proportion of monocytes from cattle 4 or 5 expressing VSP and NSP (Figure 5.10; I/J and K/L, 
respectively) compared to BTV infection in the absence of stimulus. Collectively this data indicates that 
saliva and LPS induced enhancement of BTV infection and replication occurs at the early stages of virus 
infection. Although the completion of a single replication cycle of BTV, specifically in primary bovine 
cells is unknown, a single replication cycle of BTV has been proposed within 12 h.p.i in mammalian cell 
lines (Hyatt et al., 1989). 
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Addition of C. sonorensis saliva or LPS at the same time as BTV infection 
Cattle 4                   NOTE: different axis.                        Cattle 5 
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Addition of C. sonorensis saliva or LPS at 4 h.p.i 
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Addition of C. sonorensis saliva or LPS at 24 h.p.i 
%
 o
f 
C
D
1
4
+
c
e
ll
s
e
x
p
re
s
s
in
g
 B
T
V
 V
S
P
M
o
c
k
 
B
T
V
- i
n
fe
c
te
d
S
a
li
v
a
 0
.1
 
S
a
li
v
a
 0
.1
/B
T
V
L
P
S
 
 0
.1
L
P
S
 
 0
.1
/B
T
V
0
1 0
2 0
3 0
I
7 2  h .p . i
(n  =  1 )
%
 o
f 
C
D
1
4
+
c
e
ll
s
e
x
p
re
s
s
in
g
 B
T
V
 N
S
P
M
o
c
k
 
B
T
V
- i
n
fe
c
te
d
S
a
li
v
a
 0
.1
 
S
a
li
v
a
 0
.1
/B
T
V
L
P
S
 0
.1
L
P
S
 0
.1
/B
T
V
0
1 0
2 0
3 0
J
7 2  h .p . i
(n  =  1 )
          
%
 o
f 
C
D
1
4
+
c
e
ll
s
e
x
p
re
s
s
in
g
 B
T
V
 V
S
P
M
o
c
k
 
B
T
V
- i
n
fe
c
te
d
S
a
li
v
a
 0
.1
 
S
a
li
v
a
 0
.1
/B
T
V
L
P
S
 
 0
.1
L
P
S
 
 0
.1
/B
T
V
0
2
4
6
8
7 2  h .p . i
(n  =  1 )
K
%
 o
f 
C
D
1
4
+
c
e
ll
s
e
x
p
re
s
s
in
g
 B
T
V
 N
S
P
M
o
c
k
 
B
T
V
- i
n
fe
c
te
d
S
a
li
v
a
 0
.1
 
S
a
li
v
a
 0
.1
/B
T
V
L
P
S
 
 0
.1
L
P
S
 
 0
.1
/B
T
V
0
2
4
6
8
7 2  h .p . i
(n  =  1 )
L
 
Figure 5.10 – Adding C. sonorensis saliva, or LPS, at 24 hours post-BTV infection does not alter protein 
expression by bovine monocytes 
Bovine PBMCs were infected with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour in the presence of 0.1 
µg/ml C. sonorensis saliva (saliva 0.1; batch number 6) or matched amounts of commercial LPS (LPS  0.1). The 
same saliva preparation was used for infection experiments in PBMCs from cattle 4 and 5 and a saliva 
concentration of 0.1 µg/ml resulted in an equivalent LPS concentration of ~0.1 ng/ml. Cells were washed three 
times, and the relevant saliva or LPS treatments were reapplied to the cells. At 4 or 24 h.p.i, cells that had 
previously been infected in the absence of stimulus were treated with 0.1 µg/ml C. sonorensis saliva (saliva 0.1) 
or matched amounts of LPS (LPS  0.1) for the remainder of the culture. The proportion of CD14+ monocytes 
expressing VSP and the NSP, NS2 were analysed at 72 h.p.i in PBMCs from cattle 4 and 5 in cells treated with saliva 
or LPS at the same time point as infection (A - D), at 4 h.p.i (E - H) or at 24 h.p.i (I - L).  
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5.7 Removal of the LPS component of C. sonorensis saliva and the effect on BTV infection and replication  
As it has been shown that the LPS component of C. sonorensis saliva is at least partially responsible for 
the saliva induced enhancement of BTV infection and replication within bovine monocytes, preliminary 
investigations next determined how the removal of LPS from the C. sonorensis saliva preparations 
would influence saliva induced modifications of BTV infection of monocytes. The collected saliva from 
C. sonorensis was applied to the Pierce™ High capacity endotoxin removal spin column in order to 
remove the LPS content (Section 2.3.6). As confirmed using the Pierce™ LAL chromogenic endotoxin 
test kit, the LPS removal columns were effective in reducing the LPS activity within C. sonorensis saliva 
from ~ 5700 EU/ml to 0.39 EU/ml (Figure 5.11; A), the latter of which is comparable to the low levels of 
LPS within the negative collection carried out at the same time as the respective C. sonorensis saliva 
collection. Due to the small volume of available LPS removed saliva, protein content was not re-
quantified after LPS removal. In order to visually compare the protein amounts within saliva, pre and 
post-LPS removal and to ensure that the LPS removal process did not alter the protein profile of C. 
sonorensis saliva, 1 µg of saliva and LPS removed saliva was analysed on a 10% SDS-PAGE in order to 
visualise separated salivary proteins by silver staining (Section 2.3.10). Although not quantitatively 
determined, the amounts of protein with each sample appeared comparable via silver staining 
visualisation thus the LPS removal process unlikely results in a significant loss of protein content. 
Furthermore, the protein profile of the LPS removed saliva was largely comparable between original 
and LPS removed saliva preparations (Figure 5.11; B) and only minor changes in the protein profiles 
were noted. Following LPS removal, the two bands migrating between 38 and 52 kDa appear harder to 
differentiate (black arrow) and an additional protein band can be seen following LPS removal that runs 
slightly greater than 31 kDa (blue arrow), whilst the band running slightly below 31 kDa appears to be 
more dominant (red arrow).  
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Collection/sample EU/ml 
C. sonorensis saliva  5700 (+/-269) 
Negative  0.38 
LPS removed saliva 0.39 
 
 
 
 
 
 
 
 
 
Figure 5.11 - Endotoxin activity and protein profile of C. sonorensis saliva following LPS removal 
LPS activity was determined, before and after LPS removal, by the Pierce™ LAL endotoxin chromogenic 
endpoint test kit. LPS activity was found to be effectively removed from C. sonorensis saliva to LPS 
activity levels comparable to that in the matched negative collection (A). Saliva from C. sonorensis (~ 1 
ug) was next analysed prior to and after LPS removal by 10% SDS-PAGE and visualised using silver 
staining. Lane 1: C. sonorensis saliva prior to LPS removal. Lane 2: C. sonorensis saliva post-LPS removal. 
As shown, the majority of salivary proteins appear to be unaffected by the LPS removal process however 
some slight changes in the protein profile can be seen such as the two bands migrating between 38 and 
52 kDa appear harder to differentiate (black arrow) and an additional protein band can be seen 
following LPS removal that runs slightly greater than 31 kDa (blue arrow), whilst the band running 
slightly below 31 kDa appears to be more dominant following LPS removal (red arrow).  
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The effect of LPS removed saliva on BTV and LPS induced BTV infection and replication within bovine 
monocytes was next determined. PBMCs were isolated from the blood of cattle 5 on a single occasion 
and were infected with BTV-1 Gibraltar 2007/1 KC2 BHK3 at MOI of 0.1 for 1 hour in the absence of 
stimulus (BTV) or in the presence of 0.1 µg/ml saliva (saliva 0.1/BTV), LPS at matched amounts 
comparable to that in saliva (LPS  0.1/BTV), ~0.1 µg/ml LPS removed saliva (saliva (-) 0.1/BTV) or the 
combined presence of LPS at matched amounts to that in saliva and ~0.1 µg/ml LPS removed saliva 
(saliva (-) 0.1/LPS  0.1/BTV). Mock infected cells were also treated with the above conditions. The 
saliva preparation utilised for this experiment resulted in a final concentration of ~ 0.1ng/ml LPS, 
therefore cells exposed to LPS at comparable amounts to that in saliva were treated with 0.1 ng/ml 
purified S. enterica LPS (Sigma #L6143).  
The infection of PBMCs in the presence of saliva or matched amounts of LPS lead to a two fold and nine 
fold increase in the proportion of monocytes expressing VSP and NSP, respectively  (Figure 5.12; A/B, 
respectively). In comparison, infection in the presence of LPS removed saliva (saliva (-) 0.1/BTV) led to 
a proportion of monocytes expressing VSP and NSP comparable to BTV infection in the absence of 
stimulus (Figure 5.12; A/B). BTV infection in the combined presence of LPS removed saliva and 
commercial LPS (saliva (-) 0.1/LPS  0.1/BTV), led to an induction in the proportion of monocytes 
expressing VSP and NSP that is roughly comparable to the proportion of monocytes expressing viral 
proteins following BTV infection in the presence of LPS alone (LPS  0.1/BTV) (Figure 5.12; A/B). 
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Figure 5.12 – BTV infection in the presence of LPS removed C. sonorensis saliva does not enhance BTV 
protein expression within bovine monocytes 
Bovine PBMCs were infected with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour in the absence 
(BTV) or presence of 0.1 µg/ml saliva (saliva 0.1/BTV; batch number 6), LPS at matched amounts to that 
in saliva (LPS  0.1/BTV), ~ 0.1 µg/ml LPS removed saliva (saliva (-) 0.1/BTV) or the combined presence 
of LPS removed saliva and commercial LPS (saliva (-) 0.1/LPS  0.1/BTV). The saliva preparation used for 
this experiment resulted in a final LPS concentration of 0.1 ng/ml. Post-infection, PBMCs were washed 
three times, and the treatments were re-applied to the relevant conditions. The proportion of CD14+ 
monocytes expressing VSP (A) and the NSP, NS2 (B) was analysed at 72 h.p.i in PBMCs from cattle 5.  
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5.8 Progeny virus production from PBMC cultures following BTV infection and culture in the absence or 
presence of varying amounts of C. sonorensis saliva and negative collection 
As indicated throughout chapter 4 and the current chapter, the presence of saliva or LPS during BTV 
infection is able to alter the proportion of monocytes expressing NSP, of which NSP expression can be 
used as an indication of virus replication. To confirm completion of the BTV replication cycle, progeny 
virus production from infected PBMCs cultures, in the presence of varying amounts of C. sonorensis 
saliva, was also assessed by virus titration. Although the presence of the negative collection during BTV 
infection did not appear to alter the proportion of monocytes expressing VSP or NSP, cell culture 
supernatants were titrated for comparison to the progeny virus produced from cells that were BTV 
infected in the presence of saliva. Supernatants of the PBMCs that were infected in the presence of 
varying amounts of saliva or negative collection (corresponding to the cell cultures used to determine 
viral protein expression in the presence of these additional stimulus – Figure 5.6 and 5.7, respectively) 
were harvested at 1 and 72 h.p.i and virus levels within the samples were determined by virus titration 
(Section 2.4.2).  
Virus levels within the 1 h.p.i samples were comparable across conditions, irrespective of the saliva 
concentration applied to cells and on average the virus titre remaining in the cell culture supernatant, 
post-wash, was ~102.4 TCID50/ml, indicating a comparable efficiency of virus inoculum removal between 
conditions (Figure 5.13; A). The virus titre in cell culture supernatants was seen to have increased by 72 
h.p.i indicating that the PBMCs supported a productive virus infection and replication. Progeny virus 
production was higher in the supernatants of cultures from all three cattle infected in the presence of 
0.01 µg/ml of saliva, when compared to progeny virus production from BTV infected cells in the absence 
of saliva (Figure 5.11; A), albeit at non-significant levels. BTV infection and replication (determined by 
VSP and NSP expression, respectively) in the presence of 0.001 µg/ml saliva was enhanced in the 
monocyte population of PBMCs from cattle 5 during saliva titration experiments (Figure 5.6; E and F). 
This same cattle appeared to show elevated levels of progeny virus production within the supernatants 
of BTV infected cultures in the presence of 0.001 µg/ml saliva compared to progeny virus production 
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from BTV infected cultures in the absence of stimulus. Progeny virus production by the cells from the 
remaining cattle (2 and 3) appeared to minimally increase in the presence of 0.001 µg/ml saliva (Figure 
5.13; A).  
In the presence of varying amounts of negative collection, the residual virus remaining in the cell culture 
media at 1 h.p.i was ~102.3 TCID50/ml. The virus titre within the cell culture supernatants had increased 
in all conditions by 72 h.p.i, further indicating that the PBMCs can support a productive BTV infection. 
Progeny virus production appeared to be unaffected by the presence of varying amounts of negative 
collection during infection and no significant differences were found in the virus titres within 
supernatants of varying conditions (Figure 5.13; B). 
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Figure 5.13 - The effect of varying amounts of C. sonorensis saliva and negative collection on progeny virus 
production from PBMCs 
Supernatants from bovine PBMCs, infected in the presence of varying amounts of C. sonorensis saliva (batch 
number 6) or negative collection (batch number 2)(corresponding to Figure 5.6 and 5.7), were collected at 
1 and 72 h.p.i and progeny virus production was assessed by virus titration. Each set of coloured dots is 
representative of a supernatant from one biological replicate using PBMCs from either cattle 2 (red), cattle 
3 (blue) or cattle 5 (black). Multiple dots within each coloured set of dots is representative of a technical 
titration replicate of the same cell culture supernatant from that single cattle. A minimum of two technical 
titration replicates were carried out for each supernatant to account for variation within the virus titration 
assay. Infectivity titres from different biological replicates from different PBMC donor cattle and technical 
titration replicates of the same supernatant were combined and are displayed as mean ± standard deviation. 
Statistical differences between the progeny virus production from BTV infected cultures alone and BTV 
infected cultures in the presence of varying stimulus were determined using the Tukey multiple comparison 
test.  
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5.9 Discussion  
Studies in this chapter have demonstrated for the first time that LPS is inherently present at biologically 
active amounts in the saliva secreted and deposited during the feeding of Culicoides biting midges. 
Furthermore it was revealed that LPS, similarly to C. sonorensis saliva, enhances BTV infection and 
replication in bovine monocytes within PBMCs. This suggests that the LPS component of the saliva of 
Culicoides midges might be either partially responsible or at least contribute to the observed effects on 
saliva enhanced BTV infection in monocytes. Additionally, it was highlighted that both Culicoides saliva 
and LPS have a wide biologically active range and hence C. sonorensis saliva is implicated in the 
enhancement of BTV infection and replication at much lower amounts than originally utilised in chapter 
4, thereby strengthening the suggestion that the observed effects could potentially have a biological 
role during the natural transmission of BTV from an infected Culicoides midge to a susceptible ruminant 
host. Tentatively, it was also demonstrated that C. sonorensis saliva does not enhance BTV infection of 
bovine monocytes once the LPS component has been removed.  
Although the saliva of numerous arthropods has be shown to elicit strong enhancing effects on in vitro 
and/or in vivo infection of the pathogens they transmit (Table 1.2) (Le Coupanec et al., 2013, Limesand 
et al., 2000, Limesand et al., 2003, Moser et al., 2015, Pingen et al., 2016, Styer et al., 2006, Styer et al., 
2011, Surasombatpattana et al., 2014, Surasombatpattana et al., 2012), the respective components 
within the saliva of the relevant vector that might be eliciting these responses have largely been 
unexplored. Most studies have suggested that proteinaceous components are responsible for observed 
saliva induced enhancement of pathogen infectivity and/or modulation of the cellular innate immune 
response (Bissonnette et al., 1993, Katz et al., 2000, Mendes-Sousa et al., 2016, Waitumbi and Warburg, 
1998), however the presence and effects of non-protein based molecules such as eicosanoids have also 
been highlighted, particularly in tick saliva (Carvalho-Costa et al., 2015, Oliveira et al., 2011, Poole et 
al., 2013). 
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As previously outlined, in the context of arbovirus infections, the indirect effects of arthropod saliva on 
the modulation of the host immune response are widely believed to be indirectly beneficial to the co-
inoculated pathogen. The interaction of Culicoides saliva and BTV is however unique in that serine 
proteases, such as trypsin, that are present within the saliva are able to directly modify VP2 resulting in 
an altered BTV particle infectivity for specific cell lines (Darpel et al., 2011). In this chapter, a series of 
experiments determined that concurrent trypsin treatment and BTV infection of PBMCs did not alter 
BTV infection and replication in the monocyte population of PBMCs. Key differences in the experimental 
setup, in addition to the use of very different cellular systems, offer an explanation for the divergence 
of results obtained here compared to Darpel et al., (2011). In the latter study purified virus particles 
were pre-cleaved with C. sonorensis saliva prior to determining virus infectivity for standard BHK-21 
and KC cells by virus titration, whilst the work carried out in this chapter used tissue culture supernatant 
virus and Culicoides saliva was merely added to primary bovine PBMCs at the same time as the viral 
inoculum without any prior incubation. Furthermore, due to the cell culture media containing FCS, it is 
likely that the very low amounts of commercial trypsin (and the trypsin within C. sonorensis saliva) 
would have been inactivated upon inoculation (Bundy and Mehl, 1958).  
The heat treatment of arthropod saliva is often used in order to determine if the salivary component, 
eliciting an effect on either pathogen infection or the immune response, is of proteinaceous nature 
(Bissonnette et al., 1993, Katz et al., 2000, Mendes-Sousa et al., 2016, Waitumbi and Warburg, 1998). 
These studies proposed that a salivary protein was eliciting respective observed responses as heat 
treatment of the saliva abolished the observed effect, most likely due to denaturation of the salivary 
proteins during heat treatment. In contrast, the studies carried out here have demonstrated that heat 
treatment of C. sonorensis saliva further increased the proportion of bovine monocytes supporting BTV 
infection and replication in the presence of heat treated saliva compared to infection in the presence 
of non-heat treated saliva. This may indicate that abolishing the protease function of salivary proteins 
(56°C heat treatment) may allow a slight increase in BTV infection and replication whilst the 
denaturation of salivary proteins (95°C heat treatment) allows an even more pronounced increase in 
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virus infection and replication. These experiments therefore seem to indicate that salivary proteins are 
unlikely responsible for the enhancement of BTV infection and replication within bovine monocytes. 
Alternatively, it is worthy to consider that this finding is reliant on the heat lability of the salivary 
proteins of C. sonorensis. For example, the SGE of Phlebotomus papatasi and Lutzomyia longipalpis is 
only partially susceptible to heat treatments of 80°C and above leading to continued, but reduced 
salivary protein function as determined by zymography activity, post-heat treatment (Cerna et al., 
2002). Despite this, a number of publications have shown arthropod salivary proteins to be heat-labile 
(Bissonnette et al., 1993, Katz et al., 2000, Mendes-Sousa et al., 2016, Waitumbi and Warburg, 1998) 
and zymography analysis has confirmed that heat treatment to 56 °C destroys the protease function of 
C. sonorensis saliva (Stoner, 2015).  
The implication of a non-protein salivary competent being involved in enhancing BTV infection and 
replication, led to the consideration of bacterial products that could be present within the saliva and 
potentially influencing BTV infection and replication (through direct or indirect mechanisms), due to 
their potent effect as innate immune response inducers (reviewed in (Alexander and Rietschel, 2001)). 
Although the characterisation of the arthropod microbiome has been heavily studied, including the role 
of arthropod gut flora in mediating the ability of a pathogen to infect its arthropod host (Boissiere et 
al., 2012, Cirimotich et al., 2011, Dong et al., 2009, Rodrigues et al., 2010), considerably less is known 
regarding the natural arthropod salivary gland microbiome. However, for some arthropod species such 
as Amblyomma ticks (Klyachko et al., 2007), certain species of Glossina flies (Cheng and Aksoy, 1999) 
and Ae. aegypti and An. stephensi mosquitoes (Crotti et al., 2009) the salivary glands have been shown 
to become colonised with specific bacterial species. Despite this knowledge that the salivary glands of 
arthropods may harbour a bacterial community, the majority of publications that have investigated the 
effect of salivary material, either as collected saliva, SGE or WBE, on the host immune response or 
arbovirus infection, have not commented upon LPS content within the salivary material used. Indeed, 
it is possible that whole bacteria or bacterial products from the arthropod salivary microbiome may be 
deposited alongside the saliva of an arthropod during the acquisition of a blood meal from the 
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mammalian host. The few publications that have commented on LPS content within arthropod salivary 
materials have indicated that the samples utilised contained ‘negligible levels of endotoxin’ 
(Phlebotomus papatasi sand flies SGE) (Carregaro et al., 2011, Carregaro et al., 2008) or ‘very low levels 
that were well below the FDA-approved limit for injection of solutions (<5 endotoxin units per kg per 
hour)’ (Ae. aegypti SGE) (Schmid et al., 2016). In all cases, it is hard to ascertain the role of low levels of 
LPS on the observed effects of salivary material without knowing the exact level of LPS involved. 
Furthermore, the classification of LPS based on FDA approved limits for injectable solutions was 
relevant in the context of the publication which utilised in vivo inoculations of mice (Schmid et al., 
2016), however does not allow for a direct conversion to an in vitro system.  
One of the major findings of this chapter is the identification of the bacterial product LPS within the 
collected saliva of C. sonorensis. Although there are no studies that have investigated the salivary 
microbiome of Culicoides midges, it is possible that the LPS identified within the saliva of Culicoides 
originates from the salivary microbiome or is deposited onto the filter by contaminated mouthparts 
during the collection process. It is also possible that Culicoides midges may deposit live bacteria onto 
the filters that may then release LPS. Although live bacteria would be removed by filtration during the 
processing of the saliva and would thus not be directly applied to the PBMC cultures, LPS would remain 
in the preparation. LPS content has also been confirmed, albeit exact amounts were not quantified, 
within secreted C. nubeculosus and Ae. aegypti saliva collected by the same method utilised throughout 
this thesis and the SGE of Ae. aegypti mosquitoes (Laura Tugwell, personal communication).  
Many publications have utilised LPS as a stimulus to activate or mature in vitro cultured cells, for 
example macrophages and DCs, prior to treatment with arthropod saliva. For the majority, cellular 
treatment with arthropod saliva, either before or after LPS activation, has been shown to lead to a 
reduction in LPS induced expression of co-stimulatory molecules, such as CD80 and CD86, and a 
reduction in LPS induced expression of pro-inflammatory cytokines such as IL-12, TNF-α and IFN- 
(Brake and Pérez de León, 2012, Mendes-Sousa et al., 2016, Oliveira et al., 2011, Poole et al., 2013). 
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Endotoxin tolerance can be defined as a reduced ability of an in vitro or in vivo system to respond to a 
PAMP, for example LPS, following repeat exposure. LPS tolerance has predominantly been 
characterised in humans and has been linked to a reduced biological ability to produce pro-
inflammatory cytokines in response to repeat LPS exposure, for example IL-12 and TNF-α (as reviewed 
in (Lopez-Collazo and del Fresno, 2013)). Although it is unknown if the salivary material utilised in the 
above mentioned studies contained LPS it should now be a consideration, when observing an effect of 
saliva on LPS-induced immune responses, that the salivary effects may in part be attributed to immune 
tolerance. 
Most uniquely, studies carried out in this chapter revealed that purified LPS alone mimicked the effect 
of Culicoides saliva by enhancing expression of BTV structural proteins and the NSP, NS2. The influence 
of bacterial pathogens on virus infection has been studied to the greatest extent in the context of 
enhanced enteric virus infections in the presence of commensal, intestinal microbiota. Studies have 
shown that following antibiotic treatment, to deplete the gut commensal bacteria in mice, infection 
with poliovirus (Kuss et al., 2011), mouse mammary tumour virus (MMTV) (Kane et al., 2011), rotavirus 
(Uchiyama et al., 2014) and norovirus (Baldridge et al., 2015, Jones et al., 2014) is reduced therefore 
indicating that when present gut microbiota can act to promote enteric virus infection. Two major 
mechanisms have been proposed to explain this enhancement in virus infection. Firstly, the direct 
action of bacterial products, specifically LPS, that can facilitate the stabilisation of virus particles or virus 
particle attachment to host cells, both of which have been shown for poliovirus (Kuss et al., 2011, 
Robinson et al., 2014). Secondly, that the presence of bacteria or bacterial products can lead to an 
alteration in the antiviral immune response thus indirectly altering virus infection. MMTV has been 
shown to contain LPS binding factors CD14, TLR4 and MD-2 in its viral envelope, that are acquired 
during virus egress, allowing the virus to directly bind LPS. LPS associated virus then activates TLR-4 
leading to the production of immune-regulatory cytokines, such as IL-10, thus facilitating the 
establishment of a persistent MMTV infection in the murine host (Kane et al., 2011, Wilks et al., 2015). 
Additional indirect methods by which gut microbiota can aid in enhancement of enteric virus infections 
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include, suppression of antibody production, as indicated by reduced antiviral antibody titres to 
rotavirus infection in microbial colonised mice compared to antibiotic-treated mice (Uchiyama et al., 
2014). The gut microbiota can also suppress IFN signalling leading to enhanced viral infections. 
Specifically, persistent norovirus infection of the murine model is seen to be dependent on bacterial 
colonisation in immunocompetent mice, whilst in mice lacking the IFN III receptor, persistent infection 
is seen to be independent of the presence of bacteria. This potentially indicates the interaction of 
commensal bacteria and norovirus is able to inhibit IFN- production thus altering the antiviral immune 
response (Baldridge et al., 2015). Alternatively it should also be considered that the presence of LPS 
can also have a limiting effect on virus infection. For example, the presence of LPS alongside Influenza 
virus (Short et al., 2014) and Human Immunodeficiency virus (HIV) (Devadas et al., 2010, Verani et al., 
1997) has been shown to reduce virus infection. Furthermore, DENV infection of human monocytes is 
inhibited in the presence of LPS, potentially due to the direct binding of LPS to CD14, thus indicating 
that CD14 may be involved in DENV entry mechanisms (Chen et al., 1999). It is possible that either of 
these two major hypothesis (a direct effect of LPS on virus infection or an indirect effect of LPS on the 
antiviral immune response that in turn allows an enhancement in virus infection) could be applicable 
to explain the LPS induced enhancement of BTV infection and replication within bovine monocytes. 
As highlighted in chapter 4, the monocyte population of PBMCs is unique in supporting the 
enhancement of BTV infection and replication in the presence of saliva, whilst the other cell 
populations, for example the T and B cells appear to be infected irrespective of the presence of saliva 
during infection. In this chapter, the LPS content within the saliva of C. sonorensis was found to play a 
key role in this observed enhancement of BTV infection and replication within the bovine monocyte 
population of PBMCs. This specificity in the effect of saliva may possibly be based on the expression of 
high levels of CD14 by monocytes and the integral role that CD14 plays in LPS signalling. Although CD14 
is typically reported as a monocyte and macrophage cell surface membrane protein, some human B 
cells have been shown to express CD14, albeit to much lower levels than monocytes (Ziegler-Heitbrock 
et al., 1988, Ziegler-Heitbrock et al., 1994). Unfortunately, due to the lack of dual – cell surface 
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membrane protein labelling carried out throughout this study, the presence of CD14 expression on the 
surface of B cells cannot be definitely ruled out. However, it can be considered that the FSC and SSC 
parameters (indicating cell size and granularity, respectively) associated with CD14 positively labelled 
cells appeared distinctly greater compared to those associated with B cells, thereby indicating that the 
smaller cells with lymphocyte like characteristics are unlikely to have co-expressed CD14. This apparent 
lack of CD14 expression is a potential explanation for the absence of a saliva induced BTV infection 
response in these smaller, less complex cell types (based upon flow cytometry FSC and SSC parameters, 
respectively). It should also be considered that CD14 can be cleaved from the cell surface and is found 
as a soluble form within bovine serum (Yang et al., 1996). In the presence of soluble CD14, LPS signalling 
can occur in any cell type that expresses TLR 4, thus the cellular expression of TLR 4 may also contribute 
to the cells that can support saliva/LPS enhanced BTV infection and replication. TLR 4 has been reported 
to be expressed (as determined by mRNA levels) by bovine primary monocytes from PBMCs (Werling 
et al., 2004) and bovine pulmonary epithelial cells and lung microvascular ECs (McClenahan et al., 2008). 
This expression of TLR4 by lung microvascular ECs is of particular interest as BTV infection of this cell 
type is central to the pathogenesis of the virus in the ruminant host. It is therefore possible that BTV 
infection in this cell type may be enhanced by the presence of LPS during infection. Secondary, 
opportunistic bacterial infections (e.g Pasteurella multocida, Mannheimia species and Mycoplasma 
ovipneumoniae) leading to pneumonia are commonly associated with BTV infection of ruminants 
(Williamson et al., 2008), thus it is applicable to consider the effect that such bacterial infections have 
on the synergistic infection of the ruminant host with BTV. Although these bacterial infections are often 
associated as being secondary to BTV infection, most likely as a result of virus-induced 
immunosuppression, there is also a possibility that there may be a role for bacterial infections and LPS 
in enhancing the establishment of or the course of BTV infection in the natural host.  
The specificity of saliva/LPS induced enhancement of BTV infection and replication within the monocyte 
population may also help us to understand the mechanisms underlying this novel finding. As indicated 
by experiments in this chapter, that altered the timing at which saliva and/or LPS was applied onto 
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PBMC cultures post-BTV infection, saliva and LPS are likely eliciting their effects on BTV infection at the 
early stages of infection. Potentially, the presence of saliva during the 1 hour infection is able to induce 
the passive uptake or sampling of the environment by the monocyte population thus leading to a 
greater level of virus infection. An enhancement of BTV infection and replication was also seen following 
the addition of saliva at 4 h.p.i, albeit to a lesser extent in the monocyte population of PBMCs from one 
out of two cattle PBMC donors. This could possibly be explained by LPS induced enhancement of 
residual virus uptake by the monocyte population, or the enhanced uptake of virus particles that had 
bound the monocyte surface but not entered the cell and initiated infection. As highlighted in chapter 
4, purified monocytes are also able to support saliva induced BTV infection and replication. This 
therefore indicates that the underlying mechanism of saliva and LPS enhanced BTV infection and 
replication, within the monocyte population, may be irrespective of direct or indirect contact with the 
bystander cells within PBMCs, indicating that saliva enhanced virus uptake may offer a valid hypothesis 
for the observed effects.  
Commercial LPS of S. enterica origin has been used throughout this chapter to mimic the effect of the 
LPS within saliva on BTV infection and replication, as at present the bacterial origin of the LPS within 
the saliva of C. sonorensis is unknown. Furthermore, bacteria from E. coli were also determined to 
comparably enhance BTV infection and replication within bovine monocytes (data not shown). It would 
be advantageous to determine the effect of LPS from a more applicable bacterial source on BTV 
infection and replication, for example LPS from P. multocida would be representative of a bacterial 
species that may be present alongside BTV infection of the natural ruminant host (Williamson et al., 
2008). Furthermore, the quantification kit utilised throughout this work determines the enzymatic 
activity of the LPS present within the tested sample in relation to the E. coli O111:B4 standard. This 
estimated enzymatic activity (EU/ml) is then correlated to the mass of endotoxin based on the 
assumption that 1 EU/ml equals ~ 0.1 ng endotoxin per ml. Although the kit utilised for the 
quantification of endotoxin activity is based on an FDA approved method, this approximation of LPS 
mass has its limitations as different endotoxins may vary in their potency and ability to react with LAL.  
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Despite LPS being highly heat stable (Ding and Ho, 2010), the heat treatment of saliva resulted in a two 
fold increase in the estimated activity of LPS within the saliva of C. sonorensis. This alteration in detected 
salivary LPS activity cannot be explained by the presence of trypsin within the saliva at the respective 
salivary dilutions, however other salivary components may potentially play a role in this enhancement. 
At present this finding is based on one replicate assay and as shown in Figure 5.3, there is variation 
within the quantification of salivary LPS activity across collections and within collections. Furthermore, 
the effect of LPS at comparable amounts to 0.1 and 0.01 µg/ml saliva, on BTV infection and replication 
in monocytes was investigated and it was found that in two out the three cattle tested, the 10 fold 
difference in the amount of LPS applied to cells had a minimal effect on LPS induced BTV infection and 
replication. Although the effect of a potential two fold variation in salivary LPS quantification cannot be 
discarded, the biological role of a potential two fold variation in enhancing BTV infection and replication 
is at present unknown, yet may be minimal.  
Initial experiments in this chapter may tentatively suggest a potential role for C. sonorensis salivary 
proteins, when active alongside LPS, in downregulating LPS enhanced BTV infection and replication. 
Indeed, studies that utilised the heat treatment of saliva, in order to determine the involvement  of 
salivary proteins in the observed saliva induced enhancement of BTV infection and replication, 
indicated that following the denaturation of salivary proteins saliva induced BTV infection and 
replication was enhanced. This thereby indicates that when active, salivary proteins may act to 
counteract the enhancing effects of LPS on BTV infection. Furthermore, the infection of PBMCs in the 
presence of LPS, at matched amounts to that present in 1 µg/ml C. sonorensis saliva, also led to an 
enhancement in infection and replication compared to infection in the presence of saliva (Figure 5.5), 
thereby potentially suggesting that salivary proteins can supress LPS induced BTV infection and 
replication. This notable heightened increase in viral protein expression in the presence of LPS at 
matched amounts to 1 µg/ml saliva may indicate that higher levels of salivary proteins may been 
needed to limit LPS induced BTV infection and replication. Indeed, the infection of PBMCs in the 
presence of lower amounts of C. sonorensis saliva, or matched amounts of LPS (Figure 5.7), led to a 
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more variable and inconsistent comparison in viral protein expression between these two conditions. 
The removal of the LPS component of C. sonorensis saliva, and the subsequent application of LPS 
removed saliva to PBMCs alongside LPS, led to a marginal reduction in LPS induced infection and 
replication, compared to BTV infection in the presence of LPS alone. This preliminary finding therefore 
contributes to the hypothesis that C. sonorensis salivary proteins may function to limit LPS induced BTV 
infection and replication within bovine monocytes. This latter study, utilising LPS removed saliva was 
however based upon a single replicate in which BTV infection levels appeared to be low. Further 
investigation is therefore needed to elucidate this tentative hypothesis and clarify the effects of salivary 
proteins, in the absence of inherent LPS, in the context of saliva and LPS induced modulation of BTV 
infection and ruminant immune response. 
Studies carried out in chapter 4 highlighted that the presence of C. sonorensis saliva during bovine 
PBMC infection led to an enhancement in the proportion of monocytes supporting BTV infection and 
replication. However relatively large quantities of Culicoides saliva were used in these initial trial 
experiments and the respective efficiency of saliva induced effects on BTV replication might be 
important to estimate the biological relevance of these observations. Titration experiments carried out 
in this chapter highlighted that salivary concentrations as low as 0.001 µg/ml were able to alter BTV 
infection and replication. Although it is unknown what volume/concentration of salivary molecules 
would be deposited into the skin of the ruminant host, it would be assumed that saliva induced BTV 
infection and replication at very low saliva doses would be more likely to be biologically relevant given 
that Culicoides midges are one of the smallest blood sucking arthropods (Mellor et al., 2000). 
Nevertheless, higher salivary dose may also be biologically relevant due to the aggregate feeding nature 
of Culicoides midges, whereby multiple Culicoides will collectively feed at preferential sites on the 
ruminant host (Ayllón et al., 2014), thus the cumulative dose of saliva from the blood feeding of multiple 
midges will inevitably be greater. The work of this chapter also highlighted that very low levels of LPS 
were able to enhance BTV infection and replication thus highlighting the likely biological relevance of 
LPS in the enhancement of BTV infection and replication. Furthermore, this work emphasised that LPS 
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content within arthropod salivary material and the subsequent effect on saliva induced modulation of 
the host immune response or saliva induced modulation of arbovirus infection needs to be a 
consideration in all model systems, even when LPS is detected within arthropod saliva at very low levels 
as has previously be claimed (Carregaro et al., 2011, Carregaro et al., 2008, Schmid et al., 2016).  
5.10 Summary  
Overall, the novel findings of this chapter have highlighted the identification of LPS as a component of 
the collected saliva from C. sonorensis midges and also implicated LPS in enhancing BTV infection and 
replication. The major findings of this chapter are highlighted in Figure 5.14. Investigations into the 
bacterial microbiome of Culicoides salivary glands would help advance the study of the intricate 
interactions between the salivary microbiome, the active salivary proteins and the effect of their 
interactions on Culicoides-borne pathogen infections in the vector and mammalian host.  
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Figure 5.14 - Summary schematic highlighting the major findings of Chapter 5. 
  
The saliva of C. sonorensis naturally contains bacterial LPS.  
Bacterial LPS is a likely component present within C. sonorensis saliva that is enhancing the 
proportion of monocytes, within PBMCs, expressing VSP and NSP. 
C. sonorensis saliva can enhance the proportion of monocytes, within PBMCs, expressing VSP and 
NSP at concentrations as low as 0.001 µg/ml. 
C. sonorensis saliva and/or LPS likely elicit their effects at the early stages of virus infection, 
resulting in an increased proportion of monocytes, within PBMCs, expressing VSP and NSP. 
The LPS component of C. sonorensis saliva can be removed and a preliminary study has 
highlighted that LPS removed C. sonorensis saliva may be unable to enhance the proportion of 
monocytes expressing VSP and NSP. 
A C. sonorensis salivary protein may not be eliciting the observed saliva induced increase in the 
proportion of monocytes, within PBMCs, expressing VSP and NSP. 
 
 
 
 
 
 
 
 
Chapter 6  
The effect of Culicoides sonorensis 
saliva and/or BTV infection on the 
cytokine response and viability of 
bovine PBMCs and purified monocytes 
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6.1 Introduction  
The modulation of the mammalian host cytokine response by arthropod saliva has been well 
characterised, and typically leads to a polarisation away from a virus-induced anti-viral and Th1 
response, towards a Th2 response. This generalisation of the change in immune response polarisation 
has been based on numerous studies, which have indicated a saliva-mediated reduction in arbovirus or 
stimulus induced transcription or production of typical pro-inflammatory cytokines such as IFN- 
(Agarwal et al., 2016, Brake and Pérez de León, 2012, Kovar et al., 2002, Wanasen et al., 2004, Zeidner 
et al., 1999), TNF-α (Agarwal et al., 2016, Brake and Pérez de León, 2012, Oliveira et al., 2011, Poole et 
al., 2013) and IL-12 (Brake and Pérez de León, 2012, Oliveira et al., 2011). In comparison, typical Th2 
cytokines, that control IgE production and eosinophilic responses such as IL-4, have been shown to be 
upregulated in response to the presence of arthropod saliva (Agarwal et al., 2016, Kovar et al., 2002, 
Zeidner et al., 1999). Furthermore, the expression of the anti-inflammatory cytokine IL-10, (initially 
characterised as a Th2 cytokine, although later found to be expressed by non-Th2 type cells), in 
response to virus infection or stimulus is further augmented in the presence of saliva (Agarwal et al., 
2016, Kovar et al., 2002, Menezes et al., 2008, Oliveira et al., 2011). However, there are some cases 
where the effect of vector saliva on virus induced cytokine production does not follow this overarching 
trend, for example the observed enhanced induction of IL-12 and TNF-α from DENV infected human 
monocytes in the presence of Ae. aegypti saliva (Ader et al., 2004).  
The ruminant cytokine response to BTV infection has largely been studied in the context of the 
induction of a type I IFN response by the mammalian host; a response that has been shown in the 
ruminant host both in vitro and in vivo (Chauveau et al., 2012, MacLachlan and Thompson, 1985, 
Rinaldo et al., 1975, Ruscanu et al., 2012). Additionally, following the isolation of RNA from the blood 
of sheep infected with BTV either ID, ID alongside the blood feeding of uninfected Culicoides midges or 
via infected Culicoides midge bites, Pages et al., (2014) reported variations in the expression of IFN 
inducible genes. Most notably, the inoculation of sheep with infected midges led to a significant 
reduction in the expression of CXCL10 and MX1 genes (inducible by IFN type II and type I/III, 
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respectively) when compared to ID infected sheep (Pages et al., 2014). Although the exact dosage of 
virus transmitted by the bite of infected Culicoides midges is unknown, and therefore the sheep 
infected via this method may have received less viral inoculum compared to ID infected sheep, these 
results hypothesise that the presence of Culicoides salivary proteins during the initiation of BTV 
infection can lead to a modification of the host immune IFN response that subsequently effects the 
expression of the two genes (Pages et al., 2014). Furthermore, in vivo BTV infection studies of the ovine 
host have indicated, via measuring serum cytokine protein levels, that BTV infection can induce a TNF-
α, IFN- and IL-10 cytokine response in some sheep. The cytokine response was however variable 
between infecting BTV strains, with an enhanced cytokine production seen following the infection of 
sheep with BTV-1 compared to BTV-8, with BTV-1 infection also resulting in more severe clinical disease 
(Sanchez-Cordon et al., 2015, Sánchez-Cordón et al., 2013).  
Aside from in vitro studies that have investigated the BTV induced IFN type I response, the remaining 
in vitro BTV-induced cytokine response studies have predominantly been carried out using bovine and 
ovine microvascular ECS and have indicated that the transcription of IL-1, IL-8 and IL-6 is upregulated 
in this cell type upon infection (DeMaula et al., 2002a, DeMaula et al., 2002b). Similarly IL-1, IL-8 and 
TNF-α gene expression is upregulated in bovine monocyte derived macrophage cultures following BTV 
infection (Drew et al., 2010). Furthermore, BTV infection of ovine microvascular ECs and bovine 
monocyte derived macrophages has also been shown to enhance the synthesis of the enzyme that 
produces NO, iNOS (DeMaula et al., 2002a, Drew et al., 2010), whilst C. sonorensis saliva has been 
shown to downregulate LPS induced NO production (albeit in murine macrophages) (Bishop et al., 
2006), thus indicating the possibility that C. sonorensis saliva may be able to modulate the ruminant 
immune response to BTV infection.  
Infection studies in microvascular bovine and ovine ECs have also indicated the possible role that BTV 
induced inflammatory mediators may play in inducing cellular apoptosis. Most notably, BTV infection 
of ovine and bovine microvascular ECs in the presence of IL-1, led to a marked increase in cellular 
apoptosis, compared to BTV infection alone. Furthermore, the infection of ECs with a viral inoculum 
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derived from previously infected EC cultures also enhanced BTV induced apoptosis compared to 
partially purified BTV, therefore indicating that the presence of EC derived inflammatory mediators 
during BTV infection can play a role in BTV induced target cell death (DeMaula et al., 2001, DeMaula et 
al., 2002b). Additionally, in vitro BTV infection has been shown to induce cellular death, either via 
apoptosis or necrosis, in a number of mammalian cells lines (Mortola et al., 2004, Nagaleekar et al., 
2007), ovine WC1-activated  T cells (Takamatsu et al., 2003) and bovine blood monocytes (Barratt-
Boyes et al., 1992). In vivo BTV infection of sheep has also been shown to increase the percentage of 
apoptotic cells within PBMCs and the spleen (Umeshappa et al., 2010a).  
Arthropod saliva has also been shown to have a variable effect on cell viability, albeit the effect of C. 
sonorensis saliva is yet to be characterised. SGE from Ae. aegypti mosquitoes has been shown to induce 
murine CD4 and CD8 T cell death (Wanasen et al., 2004), whilst to the contrary, secreted saliva from 
the same vector did not induce apoptosis of human monocyte derived DCs (Ader et al., 2004). 
Interestingly, in the context of arbovirus infection, this could therefore result in an augmentation of 
cellular death if both the virus transmitted by the arthropod and the saliva of the arthropod both induce 
cellular death. On the other hand, arthropod saliva could reduce virus-induced cell death as has been 
shown by a reduction in DENV induced apoptosis of human monocyte derived DCs in the presence of 
secreted Ae. aegypti saliva (Ader et al., 2004). In vitro BTV infection of bovine blood monocytes has 
previously been shown to induce cell death (Barratt-Boyes et al., 1992), however the effect of C. 
sonorensis saliva on host cell death and BTV induced-host cell death is unknown. 
In this chapter, the effect of in vitro BTV infection and/or C. sonorensis saliva on the cytokine response 
of bovine PBMC and purified monocyte cultures was assessed. Specifically, the production of typically 
Th1 cytokines IFN-, IL-12 and TNF-α, the typical Th2 cytokine IL-4 and the anti-inflammatory cytokine 
IL-10 from these cells was determined by ELISA. Infection experiments also aimed to elucidate the effect 
of BTV infection and/or C. sonorensis saliva on the viability of total PBMCs and the viability and 
composition of T and B lymphocyte and monocyte populations within PBMCs. The viability of 
monocytes within PBMCs was also compared to the viability of purified monocytes following BTV 
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infection in the absence or presence of C. sonorensis saliva. Additionally, CD14 cell surface membrane 
protein expression on monocytes within PBMCs was determined following differential treatment with 
C. sonorensis saliva either alone or alongside BTV infection. 
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6.2 Determining the effect of BTV and/or C. sonorensis saliva on the cytokine production by bovine 
PBMCs 
As described in chapter 4, infection experiments were carried out in order to determine the effect of 
C. sonorensis saliva on BTV infection of bovine PBMC populations, principally the CD14+ monocyte 
population (Section 4.3; Figure 4.3 – 4.7). Overall, bovine PBMCs were infected in the absence or 
presence of 1 µg/ml C. sonorensis saliva and at the point of harvest of these experiments, cultured cells 
were processed for flow cytometry as described (chapter 4) while supernatants were stored at -80 °C 
until further processing by ELISA, to determine the respective cytokine content. 
‘In-house’ sandwich ELISAs developed at TPI (formerly the Institute for Animal Health) for the detection 
of IL-10 (Kwong et al., 2002), IL-4 (Hope et al., 2005), IFN- (Wattegedera et al., 2010), IL-12 (Hope et 
al., 2002) and TNF-α (Kwong et al., 2010) cytokines were utilised. The specific supernatants tested for 
respective cytokine content are those of the cell cultures used to determine viral protein expression 
within the monocyte population of PBMCs (Section 4.3; Figure 4.3 – 4.8) and not those derived from 
the original screen data (Section 4.2; Figure 4.1 – 4.2). As shown in chapter 5, C. sonorensis saliva has 
been found to contain LPS thus the application of saliva onto PBMCs resulted in the following final LPS 
concentrations: cattle 1 - 18.8 ng/ml for all replicates, cattle 2 - 16.4 ng/ml for the single replicate 
displayed, cattle 3 - 16.4 ng/ml LPS for the two replicates shown and cattle 5 - either 0.09 or 1.1 ng/ml 
LPS for the two replicates shown. Statistical differences in the cytokine production between treatment 
groups was only determined for cattle 1 PBMC cultures due to the minimal replicate numbers from the 
remaining cattle. 
IL-10 was absent or minimally produced by mock infected PBMCs from all cattle at 72 h.p.i whilst in 
comparison, IL-10 production was increased by BTV infected PBMCs from cattle 1, 2 and 3 (Figure 6.1; 
A –C). Saliva only treatment of PBMCs from all cattle induced IL-10 secretion into the cell culture 
supernatant to a similar of higher level compared to BTV induced IL-10 production (Figure 6.1; A - D). 
IL-10 production was further augmented, compared to the production from BTV or saliva treated cells, 
following saliva 1/BTV infection of PBMCs from cattle 1 and 5 (Figure 6.1; A, p = 0.0304 and D). Although 
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IL-10 production was detectable within the supernatants from all cattle, the level of IL-10 production 
was much lower from differentially treated cattle 2, 3 and 5 PBMCs (≤ 90 ng/ml) compared to the scale 
of IL-10 production from cattle 1 PBMCs (≤ 205 ng/ml).  
In comparison to IL-10, IL-4 production by PBMCs from cattle 1, 2 and 5 was not detectable, irrespective 
of the varying treatment condition (Figure 6.2; A - C). The ELISAs carried out were confirmed to have 
worked via the usage of an in vitro expressed protein as an assay standard. 
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Figure 6.1 – C. sonorensis saliva induces IL-10 production by PBMCs irrespective of BTV 
infection 
Bovine PBMCs were infected with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour in the absence or 
presence of 1µg/ml C. sonorensis saliva, washed three times and saliva was replaced onto the relevant 
conditions. The application of the following saliva batches resulted in respective final LPS concentrations: 
cattle 1 – batch number 2, 18.8 ng/ml for all replicates, cattle 2 – batch number 3, 16.4 ng/ml, cattle 3 - 
batch number 3, 16.4 ng/ml LPS for the two replicates shown and cattle 5 – batch number 5 or 6, 0.09 or 
1.1 ng/ml LPS respectively for the two replicates shown. Cell culture supernatants were harvested at specific 
time points post-infection and the IL-10 content within these samples was tested by ELISA. Data is plotted 
as the mean ± standard deviation and statistical differences in the cytokine production by differentially 
treated cultures, compared to mock infected cultures, from cattle 1 PBMCs were determined using the 
Mann Whitney test. The above supernatants were obtained from PBMC cultures, where VSP expression was 
enhanced in the monocyte population following infection in the presence of saliva compared to infection in 
the absence of saliva (Figure 4.3 – 4.6). The highest average proportion of monocytes per cattle expressing 
VSP was observed in cattle 1 monocytes (~30%) whilst the lowest proportion of monocytes expressing VSP 
was observed in cattle 5 monocytes (~14%).  
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Figure 6.2 – BTV infection in the absence or presence of C. sonorensis saliva does not induce IL-4 
production by bovine PBMCs 
Bovine PBMCs were infected with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour in the absence 
or presence of 1µg/ml C. sonorensis saliva, washed three times and saliva was replaced onto the 
relevant conditions. The application of the following saliva batches resulted in respective final LPS 
concentrations: cattle 1 – batch number 2, 18.8 ng/ml for all replicates, cattle 2 – batch number 3, 16.4 
ng/ml and cattle 5 – batch number 5 or 6, 0.09 or 1.1 ng/ml LPS respectively for the two replicates shown. 
Cell culture supernatants were harvested at specific time points post-infection and the IL-4 content 
within these samples was tested by ELISA. 
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IFN- was absent or minimally produced by mock infected and saliva treated PBMCs from all cattle. 
Slightly higher levels of IFN- were however detected within the supernatants of PBMCs from all cattle 
following saliva treatment compared to mock infection at 72 h.p.i (Figure 6.3; A – D). The highest 
assayed levels of IFN- were detected within cell culture supernatants following BTV infection of PBMCs 
obtained from three out of four cattle (Figure 6.3; A, B and C). This enhanced level of IFN- production 
was significantly higher by BTV infected compared to mock infected cells from cattle 1 at 24 and 72 
h.p.i (Figure 6.3; A, p = 0.0304 for both). The BTV induced IFN- production by cattle 1 PBMCs appeared 
to be vastly greater (≤ 6200 ng/ml) compared to cattle 2 and 3 (≤ 220 ng/ml). Markedly lower levels of 
IFN- were produced by PBMCs from cattle 1, 2 and 3, following BTV infection in the presence of saliva 
compared to IFN- production by PBMCs infected with BTV alone (Figure 6.3; A, B and C). A trend 
opposing this was however seen when determining the IFN- production by PBMCs from cattle 5, 
whereby combined BTV infection and saliva treatment led to a greater production of IFN- compared 
to BTV infection alone (Figure 6.3; D). 
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Figure 6.3 – BTV infection in the absence or presence of C. sonorensis saliva induces IFN- production by 
PBMCs 
Bovine PBMCs were infected with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour in the absence or presence 
of 1µg/ml C. sonorensis saliva, washed three times and saliva was replaced onto the relevant conditions. The 
application of the following saliva batches resulted in respective final LPS concentrations: cattle 1 – batch 
number 2, 18.8 ng/ml for all replicates, cattle 2 – batch number 3, 16.4 ng/ml, cattle 3 - batch number 3, 
16.4 ng/ml LPS for the two replicates shown and cattle 5 – batch number 5 or 6, 0.09 or 1.1 ng/ml LPS 
respectively for the two replicates shown. Cell culture supernatants were harvested at specific time points post-
infection and the IFN- content within these samples was tested by ELISA. Data is plotted as the mean ± standard 
deviation and statistical differences in the cytokine production by differentially treated cultures, compared to 
mock infected cultures, from cattle 1 PBMCs were determined using the Mann Whitney test. The above 
supernatants were obtained from PBMC cultures, where VSP expression was enhanced in the monocyte 
population following infection in the presence of saliva compared to infection in the absence of saliva (Figure 4.3 
– 4.6). The highest average proportion of monocytes per cattle expressing VSP was observed in cattle 1 monocytes 
(~30%) whilst the lowest proportion of monocytes expressing VSP was observed in cattle 5 monocytes (~14%).    
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BTV infected PBMCs from cattle 1 produced IL-12 to levels significantly higher compared to mock 
infected cells (Figure 6.4: A, p = 0.0304). IL-12 was also produced by saliva treated only and saliva 
treated/BTV infected cells, albeit to a lesser extent compared to the IL-12 production from BTV infected 
PBMC cultures. Both BTV infected and saliva treated/BTV infected PBMC cultures from cattle 2 
produced IL-12 to comparable levels (Figure 6.4; B), while IL-12 could not be detected in supernatants 
from mock infected or saliva only treated PBMCs from this animal. In comparison, saliva/BTV infection 
led to the greatest amount of IL-12 production from cattle 3 PBMCs, compared to all other treatment 
conditions and only very low levels of IL-12 were detectable within the supernatants of BTV infected or 
saliva treated cultures (Figure 6.4; C). The mock infection or saliva treatment of PBMCs from cattle 5, 
resulted in IL-12 production from these cultures, whilst in comparison reduced levels of IL-12 were 
detected within the supernatants from BTV infected and saliva treated/BTV infected cattle 5 PBMC 
cultures (Figure 6.4; D).  
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Figure 6.4 – BTV infection stimulates the production of IL-12 from some cattle PBMCs 
Bovine PBMCs were infected with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour in the absence or 
presence of 1µg/ml C. sonorensis saliva, washed three times and saliva was replaced onto the relevant 
conditions. The application of the following saliva batches resulted in respective final LPS concentrations: 
cattle 1 – batch number 2, 18.8 ng/ml for all replicates, cattle 2 – batch number 3, 16.4 ng/ml, cattle 3 - 
batch number 3, 16.4 ng/ml LPS for the two replicates shown and cattle 5 – batch number 5 or 6, 0.09 or 
1.1 ng/ml LPS respectively for the two replicates shown. Cell culture supernatants were harvested at specific 
time points post-infection and the IL-12 content within these samples was tested by ELISA. Data is plotted 
as the mean ± standard deviation and statistical differences in the cytokine production by differentially 
treated cultures, compared to mock infected cultures, from cattle 1 PBMCs were determined using the 
Mann Whitney test. The above supernatants were obtained from PBMC cultures, where VSP expression was 
enhanced in the monocyte population following infection in the presence of saliva compared to infection in 
the absence of saliva (Figure 4.3 – 4.6). The highest average proportion of monocytes per cattle expressing 
VSP was observed in cattle 1 monocytes (~30%) whilst the lowest proportion of monocytes expressing VSP 
was observed in cattle 5 monocytes (~14%).   
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TNF-α production was not detectable within the cell culture supernatants of cattle 1 or 2, irrespective 
of differing treatment (Figure 6.5; A and B). The ELISAs carried out were confirmed to have worked via 
the usage of an in vitro expressed protein as an assay standard. Very low levels of TNF-α were detected 
from cattle 3 and 5 PBMC cultures at 72 h.p.i. TNF-α was produced following mock infection of cattle 3 
PBMCs and to a lesser extent by BTV infected or saliva treated cells, whilst in comparison TNF-α was 
non-detectable within cell culture supernatants following saliva 1/BTV infection (Figure 6.5; C). A single 
set of supernatants, collected at 24 h.p.i of PBMCs from cattle 5 were also assessed for TNF-α content 
which was selectively produced by saliva/BTV infected cells (Figure 6.5; D). In comparison by 72 h.p.i, 
the highest levels of TNF-α were detected in supernatants from BTV infected cells in the absence of 
saliva. TNF-α was also detected within saliva treated or saliva/BTV infected PBMC supernatants, albeit 
to a lesser extent compared to the TNF-α detected within cattle 5 PBMCs in response to BTV infection 
alone (Figure 6.5; D).  
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Figure 6.5 – TNF-α production by PBMCs from multiple cattle is variable irrespective of differing 
treatment 
Bovine PBMCs were infected with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour in the absence or 
presence of 1µg/ml C. sonorensis saliva, washed three times and saliva was replaced onto the relevant 
conditions. The application of the following saliva batches resulted in respective final LPS concentrations: 
cattle 1 – batch number 2, 18.8 ng/ml for all replicates, cattle 2 – batch number 3, 16.4 ng/ml, cattle 3 - 
batch number 3, 16.4 ng/ml LPS for the two replicates shown and cattle 5 – batch number 5 or 6, 0.09 or 
1.1 ng/ml LPS respectively for the two replicates shown. Cell culture supernatants were harvested at specific 
time points post-infection and the TNF-α content within these samples was tested by ELISA. Data is plotted 
as the mean ± standard deviation. The above supernatants were obtained from PBMC cultures, where VSP 
expression was enhanced in the monocyte population following infection in the presence of saliva compared 
to infection in the absence of saliva (Figure 4.3 – 4.6). The highest average proportion of monocytes per 
cattle expressing VSP was observed in cattle 1 monocytes (~30%) whilst the lowest proportion of monocytes 
expressing VSP was observed in cattle 5 monocytes (~14%).  
 
 
~ 236 ~ 
 
6.3 Determining the effect of BTV and/or C. sonorensis saliva on the cytokine production by bovine 
purified monocytes  
Cell culture supernatants were also collected from BTV infection experiments in purified monocyte 
cultures as described in chapter 4 (Section 4.5; Figure 4.11). Cell culture supernatants from differentially 
treated cattle 2, 3, 4 and 5 purified monocyte cultures were harvested at 24 h.p.i and stored at -80°C 
until determining the cytokine content within the supernatants by ELISA. The combined cytokine 
production from all cattle monocyte cultures are shown in Figure 6.6. The same saliva preparation was 
utilised for all experiments thus the LPS content within saliva resulted in a final LPS concentration of 
0.02 ng/ml.  
IL-10 production was significantly greater from monocyte cultures that were saliva 1/BTV infected 
compared to the IL-10 production from mock infected cultures (Figure 6.6; A, p = 0.0304). BTV infection 
and saliva treatment also enhanced IL-10 production from purified monocyte cultures, albeit to a lesser 
extent and only the latter was significantly greater compared to IL-10 production by mock infected 
cultures (Figure 6.6; A, p = 0.0304). IL-12 was produced by all purified monocyte cultures following 
differential treatment, with the highest levels produced following saliva 1/BTV infection and the lowest 
levels produced following saliva treatment alone (Figure 6.6; B). In contrast to the BTV induced IFN- 
production from PBMCs, IFN- was not produced by purified monocyte cultures irrespective of differing 
treatment (Figure 6.6; C). TNF-α production by purified monocyte cultures only occurred following BTV 
infection in the presence of saliva in cells obtained from cattle 5 (Figure 6.6; D). 
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Figure 6.6– The effect of BTV infection, in the absence or presence of C. sonorensis saliva, on cytokine 
production by purified monocyte cultures 
Purified bovine monocytes were infected with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour in 
the absence or presence of 1µg/ml C. sonorensis saliva (batch number 4), washed three times and saliva 
was replaced onto the relevant conditions. The saliva preparation used for the experiments in all four 
cattle resulted in a final LPS concentration of 0.02 ng/ml. Cell culture supernatants were harvested at 
24 h.p.i and the IL-10 (A), IL-12 (B), IFN- (C) and TNF-α (D) content within these samples was tested by 
ELISA. Data is plotted as the mean ± standard deviation and statistical differences in the cytokine 
production by differentially treated cultures, compared to mock infected cultures, were determined 
using the Mann Whitney test. The above supernatants were obtained from purified monocyte cultures, 
where viral protein expression was enhanced following infection in the presence of saliva compared to 
infection in the absence of saliva (Figure 4.11). 
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6.4 Determining the effect of BTV infection and/or C. sonorensis saliva on PBMC viability and cellular 
composition 
Although BTV has previously been shown to induce cell death of the monocyte population of bovine 
PBMCs (Barratt-Boyes et al., 1992), the effect that C. sonorensis saliva has on PBMC viability, or BTV 
induced monocyte death is unknown. The infection experiments presented in chapter 4 to determine 
the effect of C. sonorensis saliva on BTV viral protein expression within the monocyte population of 
PBMCs (Section 4.3; Figure 4.3 – 4.7) were therefore also analysed to determine the effect of BTV 
infection and/or C. sonorensis saliva, on bovine PBMC viability. A live/dead cell exclusion dye was 
initially utilised to enable the differentiation between live and dead cells. Data was analysed by a 
standardised gating strategy to exclude debris below 5µm (determined by a 5µm bead) and only include 
live, single cells as indicated by the gating strategy in Figure 6.7; A. 
The viability of PBMCs from cattle 1, 2, 3 and 5 was largely unaltered following BTV infection in the 
absence or presence of C. sonorensis saliva at 2 and 24 h.p.i (Figure 6.7; B - E). Cattle 1 PBMC viability 
was reduced at 48 h.p.i following C. sonorensis saliva treatment either alone or alongside BTV infection, 
compared to the viability of mock infected cells albeit to a non-significant degree (Figure 6.7; B). In 
comparison, by 72 h.p.i the viability of BTV infected cattle 1 PBMCs was reduced following BTV infection 
in the absence or presence of saliva compared to mock infected cells (Figure 6.7; B). Saliva treatment 
or saliva 1/BTV infection led to a reduction in the viability of PBMCs from cattle 2, 3 and 5, compared 
to mock infected cells. Saliva 1/BTV infection significantly reduced the viability of PBMCs from cattle 3, 
compared to mock infected cells at 72 h.p.i (Figure 6.7; D, p = <0.001).  
Collectively, the results from all four cattle indicate that at 72 h.p.i, PBMC viability is significantly 
reduced following BTV infection (Figure 6.7; F, p = 0.001) or the treatment of cells with C. sonorensis 
saliva alone or alongside BTV infection (Figure 6.6; F, p = <0.001 for both), when compared to the 
viability of mock infected cells.   
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Figure 6.7 – BTV infection in the presence of C. sonorensis saliva consistently reduces PBMC viability at 
72 h.p.i 
Continued… 
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Figure 6.7 – BTV infection in the presence of C. sonorensis saliva consistently reduces PBMC viability at 
72 h.p.i 
Bovine PBMCs were infected with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour in the absence 
or presence of 1µg/ml C. sonorensis saliva, washed three times and saliva was replaced onto the 
relevant conditions. The application of the following saliva batches resulted in respective final LPS 
concentrations; cattle 1 – batch number 2, 18.8 ng/ml for all replicates, cattle 2 – batch number 3, 16.4 
ng/ml, cattle 3 - batch number 3, 16.4 ng/ml LPS for the two replicates shown and cattle 5 – batch number 
5 or 6, 0.09 or 1.1 ng/ml LPS respectively for the three replicates shown. The proportion of viable PBMCs 
was determined by live cell/dead cell discrimination using PBMCs from 4 cattle. The following number 
of replicates are displayed; cattle 1 – 2 h.p.i (n = 3), 24 h.p.i (n = 4), 48 h.p.i (n = 4), 72 h.p.i (n = 4)(A); 
cattle 2 - 2 h.p.i (n = 1), 24 h.p.i (n = 1), 72 h.p.i (n = 1)(B); cattle 3 - 2 h.p.i (n = 2), 24 h.p.i (n = 2), 72 
h.p.i (n = 2)(C); cattle 5 - 24 h.p.i (n = 3), 72 h.p.i (n = 3)(D). Data from all replicates were combined (E), 
plotted as the mean ± standard deviation and statistical differences between differentially treated 
cultures, compared to mock infected cultures at respective time points, were determined using the Tukey 
multiple comparison test. The above results correspond to data shown in chapter 4 (Figure 4.3 – 4.6), 
where VSP expression was enhanced in the monocyte population following infection in the presence of 
saliva compared to infection in the absence of saliva. The highest average proportion of monocytes per 
cattle expressing VSP was observed in cattle 1 monocytes (~30%) whilst the lowest proportion of 
monocytes expressing VSP was observed in cattle 5 monocytes (~14%). Viral protein expression in other 
PBMC populations was not determined.  
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Although the results in Figure 6.1 give an indication of total PBMC viability, it does not indicate the 
effect of BTV and/or C. sonorensis saliva on the populations of cells composing the PBMCs or the 
viability of these individual populations. The data obtained from the original screen to determine the 
effect of C. sonorensis saliva on viral protein expression within cell surface membrane protein labelled 
PBMC subpopulations, as shown in chapter 4 (Section 4.2; Figure 4.1 – 4.2), was therefore analysed via 
a standardised gating strategy (Figure 6.8 A) to determine the proportion of cells composing PBMCs 
from cattle 2, 3 and 4 at 72 h.p.i in the absence or presence of C. sonorensis saliva. The saliva utilised 
for this original screen resulted in a final LPS concentration of 0.09 ng/ml (cattle 2) or 0.02 ng/ml (cattle 
3 and 4).  
Differential treatment of PBMCs and the assessment of the proportion of cellular populations 
composing this heterogeneous cell mixture highlighted that the percentage of  T cells and monocytes 
within PBMCs was notably altered between treatment groups. The  T cell proportion was higher in 
BTV infected and saliva treated/BTV infected PBMC cultures (Figure 6.8; B) when compared to the 
proportion of  T cells within mock infected PBMCs. In comparison, the CD14 monocyte population of 
PBMCs was significantly lower following BTV infection in the absence or presence of C. sonorensis saliva 
compared to mock infected cells (Figure 6.8; F, p = 0.0304). Minimal, non-significant changes in the 
proportions of CD4, CD8 and CD21+ cells composing PBMCs were seen following differential treatment 
(Figure 6.8; C, D and E, respectively).  
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Figure 6. 8 – BTV infection of PBMCs alone or in the presence of C. sonorensis reduces the 
proportion of monocytes within PBMCs 
Bovine PBMCs were infected with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour in the absence or presence of 
1µg/ml C. sonorensis saliva, washed three times and saliva was replaced onto the relevant conditions. The saliva utilised 
resulted in a final LPS concentration of 0.09 ng/ml (cattle 2; batch number 5) or 0.02 ng/ml (cattle 3 and 4; batch number 
4). The proportion of viable PBMC subpopulations was determined by live/dead cell discrimination and subsequent 
analysis of specific cell surface membrane protein positive cells. Example gating for CD4 positively labelled cells is shown 
in (A). The proportion of live, T lymphocytes within PBMCs was assessed by the cellular expression of the  T cell 
receptor (B) and the cell surface membrane proteins CD4 (C) and CD8 (D). The proportion of live, B cells and monocytes 
within PBMCs was assessed by the cellular expression of surface membrane proteins, CD21 (E) and CD14 (F), 
respectively. Results from three cattle are plotted as the mean ± standard deviation and statistical differences between 
differentially treated cultures, compared to mock infected cultures, were determined using the Mann Whitney test. The 
VSP expression from the corresponding data indicated on average low levels of infection within the T (< 2%) and B (<5%) 
lymphocyte populations irrespective of the presence of saliva during infection but higher levels of infection in the 
monocytes infected in the absence (~18%) or presence (~23%) of saliva (Figure 4.1 and 4.2).   
A 
NOTE: different axis. 
Cell surface membrane 
protein antibody labelling  
Debris exclusion 
Dead cell 
exclusion Doublet exclusion 
Isotype control 
antibody labelling  
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Although the proportions of specific cell populations within PBMCs gives a useful measure of the 
cellular subsets that compose this heterogeneous mixture of cells following varying treatment, it does 
not give an accurate measure of cell subset viability as when a fixed number of cells is collected by flow 
cytometry, changes in the proportion of one cellular population can be dependent on changes in the 
proportion of other cell populations. For example, an increase in the proportion of one PBMC 
population does not definitely indicate proliferation of this population, but may rather indicate the 
death of another subpopulation and vice versa. 
In order to characterise the viability of PBMC subpopulations, the same data as shown in Figure 6.8 was 
differentially analysed via a strategy adapted from Wanasen et al., (2004), which was used for the 
determination of the effect of Aedes and Culex mosquito SGE on murine splenocyte viability. The gating 
strategy outlined in Figure 6.9 A is based upon excluding debris below 5 µm followed by the exclusion 
of cellular doublets. Cell surface membrane protein positively labelled cells were next gated upon and 
the viable portion of this cell population was determined via the exclusion of dead cells as indicated by 
the histogram. Finally, any remaining cellular debris was excluded.  
The  TCR positive PBMC population was seen to be the most viable cell type at 72 h.p.i and this 
viability was consistent between experimental conditions (Figure 6.9; B). In comparison, CD4 viability 
varied between treatment groups with BTV infected and saliva treated/BTV infected cells being 
significantly less viable compared to mock infected cells (Figure 6.9; C, p = 0.0131 and 0.0051, 
respectively). CD8 T cell and B cell viability was also reduced as a result of PBMC infection with BTV in 
the absence or presence of saliva, albeit to non-significant levels compared to the viability of mock 
infected cells (Figure 6.9; D and E). Monocyte viability was significantly reduced following BTV infection 
in the absence or presence of saliva compared to the viability of mock infected cells (Figure 6.9; F, p = 
0.0304 for both).   
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Figure 6.9 – Differential treatment of PBMCs with C. sonorensis saliva in the absence or presence of BTV infection 
alters CD4+ T cell and monocyte viability 
Bovine PBMCs were infected with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour in the absence or presence of 
1µg/ml C. sonorensis saliva, washed three times and saliva was replaced onto the relevant conditions. The saliva utilised 
resulted in a final LPS concentration of 0.09 ng/ml (cattle 2; batch number 5) or 0.02 ng/ml (cattle 3 and 4; batch number 
4). PBMC subpopulations were determined by specific cell surface membrane protein expression and the viable 
proportion of these cells was analysed by live/dead cell discrimination. An example gating strategy for single, CD4 cell 
surface membrane protein positive cells which are viable is shown in (A). T lymphocytes were assessed by the cellular 
expression of the  T cell receptor (B) and the cell surface membrane proteins CD4 (C) and CD8 (D); B cells and 
monocytes were assessed by the expression of cell surface membrane proteins CD21 (E) and CD14 (F), respectively. 
Results from three cattle are plotted as the mean ± standard deviation and statistical differences between differentially 
treated cultures, compared to mock infected cultures, were determined using the Mann Whitney test. The VSP 
expression from the corresponding data indicated on average low levels of infection within the T (< 2%) and B (<5%) 
cell populations irrespective of the presence of saliva during infection but higher levels of infection in the monocytes 
infected in the absence (~18%) or presence (~23%) of saliva (Figure 4.1 and 4.2).  
A 
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6.5 Determining the effect of BTV infection and/or C. sonorensis saliva on the viability and proportion of 
monocytes within PBMCs 
The presence of C. sonorensis saliva during BTV infection significantly enhanced the proportion of 
monocytes expressing VSP and NSP (Section 4.3; Figure 4.3 – 4.7). The data obtained from these 
experiments were next analysed to further characterise the effect of BTV and/or C. sonorensis saliva on 
the proportion and viability of monocytes within PBMCs. The proportion of monocytes within PBMCs 
was determined via a standardised gating strategy (Figure 6.10; A).  
At 2 h.p.i, ~ 8% of PBMCs from cattle 1 and 3 were CD14+, irrespective of varying treatment (Figure 
6.10; B and D). In comparison, the proportion of monocytes within the PBMCs of cattle 2 at 2h.p.i, was 
fractionally reduced in BTV infected or saliva treated cultures, and furthermore so in saliva treated/BTV 
infected cultures compared to mock infected cells. At 24 h.p.i, the proportion of monocytes within 
PBMCs from cattle 1 was significantly reduced in all treatment groups compared to mock infected 
cultures (Figure 6.10; B, p = <0.001 for all). Saliva treatment alone or alongside BTV infection also led 
to a reduction in the proportion of monocytes within PBMCs from cattle 2 and 3 at 24 h.p.i when 
compared to mock infected cells. Although this reduction in monocyte proportion in the single replicate 
using PBMCs obtained from cattle 2 could not be statistically analysed, the observed reduction in the 
monocyte proportion of cattle 3 PBMCs could be statistically analysed and was significantly different 
compared to mock infected cells following saliva treatment or saliva 1/BTV infection (Figure 6.10; D, p 
= 0.046 and 0.019, respectively). A significant reduction in the monocyte proportion within PBMCs from 
cattle 5 was seen following BTV infection in the absence or presence of saliva at 24 h.p.i compared to 
mock infected cells (Figure 6.10; E, p = < 0.001 for both). Furthermore, saliva treatment alone also led 
to a reduction in the monocyte proportion of PBMCs compared to mock infected cells from cattle 5 
(Figure 6.10; E, p = < 0.005).  
At 48 and 72 h.p.i, the proportion of monocytes within PBMCs from cattle 1, was selectively reduced 
following BTV infection in the absence or presence of saliva, when compared to mock infected cultures 
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(Figure 6.10; B, p = <0.001 for all). By 72 h.p.i, saliva treatment and/or BTV infection led to a reduction 
in the monocyte proportion of PBMCs from cattle 2 and 3 compared to mock infected cells. This saliva 
induced reduction in the proportion of monocytes within cattle 3 PBMCs was significantly different to 
the proportion of monocytes within mock infected cells following saliva treatment alone or alongside 
BTV infection (Figure 6.10; D, p = 0.027 and 0.005, respectively). Conflicting this trend, by 72 h.p.i the 
monocyte proportion of PBMCs from cattle 5 was significantly lower in mock infected cells compared 
to saliva treated cells (Figure 6.10; E, p = 0.020). 
Combining the results from all four cattle further confirms that BTV infection in the absence or presence 
of saliva significantly reduces the proportion of monocytes within PBMCs at 24, 48 and 72 h.p.i 
compared to mock infected cells (Figure 6.10; F, p = <0.001 for all). Saliva treatment alone only led to a 
combined reduction in the proportion of monocytes within PBMCs at 24 h.p.i (Figure 6.10; F, p = <0.001) 
compared to mock infected cells. The effect of saliva alone on the proportion of monocytes within 
PBMCs varied greatly between animals and may not be a consequence of the amount of LPS present 
within C. sonorensis saliva, since the saliva batches used for infection studies, in cells obtained from 
cattle 1, 2 and 3, contained comparable levels of LPS (Figure 6.10). 
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Figure 6.10 – BTV infection in the absence or presence of C. sonorensis saliva reduces the proportion of 
monocytes within PBMCs 
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Figure 6.10 – BTV infection in the absence or presence of C. sonorensis saliva reduces the proportion of 
monocytes within PBMCs 
Bovine PBMCs were infected with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour in the absence 
or presence of 1µg/ml C. sonorensis saliva, washed three times and saliva was replaced onto the 
relevant conditions. The application of the following saliva batches resulted in respective final LPS 
concentrations; cattle 1 – batch number 2, 18.8 ng/ml for all replicates, cattle 2 – batch number 3, 16.4 
ng/ml, cattle 3 - batch number 3, 16.4 ng/ml LPS for the two replicates shown and cattle 5 – batch number 
5 or 6, 0.09 or 1.1 ng/ml LPS respectively for the three replicates shown. The proportion of live monocytes 
within PBMCs was determined by live/dead cell discrimination and subsequent analysis of CD14 cell 
surface membrane protein positive cells using PBMCs from four cattle. Example gating in shown in (A). 
The following number of replicates are displayed; cattle 1 – 2 h.p.i (n = 3), 24 h.p.i (n = 4), 48 h.p.i (n = 
4), 72 h.p.i (n = 4)(B); cattle 2 - 2 h.p.i (n = 1), 24 h.p.i (n = 1), 72 h.p.i (n = 1)(C); cattle 3 - 2 h.p.i (n = 2), 
24 h.p.i (n = 2), 72 h.p.i (n = 2)(D); cattle 5 - 24 h.p.i (n = 3), 72 h.p.i (n = 3)(E). Results from four cattle 
were combined (F) and plotted as the mean ± standard deviation and statistical differences between 
differentially treated cultures, compared to mock infected cultures at respective time points, were 
determined using the Tukey multiple comparison test. The above results correspond to data shown in 
chapter 4 (Figure 4.3 – 4.7), where VSP expression was enhanced in the monocyte population following 
infection in the presence of saliva compared to infection in the absence of saliva. The highest average 
proportion of monocytes per cattle expressing VSP was observed in cattle 1 monocytes (~30%) whilst 
the lowest proportion of monocytes expressing VSP was observed in cattle 5 monocytes (~14%).   
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As stated for the analysis of the proportions and viability of PBMC subsets (Figure 6.8 and 6.9, 
respectively), the cellular composition of PBMCs does not necessarily give an indication of cellular 
viability. Therefore, the data utilised for the analysis of the proportion of monocytes within PBMCs 
(Figure 6.10) was reanalysed in order to determine monocyte viability using the gating strategy 
described by Wanasen et al., (2004) (Figure 6.11; A).  
At 2 h.p.i, monocytes were >85% live in PBMCs from all cattle tested (Figure 6.11; B), the loss of ~ 10-
15% of monocytes may be a function of the cell handling and centrifugation steps required for the 
removal of the viral inoculum. Cattle 1 monocyte viability was significantly reduced following saliva 
1/BTV infection at 24, 48 and 72 h.p.i, when compared to the viability of mock infected cells at the 
corresponding time point (Figure 6.11; B, p = <0.001). Similarly, saliva treatment in the absence of BTV 
infection also reduced monocyte viability at 24, 48 and 72 h.p.i when compared to mock infected cells 
at the corresponding time point (Figure 6.11; B, p = <0.001, 0.003 and 0.002, respectively). BTV infection 
alone was only seen to reduce monocyte viability at 72 h.p.i (Figure 6.11; B, p = <0.001). The viability of 
monocytes within PBMCs from cattle 2, 3 and 5 was notably reduced following saliva treatment alone 
or alongside BTV infection at 24 h.p.i (Figure 6.11; C - E). This reduction in the viability of monocytes 
within PBMCs from cattle 3 (Figure 6.11; E, p = <0.001 for both) and cattle 5 (Figure 6.11; E, p = 0.006 
and <0.001, respectively) was significant compared to the viability of respective mock infected cells. By 
72 h.p.i, cattle 3 PBMC viability was significantly reduced following BTV infection, saliva treatment or 
saliva 1/BTV infection (Figure 6.1; D, p = 0.009, <0.001 and <0.001, respectively). 
Similarly to the trend seen for the proportion of monocytes within PBMC, monocyte viability was 
significantly reduced following BTV infection in the presence of C. sonorensis saliva when the results 
from all cattle were combined and compared to mock infected cells at the corresponding time point 
(Figure 6.11; F, p = < 0.001 for all). In contrast to the consistent trend of a BTV induced reduction in the 
proportion of monocyte within PBMCs, a BTV induced reduction in monocyte viability compared to 
mock infected cells was only observed at 72 h.p.i (Figure 6.11; F, p = < 0.001). A saliva induced reduction 
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in monocyte viability was however observed compared to the viability of mock infected cells at 24, 48 
and 72 h.p.i (Figure 6.11; F, p = < 0.001, 0.002 and <0.001, respectively). 
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Figure 6.11 – The viability of the monocyte population of PBMCs is reduced due to BTV infection and/or 
C. sonorensis saliva 
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Figure 6.11 – The viability of the monocyte population of PBMCs is reduced due to BTV infection and/or 
C. sonorensis saliva 
Bovine PBMCs were infected with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour in the absence 
or presence of 1µg/ml C. sonorensis saliva, washed three times and saliva was replaced onto the 
relevant conditions. The application of the following saliva batches resulted in respective final LPS 
concentrations; cattle 1 – batch number 2, 18.8 ng/ml for all replicates, cattle 2 – batch number 3, 16.4 
ng/ml, cattle 3 - batch number 3, 16.4 ng/ml LPS for the two replicates shown and cattle 5 – batch number 
5 or 6, 0.09 or 1.1 ng/ml LPS respectively for the three replicates shown. The live portion of CD14 cell 
surface membrane protein expressing cells was determined by live/dead cell discrimination. Examples 
gating in shown in (A). The following number of replicates are displayed; cattle 1 – 2 h.p.i (n = 3), 24 
h.p.i (n = 4), 48 h.p.i (n = 4), 72 h.p.i (n = 4)(B); cattle 2 - 2 h.p.i (n = 1), 24 h.p.i (n = 1), 72 h.p.i (n = 1)(C); 
cattle 3 - 2 h.p.i (n = 2), 24 h.p.i (n = 2), 72 h.p.i (n = 2)(D); cattle 5 - 24 h.p.i (n = 3), 72 h.p.i (n = 3)(E). 
Results from four cattle were combined (F) and plotted as the mean ± standard deviation and statistical 
differences between differentially treated cultures, compared to mock infected cultures at respective time 
points, were determined using the Tukey multiple comparison test. The above results correspond to 
data shown in chapter 4 (Figure 4.3 – 4.7), where VSP expression was enhanced in the monocyte 
population following infection in the presence of saliva compared to infection in the absence of saliva. 
The highest average proportion of monocytes per cattle expressing VSP was observed in cattle 1 
monocytes (~30%) whilst the lowest proportion of monocytes expressing VSP was observed in cattle 5 
monocytes (~14%).  
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6.6 Determining the effect of BTV infection and/or C. sonorensis saliva on the viability of purified 
monocytes  
In order to determine the role of BTV infection and/or C. sonorensis saliva in altering the viability of 
purified bovine monocytes from cattle 2, 3, 4 and 5 PBMCs, data that was previously generated to 
determine the effect of C. sonorensis saliva on viral protein expression by infected purified monocytes 
(Section 4.5; Figure 4.12) was reanalysed via a standardised gating strategy as shown in Figure 6.12; A. 
A single saliva preparation was used for all experiments and resulted in a final concentration of 0.02 
ng/ml. Cells were harvested at 24 h.p.i and the viability of differentially treated purified monocyte 
cultures was determined.  
Although only determined in purified monocyte cultures from one cattle, monocyte viability was 
unaffected at 2 h.p.i, irrespective of the presence of saliva and/or BTV infection. At 24 h.p.i, purified 
monocyte viability was also unaffected by saliva treatment or BTV infection compared the viability of 
mock infected monocyte cultures. In comparison, purified monocyte viability was significantly reduced 
following joint BTV infection and saliva treatment compared to the viability of mock infected monocytes 
(Figure 6.12; B, p = 0.001). This therefore indicates that combined BTV and saliva cell treatment can 
reduce monocyte viability, even at the earlier time point of 24 h.p.i (compared to the 72 h.p.i time 
points assayed for PBMCs) and may occur even in the absence of other PBMC subpopulations. As 
observed in chapter 4, a greater proportion of monocytes, that were saliva 1/BTV infected, also 
expressed higher levels of viral proteins compared to BTV infected cells alone (Section 4.5; Figure 4.12). 
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Figure 6.12 – The infection of purified monocytes in the presence of C sonorensis saliva reduces cell 
viability 
Bovine monocytes were purified from PBMCs and infected with a BTV-1 Gibraltar 2007/1 strain at MOI 
0.1 for 1 hour in the absence or presence of 1µg/ml C. sonorensis saliva (batch number 4), washed three 
times and saliva was replaced onto the relevant conditions. A single saliva preparation was used for all 
experiments and resulted in a final concentration of 0.02 ng/ml. The live portion of the purified 
monocyte cultures was determined by live/dead cell discrimination. Results are plotted as the mean ± 
standard deviation and statistical differences between differentially treated cultures, compared to mock 
infected cultures at respective time points, were determined using the Tukey multiple comparison test 
compared to mock infected cells. The above results correspond to data shown in chapter 4 (Figure 4.11) 
where viral protein expression was significantly enhanced in the presence of saliva.  
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6.7 Determining the role of the LPS component of C. sonorensis saliva in altering the proportion and 
viability of monocytes within PBMCs 
As discovered and discussed in chapter 5, the saliva of C. sonorensis inherently contains bacterial LPS 
and it is this salivary component that is likely responsible for the observed saliva induced exacerbation 
of BTV infection and replication within the monocyte population of PBMCs. In order to determine if 
there is a role for the salivary LPS component in eliciting the observed combined saliva and BTV induced 
reduction in the proportion and viability of monocytes, previously obtained results that are presented 
in chapter 5 for the determination of the effect of LPS on viral protein expression within the monocyte 
population of PBMCs (Section 5.4; Figure 5.5) were reanalysed. Briefly, PBMCs from cattle 3 and 5 were 
isolated on separate occasions and infected with BTV for 1 hour in the presence of 1 µg/ml saliva (saliva 
1/BTV) or equivalent matched amounts of LPS (LPS 1/BTV). Mock infected cells were also treated with 
1 µg/ml saliva (saliva 1) or equivalent matched amounts of LPS (LPS 1). The saliva utilised alongside BTV 
infection of cattle 3 contained LPS resulting in a final concentration of 0.02 ng/ml, whilst the saliva 
utilised alongside BTV infection of cattle 5 contained LPS resulting in a final concentration of 0.09 ng/ml. 
Commercially available LPS of S. enterica origin (Sigma #L6143) was therefore used at a final 
concentration of 0.02ng/ml and 0.09ng/ml when infecting PBMCs from cattle 3 and 5, respectively. 
Analysis was carried out using the gating strategies outlined in Figure 6.10; A and 6.11; A, in order to 
investigate the role of the LPS salivary component in reducing the proportion and viability of monocyte 
within PBMCs, respectively.  
At 24 h.p.i, the two combined biological replicates follow the same trend as previously outlined in Figure 
6.9. BTV infection or saliva treatment reduced the proportion of monocytes within PBMCs, and 
combined BTV infection and saliva treatment cumulates in a further reduction in the monocyte 
proportion of PBMCs, that is significantly different compared to the proportion of monocytes within 
mock infected cultures (Figure 6.13; A, p = 0.0304). LPS treatment of PBMCs did not vastly alter the 
proportion of monocytes within PBMCs of cattle 3 and 5 when compared to mock infected cells at 24 
h.p.i whilst BTV infection in the presence of LPS did significantly reduce the proportion of monocytes 
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within PBMCs compared to mock infected cultures (Figure 6.13; A, p = 0.0304). At 72 h.p.i, there was 
no significant differences in the proportion of monocytes within PBMCs, irrespective of differing 
treatment or infection. Conflicting the results seen at 24 h.p.i, the proportion of monocytes within saliva 
treated cultures at 72 h.p.i, was increased compared to mock infected cultures. Furthermore, saliva 
1/BTV infection, on average, did not reduce the proportion of monocytes within PBMCs (Figure 6.13; 
A).  
Monocyte viability was significantly reduced following BTV infection, saliva 1 /BTV infection or LPS  
1/BTV infection at 24 h.p.i compared to the viability of mock infected cells (Figure 6.13; B, p = 0.0304 
for all). Similarly to the trend observed at 24 h.p.i, monocyte viability was reduced following BTV 
infection, saliva 1/BTV infection or LPS  1/BTV infection when compared to mock infected cells at 72 
h.p.i, albeit these differences were non-significant.  
As discussed in chapter 5, the optimisation of C. sonorensis salivary protein concentrations for maximal 
BTV protein expression resulted in the use of saliva concentrations of 0.1 and 0.01 µg/ml. The effect of 
these salivary protein concentrations on the proportion of monocytes within PBMCs and monocyte 
viability was next determined. PBMCs were isolated from three cattle (3, 4 and 5) on separate occasions 
and cells were infected with BTV for one hour in the presence of 0.1 and 0.01 µg/ml saliva or matched 
amounts of LPS comparable to that in the saliva. Mock infected cells were also treated with 0.1 and 
0.01 µg/ml saliva or matched amounts of LPS. The same saliva preparation was used for all three 
biological replicates whereby a 0.1 and 0.01 µg/ml saliva concentration resulted in a final LPS 
concentration of ~0.1 and 0.01 ng/ml LPS, respectively. LPS treated cells were therefore also exposed 
to a final LPS concentration of 0.1 or 0.01 ng/ml using purified S. enterica LPS (Sigma #L6143). The data 
obtained from these experiments, that determined the role for reduced levels of LPS on viral protein 
expression (Section 5.5; Figure 5.7), was also reanalysed using the gating strategies outlined in Figure 
6.10; A and 6.11; A, in order to investigate the role of the LPS salivary component in altering the 
proportion and viability of monocyte within PBMCs, respectively.  
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At 72 h.p.i, differential PBMC treatment resulted in a reduction in the proportion of monocytes within 
PBMCs following BTV infection or saliva (both 0.1 and 0.01 µg/ml) treatment alone compared to mock 
infected cells (Figure 6.13; C). Collective saliva treatment (both 0.1 and 0.01 µg/ml) and BTV infection 
also resulted in a further reduction in the monocyte proportion of PBMCs albeit these differences were 
non-significantly different compared to the monocyte proportion within mock infected PBMCs. LPS 
treatment of PBMCs alone did not appear to alter the proportion of monocytes within PBMCs compared 
to mock infected cells, irrespective of the 10 fold difference in LPS applied between LPS  0.1 ng/ml 
and LPS  0.01 ng/ml treatments. Combined LPS  0.1 or 0.01 ng/ml treatment and BTV infection did, 
however, lead to a reduction in the proportion of monocytes within PBMCs, when compared to mock 
infected cells although this change did not reach significant difference (Figure 6.13; C).  
The viability of the respective monocyte population of PBMCs was significantly reduced following BTV 
infection or saliva 0.1 or 0.01 µg/ml treatment compared to the viability of mock infected cells (Figure 
6.13; D, p = 0.0051, 0.0202 and 0.0453, respectively). When combined, these treatment groups led to 
a further reduction in the viability of saliva 0.1/BTV infected and saliva 0.01/BTV infected conditions 
compared to mock infected cells (Figure 6.13; D, p = 0.0051 and 0.0306, respectively). Although LPS  
0.1 and 0.01 ng/ml treatment did not result in a noticeable reduction in monocyte viability, LPS  0.1 
/BTV infection led to a combined reduction in monocyte viability and furthermore, LPS  0.01/BTV 
infection resulted in a significant reduction in monocyte viability (Figure 6.13; D, p = 0.0131) compared 
to the viability of mock infected cells.  
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Figure 6.13 – The proportion and viability of monocytes within PBMCs is reduced following BTV 
infection in the presence of C. sonorensis saliva or LPS 
Bovine PBMCs were infected with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour in the absence or presence 
of 1µg/ml (A/B; cattle 3 and 5, batch number 4 and 5, respectively) or 0.1 and 0.01 1µg/ml (C/D; cattle 3, 4 and 5; 
batch number 6) C. sonorensis saliva, washed three times and saliva was replaced onto the relevant conditions. 
Two saliva preparations were used for the experiments displayed in A and B resulting in a final concentration of 
0.02 and 0.09 ng/ml LPS, whilst a single saliva preparation was used for the experiments displayed in C and D 
resulting in a final LPS concentration of 0.1 ng and 0.01 ng/ml (matched to saliva 0.1 and 0.01 µg/ml).  PBMCs were 
also infected in the presence of LPS at matched amounts that present within the saliva used. The proportion of 
viable PBMCs that were single monocytes was determined by live/dead cell discrimination and subsequent 
analysis of CD14 cell surface membrane protein expression (A/C) whilst viability of CD14 expressing cells was 
determined by CD14 expression and subsequent live/dead cell discrimination gates. Results from the separate 
cattle were combined and plotted as the mean ± standard deviation and statistical differences between 
differentially treated cultures, compared to mock infected cultures at respective time points, were determined 
using the Mann Whitney test. The above results correspond to data shown in chapter 5 (Figure 5.5 and 5.7), where 
VSP expression was enhanced in the monocyte population following BTV infection in the presence of LPS 
compared to mock infected cells.  
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6.8 Determining the effect of BTV infection and C. sonorensis saliva on the expression of CD14 on the cell 
surface of monocytes  
The cell surface membrane protein CD14 is the classical protein utilised to determine the monocyte 
population (Griffin et al., 1981). The expression of CD14 has been shown to be differentially altered 
following monocyte activation with LPS, albeit in humans. Some reports have indicated an upregulation 
of CD14 upon LPS treatment following extended exposure times of up to 45 hours (Landmann et al., 
1996, Landmann et al., 1991) whilst others have reported a downregulation of CD14 expression 
following short exposure times of up to three hours (Hojman et al., 1997). As the saliva of C. sonorensis 
contains LPS, the expression of CD14 on monocytes within PBMCs was assessed following saliva 
treatment alone or alongside BTV infection.  
The same data set utilised in chapter 4 to assess viral protein expression in monocytes within PBMCs, 
in the absence of presence of 1 µg/ml C. sonorensis saliva (Section 4.3; Figure 4.3 – 4.7) was also 
analysed in order to determine the effect of C. sonorensis saliva and/or BTV infection on the MFI of 
CD14 expression on the cell surface of monocytes. The application of saliva resulted in the following 
final LPS concentrations: cattle 1 - 18.8 ng/ml for all replicates, cattle 2 - 16.4 ng/ml, cattle 3 - 16.4 
ng/ml LPS for the two replicates shown and cattle 5 - either 0.09 or 1.1 ng/ml LPS for the three replicates 
shown. The cellular expression of CD14 was determined via a standardised gating strategy in which only 
live, CD14 expressing, single cells were analysed (Figure 6.14; A). An example histogram visualisation of 
the expression of CD14 on monocytes within cattle 1 PBMCs between different treatment groups and 
across time points is shown (Figure 6.14; B).  
The expression of CD14 on the monocyte population within PBMCs from all cattle was unaffected 
following differential treatment at 2 h.p.i (Figure 6.14; C – E). By 24 h.p.i, the baseline expression of 
CD14 on monocytes within PBMCs from all cattle, was increased irrespective of differing treatment 
compared to the CD14 MFI at 2 h.p.i. Within treatment group at 24 h.p.i, BTV infection appeared to 
increase CD14 MFI on the monocytes within PBMCs from two out of four cattle tested, compared to 
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the CD14 MFI on mock infected cells (Figure 6.14; C and E). This BTV induced increase in CD14 MFI was 
significantly different on monocytes within PBMCs from cattle 1 (Figure 6.14; C, p = 0.004). In 
comparison, saliva treatment reduced CD14 MFI at 24 h.p.i on the monocytes within PBMCs from three 
out of four cattle when compared to mock infected cells (Figure 6.14; C, E and F). This saliva induced 
reduction in CD14 expression was significantly different compared to the CD14 expression by mock 
infected monocytes within PBMCs from cattle 1 (Figure 6.14; C, p = 0.016). PBMC culture in the 
presence of C. sonorensis saliva, alone or alongside BTV infection, led to a reduction in the expression 
of CD14 on monocytes within PBMCs from all cattle tested at 48 (Figure 6.14; C) and 72 h.p.i (Figure 
6.14; C – F) when compared to mock infected cells, albeit this reduction was only significant on 
monocytes within PBMCs from cattle 1 (Figure 6.14; C, p = <0.001, for all at 48 and 72 h.p.i).  
Although the combined results from all cattle indicate that the presence of C. sonorensis saliva during 
PBMC culture, either alone or alongside BTV infection, downregulates CD14 expression on the surface 
of monocytes at 24, 48 and 72 h.p.i compared to mock infected cells, this downregulation was only 
significantly different following saliva 1/BTV infection at 72 h.p.i (Figure 6.14; G, p = 0.036). 
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Figure 6. 14 - The MFI of CD14 expression on bovine monocytes within PBMCs following BTV infection 
in the absence or presence of C. sonorensis saliva 
Continued… 
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Figure 6. 14 - The MFI of CD14 expression on bovine monocytes within PBMCs following BTV infection 
in the absence or presence of C. sonorensis saliva 
Bovine PBMCs were infected with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour in the absence or presence 
of 1µg/ml C. sonorensis saliva, washed three times and saliva was replaced onto the relevant conditions. The 
application of the following saliva batches resulted in respective final LPS concentrations; cattle 1 – batch 
number 2, 18.8 ng/ml for all replicates, cattle 2 – batch number 3, 16.4 ng/ml, cattle 3 - batch number 3, 
16.4 ng/ml LPS for the two replicates shown and cattle 5 – batch number 5 or 6, 0.09 or 1.1 ng/ml LPS 
respectively for the three replicates shown. The MFI of CD14 expression was determined on live, CD14 
expressing, single cells (A) from 4 cattle PBMCs. Example changes in CD14 MFI on bovine monocytes within PBMCs 
from cattle 1 (B) The following number of replicates are displayed; cattle 1 – 2 h.p.i (n = 3), 24 h.p.i (n = 4), 48 h.p.i 
(n = 4), 72 h.p.i (n = 4)(C); cattle 2 - 2 h.p.i (n = 1), 24 h.p.i (n = 1), 72 h.p.i (n = 2)(D); cattle 3 - 2 h.p.i (n = 2), 24 
h.p.i (n = 2), 72 h.p.i (n = 3)(E); cattle 5 - 24 h.p.i (n = 3), 72 h.p.i (n = 3)(F). Data from all replicates were combined 
(G), plotted as the mean ± standard deviation and statistical differences between differentially treated cultures, 
compared to mock infected cultures at respective time points, were determined using the Tukey multiple 
comparison test. The above results correspond to data shown in chapter 4 (Figure 4.3 – 4.6), where VSP 
expression was enhanced in the monocyte population following infection in the presence of saliva compared to 
infection in the absence of saliva. The highest average proportion of monocytes per cattle expressing VSP was 
observed in cattle 1 monocytes (~30%) whilst the lowest proportion of monocytes expressing VSP was observed 
in cattle 5 monocytes (~14%).  
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As the saliva of C. sonorensis contains LPS, it was next investigated whether the LPS component of saliva 
was likely responsible for the downregulation in the expression of CD14 on the cell surface of 
monocytes. PBMCs from cattle 5 were isolated on a single occasion and were infected with BTV in the 
absence or presence of 1 µg/ml C. sonorensis saliva. The saliva used for this single experiment resulted 
in a final concentration of 0.09 ng/ml, thus cells were also treated with commercially available LPS of S. 
enterica origin (Sigma #L6143) at matched amounts. The results shown in Figure 6.15 correspond to 
data shown in chapter 5 (Figure 5.5; C and D). The MFI of CD14 expression on the cell surface of 
monocytes was determined via a standardised gating strategy as shown in Figure 6.14; A. A histogram 
visualisation of the results are shown in Figure 6.15 (A). At 24 h.p.i, the expression of CD14 was 
upregulated on bovine monocytes following BTV infection, irrespective of saliva or LPS treatment 
alongside BTV infection (Figure 6.15; B). In comparison, by 72 h.p.i, the expression of CD14 on BTV 
infected monocytes was marginally reduced compared to mock infected cells (Figure 6.15; B). 
Furthermore, saliva treatment alone or concurrently with BTV infection led to a further reduction in 
the expression of CD14 compared to mock infected cells. LPS treatment either alone or alongside BTV 
infection did not appear to reduce the expression of CD14 on the cell surface of monocytes to the same 
extent as saliva, albeit the CD14 expression was slightly reduced compared to mock infected cells 
(Figure 6.15; B).  
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Figure 6. 15 – The effect of LPS or C. sonorensis saliva on CD14 expression by bovine monocytes during 
BTV infection 
Bovine PBMCs were infected with a BTV-1 Gibraltar 2007/1 strain at MOI 0.1 for 1 hour in the absence or presence 
of 1µg/ml C. sonorensis saliva or matched amounts of LPS, washed three times and saliva was replaced onto the 
relevant conditions. The saliva (batch number 5) used for this single experiment resulted in a final concentration 
of 0.09 ng/ml LPS and hence the LPS treated cultures were exposed to this concentration of LPS The MFI of CD14 
expression was determined on live, CD14 expressing, single cells from cattle 5 PBMCs (A/B). The above results 
correspond to data shown in chapter 5 (Figure 5.5; C/D).  
24 h.p.i 
LPS LPS/BTV 
72 h.p.i 
Mock BTV Saliva 1 Saliva 1/BTV 
 
 
~ 265 ~ 
 
6.9 Correlations between LPS salivary content, viral protein expression, cellular phenotype and cytokine 
production by PBMCs 
Throughout this thesis, data has been presented determining the effect of 1 µg/ml C. sonorensis saliva 
and/or BTV infection on bovine target cells, initially identifying highest viral protein expression in 
monocytes during original screen experiments (Section 4.2; Figure 4.1 – 4.2). This was followed by 
further analysis of viral protein expression by bovine monocytes within PBMCs (Section 4.3; Figure 4.3 
– 4.7), the cytokine production by these PBMC cultures (Section 6.2; Figure 6.1 – 6.5), the proportion 
and viability of monocytes within these experiments (Section 6.5; Figure 6.10 and 6.11, respectively) 
and the expression of CD14 on the surface of these monocytes (Section 6.8; Figure 6.14). However, due 
to the multiple variables present within respective experimental conditions, including the complexity 
of the variable amounts of LPS present within C. sonorensis saliva batches, it would be useful to analyse 
which factors may potentially influence the observed biological outputs. In order to determine if there 
is a relationship between these biological outputs, the data obtained within condition was subjected to 
Spearman Rho correlation analysis. The production of IL-4 by bovine PBMCs was not included in this 
analysis due to its absent expression. To account for the total number of comparisons and reduce the 
chance of false significant correlations, the value at which a correlation was deemed significant was 
adjusted using Bonferroni’s correction whereby the adjusted p value of significance was dependant on 
the critical p value (p = 0.05) divided by the number of comparisons carried out. The adjusted p value 
therefore differed between data sets from mock infected (p = 0.002), saliva treated (p = 0.001), BTV 
infected (p = 0.001) and saliva 1/BTV infected (p = 0.001) cells dependant on the number of 
comparisons carried out. As this correction results in a reserved p value, three classifications of 
significance are presented in the following heat maps (Figure 6.16). Non-significant correlations 
resulted in a p value of greater than 0.05, non-significant correlations according to Bonferroni’s’ 
correction resulted in a p value between the respective corrected p value for each condition data set 
and 0.05 and significant correlations adjusted to Bonferroni’s’ correction resulted in a  p value of less 
than the respective corrected p value for each condition data set. The following Section only highlights 
the p values and R values of those correlations where the Bonferroni’s corrected p value is met, whilst 
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all correlations with a significant p value below 0.05 are included in Table 6.1 alongside the 
corresponding R value of their correlation.  
Within the mock infected treatment group, a correlation is observed between the proportion and 
viability of monocytes within PBMCs (Figure 6.16; A, p = 0, R = 0.867), indicating the higher the 
monocyte proportion within PBMCs the higher the viability of the monocyte population. Within the 
saliva treated PBMC group, a correlation was observed between the final concentration of salivary 
containing LPS applied to PBMCs and the IL-10 production by PBMCs (Figure 6.16; B, p = 0.001, R = 
0.877) indicating that higher levels of IL-10 were produced when PBMCs were cultured in the presence 
of saliva containing higher amounts of LPS. No significant correlations that met Bonferroni’s correction 
were observed within the outputs from BTV infected or saliva 1/BTV infected PBMC treatment groups.   
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Figure 6.16 – Analysis of potential correlations between salivary LPS content, monocyte viral protein 
expression, cytokine production from PBMCs, monocyte proportion and viability and CD14 cell surface 
membrane protein expression 
PBMCs were infected with BTV in the absence or presence of 1 µg/ml C. sonorensis saliva. This saliva 
contained varying amounts of LPS resulting in a variable final concentration of LPS applied to PBMC cultures. 
Cells were harvested at 72 h.p.i to determine the effect of differential treatment and final LPS concentration 
on VSP and NSP protein expression within the monocyte population (Section 4.3; Figure 4.3 – 4.7), the 
proportion and viability of monocytes within PBMCs (Section 6.5; Figure 6.10/ and 6.11, respectively) and 
the MFI of CD14 expression on the surface of monocytes (Section 6.8; Figure 6.14). Additionally, the results 
obtained from the initial screen from chapter 4 were also included in this analysis (Section 4.4; Figure 4.1 
and 4.2). Cell cultures supernatants were obtained and the production of IFN-, IL-10, IL-12 and TNF-α was 
determined by ELISA (Section 6.2; Figure 6.1 – 6.5). Correlations between these biological outputs within 
treatment conditions were determined using the Spearman Rho test and the p value of significance was 
adjusted according to Bonferroni’s correction (critical p value (0.05) divided by the number of comparisons 
carried out). The adjusted p value therefore differed between data sets from mock infected (p = 0.002), 
saliva treated (p = 0.001), BTV infected (p = 0.001) and saliva 1/BTV infected (p = 0.001) cells dependant on 
the number of comparisons carried out. Non-significant correlations are shown in yellow, tentative p values 
below 0.05 but above the corrected respective p value are shown in green and significant respective 
correlations, according to Bonferroni’s correction, are shown in red. Correlations not determined due to the 
absence of a stimulus, for example mock infected cells were not exposed to BTV thus no viral protein was 
expressed, are shown in white. The direction of a significant relationship between two biological outputs is 
denoted (+/-). R values of those correlations that reached significance are shown in Table 6.1.   
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Table   6.1 – Significant correlations between salivary LPS content, monocyte viral protein expression, 
cytokine production from PBMCs, monocyte proportion and viability and CD14 cell surface 
membrane protein expression 
Biological output correlations P value R value 
Mock  
IFN- IL-10 0.031 0.712 
IFN-  TNF-α 0.019 -0.791 
IFN- Monocyte viability 0.033 0.6370 
TNF-α Monocyte viability  0.013 -0.782 
Monocyte proportion  Monocyte viability 0 0.867 
Saliva 1 
[Final LPS] IL-10 0.001 0.877 
Monocyte proportion  Monocyte viability  0.036 0.608 
BTV 
VSP+ Monocyte proportion  0.042 -0.594 
IFN- IL-12 0.025 0.733 
IFN- TNF-α 0.027 -0.764 
IFN- Monocyte viability 0.044 0.644 
IL-12 Monocyte viability 0.044 0.644 
TNF-α Monocyte viability 0.032 -0.710 
Saliva 1/BTV 
[Final LPS] VSP+ 0.041 0.573 
VSP+ IL-10 0.038 0.661 
NSP+ IFN- 0.033 -0.673 
IFN- CD14 MFI 0.025 0.697 
Monocyte proportion  Monocyte viability  0.008 0.720 
 
The above correlations correspond to those displayed in Figure 6.16 where relationships between 
biological outputs within treatment condition were determined using the Spearman Rho test. The p 
value of significance was adjusted according to Bonferroni’s correction (critical p value (0.05) divided 
by the number of comparisons carried out). The adjusted p values therefore differed between data sets 
from mock infected (p = 0.002), saliva treated (p = 0.001), BTV infected (p = 0.001) and saliva 1/BTV 
infected (p = 0.001) cells dependant on the number of comparisons carried out. Non-significant 
correlations are not shown in the above table, tentative p values below 0.05 but above the corrected 
respective p value are shown in black and significant respective correlations, according to Bonferroni’s 
correction, are highlighted in red. The strength and direction of the correlation between two biological 
outputs is denoted by the corresponding R value. 
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6.10 Discussion  
The studies presented in this chapter highlight for the first time that the saliva of C. sonorensis is able 
to modify the bovine host and BTV induced immune response. Furthermore, a role for C. sonorensis 
saliva in exacerbating a BTV induced reduction in the proportion and viability of monocytes within 
PBMCs was also highlighted. Finally, the cellular expression of the CD14 membrane protein on the cell 
surface of monocytes within PBMCs was found to be reduced following C. sonorensis saliva treatment 
irrespective of BTV infection, although the precise role for the salivary LPS component in the observed 
effects still needs to be further elucidated in the future. 
It has previously been shown that the saliva of numerous arthropods is immunologically active and able 
to induce a switch from a Th1 pro-inflammatory response to an immunomodulatory and Th2 regulatory 
response. Consistent with these overarching trends of saliva induced modulation of the host cytokine 
response, experiments in this chapter have shown that the saliva of C. sonorensis is able to modify 
baseline and BTV induced cytokine production by bovine PBMCs. Overall, most notably when observing 
the cytokine production from cattle 1 PBMCs, the presence of C. sonorensis saliva led to a 
downregulation in the BTV induced production of the pro-inflammatory Th1 cytokine IFN-, whilst also 
leading to an induction in the production of the regulatory cytokine IL-10. However, this response was 
not seen across all experiments using PBMCs obtained from four different cattle and in contrast the 
presence of saliva during infection further enhanced the BTV induced IFN- response from cattle 5 
PBMCs. Moreover, the IL-12 and TNF-α response to differential treatment also appeared to be variable 
between cattle. Nevertheless, saliva was able to limit BTV induced IL-12 production from cattle 1 PBMCs 
and BTV induced TNF-α production by cattle 5 PBMCs, further highlighting that C. sonorensis saliva can 
indeed act to counteract pathogen induced cytokine production. The saliva of C. sonorensis was 
however unable to induce a Th2 cytokine response, as indicated by the absence of IL-4 within PBMC 
supernatants. Although a positive assay control was included to ensure that the ELISA was functional, 
it would have been advantageous to have included a biological positive control; PBMCs would have 
been stimulated to induce the production of IL-4 thereby confirming the biological ability of these cells 
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to produce this cytokine. Indeed, bovine PBMCs have previously been shown to induce IL-4 in response 
to Con A stimulation (Hope et al., 2005). 
The observed differences in the cytokine response between cattle and even within cattle replicates are 
potentially due to a range of factors including cattle to cattle variation, the interplay of the production 
of multiple cytokines by one set of cells, the LPS content within C. sonorensis saliva and the BTV induced 
cytokine response. It was shown by correlation analysis in this chapter that increased IL-10 production 
significantly correlates with higher final salivary LPS concentrations applied to saliva only treated PBMC 
cultures, which is consistent with previous reports that LPS induces an IL-10 response by bovine cells, 
principally monocytes (Corripio-Miyar et al., 2015). Additional correlations were also drawn from the 
analysis carried out in this chapter, however, the p value of these relationships did not reach 
Bonferroni’s correction thus any interpretation of these associations must be done very tentatively.  
The induction of an IFN- response to BTV infection might potentially be positively correlated to an 
increase in IL-12 production which is consistent with previous reports that IL-12 can induce a positive 
feedback loop leading to the production of IFN- by bovine PBMCs (Hope et al., 2002). IL-10 production 
by PBMCs that were BTV infected in the presence of saliva, can be cautiously linked to a higher 
proportion of VSP expressing monocytes and higher IFN- production might be correlated to a lower 
proportion of monocytes expressing NSP. This is therefore consistent with the overarching generalised 
trend of saliva induced modulation of the host immune response whereby a viral induced Th1 response, 
such as the production of IFN-, can be limited by the presence of saliva during infection and the 
production of regulatory cytokines such as IL-10 can be enhanced following cell treatment with saliva. 
As PBMCs are a heterogeneous mixture of cells, it is unknown which population is producing the 
cytokines detected within the cell culture supernatants. It was possible, however, to compare the 
cytokine production by PBMCs and purified monocytes subjected to BTV infection in the absence or 
presence of saliva, with the greatest difference being the lack of BTV induced IFN- production by 
purified monocytes. The comparison of cytokine production by PBMCs and purified monocytes is crude 
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however and cannot be used to definitely state that the monocytes within PBMCs do not produce IFN-
, for example. Although purified bovine monocytes have been shown to express IFN- in response to 
viral infection (Choi, 2017), it is however more likely that a lymphocyte population within PBMCs, is 
responsible for the production of this cytokine. For example WC1+  T cells have been shown to be 
strong producers of IFN- in the bovine host (Guzman et al., 2014, Price et al., 2007).  
IL-10 was produced by both PBMC and purified monocyte cultures to the greatest extent following BTV 
infection in the presence of saliva. When comparing the response of PBMCs and purified monocytes to 
saliva, once again the presence of all subpopulations in PBMCs should be considered. It is unlikely that 
the monocyte population of PBMCs is the only population that is producing IL-10 as this cytokine has 
also been shown to be produced by a range of blood cells including CD4 T cells and B cells (reviewed in 
(Saraiva and O'Garra, 2010)), although this has not been specifically demonstrated in the bovine host. 
Furthermore, bovine  T cells are known to express IL-10 and it has been shown that the secretion of 
this cytokine by  T cells is likely to directly enhance the expression of IL-10 by CD14+ cells, thereby 
creating a positive feedback loop for the production of IL-10 (Guzman et al., 2014). This potential 
interaction between  T cells and monocytes may therefore contribute to the observed IL-10 
production from bovine PBMCs, although this interaction is not necessary for the production of IL-10 
from monocytes as evidenced by the secretion of IL-10 from purified monocyte cultures in the absence 
of  T cells. 
Although it can be proposed which cell populations are expressing the cytokines detected in PBMC 
culture supernatants, staining for intracellular cytokines alongside cell surface membrane proteins and 
subsequent flow cytometry analysis, would be a necessity in order to definitely determine which cell 
population is producing the cytokine of interest and the effect of BTV and/or saliva on the production 
of this cytokine. This would also enable further investigation into the opposing trends in cytokine 
production observed throughout this chapter in response to differential treatment and the interplay 
between the production of multiple cytokines by differing or the same PBMC population. Preliminary 
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data, utilising BTV infection of bovine PBMCs from cattle 2 in the absence or presence of 1 µg/ml C. 
sonorensis saliva, allowed flow cytometry analysis of intracellular cytokine labelling at 16 and 66 h.p.i 
following Brefaldin A treatment to arrest cytokine secretion. Data indicated that CD8+ and CD4+ T cells 
express IFN- in response to BTV infection and, when present during infection, C. sonorensis saliva can 
reduce the percentage of these T lymphocytes expressing IFN- by up to 50%. These preliminary results 
are therefore complementary to those presented in this chapter that have highlighted a role for saliva 
in suppressing the BTV induced production of IFN- by bovine PBMCs. 
It is well known that previous and repeated mammalian exposure to Culicoides midge bites leads to the 
sensitisation (production and subsequent binding of IgE to Fc receptors on mast cells) of the bitten 
animal and the development of a type I hypersensitivity reaction (Langner et al., 2009, Schaffartzik et 
al., 2011, Yeruham et al., 1993, Yeruham et al., 2000). It is possible however, that repeated exposure 
to Culicoides midge bites may lead to the desensitisation of hosts resulting in immune tolerance and 
suppression of Th2 mediated allergic responses. Although previous tests have found that repeated 
controlled exposure of horses to Culicoides antigens does not lead to a significant improvement in the 
clinical signs associated with IBH (Ginel et al., 2014), desensitisation to mosquito bites has been 
proposed in humans (Ariano and Panzani, 2004, Peng et al., 2004), albeit the effect of prolonged 
arthropod salivary antigen on the host cytokine response is unknown in both cases. The cattle utilised 
in this study were housed in non-insect proof animal units and therefore were likely fed upon by midges 
throughout the course of the experiments. Indeed, it has been confirmed that all animals used 
throughout this thesis have been previously exposed to Culicoides midge bites as determined by the 
detection of antibodies with reactivity towards salivary proteins within the serum of each cattle (L. 
Tugwell, personal communication). Potentially of interest, cattle 1 was housed in a different location at 
the time of blood sampling to the subsequent cattle blood donors. As highlighted above, cattle 1 
responded to the presence of saliva during culture and infection consistently with that proposed in the 
literature (a reduction in the expression of Th1 cytokines and an upregulation of regulatory cytokines), 
whilst the remaining cattle appeared to follow less of a trend between blood donors and even within 
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replicates using PBMCs from the same cattle. It is therefore possible that differences in the housing 
units of the cattle and the consequent duration or intensity of exposure of the cattle to Culicoides midge 
bites, and therefore salivary antigens, may have played a role in the observed differences in the cytokine 
response to C. sonorensis saliva. Although the immune response of cattle exposed to Culicoides saliva 
is still under investigation, it may also be of interest to determine the cytokine response of cattle to 
Culicoides salivary antigen following repeat exposure. 
Throughout this chapter the effects of BTV infection in the absence or presence of C. sonorensis saliva 
on the proportion and viability of monocytes, and to a lesser extent T and B lymphocytes, within PBMCs 
was assessed via two different flow cytometry analysis strategies to account for limitations within each 
approach. Firstly, the determination of the proportion of a cell population, within PBMCs, was 
determined based upon the percentage of the respective cell population within a constant number of 
events (cells) collected by flow cytometry. Although this provides a useful indication of the cell 
populations composing this heterogeneous cell mix at a specific time point, it does provide a limitation 
in distinguishing if changes in the proportion of one cell subset within the PBMCs is, in reality, rather a 
reflection of changes in the proportion of another population. Secondly, a gating strategy which has 
previously been published to assess the viability of murine solenocyte viability following arthropod SGE 
treatment (Wanasen et al., 2004) was additionally utilised in this chapter. There are, however, also a 
few limitations to this gating strategy for determining PBMC subpopulation viability (Figure 6.9 and 
6.11; A). Primarily, due to the order of cell surface marker inclusion, followed by dead cell exclusion 
gates, there were instances in which the resolution between cell surface membrane protein (e.g CD14) 
positively and negatively labelled cells was diminished due to non-specific antibody binding to dead 
cells. This therefore may have led to the inclusion of incorrect cellular populations into the subsequent 
gates for the determination of cell viability. For example, when aiming to determine CD14 cell viability 
the extent of the CD14 antibody non-specifically binding to dead bystander cells was unknown and may 
have impacted on the subsequent proportion of CD14 positively labelled cells that were estimated to 
be viable. Subsequent to the inclusion gate for the live cells, an additional gate was implemented to 
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allow the exclusion of any cell debris that had non-specifically bound to the antibody of interest. 
Although crude, this gate allowed a confirmation that the FSC and SSC parameters of the respective 
cells were applicable for the labelled cell type, e.g. high FSC and SSC profile for monocytes. Collectively, 
both methodologies were therefore used alongside each other to approach the assessment of cellular 
viability within PBMCs. Although there are some variations between the observed trends in the 
proportion and respective viability of cellular populations within PBMCs in response to differential 
treatment, overall both methodologies have provided preliminary evidence that suggests the presence 
of C. sonorensis saliva during BTV infection reduces the proportion and viability of monocytes within 
PBMCs across all cattle and replicates observed. As the proportion of viral protein expressing 
monocytes within PBMCs was seen to be enhanced following infection in the presence of C. sonorensis, 
compared to infection in the absence of saliva, it may be proposed that virus induced cell death could 
potentially play a role in the viability of this population.  
In comparison, changes in the proportion of lymphocyte populations within PBMCs following 
differential treatment does not follow the same trend as changes in the viability of respective cell 
populations. The highest observed proportion of  T cells, within PBMCs, was seen following BTV 
infection in the absence or presence of C. sonorensis saliva. This trend is, however, largely driven by 
one biological replicate (from cattle 2) and was not seen in the additional two replicates carried out 
utilising PBMCs from two different cattle. Interestingly, this replicate is presented in chapter 4 (Section 
4.2; Figure 4.1 and 4.2), where an elevated proportion of monocytes and B cells were expressing VSP, 
thereby further indicating that external factors, such as the immune status of the animal, could explain 
differing results in this cattle. There did not, however, appear to be any significant difference in the 
viability of the  TCR positive population across the treatment groups, thus indicating that this 
variation in the proportion of this cell population within PBMCs may not be a reflection of selective  
T cell death in mock infected or saliva treated cultures. Viral protein analysis within these T and B cell 
populations highlighted low levels of infection, irrespective of the presence of C. sonorensis saliva 
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(Section 4.2; Figure 4.1 and 4.2) thus any differences in T and B cell proportions are unlikely due to virus 
induced cell death and may rather be a function of indirect culture effects.  
Although there appeared to be a relatively consistent observed reduction in the percentage and 
viability of monocytes within PBMCs following BTV infection in the presence of C. sonorensis saliva, 
overall, other cellular treatments resulted in a more variable effect on the proportion and viability of 
monocytes within PBMCs from different cattle. The monocyte proportion of PBMCs was significantly 
reduced following BTV infection in the absence or presence of C. sonorensis saliva in the data obtained 
in the preliminary screen (Section 6.4; Figure 6.8) and in subsequent experiments using PBMCs from 
cattle 1 (Section 6.5; Figure 6.10; B). In contrast, when using PBMCs from the remaining cattle tested, 
the reduction in the monocyte proportion of PBMCs was largely driven by the presence of saliva during 
culture or infection. Furthermore, a reduction in the viability of the monocyte population of PBMCs, 
most notably from cattle 2 and 3, was also driven by the presence of saliva during culture. Despite the 
differences in the trends of the proportion and viability of monocytes within differentially treated 
PBMCs between the four cattle tested, it is clear that these two assessed parameters largely mirror 
each other when assessing the same data set, for example a reduction in monocyte viability generally 
matches a reduction in the proportion of monocytes within PBMCs.  
Interestingly, the overall viability of monocytes, even in the absence of stimulus, was reduced to a 
greater extent from 2 to 24 h.p.i in monocytes within PBMCs compared to purified monocytes. 
Furthermore, BTV infection or saliva treatment alone did not reduce the viability of purified monocytes 
by 24 h.p.i whilst these treatment conditions did affect the viability of monocytes within PBMCs. 
Collective saliva treatment and BTV infection also led to greater reduction in the viability of monocytes 
within PBMCs, compared to purified monocytes. Nevertheless BTV infection in the presence of C. 
sonorensis saliva led to a significant reduction in cell viability of both monocytes within PBMCs and 
purified monocytes. As alluded to in the introduction of this thesis, immunomodulatory molecules can 
be produced by host cells following BTV infection/stimulus exposure and these molecules may alter 
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cellular viability by acting in an autocrine loop or by affecting the viability of other PBMC populations. 
Indeed, correlation analysis carried out within treatment groups in this chapter has highlighted a 
tentative positive correlation between IFN-/IL-12 production by BTV infected PBMCs and the viability 
of the monocyte population within respective PBMCs (Table 6.1; p = 0.044; R = 0.644). The analysis has 
also highlighted a tentative negative correlation between TNF-α production by BTV infected PBMCs and 
the viability of the monocyte population of respective PBMCs (Table 6.1; p = 0.032; R = -0.710), thus 
indicating that the cytokine response may play a role in the observed trends of BTV induced reductions 
in cell viability. 
The data obtained for the determination of cellular populations within PBMCs may also be somewhat 
limited in that some populations are not accounted for via the labelling strategy utilised. When 
combined the cellular populations that were labelled with antibodies against the T and B lymphocyte 
and monocyte cell surface membrane proteins do not total to 100% thus some PBMC populations are 
not accounted for in the analysis. Furthermore, it should be considered that these findings are based 
upon selected time points post-infection and often the baseline proportion of PBMC subpopulations at 
1 h.p.i, or even before infection, were not assessed. The comparison of observed changes in PBMC 
subpopulations over time, or the survival rate of certain cell types following differential treatment, may 
therefore be difficult to interpret.  
In future, viability assays could be improved by combining the usage of a live/dead stain and an 
apoptosis marker such as annexin V (a cellular protein that binds to phosphatidylserine, a phospholipid 
that is externalised at the early stages of apoptosis (Cummings et al., 2004)), that would further enable 
the determination of BTV and/or C. sonorensis saliva induced apoptosis. 
As highlighted in chapter 5, C. sonorensis saliva inherently contains LPS. However, it was found in this 
chapter that LPS, at matched amounts to saliva, had no significant effect on the proportion of, or 
viability of monocytes within PBMCs. These results thereby indicate that the death of monocytes in 
response to C. sonorensis saliva alone is unlikely solely due to the LPS salivary content. In comparison, 
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the saliva induced increase in BTV associated monocyte death may implicate the LPS component of 
saliva as being responsible for modifying BTV reduced monocyte viability. This LPS effect on monocyte 
viability may either be via direct LPS induced cell death or indirectly by increasing the level of BTV 
infection within the monocyte population, subsequently enhancing viral induced cell death. Although 
final LPS concentration within saliva was not found to be positively correlated to the proportion of or 
viability of monocyte within saliva 1/BTV infected PBMCs in this analysis, final LPS concentration was 
correlated to the proportion of monocytes expressing VSP thus further indicating that LPS induced 
infection may consequently alter monocyte viability, a consideration that needs further attention. 
High levels of CD14 expression on the cellular surface has long been utilised as a marker for the 
monocyte population of PBMCs (Griffin et al., 1981). Throughout this chapter it has been shown, most 
consistently when utilising PBMCs from cattle 1, that the presence of saliva during cell culture can lead 
to a reduction in the expression of CD14 on the monocyte cell surface. As the saliva of C. sonorensis is 
known to contain LPS is can therefore be considered that this down regulation in CD14 expression may 
be due to the actions of LPS on the immune response or through the binding of LPS to CD14. This was 
investigated and although only assessed using PBMCs from one cattle, the culture of PBMCs with LPS 
at matched amounts to within saliva did not result in a notable difference of CD14 expression compared 
to mock infected cells. Furthermore, correlation analysis carried out in this chapter did not highlight a 
relationship between final salivary LPS concentration applied to cells and the expression of CD14 on the 
monocyte cell surface. Publications have however reported LPS induced CD14 expression (Heidenreich 
et al., 1997, Landmann et al., 1996) or in comparison an LPS induced reduction in CD14 expression 
leading to the generation of endotoxin tolerance (Hojman et al., 1997, Sugawara et al., 2000), albeit on 
human monocytes. The single replicate carried out to investigate the role of LPS on the observed 
downregulation of CD14 expression, combined with the evidence that LPS may modulate CD14 
expression, therefore highlights the need for further investigation. CD14 expression on saliva 1/BTV 
infected monocytes was however found to be tentatively positively correlated to the production of IFN-
 by PBMCs thus monocytes expressing low levels of CD14 were present within PBMC cultures 
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expressing low levels of IFN-. This tentative relationship opposes previous findings by others that have 
highlighted that reduced CD14 expression levels may instead be associated with increased levels of IFN-
 production by human monocytes (Payne et al., 1992) thus the relevance of this tentative correlation 
is unknown and CD14 downregulation may in fact be related to other factors. 
As proposed in chapter 4, based upon the visualisation of large non-CD14 expressing cells by confocal 
microscopy, it might be hypothesised that this apparent saliva induced downregulation of CD14 by 
bovine monocytes may be due to the differentiation of monocytes into effector cells, such as monocyte 
derived DCs, that typically express lower levels of CD14 (Werling et al., 1999, Werling et al., 2004). As 
the generation of monocyte derived DCs requires the presence of IL-4 (and GM-CSF) this hypothesis is, 
however, limited by the lack of IL-4 production by PBMCs in response to C. sonorensis saliva treatment 
and previous reports that the secreted saliva from R. sanguineus ticks can inhibit the cytokine (IL-4 and 
GM-CSF) induced maturation of murine bone marrow cells into dendritic cells (Cavassani et al., 2005). 
In order to fully classify the monocyte population assessed throughout this thesis and its potential 
differentiation, it would have been advantageous to have also determined the expression of additional 
cell surface membrane proteins throughout this work. For example, CD16 and CD163 expression that 
differs between monocyte subsets (Corripio-Miyar et al., 2015, Elnaggar et al., 2016, Hussen et al., 
2013) and furthermore, CD209 and CD1b that are expressed on monocyte derived DCs but not by 
monocytes (Park et al., 2016) might enable the determination of the differentiation of monocytes to 
this effector cell set. 
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6.11 Summary  
Overall the results of this chapter highlight the immunomodulatory properties of C. sonorensis saliva 
and specifically the ability of the saliva, and potentially its LPS component, to modulate the bovine 
cytokine response thus leading to the generation of an anti-inflammatory environment and reducing 
the BTV – induced pro-inflammatory cytokine response in some of the cattle tested. Furthermore, the 
saliva of C. sonorensis concurrently reduced the proportion and viability of monocytes within PBMCs 
and further exacerbated the BTV – induced cell death by this population. Overall, the major findings of 
this chapter are summarised in Figure 6.17. The exact role of the salivary LPS content either on saliva 
induced cytokine responses or cell viability needs further clarification in the future. Further 
investigations are also needed in order to determine the role of LPS in the observed saliva-induced 
downregulation of CD14 expression on the cell surface of monocytes within PBMCs and the subsequent 
effects that this downregulation of CD14 may have on LPS signalling. 
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Figure 6.17 - Summary schematic highlighting the major findings of Chapter 6. 
 
 
The presence of C. sonorensis saliva during purified monocyte culture and/or BTV infection 
increases the production of IL-10. 
The treatment of PBMCs with BTV and/or C. sonorensis saliva reduces the viability at 72 h.p.i.  
BTV infection in the presence of C. sonorensis saliva reduces the viability of purified monocyte 
cultures. 
BTV infection in the presence of C. sonorensis saliva reduces CD14 MFI on bovine monocytes, 
within PBMCs, at 72 h.p.i. 
When present during culture and/or BTV infection, C. sonorensis saliva can modulate the cytokine 
response by PBMCs, from selected cattle, resulting in an increase in IL-10 production and a 
decrease in BTV induced IFN- production. 
BTV infection in the presence of C. sonorensis saliva consistently reduced the proportion and 
viability of monocytes, within PBMCs, from all cattle. 
 
 
 
 
 
 
 
Chapter 7  
Final discussion and future work  
  
 
 
~ 282 ~ 
 
7. 0 Final discussion and future work  
The studies presented in this thesis demonstrate for the first time, that the presence of Culicoides 
vector saliva can enhance BTV infection in bovine monocytes, a natural target cell population of the 
mammalian host. Interestingly, it was further demonstrated that LPS, a major component of the gram-
negative bacterial cell wall, is present within Culicoides saliva despite filtration and is likely the major 
salivary component eliciting this effect on BTV infection and replication. The original hypothesis 
investigated in this thesis postulated that Culicoides vector saliva might indirectly influence BTV 
replication in ruminant target cells via modulation of the innate cellular immune response. Indeed, the 
obtained results indicate that Culicoides saliva can modify the cytokine profile produced by BTV infected 
PBMCs, yet individual variation between cattle did not allow changes in BTV replication to be 
consistently attributed to a specific cytokine milieu. Nevertheless, the indication that LPS containing C. 
sonorensis saliva treatment can down regulate BTV induced production of IFN- in PBMCs from some 
cattle, indicates an ability of saliva to regulate a viral induced pro-inflammatory cytokine environment. 
Furthermore, LPS containing C. sonorensis saliva treatment, either alone or alongside BTV infection, 
induced the production of the immune-regulatory cytokine IL-10 from some cattle PBMCs and 
consistently from purified monocyte cultures, thus potentially leading to a reduced innate anti-viral 
immune response which could potentially benefit BTV infection of bovine monocytes.  
The saliva of hematophagous arthropods is a complex mixture of pharmacologically active molecules 
that have been shown to have immunomodulatory properties. Furthermore, in the context of arbovirus 
transmission, arthropod saliva has been implicated in altering infectivity and virulence of numerous 
arboviruses such as WNV (Limesand et al., 2003, Schneider et al., 2010, Schneider et al., 2006, Styer et 
al., 2011) and DENV (Ader et al., 2004, Cox et al., 2012, McCracken et al., 2014, Surasombatpattana et 
al., 2012). Despite the economic and welfare implications of BT (Carpenter et al., 2013), only a very 
limited number of studies have demonstrated increased viral replication and virulence of BTV infection 
in the ovine host. Experimental studies in sheep comparing natural infection via infected Culicoides or 
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ID inoculation of virus in the presence of Culicoides salivary proteins to needle inoculation of BTV alone 
(Drolet et al., 2015, Pages et al., 2014), have highlighted a likely role for Culicoides midge bites and/or 
saliva in enhancing BTV infection within the ruminant host, although the mechanisms explaining the 
observed effects were not identified. To date, the only other study that has investigated the effects of 
Culicoides saliva on BTV infection in vitro has predominantly focused on the ability of the salivary 
protease activity to modify the structure of the virus particle, resulting in subsequent differences in 
virus infectivity for Culicoides derived KC cells and standard mammalian BHK-21 cells (Darpel et al., 
2011). The effect of salivary protease modification on BTV infectivity in ruminant target cells was not 
assessed and furthermore the potential indirect effects of Culicoides saliva, such as altered cytokine 
production, were not investigated.  
The work within this thesis aimed to investigate potential indirect effects of C. sonorensis saliva on in 
vitro BTV infection within bovine natural target cells. One of the major findings of this thesis was the 
observation that LPS is naturally present within C. sonorensis saliva and seems to be the likely 
component responsible for the observed saliva induced enhancement of BTV infection and replication 
in PBMC derived monocytes, as opposed to specific Culicoides salivary proteins. As highlighted in 
chapter 4, saliva selectively enhanced BTV viral protein expression within the CD14+ monocyte 
population of PBMCs, whilst infection in the lymphocyte populations was minimal and appeared 
unaffected by the presence of C. sonorensis saliva during infection. CD14 acts as a receptor molecule in 
the signalling of LPS (Wright et al., 1990), thus CD14 cellular expression may be involved in the ability 
of certain cellular populations to respond to salivary LPS. CD14 is however present within bovine serum 
as a secreted protein and in this form has been shown to mediate LPS mediated activation of bovine 
ECs (Yang et al., 1996), hence should CD14 be vital to saliva/LPS induced enhancement of BTV infection 
soluble CD14 could potentially provide an additional source of CD14 to those susceptible BTV target 
cells that do not express this cell surface membrane protein. 
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Consistent with the blood derived target cell infection studies carried out in this thesis, a preliminary 
experiment investigating BTV infection of bovine afferent skin migratory lymph cells ex vivo highlighted 
that viral protein expression within the monocyte population is enhanced in the presence of C. 
sonorensis saliva, thus confirming a consistent trend of saliva induced enhancement of BTV infection in 
bovine monocytes, either of blood or skin origin. Interestingly, viral infection was also observed in 
bovine dendritic cells, as determined by the expression of CD205, albeit there did not appear to be a 
role for saliva in altering the expression of NS2 in this cell population. Furthermore, differing to the 
results of this thesis, BTV viral protein expression was seen to a greater extent in skin draining T and B 
lymphocytes following infection in the absence or presence of saliva, including detectable levels of NS2 
expression. A key difference in the activation status of the lymphocyte populations originating from 
bovine blood and afferent lymph may explain these differential findings. Indeed, a significantly greater 
proportion of the lymphocyte populations within ovine afferent lymph have been shown to express the 
activation marker CD25 compared to the respective populations originating from bovine blood (Haig et 
al., 1999). It is therefore possible that cellular activation may be required in order to enable BTV 
infection of certain lymphocyte populations. Indeed, an array of antigens are likely present within the 
skin of ruminants thus providing an activation stimulus for lymphocytes, whilst in comparison the 
majority of blood derived bovine lymphocytes have been shown to be in a naïve activation state (Haig 
et al., 1999). The limited availability of skin afferent lymph cells throughout this thesis prevented 
comparable experiments to those reported here from being carried out using these cells. Nonetheless, 
it would be ideal to further investigate BTV infection in cell populations derived from the ruminant skin 
as they provide a highly relevant source of cells, not only for BTV infection but also as the first line of 
contact with Culicoides saliva during blood feeding of the vector. As a key cellular target for BTV 
infection and a cell type that is heavily implicated in the haemorrhagic disease manifestations of BTV, 
the effect of C. sonorensis saliva on BTV infection of ECs should also be considered. Importantly, BTV 
has been shown to replicate within skin endothelial cells (Darpel et al., 2012, Melzi et al., 2016) and 
these cells will likely come into contact with salivary proteins following the blood feeding by Culicoides 
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midges. Furthermore certain ECs, such as bovine lung microvascular ECs, have been shown to express 
TLR4 that is involved in LPS signalling (McClenahan et al., 2008). Thus it is possible that EC populations 
that are exposed to saliva during BTV infection may be able to respond in a similar manner to 
monocytes, resulting in salivary-LPS induced enhancement of BTV infection and replication. 
Studies in this thesis to elucidate the mechanism by which C. sonorensis saliva is upregulating BTV 
infection have highlighted that, in order for saliva and/or LPS to induce BTV infection and replication it 
must be added at the early stages of virus infection (Chapter 5). This therefore indicates that C. 
sonorensis saliva or LPS may potentially modulate virus entry into bovine monocytes or the early stages 
of virus replication. Although the entry mechanism of BTV into bovine monocytes is currently unknown, 
recent findings have highlighted that BTV enters natural ruminant target BFA ECs via clathrin 
independent macropinocytosis (Stevens, 2016). Due to the confirmed phagocytic nature of monocytes 
(Hussen et al., 2013), and the similarities between macropinocytosis and phagocytosis, it is therefore 
possible that BTV may enter these cells via either of these processes. Indeed, LPS or heat treated 
bacteria have been shown to induce phagocytosis by bovine monocyte populations (Hussen et al., 2013) 
whilst, in comparison, arthropod saliva has been shown to downregulate phagocytosis. For example, 
Ixodes ricinus tick saliva has been shown to reduce murine DC phagocytosis of Borrelia afzelii 
spirochetes (Slamova et al., 2011) and Boophilus microplus SGE reduced the phagocytic uptake of 
fluorescently labelled bacteria by monocytes within bovine PBMCs (Turni et al., 2002). The LPS content 
within saliva may therefore lead to an upregulation in monocyte phagocytosis during the one hour 
infection time utilised throughout this thesis, resulting in a greater proportion of monocytes becoming 
infected. Initial future studies to determine the effect of Culicoides saliva and/or LPS on cellular entry 
processes could include the determination of control ligand uptake in the absence or presence of saliva.  
The observed effects of LPS on BTV replication in this study raises the question if LPS of other sources 
such as bacterial co-infections, could potentially elicit the same effect on BTV replication. Recently the 
potential role of host microbiota on viral pathogens has gained significant interest and bacterial 
products have been shown to effect different viral pathogens in a highly specific manner ranging from 
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anti-viral effects observed for some viruses to significantly increased replication for others. The 
mechanisms proposed to explain how such bacterial co-infections could impact on viral pathogens, 
frequently involve bacterial surface glycans, such as LPS, that signal through TLRs and facilitate viral 
particle interactions with host cell receptors (Karst, 2016, Robinson et al., 2014, Wilks et al., 2015). 
Interestingly, microbiota can modify the infectivity of viruses of the Reoviridae family, to which BTV 
belongs, albeit from a different vector-borne genus. Microbiota enhanced reovirus replication and 
pathogenesis has been reported in vivo in the murine model (Kuss et al., 2011) whilst in contrast, soluble 
factors from commensal bacteria appear to block infection of intestinal ECs in vitro for rotavirus 
(Varyukhina et al., 2012) thus highlighting a specificity in the interactions between bacterial products 
and viruses. Furthermore, it has also been shown for other enteric pathogens, such as poliovirus, that 
LPS can stabilise the virus particle and facilitate cellular attachment to mammalian cell culture lines 
(Robinson et al., 2014). Direct interactions between LPS and viral pathogens have also been reported 
for HIV, whereby LPS can bind to specific viral proteins, that in turn reduces virus binding to target T 
lymphocyte cell lines (Majerle et al., 2011). It also noteworthy that LPS mediated changes in cellular 
immune responses may also indirectly alter virus infections. For example, soluble chemokines produced 
by macrophages as a result of LPS treatment of human monocyte derived macrophages has been shown 
to reduce HIV infection (Verani et al., 1997), whilst to the contrary an enhancement of MMTV infection 
and persistence has been linked to LPS induced IL-10 production as a result of TLR-4 signalling, leading 
to an induction of viral tolerance to this retrovirus in the murine host (Kane et al., 2011). All of these 
above mechanisms, alongside the evidence of LPS induced TLR4 endocytosis (Zanoni et al., 2011) 
potentially facilitating virus entry into TLR4 expressing cells such as bovine blood derived monocytes 
(Werling et al., 2004), may provide conceivable theories for the LPS enhancement of BTV infection and 
replication, either via a direct interaction between LPS and BTV virions or via passive cellular uptake. 
Overall, the data presented in this thesis, alongside the ever increasing evidence of microbiome induced 
alterations of viral pathogen infections, highlights the necessity for future research into the effect of 
bacterial co-infections on BTV replication within the ruminant host.  
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In the absence of the knowledge of the LPS bacterial species origin within the collected saliva, 
commercial LPS from E. coli (data not shown) and S. enterica (Chapter 5) was utilised throughout this 
thesis. These sources of LPS have provided an initial insight into the effects of bacterial products on BTV 
infection, however it would be highly beneficial to extend these studies to LPS from other biologically 
relevant bacterial species such as P. multocida, that has been implicated in secondary bacterial 
infections associated with BT disease (Williamson et al., 2008). There have been only a limited number 
of studies that have considered the salivary microbiome of Culicoides midges (Campbell et al., 2005) 
whilst others have focused on the microbiome of the whole midge (Lewis et al., 2014, Mee et al., 2015, 
Nakamura et al., 2009). Furthermore, there is limited knowledge if the microorganisms within the 
arthropod microbiome, that are either commensal or acquired during haematology, are fixed to a single 
organ or are fluid and migrate between organs. Indeed, a 2009 study by Crotti et al observed the 
colonisation of Ae. Aegypti and An. stephenesi mosquitoes with Asaia, a commensal bacteria of 
mosquito species, expressing a plasmid encoded fluorescent protein. This study determined by confocal 
microscopy analysis, that the feeding of mosquitoes upon a meal containing the modified Asaia bacteria 
lead to the bacterial colonisation of the gut and salivary glands (Crotti et al., 2009). Although crude, it 
is thus possible that commensal microorganisms within an arthropod could migrate to the salivary 
glands and even be deposited into the skin of the mammalian host during the acquisition of a blood 
meal by the vector. This is therefore of great consideration as live bacteria or bacterial products will 
indeed have a considerable impact on the mammalian host immune and inflammatory response 
(Alexander and Rietschel, 2001). Furthermore, it is also possible that symbiotic relationships between 
microbiota and the viruses that are transmitted by Culicoides may exist that could in turn impact on 
BTV transmission, thus potentially providing an additional explanation for the observed efficiency that 
a single infected midge bite can reliably infect the ruminant host (Baylis et al., 2008). Differences in the 
microbiota between Culicoides species may also provide an additional hypothesis for the varying VC 
rates observed between midge species, for example the low VC rate of C. nubeculosus compared to 
other midge species (Boorman, 1974, Jones, 1957).  
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Future work relating to the microbiome of Culicoides midges in the context of BTV infection would 
therefore ideally aim to determine the species of bacteria residing within the salivary glands and thus 
the origin of the LPS within the secreted saliva. Furthermore, it would be ideal to dissect salivary glands 
from Culicoides midges to enable further confirmation that the LPS content within the secreted saliva 
originates from the salivary gland and is not merely carried and introduced from the exterior of the 
midge mouthpart. Subsequent infection experiments with identified bacterial strains or LPS could then 
confirm the role for these specified bacterial species in BTV infection. In order to investigate the 
potential for in vivo bacterial transmission by Culicoides midges into the skin of the ruminant host 
alongside BTV, confocal microscopy analysis could be utilised to visualise fluorescently tagged bacteria 
within the skin of the ruminant host at the bite site following midge feeding. Although LPS should now 
be considered to be a potential component of the saliva from all arthropods, other immune activators 
and TLR agonists that may be present within the saliva should not be ignored, such as lipoproteins from 
bacterial origin that may signal through TLR-2 (Kawasaki and Kawai, 2014). 
As previously outlined, the saliva of numerous arthropods is able to modulate the host cytokine 
response leading to a generalised reduction in the production of Th1 cytokines and an upregulation in 
the production of TH2 or immunomodulatory cytokines (Table 1.2). The findings of this thesis have, to 
some extent, highlighted that the saliva of C. sonorensis can modulate the cytokine response from 
bovine PBMCs or purified monocytes to match this overarching trend, although LPS within saliva is also 
likely to influence cytokine modulation. The BTV induced production of the pro-inflammatory, Th1 
cytokine, IFN-, was downregulated in the presence of saliva in three out of four cattle PBMCs tested. 
In comparison, the immunomodulatory cytokine, IL-10, was upregulated following the infection of 
PBMCs from two out of four cattle or from all purified monocyte cultures in the presence of saliva. IL-4 
was however not produced in response to saliva treatment thus indicating that unlike the saliva from 
other insects, Culicoides saliva may not induce a typical TH2 cytokine response in PBMCs. As BTV is a 
strong inducer of type I IFN both in vitro (Chauveau et al., 2012, Ruscanu et al., 2012) and in vivo (Foster 
et al., 1991, MacLachlan and Thompson, 1985), it would be interesting to determine if the presence of 
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saliva during infection can modulate this response. Intra-cellular cytokine staining and detection by flow 
cytometry would not only allow for the detection of relevant cytokines but would also allow the 
simultaneous determination of the specific cellular populations expressing the cytokine of interest. 
Furthermore, this technique would allow the investigation of the potential effects of C. sonorensis saliva 
on the cytokine production by bystander and/or low level infected lymphocyte populations within 
PBMCs which might, in turn, impact on BTV infection in monocytes. In addition to a saliva induced 
modulation of cytokine production, numerous studies have also reported a role for arthropod saliva in 
modulating other immune functions such as phagocytosis, co-stimulatory marker expression (Brake and 
Pérez de León, 2012, Slamova et al., 2011, Turni et al., 2002) and cell proliferation in response to a 
mitogen (Bishop et al., 2006, Bizzarro et al., 2013, Wanasen et al., 2004, Wasserman et al., 2004). Thus 
future work should also investigate the breadth of ability of Culicoides saliva to modulate such functions 
in the ruminant host.  
As the main effects of Culicoides saliva on BTV replication in monocytes may potentially be largely 
attributable to the LPS component of saliva, the question remains regarding the specific role of 
Culicoides salivary proteins on BTV infection. Preliminary investigations, either based upon the heat 
denaturation of respective salivary proteins or the removal of the vast majority of salivary LPS via an 
endotoxin removal column (Chapter 5), tentatively suggest that salivary proteins might have 
suppressive effects on BTV infection of bovine monocytes. This hypothesis is based upon the usage of 
1 µg/ml salivary proteins (salivary protein denaturation study) or 0.1 µg/ml (LPS removed saliva study), 
thus further consideration needs to be applied to the role of differing amounts of LPS removed saliva 
proteins in altering BTV infection and replication. Although numerous publications testing salivary 
functions have utilised concentrations of 1 µg/ml (Bishop et al., 2006, Brake and Pérez de León, 2012, 
Menezes et al., 2008), some have also tested salivary concentrations up to 40 µg/ml (Bizzarro et al., 
2013). The exact salivary amount/concentration deposited in the skin by an insect vector during the 
acquisition of a blood meal is unknown, nonetheless the biological relevance of salivary concentrations 
up to 40 µg/ml may be questionable. Investigations into the specific properties of C. sonorensis saliva 
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proteins on BTV infection, compared to LPS, therefore need to utilise a wide range of salivary protein 
concentrations.  
Previous work has clearly demonstrated a specific, LPS independent role for salivary proteases in 
modifying BTV particle structure following co-incubation, which subsequently results in virus particles 
that have an altered infectivity for mammalian and insect cell lines (Darpel et al., 2011, Mertens et al., 
1996). However, in the study here, C. sonorensis saliva and BTV were merely added to the cell culture 
medium containing FCS and the virus was not pre-cleaved with C. sonorensis saliva prior to the 
application to cell cultures. Moreover, commercial trypsin, when applied to cell cultures, did not elicit 
any effect on BTV infection or replication within the monocyte population of PBMCs (Chapter 5). Hence, 
the data presented here led to the proposition that in this experimental setup the observed saliva 
induced enhancement of BTV infection and replication is not attributable to the trypsin present in C. 
sonorensis saliva. Nonetheless, the role of VP2 cleavage in altering BTV infection of ruminant immune 
cells will need further research. At present it is unknown which infectious particle type is transmitted 
from an infected midge to the ruminant host and if different BTV particle types (whole virus, ISVPs and 
cores) will display a differential infectivity for natural target cells. It has been shown that the cleavage 
of VP2 by C. sonorensis saliva is more efficient at higher temperature such as those of the mammalian 
host (Darpel et al., 2011). It is therefore possible that VP2 cleavage may not occur until viral particles 
and C. sonorensis saliva are co-inoculated into the raised temperature, skin environment of the 
mammalian host. Furthermore, it is unknown if whole virions and ISVPs induce comparable cellular 
responses within the mammalian host, thus further investigation is needed in order to determine if 
these differing viral particle types can induce different anti-viral mechanisms. 
Alongside the presence of pharmacologically active proteins, the saliva of arthropods also contains an 
array of non-protein, anti-inflammatory, anti-haemostatic and immunomodulatory molecules such as 
eicosanoids. Indeed, prostaglandin content within tick SGE has been reported on numerous occasions 
and the PGE2 content in Rhipicephalus sanguineus SGE has been proposed to downregulate LPS induced 
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IL-12 and TNF-α production and to upregulate IL-10 production from murine bone marrow derived DCs 
(Oliveira et al., 2011). Although these molecules are potentially highly relevant to the biological actions 
of C. sonorensis saliva on the ruminant immune and inflammatory response, they were not considered 
throughout this thesis due to their unlikely presence in the final saliva preparations used in this study. 
As discussed in Chapter 3, post-collection the salivary proteins are present within a large volume of 
buffer (~ 100 ml), thus to concentrate the saliva to a volume applicable to in vitro infection studies, the 
saliva containing buffer was applied to a size exclusion column with a 3kDa cut off. Although the 
detection of small peptides and salivary components within secreted saliva may be technically difficult 
using the current collection setup, the isolation of C. sonorensis SGE may provide the opportunity to 
determine the presence of these molecules. Future SGE isolation and subsequent fractionation of the 
compounds present within insect saliva will therefore enable the identification and biological functions 
of possible Culicoides salivary components that are less than 3kDa in size, which have potentially not 
been identified to date.  
Mammalian cells, saliva and BTV particles will inevitably come into contact during the process of midge 
feeding. The duration of direct contact time between mammalian cells, saliva and BTV particles, the 
duration of biological activity of the salivary proteins and the exact dose of saliva or BTV deposited by 
the midge into the ruminant skin are however unknown. Nevertheless, the inflammatory reaction of 
the ruminant skin following midge feeding (Figure 1.6) can last several days thus pre-exposure of the 
ruminant skin to Culicoides midges bites may induce an inflammatory and/or immune response that 
can indirectly impact on BTV infection. Future experiments should investigate the impact of pre-
treatment of cells to Culicoides saliva and LPS removed saliva, in order to determine if such exposure 
can alter the ability of the LPS or protein salivary component of vector saliva to modify BTV infection 
and replication or the mammalian immune response. 
To date, it is still not understood why BTV infection results in such varying clinical disease between its 
predominant ruminant hosts, cattle and sheep. Thus further investigation is needed to understand the 
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underlying mechanisms and potentially different pathogenesis or antiviral immune responses towards 
BTV in both hosts. Understanding these factors in the context of BTV infection, within its multi-host 
system, will consequently greatly advance the development of targeted control measures. Within this 
thesis the potential of C. sonorensis saliva, and by discovery LPS, was only investigated in the bovine 
host, thus the question therefore arises whether there is a role for C. sonorensis saliva and LPS induced 
modulation of the ovine immune response and/or BTV infection in explaining the differences in clinical 
signs associated with BTV in different ruminant species. Indeed, previous reports have highlighted a 
potential role for Culicoides midge feeding and/or saliva in enhancing BT disease severity in the ovine 
host in vivo (Drolet et al., 2015, Pages et al., 2014), however further investigation is needed in order to 
characterise the potentially differential effects of Culicoides saliva on BTV infection within specific ovine 
target cell populations and the saliva induced immune modulation.  
Collectively, the work presented in this thesis highlights for the first time that the saliva of C. sonorensis 
can enhance BTV infection and replication within bovine target cells, most likely due to salivary LPS 
induced interactions with either the virus itself or mammalian host cell populations that subsequently 
benefits virus infection and replication. Modulation of the host cytokine response or the BTV induced 
host cytokine response also further provides evidence that the observed saliva modified BTV infection 
may be a result of indirect alterations of the cellular innate immune response. Furthermore, the novel 
identification of LPS as a Culicoides salivary component, that can itself alter BTV infection and 
replication, has further highlighted the complexity of the relationship between BTV, Culicoides 
midges/midge saliva and the mammalian host. Moreover the tentative proposal that Culicoides salivary 
proteins alone may downregulate LPS induced BTV infection and replication indicates that multiple 
salivary components with opposing actions may be present within Culicoides saliva. The work in this 
thesis has not only contributed to the knowledge of BTV infection within the ruminant host but has also 
impacted on the knowledge of vector-virus-host interactions due to novel findings of non-protein 
salivary components that can influence arbovirus infection. Going forward, LPS needs to be considered 
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as a possible component of the saliva from all arthropods and thus the effect of salivary LPS on saliva 
induced modulation of the host immune response or arbovirus infection needs to be evaluated.  
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Table A1 – Summary table of cattle number, saliva batch number and LPS content within saliva batch 
used per experiment. 
Experiment Figure 
number 
Cattle 
number 
Saliva batch 
number 
Final [LPS] 
(ng/ml) 
Chapter 4 
Determining the effect of saliva on the 
proportion of PBMC subpopulations 
expressing viral proteins following BTV 
infection  
4.1  2  5 0.09 
3 4 0.02 
4 4 0.02 
4.2 2  5 0.09 
3 4 0.02 
4 4 0.02 
Determining the effect of saliva on the 
proportion of the monocyte subpopulation of 
PBMCs expressing viral proteins following 
BTV infection 
4.3 1  2 18.8 
4.4 3  3 16.4 
4.5 5 5 
6 
0.09 
1.1 
4.6 2 3 16.4 
4.7 1 2 18.8 
2 3 16.4 
3 3 16.4 
5 5 
6 
0.09 
1.1 
4.8 1  2 18.8 
4.9 3  4 0.02 
4.10 3 4 0.02 
4.11 3 4 0.02 
Determining the effect of saliva on the 
proportion of purified monocytes expressing 
viral proteins following BTV infection 
4.12 2 4 0.02 
3 4 0.02 
4  4 0.02 
5 4 0.02 
4.13  3  4 0.02 
4.14 3 4 0.02 
Determining the effect of saliva on progeny 
virus production from PBMC cultures 
following BTV infection 
4.15 1 2 18.8 
4.16 2 6 1.1 
3 6 1.1 
5 6 1.1 
Determining the effect of saliva on progeny 
virus production from purified monocyte 
cultures following BTV infection 
4.17 2 4 0.02 
3 4 0.02 
4 4 0.02 
Chapter 5  
Determining the effect of trypsin on the 
proportion of the monocyte subpopulation of 
PBMCs expressing viral proteins following 
BTV infection 
5.1 3 4 0.02 
5 5 0.09 
Determining the effect of heat treated saliva 
on the proportion of the monocyte 
subpopulation of PBMCs expressing viral 
proteins following BTV infection 
5.2 2 3 16.4 
4 4 0.02 
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Determining the effect of LPS on the 
proportion of the monocyte subpopulation of 
PBMCs expressing viral proteins following 
BTV infection 
5.5 3 4 0.02 
5 5 0.09 
Determining the minimum dose of saliva that 
induces the proportion of the monocyte 
population of PBMCs to express viral proteins 
5.6 2 6 1.1 
3 6 1.1 
5 6 1.1 
Determining the effect of reduced 
concentrations of LPS on the proportion of 
the monocyte subpopulation of PBMCs 
expressing viral proteins following BTV 
infection 
5.7 3 6 1.1 
4 6 1.1 
5 6 1.1 
Determining the effect of delayed addition of 
saliva or LPS on the proportion of the 
monocyte subpopulation of PBMCs 
expressing viral proteins following BTV 
infection 
5.10 4 6 1.1 
5 6 1.1 
Determining the effect of LPS removed saliva 
on the proportion of the monocyte 
subpopulation of PBMCs expressing viral 
proteins following BTV infection 
5.12 4 6 1.1 
Determining the effect of varying amounts of 
C. sonorensis saliva on progeny virus 
production from PBMCs 
5.13 2 6 1.1 
3 6 1.1 
5 6 1.1 
Chapter 6  
Determining the effect of saliva and/or BTV 
infection on IL-10 production by PBMC 
cultures 
6.1 1 2 18.8 
2 3 16.4 
3 3 16.4 
5 5 
6 
0.09 
1.1 
Determining the effect of saliva and/or BTV 
infection on IL-4 production by PBMC 
cultures 
6.2 1 2 18.8 
2 3 16.4 
5 5 
6 
0.09 
1.1 
Determining the effect of saliva and/or BTV 
infection on IFN- production by PBMC 
cultures 
6.3 1 2 18.8 
2 3 16.4 
3 3 16.4 
5 5 
6 
0.09 
1.1 
Determining the effect of saliva and/or BTV 
infection on IL-12 production by PBMC 
cultures 
6.4 1 2 18.8 
2 3 16.4 
3 3 16.4 
5 5 
6 
0.09 
1.1 
Determining the effect of saliva and/or BTV 
infection on TNF-α production by PBMC 
cultures 
 
 
 
6.5 1 2 18.8 
2 3 16.4 
3 3 16.4 
5 5 
6 
0.09 
1.1 
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Determining the effect of saliva and/or BTV 
infection on IL-10, IL-12, IFN- and TNF-α 
production by purified monocyte cultures  
6.6 2 4 0.02 
3 4 0.02 
4 4 0.02 
5 4 0.02 
Determining the effect of saliva and/or BTV 
infection on PBMC viability  
6.7 1 2 18.8 
2 3 16.4 
3 3 16.4 
5 5 
6 
0.09 
1.1 
Determining the effect of saliva and/or BTV 
infection on the proportion of cellular 
subpopulations within PBMCs 
6.8 2 5 0.09 
3 4 0.02 
4 4 0.02 
Determining the effect of saliva and/or BTV 
infection on the viability of cellular 
subpopulations within PBMCs 
6.9 2 5 0.09 
3 4 0.02 
4 4 0.02 
Determining the effect of saliva and/or BTV 
infection on the proportion of monocytes 
within PBMCs 
6.10 1 2 18.8 
2 3 16.4 
3 3 16.4 
5 5 
6 
0.09 
1.1 
Determining the effect of saliva and/or BTV 
infection on the viability of monocytes within 
PBMCs 
6.11 1 2 18.8 
2 3 16.4 
3 3 16.4 
5 5 
6 
0.09 
1.1 
Determining the effect of saliva and/or BTV 
infection on the viability of purified 
monocyte cultures 
6.12 2 4 0.02 
3  4 0.02 
4 4 0.02 
5 4 0.02 
Determining the effect of saliva or LPS and/or 
BTV infection on the viability of purified 
monocyte cultures 
6.13 A/B 3 4 0.02 
5 5 0.09 
6.13 C/D 3 6 1.1 
4 6 1.1 
5 6 1.1 
Determining the effect of saliva and/or BTV 
infection on the MFI of CD14 expression of 
the monocyte population of PBMCS 
6.14 1 2 18.8 
2 3 16.4 
3 3 16.4 
5 5 
6 
0.09 
1.1 
Determining the effect of LPS and/or BTV 
infection on the MFI of CD14 expression of 
the monocyte population of PBMCS  
6.15 5 5 0.09 
 
 
